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From the early days of its recognized occurrence, AIDS has been per-
ceived as posing tremendous threats, burdens and challenges to human 
beings. Individuals, societies and, in a global point of  view, mankind are 
affected by the effects of the HN infection, the nature and extent of 
which is still unclear in many ways. In the beginning only biomedical and 
epidemiological analyses of the problem were the top research priori-
ties, the former laden with great hopes that it may soon be possible to 
stop the spread of the disease and to overcome its physical impact. Yet it 
soon became clear that AIDS would be something to be reckoned and 
coped with on a long-term basis, making a thorough investigation of its 
impact absolutely mandatory. 
AIDS has serious economic consequences. Taken seriously, they can-
not be confined to predictions of costs intended to support the AIDS 
issue in the struggle for resources. Besides cost calculations-a method-
ologically tricky and wide-ranging topic in itself-and their application to 
cost-effectiveness and other analyses, economic issues include identify-
ing and assessing patterns of care,  analyzing problems of financing, 
exploring impacts on markets other than health care, and modelling 
scenarios for future developments and strategies. At present, the eco-
nomic aspects of AIDS still constitute a very recent topic in European 
health economics and health systems research. Many projects are just 
about to start,  and there must be a  better exchange of information 
between research groups. 
On behalf of the Concerted Action Committee (COMAC) on Health 
SelVices Research (HSR), the GSF-Institut fur Medizinische Informatik 
und Systemforschung (MEDIS)  convened an international conference 
on "Economic Aspects of AIDS and HN Infection" in Munich, 16-18 
March 1989. The conference forms a major part of  a study contracted by 
COMAC-HSR to Professor Schwefel of GSF-MEDIS. In conducting the 
study,  Professor Schwefel was assisted  by Dr.  Leidl.  The full  study 
comprises the examination of r~earch groups and issues (which was 
conducted in the study phase prior to the Munich meeting), the con-
ference,  and support for  stimulating  concerted  European  research 
action in this field. 
The participants of the workshop were invited according to a number of 
criteria. The topics relevant to European countries were to be repre-
sented adequately, and there was to be balanced representation of 
researchers  from  the various  European countries.  Furthermore,  re-
searchers and experts working in international organizations were asked VI 
to participate. Rnally, each participant was asked to play an active role 
by giving a lecture and writing a paper. 
Researchers from nearly all the countries of the European Communities 
accepted the invitation; some workers from neighboring countries like 
Sweden, Switzerland, and the United States of America also participat-
ed. Within the groups of EC countries,  however, some were slightly 
overrepresented, others slightly  underrepresented at the conference. 
This was due to the selection criteria and the response rate. 
The papers given at the conference form the basis of this publication. 
Some contributions not presented at the conference were also accept-
ed. All papers submitted passed through an editorial review process. The 
review was supported by Professor Rovira, who was reponsible for the 
sections 'Exploring Spread and Context' and 'Patterns of Health Care 
and Social Support Systems', Professor Drummond who commented 
on the section 'Costs of AIDS',  and Dr.  Leidl who took care of the 
sections 'Rnancial Aspects', 'Scenarios and Policies', and 'Prospects'. 
Besides the COMAC-HSR study, other activities in the European region 
are also concerned with the economic aspects of AIDS. To avoid un-
necessary duplication and to coordinate the planning of international 
research, an exchange between these projects has been arranged. One 
study  focuses  more  on  the  methodological  aspects,  especially  of 
costing issues;  it was initiated by the World Health Organization, Re-
gional  Office  for  Europe.  Another project,  promoted by the same 
institution,  is  concerned with  scenarios on the social  and economic 
impact of AIDS. 
The focus of the COMAC conference and of this book is on the ex-
ploration  of  economic  aspects,  on empirical  approaches,  on case 
studies, and, last but not least, on modelling techniques for economic 
scenarios. We hope this collection provides an up-to-date overview of 
the state of economic research on AIDS  in  Europe, and that it may 
stimulate further work to come. 
Rnally, we are greatly indebted to our colleagues at the MEDIS Institute 
whose steady and thorough team work transformed the pile of manu-
scripts into a camera-ready publication. In the editorial assistance, Mrs. 
Ursula  Weber managed the technical  production of texts,  graphics, 
references, and the general bibliography. Mr. Darwin Santo took over 
the tremendous task of processing all  the manuscripts into their final 
form.  Mrs.  Frauke  Hornig supplemented some of the graphics.  Dr. 
Walter Satzinger and Dr.  Andreas Mielck assisted in  the editing of a 
number of papers. 
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D. Schwefel 
Threats can be challenges. But AIDS,  today still, seems to be only a threat rather than 
a positive challenge- individually, socially as well as professionally. 
Since the hope for individual survival of the disease is  practically non-existent for 
the time being, coping with the unalterable is  the main option for people afflicted 
with AIDS; there is little room for other ways out of this life destroying catastrophe. 
Being members of social minorities,  infected  and affected  people generally tend 
not  to  get  the  human  affection  they  need,  but  are  most  probably  socially 
stigmatized; the challenge to bridge the gap between strong majorities  and weak 
minorities  is  not  yet  taken  seriously  other  than  rhetorically  in  lV spots  and 
newspaper advertisements. 
The different professions and academic disciplines, up to now, have rarely met the 
challenge  of  bringing  biomedical  and  socioeconomic  research,  medical  and 
psychosocial care together in concerted action. 
Some joint statements,  rather than actions,  have  however  evolved  at national 
levels;  ministers  of health from  many a  country convene rather often to discuss 
policies.  At least at this  level,  the threat of AIDS  has been taken as  a  challenge 
towards extended international understanding in health affairs. 
This rather pessimistic outlook on individual, social and professional responses to the 
threat  of  AIDS  was  thus  complemented  in  the  eighties  by  a  slowly  growing 
international understanding of the global challenges to be met - a first marker for hope. 
1.  Social sciences and AIDS 
To  overcome  the threat  of  AIDS,  effective  vaccination  and/or treatment  is  indeed 
needed. But the prospects for that are rather dim.  Therefore prevention is  crucial, and 
the alleviation  of hopelessly  dying  must  also  be  at the  top  of the agenda.  Even  if 
vaccination and treatment are available soon, prevention through behavioural changes 
and policies, management and/or alleviation through socioeconomic and psychosocial 
(coping) strategies, and the widest possible extension of the best care by the most cost-
effective measures will be of highest importance. 
Through its task force on AIDS,  the Concerted Action Committee (COMAC) on Health 
Services Research (HSR)  of the European Community has tried to open avenues for 
social science research in this field. It identified four main areas which so far have been 4 
lacking sufficient scientific attention and public funding: 
Studies  on  risky  and  risk  avoiding  behaviour  before  and  after  preventive 
interventions are being conducted in  some places  now to test their effectiveness 
and acceptance. Nevertheless, coordination and concerted actions in this field  are 
still  needed  and  would  benefit  patients,  professionals  and  politicians  alike. 
Behavioural studies should also  include the behaviour of providers, professionals 
and politicians  and not only  that of  "ordinary"  people  and patients.  Sociology 
could and should play a  role in  this field  as well as in  analysing and interpreting 
social responses to this threat. 
The  existing  incurability  of  AIDS  imposes  severe  emotional  burdens  on  the 
affected and their fellows.  The risk  of infection during service adds another load 
onto the helping professions. Mass reactions in terms of social psychology are real 
and to be anticipated. Psychology could and should bring information, knowledge 
and advice. 
Policies quite often reflected prejudices rather than results of analyses (which were 
not available, one has to add). So far policy responses have rarely relied on sound 
analyses  of  initiatives,  their  implementation  and  impacts.  In  this  double  sense, 
policy  sciences  could  and  should  support  regional  and  national  prevention 
strategies and health policy planning. 
Being relatively  weak in  the  range  of social  science  approaches  to  health  and 
health care, these three disciplines - sociology, psychology and political science -
are being outpaced by health economics.  Direct and indirect costs  of AIDS  and 
HIV infection were estimated or calculated relatively early; remarkable differences 
in  approaches,  results  and  implications  make  a  more  extensive  and  intensive 
economic analysis of AIDS advisable. 
Other  aspects  should  certainly  not  be  disregarded.  Ethical  questions  have  to  be 
addressed as well  as  legal ones, questions which are interwoven with the approaches 
mentioned. The social sciences mentioned can support concerted actions on AIDS and 
HIV  infection  quite  a  bit  - concerted  actions  between  patients  and  professionals, 
between  helping  professions,  between  academic  disciplines  and  between  bio- and 
sociomedical  endeavours.  Concerted  actions  bridging  bio- and  sociomedical 
approaches  may  be far  ahead of  us.  COMAC-HSR's  task force  on AIDS  therefore 
advocated  first  of all  sound disciplinary  responses  in  the  fields  of  social  sciences  -
sociology, psychology, political sciences and economics- as a starting point. 
2.  Economics of AIDS 
One  of  the  project  proposals  - the  one  on  economic  aspects  of  AIDS  and  HIV 
infection - got approval by COMAC-HSR first.  It intended to study direct and indirect 
costs of AIDS  and HIV infection for individuals, families,  health services and societies 
and to try to prepare concerted actions for further research in this field. 5 
At  the beginning,  direct  and indirect costs  of AIDS  and HIV  infection seemed to be 
relatively  high.  First  estimates  in  USA  (Hardy  et  al.,  1986;  Scitovsky  et  al.,  1986; 
Scitovsky  and  Rice,  1987;  Hatziandreou  et  al.,  1987)  differed  quite  considerably 
regarding the costs  involved,  methodology of cost estimations,  underlying treatment 
pattern, etc.  Most of them stressed - in  addition to the high direct personal costs - the 
importance of  indirect costs  in  terms  of lost  life  years  (quality  adjusted  life  years  or 
QALYs, productive life years, etc.) and of lost output due to a reduction of productivity 
caused by premature morbidity and mortality.  Beyond these direct and indirect costs 
wider impacts  of AIDS  and HIV  infection  are to be considered when exploring the 
socioeconomic context of this topic: impacts on demography, on markets and the like. 
Recent thoughts  and calculations  (Reinhardt,  1988;  Pedergnana,  1988}  hint at cost 
levels  much  lower  than  expected  at the  beginning.  Only  very  few  studies  tried  to 
compare the cost of AIDS with costs of other diseases (Hatziandreou et al., 1987}. Only 
rarely does a study -as far as  we know -stress the political and social context of cost 
and financing of AIDS  (Fox,  1986). These three points indicate that we still  know too 
little in this field,  in absolute, relative and contextual terms. But we are quite sure that 
all  over the world,  and in  Europe, social  scientists  are beginning to  deal with  such 
questions. This is  why a study contracted by COMAC-HSR  first of all tried to explore 
what is going on in this field of research and action. 
2.1  Exploration 
First, a worldwide literature survey and a European project survey were undertaken by 
the Institute  for  Medical  Informatics  and Health Systems  Research MEDIS  of GSF -
National Center for  Radiation  and Environmental  Research Munich,  to explore the 
field.  The literature survey covered the wide field of social science approaches dealing 
with AIDS and HIV infection. There has obviously been a steep increase in the number 
of relevant publications, starting quite late in the eighties. Nevertheless, since many of 
the projects  are still  going on and have not rendered publications yet,  an additional 
project survey was required that involved sending a questionnaire to as many health 
systems  researchers  in  Europe  as  possible  and  discussing  with  many  researchers 
results, studies and research plans. 
2.2  Pattern of concerns 
Taking  into  consideration  some  of  the  more  recent  representative  and  relevant 
publications in this field,  a quite diversified pattern of research emerges: 
1.  General aspects 
overview of topics (7,8,34,46,48,55} 
bibliographies (38,57), e.g. on cost studies (6) 
review of cost studies (20,21,25,31,74,82,83) 
patterns of care (5,20,36,43,51) 6 
2.  Cost studies 
hospital costs (5,36,37,39,43,51,63,65,72,76,78) 
regional and national costs (26,27,44,49,77) 
patient costs (12,14,28,29,31,39,42,66,67) 
general aspects and cost projections (31,59,68,80,81,82,83) 
3.  Other economic aspects 
financial aspects (2,8,22,32,68,82,83), e.g., for insurers 
resource allocation considerations (83) 
evaluations, e.g. of treatments (21,45) 
cost-effectiveness approaches (1,12,64,68) 
effectivity measures, e.g. QAL.Ys  (21,30,67,73,86) 
4.  Wider approaches 
policy studies (4,24,25,61,68) 
behavioural studies (40, 75) 
cognition, attitudes and perceptions (4,10,13,16,17,23,41,50,52,53,54,56,79) 
general remarks (58) 
5.  Projections and scenarios 
disease projections (3, 15,18,21 ,32,33,35,60,69, 70,71 ,84) 
scenarios (47,62) 
6.  Impact studies 
impacts on care (19,85) 
demographic impacts (15,86) 
social impacts (  11) 
ethical aspects (9) 
global impacts (87) 
This  picture  takes  into  account literature  reviews,  results  of previous  research  and 
preliminary  results  of ongoing socioeconomic research  on AIDS  and HIV  infection. 
This  pattern  of  concerns  shows  clearly  that social  research  is  available  for  policy 
makers to  learn from.  Some aspects,  though,  deserve special support:  wider impact 
analyses  - especially  asked  for  in  the  original  COMAC-HSR  proposal  for  studying 
economic  aspects  of  AIDS  and  IV  infection  - and  cost-effectiveness  analyses,  for 
example, are certainly not being conducted in sufficient number and intensity. 
A preliminary  analysis  of  the  results  of  our research  survey  showed  the  following 
pattern  of  research  concerns  in  terms  of  research  groups  dealing  with  the  topics 
indicated: 
patterns of care 
direct costs 
of hospitals 
of districts, regions, nations 
of insurances 
of patients, families 
indirect costs 
cost-effectiveness (benefit/utility) analysis 
4 groups 
7 groups 
4 groups 
8 groups 
8 groups 
15 groups 
12 groups 
9 groups financing problems 
methodological issues 
impacts on demography 
other impacts 
prediction and scenarios 
2.3  Lessons 
4 groups 
10 groups 
4 groups 
2 groups 
12 groups 
7 
This  pattern  of published  and ongoing  research  shows  several  remarkable  features 
when interpreted and compared with already published studies. 
First,  the main track of  research  is  and will  be cost studies.  Studies on hospital 
costs are a rather dominant starting point for economic analyses - the most feasible 
one. 
Second, financing problems are quite less a prominent research topic in European 
research  as  compared to  the  American  one.  This  may  reflect  the  wide  spread 
coverage  of  public  insurances  for  health  and of social  security  systems  for  the 
majority  in  European countries,  a  major feature  with  important implications  for 
AIDS and HIV infection as well. 
Third,  other impacts  of AIDS  and HIV  infection  are rarely taken up  as  research 
topics;  this  is  valid  for forgone  and ongoing research. Some of these aspects are 
taken  into  consideration,  nevertheless,  in  the  drafting  of  scenarios,  a  rather 
prominent approach in Europe. 
Scenario approaches are still linked very much to basic epidemiological questions 
and based on the development and adaptation of mathematical tools. Economics 
is coming in hesitantly. 
A fifth  point is  that cost-effectiveness or cost-utility studies are still  rare,  and that 
comparative effectivity measures need further research and application. 
Sixth, methodological approaches could and should be supported much more, so 
should approaches which compare AIDS  and HIV infection with other killers and 
cripples,  and those that compare the social  and economic contexts of treatment 
patterns of other diseases. 
Finally,  research  in  these  areas  seems  to  be  a  bit  isolated  from  research  in 
biomedical environments except for cost studies in hospitals. This not only reflects 
isolation, but also that applied health economics research addresses its messages to 
much wider audiences than to the clinical establishment, since social and not only 
clinical management is the focus. 
These  aspects  of the  actual  and  emerging  pattern  of  research  on some  economic 
aspects of AIDS  and HIV infection should be taken into consideration when trying to 
bridge  existing  gaps  between  the  research  of  different  professions,  disciplines  and 
countries. 8 
3.  Outlook 
We do not know enough about the socioeconomic context of diseases and patterns of 
treatment and  care.  Too  often  rather  narrow  approaches  were  used  to  look  into 
incidences and prevalences alone, but not into life years lost,  productive life years lost, 
quality adjusted life  years lost,  labour and human productivity lost,  welfare and well-
being lost. The psychosocial and socioeconomic context of diseases is much wider than 
mostly  analyzed.  In  this  sense  socioeconomic  research  on AIDS  and HIV  infection 
bears the challenge of applying such  a wider view.  AIDS  is  too awful  a  threat as  to 
analyse its  incidences and prevalences only.  It is  the social, psychological, economical 
and political context of this disease which plays an important role, and to neglect this 
would  mean to  close  the eyes  where  twilight  should  stimulate  rather than prevent 
research. The same may be true for the psychosocial and the socioeconomic context of 
actions to alleviate the burden for  the affected and their fellow-men  and to prevent 
AIDS as far and fair as possible. Socioeconomic research on AIDS and HIV infection, if 
it accepts these challenges, could also be fruitful for preventing and treating, effectively 
and efficiently,  other patterns of disease. Social sciences,  including economics,  could 
and should try to tum the threat of AIDS to hopeful challenges. 
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of AIDS and HIV Infection Patterns of AIDS and HIV Infection in Europe 
A.M. Downs, R.A. Ancelle-Park, I. de Vincenzi, J.-B. Brunet 
1.  Introduction 
Since 1983, countries belonging to the WHO European region have participated in the 
surveillance  of  AIDS  in  Europe by  reporting to  the WHO  Collaborating Centre on 
AIDS  in  Paris.  Data are supplied to the Centre, at regular intervals and according to 
agreed standardized formats,  by  a  single,  nationally  recognized  source  per country, 
each source being responsible for the quality of the data provided. 
To  date, surveillance has been primarily concerned with  cases of AIDS,  diagnosed in 
accordance with  successive  updates of the Centers  for  Disease  Control  (CDC)  case 
definition.  However,  the  clear  need for  good  quality  data  on the  prevalence  and 
incidence of HIV infection has recently lead to increased activity in this important area. 
Some  recent  results  from  both  of  these  aspects  of  surveillance  are  presented  and 
discussed below. Further details may be found  in  the regular quarterly reports issued 
by the Centre and available on request. 
2.  AIDS surveillance data 
By  31st December 1988,  a total of  19,058 cases  of AIDS  had been reported by 31 
countries  (see  Table  1),  with an increase of 87%  (8,877  newly  reported cases)  since 
December 1987 (WHO  Collaborating Centre on AIDS,  Paris,  1988). The cumulative 
incidence per million  population remained highest in Switzerland  (106.4)  and France 
(101.7),  followed  by  Denmark  (70.2).  Countries  in  the  eastern  part  of  the  region 
reported much lower numbers of cases, with rates of less than 3 per million population. 
The equivalent rate in  the USA was  339.5 per million  at 2nd January 1989 (Centers 
for Disease Control, 1989). 
Considering all  cases diagnosed in  adults  or adolescents  (over 12 years of  age), the 
male:female sex ratio was  7. 7.  This  ratio  was  however much  closer to unity  among 
intravenous (IV)  drug users  (3.1), persons presumed infected by heterosexual contact 
(1.6) and transfusion recipients (1.3)  (see Table 2). 
Among the 18,603 cases in adults/adolescents, 53% were diagnosed in homosexual or 
bisexual  men  and 26%  among  IV  drug  users  (a  further  2%  being both  homo- or 20 
Table 1.  Cumulative AIDS cases reported by 31 European countries and estimated cumulative incidence 
rates per million population 
Country  Date of report: 
Dec. 87  Mar. 88  June 88  Sept. 88  Dec. 88  Rate per 
million 
Albania  0  0  0  0  0.0 
Austria  139  158  191  191*  191*  25.1 
Belgium  277  336  368  408  424  42.8 
Bulgaria  1  1  3  3  3  0.3 
Czechoslovakia  8  10  11  12  12  0.8 
Denmark  228  262  292  319  358  70.2 
Finland  24  27  32  37  41  8.4 
France  3,073  3,628  4,211  4,874  5,655  101.7 
German Dem. Rep.  6  6  6  6  11  0.7 
Germany, Fed. Rep.  1,669  1,906  2,210  2,488  2,779  45.6 
Greece  88  106  127  151  170  17.0 
Hungary  8  11  13  14  17  1.6 
Iceland  4  5  6  7  10  50.0 
Ireland  33  37  49  64  74  21.1 
Israel  47  58  65  67  76  17.3 
Italy  1,411  1,736  2,094  2,556  3,008  52.4 
Luxemburg  9  10  12  13  13  32.5 
Malta  7  10  12  12  14  35.0 
Netherlands  420  487  539  605  694  47.5 
Norway  70  81  88  91  100  23.8 
Poland  3  3  3  3  5  0.1 
Portugal  90  123  139  173  199  19.3 
Romania  3  4  8  9  10  0.4 
San Marino  0  0  0  0  0.0 
Spain  789  1,126  1,471  1,850  2,165  55.5 
Sweden  163  181  205  223  256  30.5 
Switzerland  355  439  502  605  702  106.4 
Turkey  10  17  0.3 
United Kingdom  1,227  1,429  1,598  1,794  1,982  34.9 
USSR  3  3  4  4  7  0.0 
Yugoslavia  26  38  40  58  65  2.8 
Total  10,181  12,221  14,299  16,647  19,058 
Source: WHO Collaborating Centre on AIDS, Paris, 1988 
*  June 1988 data 
bisexual  and  IV  drug  users),  while  8%  were  presumed  to  be  infected  through 
heterosexual contact.  Among the 2,134 adult female  cases,  more than half  (54.5%) 
were IV drug users. There is  however a considerable between-country variation in the 
distribution  of  cases  by  transmission  group,  as  shown  in  Fig. 1.  Whereas,  in  five 
northern European countries, over 70% of all cases have occurred in  homo-/bisexual 21 
Table2.  Cumulative AIDS cases by transmission group for 31 European countries* (as reported by 31st 
December 1988) 
Transmission group  Adults/adolescents  Paediatric  Total 
Male  Female  < 13 years  No.  % 
Homo-/bisexual  9,812  9,812  51.5 
IV drug user  3,641  1,163  4,804  25.2 
Homosexual IV drug user  415  415  2.2 
Haemophilia/coag.disorder  637  7  48  644  3.4 
Transfusion  389  289  55  678  3.6 
Heterosexual contact  882  550  1,432  7.5 
Mother-to-child  350  350  1.8 
Other/unknown  693  125  2  818  4.3 
Total  16,469  2,134  455  19,058  100.0 
Source: WHO Collaborating Centre on AIDS, Paris, 1988 
*  Albania,  Austria,  Belgium,  Bulgaria,  Czechoslovakia,  Denmark,  Finland,  France,  German  DR, 
Germany  FR,  Greece,  Hungary,  Iceland,  Ireland,  Israel,  Italy,  Luxemburg,  Malta,  Netherlands, 
Norway,  Poland,  Portugal,  Romania,  San  Marino,  Spain,  Sweden,  Switzerland,  Turkey,  United 
Kingdom, USSR, Yugoslavia 
men,  in  Italy  and Spain 65%  and 60%  of cases  respectively  have occurred  among 
heterosexual  IV  drug  users.  Amongst  the 455  paediatric cases  reported  (Table  3), 
mother-to-child transmission was the main mode of transmission (77% of cases); within 
this group, 55% of the mothers were IV drug users. 
The overall proportion of adult cases diagnosed among heterosexual IV drug users has 
increased  sharply  over the  last four  years,  from  1%  in  December  1984 to  26%  in 
December 1988  (see  Fig. 2).  These  cases  are  concentrated  particularly  in  southern 
Europe, with 85% of them reported from Italy, Spain or France. The seriousness of this 
situation has been repeatedly stressed (Ancelle-Park et al., 1987; Ancelle-Park and De 
Vincenzi,  1988),  particularly  in  regard  to  the  potential  spread  of  HIV  in  the 
heterosexual population and to the increase in  vertical (mother-to-child) transmission 
of  HIV.  In  the  latter  context,  it  should  be  noted  (Table  3)  that  74%  of  all  cases 
attributed  to  mother-to-child  transmission  have  been  reported  from  Italy,  Spain  or 
France. 
The proportionate increase in  cases among IV  drug users  has been accompanied by 
other changes in the characteristics of reported AIDS cases in Europe. In particular, the 
distribution  by  age  and sex  (Fig. 3)  shows  percentage  increases  in  women  and  in 
younger men;  between December 1984 and December 1988, female cases increased 
from 8% to 12% of the total, while, amongst all adult male cases, the percentage under 1
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Table 3.  Cumulative paediatric AIDS cases* by country of diagnosis and transmission group as reported 
by 31st December 1988 
Country of  Mother with AIDS or at risk for AIDS 
diagnosis  Haemo- Trans- Other/ 
IVDU  Trans  Hetero  Oth/Unk  philiac  fusion  unknown  Total 
Austria  4  0  0  1  1  1  0  7 
Belgium  0  0  12  0  1  0  0  13 
Denmark  1  0  1  0  0  0  0  2 
France  44  4  60  13  3  25  1  150 
GermanyFR  15  1  4  4  3  7  0  34 
Greece  0  0  0  2  3  1  0  6 
Ireland  3  0  1  0  0  0  0  4 
Italy  57  0  21  4  5  4  0  91 
Netherlands  1  1  1  1  0  6  0  10 
Portugal  0  0  1  0  2  0  0  3 
Spain  56  0  1  0  21  5  1  84 
Sweden  0  0  3  0  1  0  0  4 
Switzerland  7  0  1  5  0  1  0  14 
Turkey  0  0  0  0  1  0  0  1 
United Kingdom  3  5  8  3  6  5  0  30 
USSR  0  0  1  0  0  0  0  1 
Yugoslavia  0  0  0  0  1  0  0  1 
Total  191  11  115  33  48  55  2  455 
Source: WHO Collaborating Centre on AIDS, Paris 
*  under 13  years;  IVDU:  Intravenous drug  user;  Trans:  Transfusion recipient;  Hetero:  Heterosexual 
contact; Oth: Other; Unk: Unknown. 
No paediatric cases were reported in: Albania, Bulgaria, Czechoslovakia, Finland, German DR, Hungary, 
Iceland, Israel, Luxemburg, Malta, Norway, Poland, Romania, San Marino. 
100 
0/o 
cases 
80 
60  C  homo/bosexual 
Cother 
40  •  IV  drug user 
20 
12/84  06/85  12/85  06/88  12/88  06/87  12/87  06/88  12/88 
date  of  report 
Fig. 2.  Percentage distribution of cumulative AIDS cases among the main transmission groups, by date 
of report; 31 European countries 24 
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Fig. 3.  Distribution of cumulative  AIDS  cases  by  age  and  sex  at  31st  December  1988;  31  European 
countries 
30 years of age increased from  16% to 30%. A change has also been observed in the 
distribution by disease category at diagnosis;  the proportion of cases presenting with 
opportunistic infections alone (i.e. unaccompanied by Kaposi's sarcoma) has increased 
from  64% at December 1984 to 74.5% by December 1988, reflecting the significantly 
lower  occurrence  of  Kaposi's  sarcoma  in  IV  drug  users  than  in  homosexual  men 
(Ancelle-Park et al., 1987). 
3.  Trend analyses and short-term predictions 
Since  December  1985,  statistical  analyses  of  the  European AIDS  surveillance  data 
have been carried out at 6-monthly  intervals,  with  the  dual aim  of  monitoring  and 
comparing the evolution of the epidemic,  within  individual countries  and within  the 
principal  transmission  groups,  and of providing short-term predictions.  The  method 25 
adopted (Downs et al.,  1987, 1988)  is  based on fitting  an exponential model to half-
yearly incidence data over successive periods of 3 years, in order to obtain successive 
estimates  of  average  doubling  times  over  the  chosen  time  windows.  Despite  the 
crudeness  of  this  approach,  we  believe  that  it  has  proved  particularly  useful  in 
providing early indicators of trends within particular geographical or behavioural sub-
populations. Since doubling times  in  given subpopulations are generally found to be 
lengthening, forward  extrapolation on the basis  of latest estimated doubling times  is 
expected  to  produce  overestimates  of  future  cases.  Nevertheless,  short-term 
predictions,  for  up to  two  years  ahead,  can  be  of  some  value,  provided  that the 
exponential model fits sufficiently well over the most recent 3-year period. 
As  the analysis  is  based on the numbers  of  incident  cases  by  period  (half-year)  of 
diagnosis,  and not by period of report,  the data must first  be adjusted for  delays  in 
reporting.  This  is  done  using  a  maximum  likelihood  approach  (Heisterkamp  et  al., 
1988, 1989), with data from successive surveillance reports. 
Table 4.  Estimated average  doubling times  of cumulative AIDS cases over the period January 1986  -
December 1988, by country of diagnosis and transmission group (at least 50 reported cases) 
Country  All cases  Homo/bi  IVDU  Hetero 
Denmark  23.2  24.1 
FR Germany  23.0*  23.3*  ***  *** 
United Kingdom  22.8  24.3  14.2* 
Netherlands  20.4*  23.5*  11.6*
0 
Switzerland  16.0  24.8*  10.8  8.2** 
France  15.6  18.6  10.5  13.7 
Spain  12.4  16.0*  10.5  9.7 
Italy  10.8  15.9  10.4  7.3 
Greece  11.9* 
Austria+  10.9+ 
Portugal  10.9 
Yugoslavia  8.8 
Ireland  8.2 
Belgium  *** 
Israel  *** 
Norway  *** 
Sweden  *** 
E.C.  15.6  20.4  10.8  12.5 
+  June 1988 estimate 
E.C.:  European Community (pooled data) 
45 reported cases only 
*  0.80  < R2  < 0.90 
**  R2  = 0.76 
***  R2  < 0.70 
in all other cases: 
R2  >  0.90 26 
Selected  results  from  the  analysis  of  data  reported  by  31st  December  1988  are 
presented in Fig. 4 - 6 and Table 4.  Fig. 4 is  based on pooled data from the countries 
of the European Community (which together account for 92% of all European cases) 
and shows the evolution in  estimated doubling times in the two principal transmission 
groups  and  for  all  groups  combined.  The  overall  epidemic  doubling  time  has 
lengthened steadily from around 7 months in the early stages of the epidemic (only 21 
cases are reported to have been diagnosed before 1981) to a latest estimate (for the 
period  1986 - 1988)  of  15.6  months.  As  most  of  the  early  cases  were  among 
homo-/bisexuals, the early evolution was in large part a reflection of the trends in this 
group.  However,  since the onset of a separate epidemic among IV drug users, with  an 
Months 
25 
20 
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DIAGNOSED  81  82  83  84  85  86 
BETWEEN YRS:  83  84  85  86  87  88 
ALL  .. 7.3  7.9  8.5  9.7  12  15.6 
HOMO  IIIIll  6.5  8  8.8  10.9  14.5  20.4 
IVDU  c=J  4.4  5.8  8  10.8 
Fig. 4.  Trends in the AIDS epidemic among homosexuals (HOMO), among IV drug users (IVDU) and 
for all transmission group combined (ALL), in the countries of the European Community (pooled data). 
Estimated average doubling times of diagnosed AIDS cases over successive 3-year periods, are indicated 
in months 27 
estimated initial  doubling time  (4.4 months)  much shorter than that ever observed in 
the  homo-/bisexual  group,  overall  doubling  times  have  been intermediate  between 
those in these two groups. Although both groups show lengthening doubling times, the 
more  rapid  rise  in  incidence  among  IV  drug  users  is  confirmed  by the  consistently 
shorter estimates for  this  group  (10.8 months versus 20.4 months over the last three 
years). The estimated doubling time for  cases attributed to heterosexual transmission 
has remained relatively stable  at around 12 - 13 months since  1984 (latest estimate: 
12.5 months). 
Extrapolation on the basis of the above estimates would predict a cumulative incidence 
of 64,600 cases in the EC by the end of 1990 (Fig. 5). As discussed above, this figure is 
probably an over-estimate. Due to delays  in  reporting, the number of cases  actually 
reported by the end of 1990 can in any case be expected to be considerably less than 
the projection  given  here,  which  relates  to  diagnoses  and  not to  reports  (typically, 
around 75% of cumulated diagnosed cases are estimated to be reported at any given 
moment). Nevertheless, since the resources needed for the care of AIDS patients would 
seem not to depend on whether or not they have been reported to the surveillance 
system, this seems a more useful quantity for planning purposes. Extrapolations in the 
separate transmission  groups suggest that incident cases  among IV  drug users  could 
well exceed those among homo-/bisexual males from mid-1989 onwards, with equality 
in terms  of cumulative cases towards the end of 1990 (28,400 IVDU  cases v.  26,100 
homo-/bisexual cases projected to be diagnosed by the end of 1990). 
Epidemic trends within  individual European countries show considerable variation. A 
large part of this variation can be explained by differences in epidemic onset times and 
in  the  distribution  among  transmission  groups.  Lengthening  doubling  times  are 
generally observed whenever the epidemic in  the population concerned is  sufficiently 
advanced for such a trend to be detectable. Although there are indications that these 
trends are probably continuing,  half-yearly  (adjusted)  incidence continues to increase 
in  most populations. Exceptions have been noted, however,  in  Norway, Sweden and 
Belgium, for which observed decreases in  incidence for  the last two  half-years persist 
even after adjustment for reporting delay (for Belgium, where the epidemic pattern has 
been  much  influenced  by  contacts  with  Africa,  this  d~crease remains  when  cases 
among residents only are considered). In The Netherlands and FR Germany, adjusted 
incidence has remained almost constant over the last 3 half-years,  as  had previously 
been noted for Sweden. 
The extent to which  the exponential model fits  the data over the last three years  is 
quite variable.  In  some  cases  it  is  clearly  no longer satisfactory,  while  in  others the 
coefficient of determination  (R2) remains high.  Latest estimated doubling times for  all 
populations  with  at  least  50 reported  cases  and  for  which  R2>0.80  are  given  in 
Table 4 and Fig. 6. Those countries in  which overall doubling times  (1986- 1988) are 
shortest (8.2 - 12.4 months)  are those in  which  either the epidemic  is  at a  relatively 
early  stage  (Ireland,  Yugoslavia,  Portugal,  Greece)  or  the  predominant  mode  of 28 
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Fig. 5.  The AIDS epidemic in the European Community: observed half-yearly incidence of AIDS cases, 
adjusted for reporting delays, to December 1988 and projections, based on doubling times estimated over 
1986-1988 (Fig. 4),  to December 1990  (see text).  Projected cumulative  cases to  December 1990  are 
64,600  (ALL), 26,100  (HOMO) and 28,400  (IVDU). HOMO: homo-/bisexuals; IVDU:  IV  drug users; 
ALL: all transmission groups combined 
transmission is through IV drug use (Italy, Spain). Both Ireland and Yugoslavia have a 
rather high proportion of IV  drug users among a small total number of cases (21n4 
and 21/65 respectively).  Data from  Austria  were not available  for  analysis,  but the 
rather short doubling time  of 10.9 months estimated from  data reported up to 30th 
June 1988 may also be related to the rather high (25%) proportion of cases among IV 
drug users.  Doubling times are longest (20.4 - 23.2 months)  in The Netherlands, The 
United  Kingdom,  FR  Germany  and Denmark,  in  all  of which  the  homo-/bisexual 
transmission group  is  predominant (>70% cases).  France (15.6 months;  15% IVDU) 29 
Months 
0  IVDU  -HOMO  - ALL 
30 
25 
20 
15 
10 
5 
DEN  NET  FRA  ITA  AUS  YUG 
FRG  UK  SWI  SPA  GRE  POR  IRE 
Fig. 6.  Estimated  average  doubling  times,  in  months,  of diagnosed AIDS  cases  over  the  three  year 
period from January 1986 to December 1988, by country of diagnosis and transmission group, for groups 
with at least 48  reported cases.  No estimation was  possible  for  Norway,  Sweden,  Belgium,  Israel and 
IVDU in FR Germany (see text). HOMO: homo-/bisexuals; IVDU: IV drug users; ALL: all transmission 
groups combined 
and Switzerland (16.0 months; 28% IVDU)  occupy intennediate positions. Due to lack 
of fit  of the model, it was not possible to estimate doubling times  in Norway (where 
incidence has decreased), Sweden (incidence stable), Belgium and Israel. 
Estimated  doubling  times  among IV  drug  users  are  remarkably  similar  (10.4 - 11.6 
months) in five of the six countries with at least 45 reported cases (Italy, France, Spain, 
Switzerland, The Netherlands). In  FR Gennany, adjusted incidence in  this  group has 
decreased since December 1987 and no estimation was possible. Short doubling times 30 
in  cases attributed to heterosexual transmission are noted in Italy  (7.3 months), Spain 
{9.7  months)  and Switzerland {8.2  months),  although the latter estimate  is  based on 
only 63 reported cases. It is understood that the majority of these cases have occurred 
in partners of IV drug users. 
4.  HIV seroprevalence data 
Data on the prevalence of HIV infection are much less comprehensive and much more 
difficult to interpret than data on cases of AIDS. 
In  a  number of  countries,  results  of  HIV  antibody  tests  are  reported  routinely  by 
laboratories,  alternate testing sites  and/or sentinel physicians.  These data can be of 
considerable value in  helping to measure the effects of information campaigns and in 
determining the characteristics of those known to be infected. They are, however,  of 
very limited  value in  the assessment of seroprevalence, reflecting  as  they do merely 
rates among those who, for one reason or another, choose to be tested. 
Numerous surveys and studies which include HIV testing have been carried out in both 
high and low risk populations. Many of these studies were not specifically designed for 
the  assessment  of  seroprevalence  in  the  population  concerned.  Protocols  differ 
considerably and practically all studies are subject to some degree of self-selection bias, 
while demographic and socio-behavioural information necessary for the interpretation 
of  the  results  is  often  missing.  Despite  these  limitations,  it  nevertheless  seemed 
worthwhile to attempt to gather together the considerable amount of such data now 
existing in Europe. 
As  a  first  step,  national  AIDS  surveillance  organisations  were  asked  to supply,  on 
standardized  forms,  basic  details  and  results  of  both  published  and  unpublished 
surveys/studies  known  to  have  been carried  out within  their countries  since  1984. 
Details to be supplied included dates of the study, characteristics of study group, study 
site,  sampling method, number tested,  number positive and source of the data, with 
reference where available.  Data relating to  over 380 studies  were  reported from  28 
countries. The breakdown of these studies  by population group and starting date of 
the study is given in Table 5. After careful validation, these data will form the basis of a 
European data base on HIV seroprevalence. 
While  bearing in  mind the difficulties  of interpretation mentioned above and the fact 
that the  data base  is  as  yet far  from  complete,  some  preliminary  observations  can 
nevertheless be made. 31 
TableS.  Numbers of European seroprevalence studies entered in the Paris data base at 30 Apri11989, 
by population group and starting date of the study 
Group  Starting date: 
<84  84  85  86  87  88  Total 
Blood donations/donors  0  0  17  8  29  9  63 
General population  0  0  3  7  7  2  19 
Haemophilic etc.  0  2  8  8  5  3  26 
Health care workers  0  0  2  2  1  0  5 
Heterosexuals  0  1  4  5  5  3  18 
Homo-/bisexuals  6  6  13  8  8  4  45 
Hospital patients  0  2  1  1  2  1  7 
IV drug users  7  11  23  9  18  13  81 
Military  0  0  3  0  1  0  4 
Pregnant women  0  0  3  6  11  2  22 
Prisoners  0  0  2  0  2  2  6 
Prostitutes  0  1  9  5  4  3  22 
STD patients  1  0  4  9  7  6  27 
Transfusion  0  0  4  1  1  2  8 
Others  0  1  14  7  6  7  35 
Total  14  24  110  76  107  57  388 
HIV prevalence among populations assumed to be at high risk 
Over the period 1984 to 1988, prevalence rates of up to 40% were reported among 
groups of homosexual and/or bisexual men. The highest rates (25%- 40%)  have been 
observed in  major cities  of the northern part of Europe (Table 6),  with slightly  lower 
rates (15%- 25%)  reported from  unpublished studies in  Madrid,  Berlin and Portugal. 
Seroprevalence  among  homosexuals  attending  sexually  transmitted  disease  (SID) 
clinics  in London in 1987 was also estimated (Department of Health Working Group, 
1988)  to be in  the range  15% to  25%,  but the estimated  prevalence  among other 
homosexuals in London and those outside London was much lower (around 5%). The 
few  studies  which  have been conducted outside  large  cities  also  report much  lower 
rates  (  < 10%).  Extensive  testing,  up  to  and  including  1988,  of  homosexual  men 
attending SID clinics in several countries of eastern Europe revealed rates of not more 
than 6%. 
Most  of the studies  among  IV  drug  users  have  been conducted either in  treatment 
centres or in  prisons.  Particularly  high  seroprevalence rates  (40%- 70%)  have been 
reported from France, Italy, Spain, Switzerland and the UK (Edinburgh only). Reported 
rates are intermediate (15%- 35%) in parts of Austria, Denmark, FR Germany, Ireland 
and Yugoslavia,  and  lower  (  < 15%)  in  twelve  other  countries  (Belgium,  Bulgaria, 
Czechoslovakia,  Finland,  Greece,  Iceland,  The  Netherlands,  Norway,  Poland, 
Portugal, San Marino, Sweden). 32 
Table 6.  Highest reported seroprevalence rates among homo-/bisexual men in a number of European 
cities 
Date  City  Site  N  %HIV+ 
1984  Copenhagen  mail  134 
1984-85  Copenhagen  ATS  662 
1984-87  Stockholm  166 
1984-87  Amsterdam  STD  746 
1986  Paris  mail  267 
1986  London  STD  420 
1986  London  STD  212 
1987  London  STD  213 
ATS: Alternate test site; STD: Sexually transmitted disease clinic 
*  Abstract: National Meeting of Swedish Physicians, 1987 
26 
27 
37 
39 
33 
25 
25 
21 
Source/reference 
Melbye et al., 1986 
Kolby et al., 1986 
Sandstrom et al., * 
Van Griensven et al., 1989 
Pollak et al., 1987 
Carne et al., 1987 
Evans et al., 1989 
Evans et al., 1989 
Among haemophiliacs, seroprevalence appears to be highest (around 50% in  1986} in 
France  (Allain,  1986}.  Within  France, observed prevalence rates varied considerably 
between regions  (from  16% to  72%}.  Studies  carried  out at various  dates between 
1984 and  1988 found  rates  of between 25%  and 45%  in  Denmark,  FR  Germany, 
Greece, Italy, United Kingdom and Yugoslavia, and between 5% and 20% in Belgium, 
Ireland  and  Norway.  Rates  below  5%  have  been  reported  from  four  countries  of 
eastern Europe (Bulgaria, Czechoslovakia, Hungary, Poland}. 
Prostitutes  form  a  very  heterogeneous  group.  Their  motivation  for  participation  in 
studies  is  generally  low  and it  is  difficult  to  obtain  representative  samples.  In  some 
countries,  information  has  been obtained  from  registered  prostitutes.  Some  studies 
have been undertaken on the street or in bars etc. Information has also been obtained 
from prostitutes attending SID clinics. The studies which have been carried out suggest 
that prevalence remains  low  (  <2%}  among non IV  drug using prostitutes  in  Europe. 
However,  in  a study in  Amsterdam  (Van  den Hoek et al.,  1988},  83% of 166 female 
drug users reported prostitution and prevalence rates among groups such as this reflect 
rates among IV drug users. 
Seropositivity rates among heterosexual partners of infected persons vary considerably 
according to the risk group of the index case and other characteristics of the couple. 
Two ongoing studies (Johnson et al.,  1988; European Study Group, 1989} in which a 
majority of the index cases were either IV drug users or bisexual men have reported 
male to female transmission rates of 17% (N=60}  (Johnson and Laga, 1988} and 27% 
(N=155}  respectively.  Higher rates  (40%- 58%}  have been reported in  groups with 
significant  African  connections  (Staszewski  et  al.,  1988;  Laga  et  al.,  1988}. 
Comparatively low rates of transmission, 7%  in France (Allain,  1986} and 10% in FR 
Germany  (Kamradt  et  al.,  1988},  have  been  reported  from  haemophiliacs.  These 
observations are consistent with the results of other studies conducted outside Europe 33 
(see Johnson and Laga, 1988; Anderson and May,  1988). The observed differences in 
transmission  rates between different groups may  however be considerably less  when 
risk factors are taken into account (European Study Group, 1989). 
Few  studies  have  been reported  on  HIV  seropositivity  rates  in  non  IV-drug  using 
heterosexuals attending SID clinics. In most cases, the extent to which homo-/bisexual 
men and IV  drug users have been excluded  is  unclear. Studies carried out in  the UK 
suggest that the level  of seroprevalence probably lies  between  0.1%  and 0.5%,  with 
higher  rates  in  the  London  area  than  elsewhere  (Department  of  Health  Working 
Group,  1988).  Rates  in  this  range  are reported from  Belgium,  Finland and Sweden, 
with rather higher rates (up to 3%)  reported from  limited studies in Denmark, France 
and The Netherlands.  Lower rates  are reported from  Norway and from  countries  of 
eastern  Europe.  This  population  represents  one  of  a  number  of  potential  bridges 
between the established high risk groups and the general heterosexual population and 
careful monitoring could provide a sensitive indicator of the spread of HIV. 
HIV prevalence among selected groups of the general population assumed to 
be at low risk 
Blood donations are tested routinely in  all European countries. Among donations (as 
opposed to donors)  screened  in  1987,  HIV  positivity  rates were  highest  (0.03%)  in 
Spain,  France  and  Portugal,  followed  by  Italy  (0.02%),  Switzerland  (0.01 %)  and 
Greece (0.01 %)  (WHO  Collaborating Centre on AIDS,  Paris,  1988). Elsewhere, rates 
did not exceed 0.005%.  Direct comparisons between countries are however not very 
meaningful due to  differences  in  methods of organization of national blood donation 
systems  and to differences  in  the extent of the provision  of alternate test sites.  Most 
countries reported lower rates than in 1986, but this result is also difficult to interpret as 
it  is  related  to  better selection  of  donors  and to  improved  self-deferral  of  high  risk 
donors.  The  screening of  blood donors  is  carried  out in  order to  protect the blood 
supply  and  is  not  designed  for  the  assessment  of  seroprevalence  in  the  general 
population.  Blood  donors  are  not  representative  of  the  general  heterosexual 
population in  a country, nor do they form  a stable population over time, and neither 
prevalence rates nor their changes with time are easily interpreted. 
Results  from  the screening of pregnant women  have been reported by  13  countries. 
Most results  relate to 1987 and/or 1988, although a  few  studies were  undertaken in 
1985/86. Screening was in  most cases by consent (two surveys incorporating unlinked 
anonymous  testing  were  carried  out  in  London).  Refusal  rates  were  stated  for  six 
studies only and were between 0.4% and 8%  in  five  of these, the refusal rate in  the 
remaining study being as high  as  18%. Even low refusal rates can crucially affect the 
outcome of screening programmes intended to assess seroprevalence rates in  low  risk 
populations.  In  only three  countries  (Bulgaria,  Norway,  Sweden)  can the studies be 
regarded as  representative at a national level,  other studies being mostly  confined to 
particular  cities  or  regions.  Reported  prevalence  rates  are  lowest  (  <0.005%)  in 34 
Bulgaria,  Finland,  Iceland,  Norway,  San  Marino  and  the  USSR,  intermediate  in 
Sweden  and  Greece,  and  higher  (0.1%- 0.7%)  in  certain  regions  of  France,  FR 
Germany,  The Netherlands, Switzerland  and The United  Kingdom.  The highest rate 
(0.7%) was observed in a study carried out in the Paris area during 1987-88 (Brossard 
et al.,  1988). Of 28,715 women tested (refusal rate 2%)  over a 17 month period, 218 
confirmed  positive  results  were  obtained  (pers.  comm.).  Among  these,  165 women 
were already known to be HIV  positive, and many of these had been referred to the 
hospitals  in  the  study  for  this  reason.  The  seropositivity  rate  among  previously 
unscreened women was thus 0.2%.  Most  of these  (53)  women reported at least one 
known  risk  factor  for  HIV  infection.  This  study  thus  concluded  that  heterosexual 
transmission in the absence of other recognized risk factors  remained rare in  Paris in 
1987. 
Results  of screening of military  recruits  and/or military  personnel are available  from 
only four countries. Reported seroprevalence rates range from 0% to 0.05%. 
Prevalence of HIV-2 infection 
Infection  with  HIV -2  is  a  problem  of particular  concern  in  Portugal,  where  HIV -2 
seroprevalence rates  similar to or greater than those for  HIV-1  were  observed in  a 
1987  study  of  prostitutes  attending  an  STD  clinic  in  Lisbon,  in  the  screening  of 
pregnant women with risk factors  (1987/88),  in Africans  requesting testing (1987) and 
in  heterosexual contacts of infected persons  (1986-88).  Infection among homosexual 
and bisexual men and among IV drug users is,  on the other hand, almost exclusively 
with HIV-1. 
Very little  data is  available from  other European countries. However, a study carried 
out in  1987 (Courouce et al.,  1988) suggests that HIV-2  infection in  France remains 
uncommon. Among a sample of 100,114 blood donors, 30 of whom tested positive for 
HIV-1,  no sample  was  confirmed  as  positive  for  HIV-2.  Among  a  total  of  10,004 
persons requesting HIV testing, 713 (7.1 %)  were HIV-1 positive, while 9 (0.09%) were 
confirmed  as  positive  for  HIV-2  (eight  of  these  cases  were  directly  or  indirectly 
connected with  West Africa,  the other being  a transfusion  recipient).  It thus seems 
probable that,  Portugal excepted,  HIV-2  infection  rates remain very  low  throughout 
Europe. 
Incidence of HIV infection 
Several recent studies, in  particular in  the UK  (Came et al.,  1987; Evans et al.,  1989) 
and in  The Netherlands (Van  Griensven  et al.,  1989), suggest that incidence among 
homosexual men has been falling since at least 1985. A similar evolution, due largely 
to changes in behaviour, is believed to be occurring in many other countries. 35 
In  general,  however, incidence,  as  opposed to prevalence, rates of HIV  infection  in 
specific  population  groups  are  extremely  difficult  to  assess,  particularly  in  low 
prevalence  populations,  and  most  of  the  available  data  are  inadequate  for  this 
purpose. Many of the data were collected with other purposes in mind (e.g. protection 
of the  blood  supply,  assessment  of  risk  factors)  and,  although,  in  some  countries, 
reported prevalence rates in  certain groups are reported to have declined over time, 
probable  unquantified  changes  in  the  nature  of  the  (often  self-selected)  samples 
studied make interpretation hazardous. 
Monitoring  the  future  spread  of  HIV  infection,  particularly  in  the  low  prevalence 
sectors of the population, will require carefully designed, large scale surveys sustained 
over several years.  Unlinked  anonymous screening  (UAS)  provides the possibility  of 
removing self-selection biases, thus improving the accuracy of estimation of incidence 
rates in  the selected populations. Surveys which continue to rely on named testing of 
volunteer subjects will almost certainly be flawed by changing attitudes of both subjects 
and professionals in consenting to the test. 
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At present AIDS is still a minor cause of death in France, despite the fact that it is the 
second country in  the world  in  terms  of numbers of cases  notified.  However,  in  the 
next few  years, its  impact on demography may well be of importance because of two 
obvious reasons:  First,  the number of  cases  has gradually  increased and, before the 
discovery of an efficient treatment, the number of deaths will  follow  the same trend. 
Secondly, AIDS  is  a cause of death which,  like  motor vehicle crashes, kills  selectively 
young people:  only 19% of the 4,887 cases of AIDS  in  men which were notified by 
December 31,  1988 to the General Department of Health  (Direction  Generate de  Ia 
Sante)  in  France were  over 45,  while  the figures  were 95.6% for  cancer,  97.3% for 
cardiovascular diseases, 59% for suicide. 
Quantitative  estimates  of  the  likely  AIDS  impact  in  France  on  two  demographic 
indicators, loss of life  expectancy (UE) and potential years of life  lost (PYLL)  in men, 
were provided in  1987 for the 1988-1990 period, assuming that the number of cases 
would continue to increase exponentially (Randre and Valleron, 1988). There is  now 
evidence that the annual incidence is  slowing down and this paper will  provide new 
estimates  for  the  1989-1991  period  which  will  be  compared to  the  corresponding 
values presently observed in  six causes of death:  cancers, diseases  of the circulatory 
system, infectious diseases, alcoholic psychosis, suicides, motor vehicle crashes. 
Material and methods 
The  causes  of  death  which  are  considered  in  this  paper  are:  AIDS,  cancer 
(International Classification of Disease numbers  (lCD),  9th revision,  ranging between 
140 and 208), diseases of the circulatory system (lCD 390 to 459), infectious diseases 
(lCD  1  to  139),  alcoholic  psychosis  (lCD  291-303),  suicide  (lCD  950-958),  motor 
vehicle crashes (lCD 810-819, 826-829). 
The computation of the loss of life expectancy due to a cause of death requires the age 
distribution of the population and the number of deaths by age for  all causes and for 
the considered cause. The computation of the potential years of life lost requires only 
the latter.  The age  distribution  of the male  French population which  is  used in  this 
paper is  that of  1985 as  provided  by  the  Institut  National  de  Ia  Statistique  et des 
Etudes Economiques (IN SEE). 39 
The year by year estimation of the number of deaths by AIDS  in  each age class  has 
required several steps.  Indeed, we need this  information for the years 1989 to 1991. 
However, the 1989 values are not available and projections are necessary to forecast 
the 1989, 1990 and 1991 figures.  The first  step of the estimation used the incidence 
data published  by  the  French  General  Health  Department  from  June  1,  1984 to 
December 31, 1988. In the second step we computed corrected incidences taking into 
account the delay of notification of the cases according to the method provided by 
Downs et al.  (1987).  At this  point, we  had estimates of the incidence till  the end of 
1988.  To  get  estimates  of  the  incidence  till  1991,  we  performed  a  linear-logistic 
regression. The estimated annual incidence for the years 1989 to 1991 are presented 
in Table 1. Finally, the predicted distribution of the number of male cases in each age 
class was obtained by applying the sex and age distribution observed by December 31, 
1988 (Direction Generate de Ia Sante, 1989) to these annual incidences. 
In the third step, we deduced from  these values the expected number of deaths in the 
next  years.  To  describe  the  duration  of  the  disease,  we  apply  an  exponential 
distribution of mean 1.14 year supplemented by a 8% probability of zero survival time 
(Reeves, 1988). 
The computation of the loss of life  expectancy due to a given  cause (e.g.  AIDS)  was 
done by the standard techniques of life  table  and mortality  analysis  (Chiang,  1978) 
where mortality statistics were those published by the Institut National de Ia Sante et 
de Ia Recherche Medicate (INSERM) for the year 1985. The loss of life expectancy due 
to a cause is defined as the difference between the observed expectation of life at birth 
and  the  one  that  is  expected  under  the  assumption  that  the  disease  has  been 
eliminated as a risk of death. Independence between causes of deaths is assumed. For 
each cause of death, the number of Potential Years of Life  Lost (PYLL)  is  computed 
(Romeder and McWhinnie, 1978) modifying each death at a given age (older than 1) 
by the difference between 65 and this age. The percentage of potential years of life lost 
associated with a cause is computed by dividing the total numbers of PYLL due to this 
cause by the total number of PYLL due to all causes. 
Table 1.  Estimated annual incidences and confidence intervals (C.I.) 
Year 
Incidence 
C.I. 
1989 
4295 
(3205-5384) 
1990 
5245 
(3797-6693) 
1991 
6035 
(4108-7%2) 40 
Results 
Assuming a constant sex-ratio, the linear-logistic model provides  estimates of annual 
AIDS incidence in men of 3,650 in 1989, 4,460 in 1990, 5,130 in 1991. The expected 
numbers of deaths by AIDS are 2,727 in 1989, 3,610 in 1990, 4,385 in 1991. The loss 
of  life  expectancy and the percentage of potential years of  life  lost  associated with 
AIDS in  1989 and 1991 together with their corresponding values for the other causes 
of death (1985) which we have considered are presented in Table 2. 
Whatever the indicator used,  AIDS  represents  a cause of death whose demographic 
impact is  smaller that the one associated with  cancer, motor vehicle crashes, diseases 
of the circulatory system  or suicide.  But even for  1989,  AIDS  is  a  greater cause of 
mortality than all the infectious diseases. Projections for 1991 emphasize this tendency; 
at that time AIDS  could have an impact of the same order of magnitude as  the one 
associated with suicide. 
Discussion 
The two demographic indicators we have used in this paper are and have been widely 
used to assess the impact of various causes of death on the population. The Centers 
for Disease Control (CDC)  - for  instance- regularly provides estimates of PYLL  in  its 
Morbidity  and  Mortality  Weekly  Report  (MMWR).  The  results  we  present here  are 
based on estimated values of the numbers of AIDS  cases and numbers of deaths. The 
security of our estimations relies on the fact that we  make short term predictions. The 
Table 2.  Demographic  impact  of  AIDS  compared  to  six  other  causes  of  death  (France,  male 
population). For AIDS, number in parentheses indicate the 95% confidence interval  of the estimates. 
LLE stands for loss of life expectancy and PYLL stands for potential years of life lost. For all causes 
(except AIDS) LLE and PYLL are based on the 1985 vital statistics 
Cause of deaths 
AIDS: 1989 
AIDS: 1991 
Suicide 
Motor vehicle 
crashes 
Cancer 
Diseases of the 
circulatory system 
Infectious diseases 
Alcoholic psychosis 
lCD No. 
950-958 
810-819 
826-829 
140-208 
390-459 
1-139 
291-303 
LLE (years)  PYLL(%) 
0.24 (0.16-0.32)  5.5 (3.8-7.3) 
0.39 (0.27-0.5)  8.9 (  6.3-11.5) 
0.61  11.0 
0.65  15.0 
3.84  21.9 
4.11  13.1 
0.16  1.2 
0.14  1.7 41 
curve for empirical forecasting chosen is the linear-logistic. Predictions made under this 
model are  optimistic,  relative  to  other types of mathematical curves  (Department of 
Health Working Group, 1988). In  the initial stages of the epidemic, future cases were 
predicted by  using  an exponential model.  The  demographic  impact of  mortality by 
AIDS  based on these estimates was therefore greater (Flandre  and Valleron,  1988). 
Even with the present extrapolations, AIDS  impact in France between 1989 and 1991 
on the two demographic indicators studied in men is  considerable. While there may be 
a certain amount of imprecision in the figures we present - and this  is  documented by 
the confidence intervals provided in Table 2 the general tendencies we found will very 
likely be observed. 
Conclusion 
Because  AIDS  kills  selectively  the  young  people,  its  demographic  impact  is  not 
negligible even in 1989 when it  is compared to causes of death like infectious diseases 
or alcoholic psychosis. In 1991, AIDS will likely have a demographic impact in terms of 
loss  of life  expectancy and of potential years of life  lost close to those of suicide and 
motor vehicle crashes. 
AIDS  is  becoming a cause of death which lowers the life  expectancy, a criteria whose 
continuous increase in  most countries bears witness to improved health programmes, 
and is  responsible for a significant percentage of potential years of life  lost between 1 
and 65 years. 
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J. Santos Lucas 
The AIDS  epidemic is  an evolving phenomenon. Instead of one epidemic, we ended 
up with a set of epidemics: the HIV epidemic, the AIDS epidemic, and the epidemic of 
fear.  It  started  as  a  medical  problem  and  was  converted  into  a  multidimensional 
process.  Ethical,  political,  social,  managerial,  and  economic  issues  emerged  in 
connection with it. 
Rational  decision  making  has  been  confronted  with  a  large  variety  of  value 
implications. Clinical reasonings, as well  as planning the allocation of resources, have 
to deal with different perceptions, conflicting demands, and pressure group politics. 
In this  paper we try to stimulate health planners, health economists and health policy 
makers to go through different matters and assess their social and economic aspects. 
AIDS and the HIV infection in the policy agendas 
At the begining of this decade there was some resistance, even in WHO, to accept that 
a  new  epidemic was  emerging.  It took some  time  for  the  WHO  to  adopt specific 
policies with regard to the HIV epidemic and to take action. 
Governments gave, and some are still  giving, a halfhearted response to the epidemic. 
They were  unwilling  to go  ahead with  any kind  of political  decisions.  This  attitude 
might  be associated  with  several  factors,  among them  with  the  perceptions  of the 
policy actors. In the developed world, AIDS was initially perceived and conceptualized 
as a disease resulting from abuse of sex and sex deviance, as a result of casual sex and 
homosexuality. As  the disease used to be regarded as specific to marginalized groups, 
it was perceived as not posing a threat to the whole population. Therefore, AIDS issues 
got little attention and were introduced very slowly into the policy agendas. 
In  the  meantime,  some  changes occurred  within  the AIDS  policy  community.  New 
policy  actors  were  involved  in  promoting,  formulating,  and  implementing  AIDS 
policies.  Gay  leaders  may  be singled  out  as  the  first  "intruders".  In  the  USA,  the 
Centers for Disease Control Task Force initiated and maintained constant consultation 
with  gay  groups.  In  most  European  countries,  Canada  and  Australia,  the  gay 
movement  was  officially  r_ecognized  in  government  dealings  with  AIDS  matters. 
Haemophiliac' s  associations  were  very  active,  putting  pressure  on  governmental 
decision-making related to blood quality control. 44 
To  the extent that the epidemic crosses  sexual boundaries  and becomes more and 
more prevalent among heterosexuals and children,  and among every segment of the 
productive society,  it  is  likely  that other social leaders  will  commit themselves to the 
AIDS  struggle  and  get  involved  in  policy  making.  We  are  already  seeing  family 
associations, community leaders, medical and other health professional's associations, 
unions and employer's associations  debating the  implications  of AIDS  for their own 
lives and organisations. 
The integration of representatives of infected people, AIDS  patients, and those social 
groupings just referred to, in  National Committees on AIDS  is  likely to improve their 
effectiveness.  It is  expected that very  shortly  every  country in  Europe will  have an 
explicit and consistent set of AIDS  policies, with clear objectives, principles, measures, 
programmes and activities. 
Conflicting demands 
The  AIDS  epidemic  puts  many  demands  in  conflict,  such  as  prevention  versus 
treatment,  general  or  segmented  approaches,  priority  groups,  dominance  of  the 
medical profession or combination of volunteer and community care. 
To give  an example,  in  USA  and in  many countries of Europe, it  is  anticipated that 
drug use will become, in the coming years, the principal route by which the HI  virus 
will be transmitted. Which priority should be given to drug rehabilitation programmes 
as a consequence of that fact is a matter of policy choice. 
Private  and  public  expenditures  in  caring  for  AIDS  patients  are  nsmg.  Alternative 
models  of  caring  for  AIDS  patients  may  produce  different  outcomes  and generate 
different cost estimates. If there is  not sufficient empirical evidence to support different 
options,  personal  judgement  is  likely  to  be  called  upon.  This  happened  to  me, 
sometime ago, when I had a meeting with some doctors in order to discuss a project to 
support  AIDS  patients  that  were  excluded  from  their  families.  Within  this  project 
alternative housing,  emotional and practical support and transportation to  and from 
the hospital  would be provided. Some of the participants,  however,  claimed  that a 
special  hospital  would  do  a  better  job  for  these  patients.  The  weakness  of  the 
discussion  rested  with  the  fact  that both  solutions  were  based  on  different  belief 
systems more than in sound evaluation. 
Whether AIDS prevention should be considered a public good, is a matter of dispute. If 
so, one could advocate preventive programmes to be fully  financed by governments. 
Yet,  could  we  hold  that  condoms  should  be  provided  free?  What  would  be  the 
expected social costs and benefits, and the economic costs of this option at national or 
regional level? 45 
Screening 
Screening is not a consensus issue but one that prompts a lot of controversy. A couple 
of years ago, mass screening was  mentioned but very quickly rejected. In  these days 
no one believes in  the usefulness  and economic feasibility  of regulary screening the 
general population with regard to the HIV antibody. However, some specific forms  of 
universal screening could be defensible, such as universal premarital screening. Should 
it be enforced? What are the expected costs and benefits of such a decision? The same 
questions could be raised with reference to mothers-to-be and their newborns. 
There are special situations and special groups that could be submitted to mandatory 
screening. It is  well  accepted that blood donors must be tested at the point of entry. 
However, should specific workers, such as health professionals, pilots or bus drivers, be 
screened periodically? What are the advantages and disadvantages? Many admit that it 
should  be  enforced  that  prostitutes  be  screened  periodically.  How  effective  this 
programme could be remains to be seen, too. 
Informed consent and mandatory counselling 
Although  informed  consent  is  already  a  common  practice  in  many  places  where 
mandatory  screening  and  testing  are  performed,  it  is  not  yet  universal.  Should 
informed  consent  be  mandatory  whenever  individuals  are  tested?  Should  policies 
regarding informed consent be adopted in  blood institutes,  health centres, clinics  and 
hospitals before testing? 
Disclosure  of a  test  result  has  many  implications,  particularly  at psychological  level. 
Therefore it may be pondered whether pre- and post-test counselling be mandatory as 
a prerequisite for testing. If so, costs of testing should take account of the adoption of a 
mandatory  counselling  policy  and  its  expenses.  In  some  cases,  counselling  will  be 
provided by psychologists or social workers,  in  others by volunteers. More frequently 
GPs have this  responsibility.  Different models  of counselling provision have different 
cost implications to be taken into account. 
Confidentiality 
The individual right to privacy prevents disclosure  of any kind  of information  about 
test results.  However, public health values conflict with the right to privacy whenever 
someone puts others at direct risk.  Accordingly,  Daniel Koshland  has challenged the 
idea  of  keeping the  information  of  seropositivity  secret. 
11Should  confidentiality  be 
preserved at any cost?
11
,  he asks. 
11What is the responsibility of a physician in informing 
spouses and children, to say nothing of others who might become infected?
11 46 
If confidentiality is to be broken, counselling should be provided to support the person 
in revealing his or her health status. Yet, he or she may refuse or avoid it. 
Infected prostitutes may be an even worse case for  concern. Similarly,  infected drug 
addicts who involve themselves in transmitting the virus deliberately, may give grounds 
for  disclosure  of their condition.  What kind  of  policies  and programmes should be 
adopted  and implemented  regarding these  two  groups  of the  infected  population? 
What are the alternatives and at what cost? 
Connected with  the disclosure of the seropositivity status is  contact tracing.  Through 
this  measure  anyone potentially  at risk  is  contacted  in  order to reduce  his  or her 
probability  of  (re)infection  and  to  contain  the  spread  of  the  disease.  Again,  the 
acceptability of mandatory contact tracing for infected people is a matter of debate. 
Discrimination 
Confidentiality mingles with discrimination issues. Should a doctor reveal test results to 
an insurance company? Concurrently, should society allow an insurance company to 
discriminate  and refuse  an  HIV  infected  person to  subscribe to an health  insurance 
policy? The financial consequences of such decisions are obviously very important for 
the individual as well as for the whole society. 
Discrimination at the work place is  another complex issue, with great implications for 
both the employees and the management of companies. Firing HIV infected people is 
less likely than firing AIDS patients. Some countries have already started to oppose this 
behaviour.  In  the  USA,  the  Rehabilitation  Act  is  now  protecting  AIDS  victims  and 
seropositives.  A policy  statement was  issued  by  the  US  President requiring  federal 
employees to treat HIV  infected employees on a case-by-case basis in  evaluating job 
performance,  health  and  safety  factors,  just  like  any  other  employee  for  other 
purposes. 
How much protection from the law does any infected person have in order to rule out 
discrimination in hiring procedures? If the epidemic grows more serious, as is expected, 
what may the impact on the economy as a whole and on the financial stability of some 
companies be? 
Discrimination in  the education system  has been observed. Seropositive children are 
facing  enormous difficulties  in  many places to pursue their studies. These vulnerable 
children from vulnerable families  are getting into even more precarious situations. The 
result  is  not  only  human  suffering  but a  new  burden  to  society.  Landlords  and 
neighbours are also a source of discrimination. Cases of eviction have been reported. 47 
Discrimination also takes place in health care systems. Some doctors avoid performing 
surgery in infected patients. Some nurses avoid direct contact with them and quit jobs 
in hospitals that treat AIDS patients. How to reverse this trend? What kind of incentives 
to put at work? 
AIDS  is  still  a  stigmatized  disease.  Education  and counselling  of those  involved  in 
discriminative behaviour would stimulate a change in  attitudes and behaviours, but at 
a certain cost. 
Social implications 
Seropositives and AIDS  patients go through a course of disruptive events. On top of 
their  infection  or  disease,  some  will  experience  light  or  severe  psychological 
imbalances, isolate themselves or be excluded from their social networks. Their family 
structures or stable sexual relations are likely  to be ruined. They will  have to rebuild 
their sexual networks at a time of low morale. They would benefit from being involved 
in  leisure activities which could help them in  buffering stress factors.  This can also be 
costly. Yet, they are more likely to be absent from work, to be fired,  not to be hired, to 
see a reduction of earnings, to have more medical and pharmaceutical bills to pay. As 
a result of separation many will  need a new place to live,  without having very much 
money available to pay for it Financial insolvency is expected. 
Community-based groups have been at the forefront of the fight against AIDS. Should 
or should  not funding  be provided to community-based groups to care for  infected 
people and AIDS  patients,  to provide  counselling,  emotional  and practical support, 
and to provide housing?  Should or should not funding be provided to community-
based groups to train counsellors, educators, and home helpers? Should or should not 
volunteer work be strengthened? Should professional work replace volunteer work in 
AIDS prevention? Will professional work be sufficient to face the needs? 
Concluding remarks 
These are just a few  of many social  and policy  issues that we  are now facing while 
coping with  this  deadly  disease.  It  is  important to  have economic measures  of each 
alternative, related to each type of action, either to preventive care or palliative cure. 
Nevertheless,  decisions  are  marginally  determined  by  those  quantifications.  To  be 
effective, planners and economists should work with policy actors, inside and outside 
government. Their contribution is  likely to be of great importance in winning the war 
against AIDS. 48 
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Introduction 
This paper tries to set up a conceptual framework which would allow us  to place the 
different  possible  economic  approaches  to  AIDS  and  HIV  infection  into  a  broad 
perspective and to discuss the potential usefulness and limitations of these approaches. 
"Economic aspects" and "economic approaches" are very loose expressions, which may 
have different meanings to different people. Therefore, for the purpose of this paper it 
seems  advisable  to  start  by  trying  to  define  their  content  and  boundaries.  An 
enlightening  starting  point  to  this  discussion  is  the  distinction  made  by  Williams 
between a topic - i.e. area of study - and a discipline - i.e. mode of thinking (Williams, 
1979). 
Economic analysis  is a discipline which can be applied to the study of the economy -
i.e.  the economic system  -,  a topic whose boundaries are conventionally defined  as 
embracing  those  phenomena  of  society  that  are  related  to  resources,  wealth, 
consumption, production,  distribution,  and so on;  but the tools  of economic analysis 
can and have been applied  to  other topics,  which  fall  clearly  outside  what people 
usually  include  in  the  substantive  meaning  of  "the  economy":  criminal  behaviour, 
marriage or health are examples of topics which have also been the focus of economic 
analysis. 
Health Economics can be defined as  the application of the discipline  "economics" to 
the topics "health" and "the health system". In the same line of reasoning, the economic 
effects of AIDS and HIV infection can be thought of as the application of "economics" 
to these specific sub-areas within the broader area of "health". 
The rest of this paper is divided into two parts: 
The first part will focus on substantive aspects, i.e.  on the areas of study which should 
be considered in  applying economic analysis to  AIDS  and HIV  infection. The second 
part will  consider the analytical tools of economics which can be applied to the study 
of AIDS  and HIV  infection  and their impact  on the economy  and the society  as  a 
whole. 50 
Areas of study in the economic analysis of AIDS and HIV infection 
The effects  of AIDS  and HIV  are not limited  to health and to the health sector,  but 
spread  out  through  most  aspects  of  the  economy  and  the  social  system,  which 
therefore need to be taken into account in  the analysis. Well-being,  however broadly 
or narrowly it may be defined, is another topic to be considered, for it has traditionally 
been one of the basic concerns of economic analysis, especially in normative, but also 
in positive analysis. Within positive economics, human behaviour is  usually explained 
by supposing that people are always trying to attain a maximum level of well-being. In 
normative  economics,  the maximization  of well-being  is  explicitly  the final  objective 
that justifies the conclusions drawn from the analysis. 
Our  review  will  therefore  proceed  from  the  six-area  scheme  outlined  in  Fig.  1, 
accepting the relative arbitrariness of the resulting framework1). AIDS can affect and be 
affected directly and indirectly by factors pertaining to any of the five  remaining areas. 
The resulting set of relationship will be taken as the classification criterion. 
SOCIAL SYSTEM  I  ~ ----------------- > I  WEll-BEING I  < 
~---E_c_o_N_o_M  __  Y  ____  ~I<----------~  HEALTH 
I  II 
HEALTH sEcroR  I  _< ____________  >  1~.....--_AID  __  s  __  .....~ ---~ 
Direct effects  > 
Indirect effects -------> 
Fig. 1.  The economic aspects of AIDS: main areas of study 
1)  AIDS may alternatively be included in the area of health and health in that of well-being. Similarly, 
the health sector is part of the economy, which in turn is part of the social system. In the proposed 
scheme, the social system is assumed to exclude the economy, and the economy to exclude the health 
sector; moreover, AIDS, health and well-being are conceptualised as separate entities. 51 
Effects of AIDS on health 
With AIDS being a disease, it is obvious that its existence and spread mean a reduction 
in  health in  the form  of reduced life  expectancy and quality of life  to those suffering 
from  the  disease.  The  high  mortality  rate  associated  with  AIDS  as  well  as  the 
irreversibility  and  severity  of  the  disease  have  a  significant  demographic  impact, 
especially among the high risk groups,  which  in  tum will  have indirect effects on the 
health sector and on the economy as a whole, e.g., changes in the utilization of health 
services and in productivity. 
However, indirect positive effects of AIDS on health are also likely,  measures aimed at 
preventing AIDS transmission will probably reduce the incidence of other transmissible 
diseases  like  Hepatitis B or SID (Sexually Transmitted Diseases).  Likewise,  the high 
incidence of AIDS among IVD  (intravenous drug)  users,  coupled with the low survival 
rates of those contracting the disease, may result in the reduction of drug addiction as 
a public health problem. 
These kinds of benefits are usually neglected when estimating the costs of AIDS. 
Effects of health on AIDS 
A high  prevalence  of  IVD  addiction  is  a  factor  enhancing the spread  of the AIDS 
epidemic. At the individual level, the presence of some SID seem to increase the risk 
of sexual transmission of the HIV. 
Effects of AIDS on well-being 
AIDS,  like  any other disease, is  a source of pain and distress not only for the patients 
but also for their relatives and friends. The loss of well-being is a result not only of the 
physiological but also of the psychological and social consequences of AIDS,  such as 
the stigma and discrimination associated with the disease. 
Loss of well-being also reaches healthy individuals who fear the likelihood of contagion 
and are induced to restrict their behaviour, especially, their sexual behaviour. 
Societal  well-being  is  also  indirectly  affected  by  a  reduction  of  resources  which, 
because they need to be diverted to AIDS, are no longer available for other ends. 
Effects of AIDS on the health sector 
AIDS  increases  the requirements  of health  care resources.  These resources  must be 
detracted from other uses within the health sector, or obtained from outside it,  in order 
to be  allocated  to  the  personal  care  of AIDS,  ARC  and  HIV  patients.  Preventive 
measures not directly involved in treating AIDS patients, include the screening of blood 52 
donations,  the generalization  of the  use  of rubber  gloves  by  health  personnel,  and 
general  preventive  activities  undertaken  by  the  health  sector  such  as  information, 
health education, etc. 
The premature death of most AIDS  patients means a reduction in their future general 
health  care  consumption.  Moreover,  there  seem  to  be  other effects  on  health-care 
resource availability:  some people are less  willing  to consume blood products, while 
the number of blood donations may rise as a result of the added inducement, to some 
individuals,  of  a  free  HIV  test.  (However other people may be reluctant to  donate 
blood out of an irrational fear of contracting AIDS.)  Autologous transfusion may rise 
because of people trying to avoid any possibility of transmission by blood transfusion. 
AIDS  may  also  change  the  attitudes  and behaviour of  health  personnel,  who  may 
refuse to treat AIDS and HIV patients or even risk groups, or at least may ask for safer 
working conditions or higher salaries. 
AIDS can affect the behaviour of health care insurers, especially private insurers, who 
may refuse  to insure  AIDS  treatment costs.  The  unwillingness  of private  insurers  to 
cover these  risks  may  induce  the  public  system  to  take  up  the  coverage  of  AIDS 
treatment. The final outcome could be a change in the public-private mix,  maybe with 
far-reaching consequences. 
The  high  cost  of  AIDS  treatment  can  induce  the  setting  up  of  new  cost  control 
mechanisms, which may later be applied to other activities. This seems to have been 
the case of zidovudine prescription control in Spain, which may be extended to other 
drugs in the future. 
Effects of the health sector on AIDS 
The amount of resources devoted to AIDS will  depend in part upon the ability of the 
health sector to attract new resources or redeploy the existing ones. 
Although the interventions of the health sector have had, up to now,  only a limited 
impact  on  the  natural  course  of  the  disease  at  individual  level  once  the  virus  is 
transmitted, there is a wide scope for influencing the spread of the epidemic by means 
of preventive measures, as well  as  for  mitigating the effects  of AIDS  on the patients' 
well-being. 
The effects of AIDS on the economy 
Insofar as the resources devoted to AIDS are not diverted from  other health activities, 
the result will be a reduction either of public or private expenditure, or both, for other 
activities. 53 
However, some industries providing medical and paramedical goods (pharmaceutical 
industry,  condom  production)  will  increase  their  output,  investment  and  research 
activities. 
The  mortality  and morbidity  of AIDS  will  cause  productivity  losses,  which  may  be 
relatively high in comparison to other diseases because of the relatively low age of the 
individuals affected. This effect may be counter-acted by the probably low activity rate 
of some of the main risk groups, e.g., IVD users. 
AIDS  will  pose important resource requirements on the public and voluntary welfare 
services  - especially  personal  social  services  - and  on  income  maintenance 
programmes, such as sickness  subsidies.  However,  as  in  the case of health services, 
some future expenditures (e.g., pensions) will decrease due to early mortality. 
Life insurance is one of the economic activities that may experience the biggest impact. 
The insurers will  undergo unexpected losses  and may try to discriminate against HIV 
carriers and even against high risk groups, by denying them insurance or by setting up 
high premiums which may be impossible for  many individuals to afford, thus leaving 
them without coverage. Here again, a response by the public sector may come up to 
compensate for the withdrawal of the private sector. 
Tourism to areas with  a  high  prevalence of AIDS  may go  down;  where tourism  is  a 
relatively  dominant  activity,  this  can  generate  acute  economic problems  for  whole 
areas. 
Prostitution will probably decrease as long as it is perceived to be a high risk activity. A 
similar  trend  may  occur  in  the  illegal  IVD  market,  as  a  result  both  of  changes  in 
behaviour and of reduction in the population involved in this market due to mortality. 
Effects of the economy on AIDS 
The main effects under this heading probably follow an indirect path, on the one hand 
via  the  amount of  resources  which  can  be allocated  to  the  health  sector  and,  in 
general, to preventive actions and, on the other, via  lifestyles,  educational levels  and 
attitudes associated with income and wealth. 
Effects of AIDS on the social system 
It is  apparent that AIDS  is  changing social values and attitudes towards some types of 
behaviour, patients and risk groups. The degree of acceptability of homosexuality and 
drug addiction,  sexual freedom,  intimacy  and  individual rights  may be some of the 
areas where AIDS can produce far-reaching changes. 54 
Effects of the social system on AIDS 
The  extension  of  some  types  of  sexual  behaviour  is  probably  the  prime  factor 
influencing the spread of AIDS.  Moreover, the attitudes of society towards the sick and 
the risk groups will  influence societal responses, such us  a  commitment to preventing 
AIDS,  acceptance or discrimination of those affected, which will  have a clear effect on 
the development and consequences of AIDS. 
Economic approaches to AIDS 
One article in this volume presents an overall view of a worldwide literature survey and 
a  European  project survey  on  the  economics  of  AIDS  undertaken  by  the  MEDIS 
Institute,  which  allows  us  to  draw  some  conclusions  as  to  the  pattern  of  research 
activities in this field  (Schwefel, this volume): 
1.  The cost of AIDS  is the topic that seems to attract most attention. However, most 
studies deal only  with  hospital  cost.  The financing  of expenditure  on AIDS  has 
attracted some attention in  the USA where, given the limited public coverage, the 
financial  consequences  of  AIDS  can  be  very  disruptive  for  patients  and  their 
families. 
2.  A lot of work has also been done in the area of projecting the future development 
of AIDS, but so far these studies have had limited or no economic content. 
3.  There  are  few  "truly"  economic  studies,  like  cost-benefit  or  cost-effectiveness 
analyses,  or  other  types  of  approaches  focusing  on  efficiency  or  resource 
allocation problems related to AIDS. 
To  evaluate the  relevance  and priorities  to be attached to the  different topics  and 
methodologies which have been or can be applied in the economic studies of AIDS,  it 
is  important to consider their usefulness  and the objectives they try  to attain.  These 
objectives are rarely explicit,  and many studies seem to have been carried out mainly 
to  show  the  magnitude  of  the  burden  of  AIDS  on  society,  which  can  provide  a 
justification - however fallacious - of the need to devote more resources to the different 
activities  - prevention,  treatment,  or  research  - related  to  AIDS.  Of  course,  these 
activities should be advocated on the basis of their ability to reduce that burden or to 
attain  health  policy  objectives.  The  proper  economic  approach  to  assist  decision 
making in  these matters is the economic evaluation of the programmes or alternatives 
designed to reduce the disease, not the total burden of the disease. 
Cost studies can be seen as a first step towards evaluative or projective studies, which 
can be useful tools in planning and decision making. Cost studies can also be carried 
out with the objective of setting up reimbursement fees for health care providers or to 
more specific ends. But if they are to serve these purposes, the costs computed should 55 
refer to individual patients and, optimally, to the lifelong flow  of costs generated by an 
HIV  or AIDS  patient.  Aggregated  costs  at the  level  of  institution  or region  do  not 
provide any useful starting point for evaluative or projective studies. 
Another  important  issue  to  consider  is  the  range  of  costs  which  are  relevant  for 
decision making. Economists have tended to develop their own rules and procedures 
for defining, measuring and valuing costs. The net social cost - or opportunity cost - is 
probably the most favoured cost concept among economists, because of its foundation 
on  welfare  theory,  but it  may  not  be the  prime  concern  of  decision  makers  and 
planners. Intangible effects which are often quoted but seldom estimated in  economic 
analyses may well play a major role in the case of AIDS decision making. 
Productivity losses, an increasingly criticized but still the most usual way of quantifying 
indirect costs, may be especially unsuited to the evaluation of AIDS policies, as there is 
a varying but, in some countries,  large number of AIDS patients who are not labour-
active. 
One example can illustrate the lack of tuning between economic analysis and decision 
making.  A study on the cost-benefit  aspects of AIDS  prevention  (Ochi  et al.,  1987) 
concluded that systematic screening of blood donors for HIV was not justified in Japan 
on economic grounds. Shortly after its publication, the measure was enforced (Lee and 
Moss, 1987). 
Conclusions 
The main contributions of economic analysis to decision making in  the field  of AIDS 
can probably be found in one of the following areas: 
1.  Projecting future  needs or resource  requirements within  and outside the  health 
sector. 
2.  Foreseen  changes  in  specific  markets  or  sectors  - e.g.  life  and  health  care 
insurance, labour markets, etc. 
3.  Evaluating alternative  courses  of action  within  and outside the health  sector in 
order to prevent, treat and reduce the negative effects of AIDS  on the welfare of 
society. 
To  attain  a  higher  credibility  and,  hence,  effectiveness  economic  analysis  should 
probably: 
1.  Adopt broader approaches, which does not mean to give  up the traditional ones, 
but to  enlarge them with new dimensions and perspectives which  are felt  to be 
relevant by society and decision makers. 56 
2.  Collaborate  closely  with  other  disciplines  - health  and social  sciences  - to  take 
advantage  of  the  complementarity  of  their  different  points  of  view  and 
methodologies. 
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Social Support Systems The US Hospital AIDS Survey: Structure and Substance 
D.P. Andrulis 
The U.S. hospital AIDS survey: structure and substance 
Acquired Immune Deficiency Syndrome (AIDS} throughout the 1980s has evolved into 
a formidable challenge for the health care systems of the affected countries. While the 
spectrum of health care providers are or will be involved with treating the individuals 
afflicted with this condition, it is  the hospital sector that represents the primary if not 
only source of treatment for so many people with AIDS. 
In 1986 and again in 1988, the National Public Health and Hospital Institute (NPHHI) 
developed and disseminated  national surveys  on  hospital care  for  patients afflicted 
with  AIDS  in  the  United  States.  The  first  survey  requested  1985  calendar  year 
information from  4.65 members of two hospital associations: the National Association 
of Public Hospitals, which  represents primarily large  city,  publicly  owned or publicly 
subsidized institutions,  and the Association of American Medical Colleges'  Council of 
Teaching Hospitals,  which  represents  major public  and private  teaching  institutions. 
The  1988 version  requested  similar  1987  information  from  members  of  these  two 
associations  as  well  as  institutions  represented  by  the  National  Association  of 
Children's Hospitals and Related Institutions and the National Council of Community 
Hospitals, bringing the total number of participating facilities to 623. Results from these 
two  surveys  currently  represent  one  of  the  most  comprehensive  examinations  of 
hospital care for people with AIDS  (PWAs}.  (A  1989 version of the survey has been 
disseminated  to  members  of  these  four  organizations  as  well  as  the  600  hospitals 
belonging to the Catholic Health Association.) 
This  report  discusses  how  the  surveys  were  developed.  It  does  not review  survey 
methodology in  general. Instead,  it  describes the methodology behind the study and 
presents  the  procedure  conducted  for  its  execution,  identifying  strengths  and 
limitations.  A  final  section  considers  the  feasibility  of  replicating  such  a  study  in 
European Community countries. 
Scope of the study 
Constructing  the  Hospital  Study  Universe.  Selection  of  the  hospitals  for  study  is 
obviously critical  to the value of the research.  It affects  generalizability,  validity  and 
ability to monitor AIDS care over time. 60 
Determining which hospitals should be included in an AIDS survey, if all hospitals are 
not to be contacted, is  dependent on the questions under study. What proportion of 
patients and characteristics of patients served by study hospitals would be sufficient to 
represent the nation's AIDS  population? Should the study focus  on hospitals treating 
the highest proportion of AIDS patients? Is the study attempting to document treatment 
characteristics  in  an  "average"  hospital?  Is  there  a  specific  target  population  of 
particular interest?  Implied  in  these questions are the research  and policy needs the 
study is  intended to address: identifying AIDS resource and financing decisions at the 
national regional,  city  or hospital  levels;  identifying the burden of  care distribution; 
assessing the effect of alternative treatment programs;  monitoring changes in  hospital 
use  and  costs.  Determining  these  and  other  primary  study  needs  should  provide 
substantial direction for answering the key questions regarding scope of the project. 
Lessons from the U.S. Hospital AIDS Survey have indicated that two key factors set the 
stage  for  any  analyses  that  follow.  AIDS  has  most  frequently  affected  individuals 
residing  in  large  U.S.  cities.  Even  as  it  spreads throughout the country  rather than 
being concentrated on the east and west coasts, the epidemic continues to be found 
most often in urban areas. 
The composition of the AIDS population also affects the type of hospitals most likely to 
provide treatment.  For example,  in  the U.S.,  PWAs  who are  insured,  employed and 
who have more than a subsistence income are likely to be treated in private hospitals. 
Conversely,  unemployed  and/or uninsured  patients with  few  personar resources  will 
come to rely on public hospitals and a relatively few  private institutions for their care. 
PWAs who happen to be homeless,  IV drug users and prostitutes are also likely to be 
treated in public hospitals. 
Successfully soliciting the active cooperation of associations representing hospitals to 
be  surveyed  was  an  essential  component  of  the  U.S.  study.  Perceived  by  their 
memberships  as  advocates,  their  hospitals  are  more  likely  to  respond  positively  to 
association  requests  for  information  than  outside  organizations  or  governmental 
agencies that may be seen as antagonistic to the goals of many institutions. Moreover, 
the  success  in  building  coalitions  among  various  groups  is  a  valuable  method  of 
collecting important information. 
Selection of survey questions.  Once the parameters and limits of the U.S.  study were 
set, we identified the survey topics and specific items that would address our concerns. 
In  both  1985 and  1987, we  developed  questions  around five  issue  areas:  hospital 
utilization;  patient  demographic/risk  group/residence  characteristics;  hospital 
organization, staffing and community relationships; outpatient care; and financing and 
sources  of support.  In  1987 we  added a  section  on Zidovudine  and other specific 
treatments.  Where  appropriate,  definitions  of  terms  were  provided  (e.g.  the  CDC 
definition  of AIDS,  identifying what constitutes  an outpatient visit).  Where we were 61 
unable to devise a universally acceptable description (e.g.,  other HIV  infections,  case 
management), we asked responding institutions to define the term. 
Critical to the value of the survey was the inclusion of questions to validate responses. 
For example, the number of inpatient days should equal the sum of acute and special 
care days. The number of patients should not exceed the number of discharges. Cross-
checking responses to these items  allowed us  to assess data quality and difficulties  in 
survey completion. Finally,  we contacted all  participating hospital associations, asking 
them  to  pilot  the  instrument  to  one  or  two  of  their  members.  We  also  obtained 
assurances from  each association that they would actively assist  in  encouraging their 
respective memberships to respond to the survey. 
Conducting the survey 
Obtaining successful  information  is  contingent  on providing detailed  instructions  for 
survey  completion  and  describing  how  the  survey  information  will  be  used.  We 
stressed that results of the study would assist in developing policy at national and state 
levels.  We  also  strongly  guaranteed  confidentiality  of  hospital  information.  No 
individual hospitals would be reported nor would hospital specific data be identified. 
While some guidance can be incorporated into the instrument, the cover letter is  the 
vehicle  for  providing overall  direction.  The  U.S.  Hospital AIDS  Survey cover letter, 
which was addressed to the hospital chief executive officer or administrator, included 
suggestions for three specific areas: 
Survey coordination.  Since  completing  the survey  required the  participation  of 
several departments within the hospital (e.g., infectious disease, pediatrics, finance, 
outpatient), we recommended that an individual be designated to coordinate all 
responses. Hospitals were also asked to designate a contact person and telephone 
number for follow-up. 
Obtaining  financial  information.  Completion  of  financial  information  on  AIDS 
hospital treatment, while  important, should not deter potential respondents from 
returning the survey. Still, we advised hospitals to supply as much of the requested 
cost and revenue data as possible, preferably by finance office staff. 
Returning the survey. Since it was our intention to obtain responses from as many 
hospitals as possible, we advised all hospitals treating any number of AIDS patients 
or no AIDS patients at all to return the survey.  As with the financial  information, 
we also suggested that the inability to complete one section of the survey should 
not preclude responding or result in inordinate delays. 
The cover letter also allowed a turnaround time of two months for hospitals to fill  out 
and return the survey. A second mailing followed  approximately two weeks after the 
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current and future response, we also  noted that all  hospitals would receive copies of 
reports based on the survey results. 
As  hospitals replied,  all  answers were reviewed before computer entry.  As  necessary, 
hospitals were called to clarify  information.  We identified,  in  particular, key questions 
that  were  not  being  answered  (e.g.,  financial  information)  and  sought  additional 
responses. 
Survey results and survey analysis 
The response to the 1987 U.S.  Hospital AIDS  Survey was  very positive.  In  all,  341 
hospitals  responded,  and 59% of the universe  that formed  the analytical base. Two 
hundred  and  seventy-six  hospitals  provided  information  on  14,145  AIDS  patients 
treated during 1987, representing 52% of the estimated number of patients alive at any 
one time in that year, according to the U.S. Centers for Disease Control. 
For the  purposes  of the  U.S.  analysis,  we  examined the  hospital survey  responses 
according to two primary characteristics: hospital ownership (i.e. public or private); and 
region  of  the  country  (i.e.,  census  regions:  northeast,  midwest,  south,  and west) 
(Andrulis,  Weslowski and Gage, in  press). Subsequent analysis compared major cities 
in  the U.S.  (i.e.,  Los  Angeles,  San Francisco,  Chicago,  Houston, Washington,  New 
York/Newark)  according to changes in  utilization,  patient mix  and financing for 1985 
and  1987 (Andrulis  and Weslowski,  1989).  Other published  reports  have examined 
ambulatory care  (Andrulis  and Beers,  1988),  long term  care issues  (Andrulis,  1989), 
the  effect  of AIDS  on public  hospitals  specifically  (Andrulis,  in  press),  the  role  of 
Medicaid  (Andrulis,  Beers,  Bentley  and  Gage,  1987),  and  the  characteristics  of 
pediatric AIDS in this country (Andrulis, Weslowski, Brady, Hintz and Parrott, 1987). 
Strengths and limitations of a hospital based AIDS research methodology 
Accurately  monitoring  and assessing  the  effect  of  the  AIDS  epidemic  on  hospitals 
nationally cannot be accomplished through one approach. However,  a survey based 
methodology can provide a useful perspective which, in conjunction with local, state or 
regional studies, can examine a broad spectrum of issues. 
The U.S.  Hospital AIDS  Survey has a number of potentially valuable strengths. It can 
capture a large amount of information on AIDS related issues from many hospitals. It is 
sufficiently  flexible  to  allow  a  nation  to  include  all  hospitals,  to  survey  hospitals  in 
certain cities or regions,  or to target institutions with specific mixes of patients or other 
characteristics of concern. Since interest in  institutional effect is  likely to remain high, 
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example, and as noted above, different parts of the 1985 and 1987 U.S. Hospital AIDS 
Survey results have been reported in a number of journals and books. 
Critical to  a successful  response is  the guarantee of institutional confidentiality.  The 
survey enables  confidentiality to be incorporated  effectively  into  the study protocol. 
Hospitals are promised that, without their permission, provider-specific information will 
not  be  released  to  anyone  or  any  organization  under  any  circumstances.  Only 
aggregated hospital information will be released. The analysis can be conducted in the 
study  country  by  an  objective  organization,  perhaps  in  conjunction  with  other 
interested parties  (e.g.,  hospital associations). Another option would allow a research 
institute from another nation to analyze available data. 
Its relative methodological simplicity may make the survey easier to undertake, since it 
relies on information many hospitals capture or can obtain. Such an approach can be 
relatively easily modified from year to year to adapt to changes in treatment or service 
delivery technology, and to allow for monitoring of trends. This methodology may also 
assist  in  monitoring  other  measurements  of  the  AIDS  epidemic.  For  example,  the 
Centers for Disease Control is providing support to validate pediatric HIV responses to 
the  U.S.  Hospital  AIDS  Survey which,  when completed,  will  represent a  reference 
point  for  comparing  information  on  this  affected  population.  Finally,  the  relative 
universality of many terms in the instrument (e.g.,  average length of stay, number of 
hospital days,  number of  deaths, demographic and risk  group characteristics) would 
facilitate international comparisons for a period of time and over several years. 
While the survey-based technique for AIDS  hospital research represents a number of 
potential strengths,  its  composition  also  includes  uncertainties and limitations.  These 
factors  must be weighed before  using  this  approach and must  be monitored  if  the 
survey is undertaken. 
Most importantly, the survey information is  only as good as the data provided by the 
hospitals. If the hospitals find some of the information too difficult to supply, responses 
are  less  likely  to  represent  an  accurate  portrayal  of  the  AIDS  situation.  Such 
encumbrances  may  also  decrease  responses  and decrease  the  likelihood  that non-
inpatient information can be reported. 
Conflicting  political  agendas  (e.g.,  a  hospital  association  antagonistic  to  an  entity 
financing  the  research)  may  further  becloud  reporting  of  accurate  information  if 
allowed to enter into the data collection process. 
While the structure of the survey  is  relatively  straightforward,  responses  will  require 
hospital staff to devote a  substantial amount of time  completing  it.  This  is  especially 
likely if they treat large numbers of AIDS cases. 64 
While the survey is  adaptable, major changes in the instrument or in the composition 
of hospital response groups from  year to year may encumber comparisons over time. 
For example, if key questions are modified or if new hospitals are added between two 
study years, the information reported by the institutional group in the second year may 
represent something quite different from the first study year results. 
Because the institution is the unit of analysis, the survey cannot capture patient-specific 
information. Thus this approach cannot determine the extent to which an AIDS patient 
has used more than one hospital for treatment. It also cannot provide data on multiple 
characteristics  of  patients  (e.g.,  comparing  length  of  stay  for  IV  drug  users  with 
homosexuals' length of stay), unless it uses a hospital breakdown that may not provide 
accurate information (e.g., examine the length of stay in  hospitals treating the highest 
proportion  of  IV  drug  users  with  hospitals  treating  the  highest  proportion  of 
homosexuals). 
Considerations for study replication in other countries 
The  survey  based  approach  to  measuring  the  effect  of  AIDS  on  hospitals  may 
represent a  useful tool for  other countries to consider. However,  before electing this 
methodology, there are a number of key issues that should be addressed. 
Hospital concern regarding AIDS.  It is important to assess the level of concern for AIDS 
and its  impact on hospitals. If concern is  high  (but not necessarily a  high AIDS  case-
load),  cooperation  could  be  increased  as  well.  Conversely,  if  only  a  few  hospitals 
perceive the need to monitor the epidemic's institutional effects closely, a survey that 
extends much beyond that group may not yield much useful information. 
Hospital data base sophistication. While many of the questions in the survey may seem 
basic,  it  is  important to determine  if  hospitals can actually provide such information. 
Working with representative associations and piloting the instrument would answer this 
question. If institutions cannot respond or can supply requested data only with great 
difficulty, another approach may be necessary (e.g., special studies in a few hospitals). 
Hospital  association  support.  While  not  essential,  gaining  the  cooperation  and 
endorsement of associations representing study group hospitals will  work to insure a 
successful  study.  These  organizations  can  also  be  recruited  to  assist  in  obtaining 
accurate information from as many facilities as possible. 
Participation by major providers of AIDS treatment. While broad based participation is 
important, the involvement of the major providers of care to AIDS patients is  essential 
if the study is  to ascertain accurately the effect of the epidemic for  the most heavily 
involved institutions. Also, including these hospitals is likely to capture a large segment 
of the AIDS population. 65 
Uniform definition of AIDS. It is imperative that the hospitals under study use the same 
definition of AIDS  in  completing the survey.  Without this  uniformity,  reported results 
will be virtually uninterpretable. Whatever definition is used, it should be included with 
the survey when it  is  disseminated. Acceptance of a more widely used definition  (e.g. 
the Centers for Disease Control definition) may facilitate cross country comparisons. 
Conclusion 
The U.S.  Hospital AIDS  survey may be a  useful tool for  many countries  concerned 
with  the  current  and  future  effects  of  the  epidemic  on their  primary  health  care 
providers.  Its  capacity  to  yield  a  broad-based  representation  of  utilization,  patient 
characteristics  and  financing  among  key  providers,  when  incorporated  with  more 
patient- or institution-specific studies,  can result in  an effective method of monitoring 
the course of AIDS  services. It could also assist governmental and other organizations 
in  identifying  service  needs,  problems  in  health  care  delivery,  the  effect  of  new 
interventions, changing characteristics of AIDS care and in setting health care program 
objectives. 
As this epidemic continues through the 1990s, it will be important to compare its health 
care impact internationally as  well.  In  this  context,  such an approach could  assist in 
furthering  efforts  to direct the development of an international health care policy to 
combat this tragic illness. 
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for AIDS Patients and HIV Infected Persons 
G. Brenner 
The number of persons with AIDS  in the Federal Republic of Germany is known from 
the cases reported to the AIDS  Centre at the Federal Health Office.  On 31 December 
1988, 1,823 living  people were registered there as  suffering from  AIDS.  No  reliable 
statistics,  however,  exist  with  respect  to  the  number  of  people  infected  with  HIV. 
Widely differing estimates render it impossible to make any statements on the rate of 
infection. 
Similarly, there is also little information available on the extent to which physicians in 
private practice are involved in  providing outpatient care for  AIDS  patients and HIV 
infected persons, or on any other institutions with which they might be cooperating in 
this field. 
However, such information is  urgently required in the interests of health care planning, 
in  particular for  preventive actions and for  specific support to be directed at doctors 
providing care. A fairly  accurate quantitative basis is  also necessary for an assessment 
of the economic impact of AIDS on outpatient care. 
In  October  1987  and  again  in  October  1988,  the  Central  Institute  conducted  a 
comprehensive survey  among all  doctors  working  in  outpatient care in  the Land  of 
Hesse, where 9.1% of the inhabitants of the Federal Republic of Germany live,  and 
9.5%  of West  Germany's  office-based  physicians  work  (Fig.  1).  Both  the structural 
composition of the population and the regional distribution between urban and rural 
areas mean that the results from  the Hesse survey can be extrapolated to give  a fair 
idea of the situation in the Federal Republic of Germany as a whole. 
In the following,  some of the results of the survey conducted in  October 1988 will be 
presented. On a questionnaire all6,000 office-based physicians in Hesse were asked to 
give  the  number  of  HIV  positive,  LAS/ARC  and  AIDS  cases  receiving  outpatient 
treatment  or  care.  The  answers  were  categorised  according  to  sex  and  high-risk 
groups. We also asked for information on the number of HIV  (EUSA)  tests performed 
or arranged as well as on the type of cooperation with other institutions outside their 
own practices. 
Replies came from  3,318 physicians,  representing 56% of all  questionnaires sent out. 
Taking  this  response  rate  as  a  basis,  some  generalised  statements  for  the Land  of 
Hesse, and even for the Federal Republic of Germany as a whole, are possible. 68 
Fig. 1.  Land Hesse in the FRG 
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Fig.  2 shows that, while many types of office-based  physicians were involved in  the 
treatment and care of :HIV  and AIDS  patients,  77.2%  of all  cases  concentrated on 
general practitioners,  internists and dermatologists.  It  is  with  these doctors that most 
initial contacts are made. 22.8% of :HIV patients and 25.0% of AIDS patients, however, HIV /LAS/  ARC/  AIDS 
39.2% 
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IIIII  practitioners  lllD  internists 
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0  other 
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Fig. 2.  HIV infected, LAS/ARC and AIDS patients in outpatient care in 3/1988 in Hesse 
69 
were treated by other specialists. It can be assumed that most contacts with these were 
secondary contacts.  In  order to avoid duplications these contacts are not included in 
the absolute figure. 
Taking account for the rate of participation and the population of Hesse, it  is possible 
to  calculate  from  this  basic  table  that  221  AIDS  cases  and  1,369  cases  of  HIV 
(including LAS/ARC patients) were treated by doctors in private practice. These figures 
do not contain the contacts with specialists. 
The  possibility  of  biases  cannot  be  totally  excluded.  The  extrapolated  figures  are 
calculated under the  condition that those 56% of the  physicians  who answered the 
questionnaire,  are representative for  all  physicians  in  Hesse.  If one assumes  that all 
physicians  in  Hesse  who are  involved  in  the treatment and care  of HIV  and AIDS 
patients, had in fact answered the questionnaire and none of the non-respondents had 
any HIV or AIDS  patients, then the absolute figures  mentioned above would have to 
be  lower;  under this  assumption,  767  HIV  and  124 AIDS  persons  would  be  the 
minimum figure. 
A comparison of the clinical picture obtained from the results of the Hesse survey with 
the  number of AIDS  cases  registered  at the  Federal  Health  Office,  reveals  a  good 
degree of correspondence. Based on Hesse's 221 AIDS  cases we would arrive at the 
extrapolated figure  of 1,841 people suffering from AIDS  and receiving outpatient care 
in the Federal Republic of Germany.  As  mentioned before, on 31 December 1988 in 
fact 1,823 AIDS cases were registered at the Federal Health Office. 70 
Given the close degree of congruence between the figures extrapolated from the Hesse 
survey and the actual figures  for  the Federal Republic  of Germany,  it  is  possible to 
conclude the following: 
1.  The number of AIDS cases reported in the Federal Health Office's AIDS register is 
identical with the number of AIDS cases receiving outpatient medical treatment. In 
other words,  all  known  AIDS  patients  are  also  known  to the  ambulatory  care 
sector. 
2.  Cases  that  are  not known  in  the  outpatient  sector  are  not receiving  hospital 
treatment either. 
3.  If there was a significant number of initial contacts that receive hospital treatment 
only,  the  actual  number of AIDS  cases  registered  at the Federal  Health  Office 
would be too low. 
I tend to agree with the first  two  assumptions,  as the outpatient sector is  usually the 
first point of contact for all diseased people, with hospital treatment only following at a 
later stage. If one considers this argument a plausible one, then the results of the Hesse 
survey can be generalized. 
An  important conclusion  to  be drawn  from  the  study  appears  to  be that the  ratio 
between the number of AIDS  cases treated and the number of HIV  positive patients 
(including lAS/ARC patients}  receiving treatment  is  around  1:7.  Although  this  may 
give  us  correct information on the number of HIV  positive cases treated,  it  does not 
help to estimate the actual number of HIV positive persons in the population at large. 
For the Federal Republic of Germany as a whole, this would mean that, in addition to 
the approximately 1,800 registered cases  of AIDS,  a  number of around 12,000 HIV 
patients  (including  lAS/ARC  patients}  received  treatment  from  doctors  in  private 
practice. 
The computation of the estimates for the Federal Republic is based on the assumption 
that the situation in Hesse is representative for the country as a whole. As we know, in 
terms  of  the  structure  of  population,  physicians  and  even  of  morbidity  Hesse 
represents well the situation in the Federal Republic. But one can still be in doubt if the 
AIDS problem, too, follows these general aspects (Fig. 3}. 
Other estimates put the number of people in the Federal Republic of Germany infected 
with HIV at between 30,000 and 100,000. If the lower figure  of 30,000 is  correct, it is 
possible  to  say  that  around  40%  of  the  infected  people  are  currently  receiving 
outpatient medical treatment. In other words, a large proportion of infected people do 
obviously not yet require any medical treatment. 12,000 
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Fig. 3.  AIDS cases and HIV infected persons treated in outpatient medical care 1988 in  Hesse and in 
the Federal Republic 
The number of positive tests (EUSA) for antibodies to HIV (0.9%) also reveals that the 
actual number of people infected with HIV  is  significantly higher than the number of 
HIV positive cases receiving treatment (Fig. 4). 
From the reports submitted by the doctors we must assume that at least 36,000 tests of 
antibodies to HIV were performed or arranged in  Hesse by office-based physicians in 
the third  quarter of  1988 alone.  However,  the average  number of tests  charged  to 
health insurance funds in  Hesse per quarter of the year was only around 12,500 (Fig. 
5). From this I am able to conclude as follows: 
1.  The number of HIV  antibody tests  undergone by the general public is three times 
higher than indicated by the official clearing statistics. 
2.  People are highly aware of the AIDS  issue and prefer to pay for tests privately in 
order to avoid any record of them being kept. 
Consequently, it  is  possible to estimate that each year 1.2 million  HIV  antibody tests 
are performed in the Federal Republic of Germany on an outpatient basis as opposed 72 
positive 
152 = 0.97. 
Fig. 4.  Calculation of positive results of HIV antibody tests made by laboratories in Hesse in 3/1988 
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Fig. 5.  Performed versus charged HIV antibody tests in 3/1988 
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to 400,000 charged to the health insurance funds.  Assuming that 0.9% of tests prove 
positive, this would mean that there are around 11,000 new carriers of HIV each year 
(Fig. 6). 
If one converts the results  of the study conducted in  Hesse to the reference figure  of 
100,000 inhabitants,  it  can  be shown  that,  for  physicians'  practices  in  the  Federal 
Republic of Gennany, the annual figures  per 100,000 inhabitants would be 3 AIDS 
patients and 19 HIV positive patients  (including LAS/  ARC)  who receive treatment, as 
well as 18 persons who test positive (Table 1). 
I should now like to examine briefly the number of doctors involved in the treatment of 
AIDS patients and people infected with HIV. The study revealed that 84.0% of doctors 
in private practice did not have any HIV patients under care, 9.2% of them had only 1 
such patient, 5.6% were treating between 2 to 5 patients, with 1.2% of doctors having 
more than 6. In individual cases, doctors had more than 50 HIV patients (Table 2). 
The  fact,  however,  that  as  many  as  84.0%  of  physicians  did  not treat  any  AIDS 
patients  or people  infected  with  HIV,  should  not  lead  to  the  conclusion  that the 
problem of AIDS  is  not an issue in their practices - witness the extremely large number 
of HIV antibody tests which are either carried out or arranged there. 
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Fig. 6.  Performed and positive HIV antibody tests in Hesse and the Federal Republic compared (1988) 74 
Table 1.  Cases per 100,000 inhabitants in outpatient medical care in the Federal Republic of Germany 
Treated AIDS patients 
Treated HIV infected, included LAS/ARC 
HIV tests p.a. (ELISA) 
Positive tests p.a. 
Hesse 
4 
25 
2,620 
24 
Federal Republic 
3 
19 
1,980 
18 
Table 2.  Distribution of physicians with HIV, LAS/ARC or AIDS patients in 1988 
Number of patients 
no cases 
1 
2-5 
6-10 
11-50 
51-100 
>100 
Proportions of physicians in % 
84.0 
9.2 
5.6 
0.6 
0.5 
0.1 
0.0 
Around two thirds of all doctors have arranged for HIV tests to be performed, in other 
words, the question of AIDS must play a role in diagnostics, treatment, and discussions 
with patients in at least two thirds of all practices. In addition, one can also assume that 
at least some of the remaining one third of doctors who have not arranged for  any 
diagnostic  AIDS  measures,  deal  with  the  AIDS  problem  in  their  consultations  with 
patients (Fig. 7). 
On average, the doctors who had arranged for  an HIV antibody test to be performed 
had arranged 12 tests per quarter of the year. Even the number of patients with whom 
the AIDS  problem had to be discussed  in  preparation of tests to be arranged,  is  22 
times  higher  than  the  number  of  AIDS  cases  or  HIV  positive  patients  treated  in 
ambulatory practices. 
As  to the question of cooperation in  the treatment and care of people infected with 
HIV  and AIDS  patients,  70%  of  doctors  believe that cooperation  with  a  hospital  is 
necessary, well above 30% cooperate with self-help groups, around 18% are in favour 
of cooperation with psychologists or social workers, and 12% believe that cooperation 
with  some  form  of  home  care  services  is  necessary;  less  than  10%  mentioned 
theologians and other institutions (Fig. 8). 
As to whether AIDS  and HIV  patients should be treated within the normal course of 
business  of  practice,  39%  of  the  doctors  questioned  regarded  the  care  of  people 
infected with HIV and AIDS patients within the normal course of business of a practice 
as  problematic,  while  42%  of doctors  did  not see  any problems in  such integration. 75 
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Fig. 7.  Distribution of physicians arranging HIV antibody tests in Hesse in 3/1988 
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Fig. 8.  AIDS related cooperation of office-based physicians with other professions 76 
Only  15%  of all  physicians were  clearly  in  favour of treating a  higher-than-average 
number of AIDS  patients in  their practices,  while  55% of them were against such an 
extension of their work. 
In brief, the survey revealed 
That,  in  the practices  of office-based  physicians,  the  care of AIDS  patients  and 
people infected with HIV takes place on a large scale 
That there is a great deal of cooperation, particularly with hospitals 
That the number of people who were tested for  HIV  antibodies  is  considerably 
higher than indicated by the official clearing statistics 
That  it  is  possible  to  determine  basic  figures  required  for  quantifying  the 
prevalence and incidence of AIDS and HIV in physicians' practices. Association of Office-Based Ambulatory 
Physicians of Hesse 
Corporation under Public Law 
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Central Institute for Office-Based 
Ambulatory Care in the Federal 
Republic of Germany 
AIDS in Office-Based Ambulatory Care 
Questionnaire 
1.  Do you treat, and take care of, patients with HIV infection, LAS, ARC oder AIDS in your office? 
D  no  (go on with question 4) 
2.  How many cases do you treat or take care of at the moment? 
HIV positives (asymptomatic) 
LAS/ARC cases 
AIDS cases 
0  yes 
male  female 
3.  How many of these cases are, according to anamnesis, attributable to the individual risk groups? 
homosexuals 
i.v. drug users 
haemophiliacs, other recipients of blood products 
prostitutes 
foreigners from endemic areas (Central Africa, 
Haiti, Brazil) 
children of infected mothers 
other risks 
risk group unknown 
no risk 
male  female 
4.  a)  How many HIV antibody-tests did you order or perform during the last quarter of the year? 
D  none  approx. number  ........... . 
b)  Where do you have your confirmatory tests (western-blot, immunofluorescence) performed? 
D  lab physician  0  institute 78 
5.  In the treatment and care of AIDS patients, cooperation with other medical or non-medical experts 
and institutions is  sometimes necessary.  With whom would you  think cooperation is  necessary and 
which cooperation would you initiate? 
0  clinic:  ....................................................................................... . 
0  institute:  .................................................................................. . 
0  home care service 
D  self-help group 
D  social worker 
D  others, i.e.:  .............................................................................. . 
D  psychologist 
D  theologian 
6.  a)  Are there any problems in integrating the care for HIV infected and AIDS patients in the every 
day work of your office? 
D  yes  D  no 
b)  If  yes, would you agree to primarily treat AIDS patients in your office? 
D  yes  D  no 
c)  Would you actively participate in AIDS education (e.g. in schools)? 
D  yes 
Comments: 
Are you 
Office-based physician  D 
with access to hospital beds  D 
Hospital based physician with ambulatory practice  D 
Hospital based physician with out-patient office  D 
Thank you very much for your cooperation. 
0  no 
Date  Stamp Association of  Oftice-Based Physicians 
for Ambulatory Care of Hesse 
Central Institute for Oftice-Based 
Ambulatory Care in the Federal 
Republic of Germany 
AIDS in Office-Based Ambulatory Care 
Questionnaire for lab physicians and laboratory associations 
1.  How many HIV antibody tests (ELISA) did you perform during the last quarter year? 
number:  ........... . 
0  none 
2.  How many tests were positive? 
number:  .......... .. 
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3.  Do you perform the confirmatory tests yourself? If  so, please report the number of tests performed 
during the last quarter. 
0  no  (please go on with question 5) 
0  yes,  number of western-blot tests: 
number of immunofluorescence tests: 
4.  How many confirmatory tests were positive? 
number of positive tests (western-blot): 
number of positive tests (immunofluorescence): 
5.  Do you send serum to other labs for confirmatory tests? 
0  yes 
0  no 
Comments: 
Thank you very much for your cooperation. 
Date  Stamp Social Support Systems for People Affected by AIDS. 
Observations from West Germany 
W. Satzinger 
To deal with the subject of "social support systems"  in  relation to AIDS,  is  - from  the 
outset- like entering a scientific jungle. For, as one approaches it,  one is  faced with a 
broad  array  of  highly  different  conceptual  frameworks,  methodological  issues  and 
research  designs,  which  originate  from  several  academic  disciplines  and  have 
produced a lot of diverse, even contradictory evidence. What can be attempted in this 
article is only to give a brief overview of 
The definitions and hypotheses surrounding the concept of social support 
General systems  of social  support and their relationship  to provisions  of social 
security and welfare 
The forms and flaws of AIDS specific social support systems in West Germany. 
Social support 
It was in  the mid-1970s that "social support" became the catch-word around which  a 
(not entirely new, but so far fairly neglected} area of sociomedical and epidemiological 
research was opened up. "Social support began to be examined in the context of the 
psychosocial  dynamics  of  physical  and  mental  health",  and  conceptually  it  was 
"integrated into the (familiar) stressor-illness model" (Lin et al., 1985, 247). 
Since then, research on the forms  and roles of social support and, particularly, on the 
measurement of its effects has had a tremendous boom (House and Kahn, 1983, Table 
1}, and today the relevant literature fills shelves. 
Irrespective  of all  the  differences  in  purpose,  methods  and results  of those  studies, 
there  seems  to  be  some  agreement  as  to  the  components  of  the  social  support 
construct. Those are the quantity and quality as well as the types and sources of social 
support, which can be described in  the following terms (see Ostfeld and Eaker, 1985, 
68,99; Jacobson, 1986, 252}: 
Quantity of social support 
- number of social relationships 
- size and density of social networks 
- frequency of social interactions Quality of social support 
- accessibility 
- symmetry/reciprocity of supportive actions 
- intimacy of contacts 
- sociodemographic homogeneity of networks 
Types of social support 
- emotionaVaffective 
- cognitive/informational 
- materiaVinstrumental 
Sources of social support 
- family, relatives 
- friends, colleagues, neighbours 
- significant others 
Of course, there exist some variations to this theme: 
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Jacobson  (1986,  256),  for  instance,  points  out  that  the  question  of  the 
effectiveness  of any social support is  not only one of quantity,  quality,  type and 
source but also of its timing:  that means one should not only ask "Who gives what 
to  whom  regarding  which  problems?",  but  also  when  this  is  done  within  the 
process of stress-experiences and situations of need for help; 
Wethington  and  others  (Wethington  and  Kessler,  1986)  claim  that  perceived 
(potential) support might well be more important than actually received support in 
helping somebody to adjust to adverse life events. 
But, all  in all,  scholars today demonstrate a high degree of conformity when it comes 
to  the  basic  properties  of  the  social  support concept.  Far  less  harmony,  however, 
exists,  with  respect to  the assessment  of the effects  of social  support on a  person's 
health. There, opinions and even experiences differ widely,  depending on the various 
frames  of reference,  theoretical paradigms  and practical settings  in  relation to which 
specific observations have been made.1) 
1)  In the context  of this  article, it  is  by no  means possible to address this issue adequately. It must 
suffice to mention some of the research literature involved, e.g.: 
Kaplan, B.H. et al. (1977). Social support and health. Medical Care 15, Suppl. 5, 47-58; 
Schaefer,  C.  et  al.  (1981).  The health-related functions  of social support.  Journal of Behavioral 
Medicine, 381-405; 
Bell,  R.A.  et al.  (1982).  Evaluating  the  mediating  effects of social support upon life  events  and 
depressive symptoms. Journal of Community Psychology 10, 325-340; 
Broadhead, W.E. et al.  (1983). The epidemiologic evidence for a relationship between social support 
and health. American Journal of Epidemiology 117(5), 521-537; 
Hammer, M.  (1983). "Core" and "extended" social networks in relation to health and illness. Social 
Science and Medicine 17(7), 405-411; 
Asher, C.C. (1984). The impact of social support networks on adult health. Medical Care 22(4), 349-
359; 
Badura,  B.  and Waltz,  M.  (1984).  Social  support  and  the  quality  of life  following  myocardial 
infarction. Social Indicators Research 14, 295-311; 
Sarason, I.G.  and Sarason, B.R.  (eds.)  (1985).  Social support:  theory,  research and applications. 
Martin  us Nijhoff Publishers, Dordrecht; 82 
Putting all particulars aside, the leading hypotheses in this respect, however, contend 
that social  support may be beneficial  to  health  by performing four  functions  while 
playing two basic roles (see Ostfeld and Eaker 1985, 65,84): 
First, as regards receiving good health care 
social support may 
- facilitate the finding of good health care (informational function) 
- directly,  i.e.  through  money,  transport,  etc.,  assist  the  obtaining  of  care 
(instrumental function); 
Secondly, by improving personal behaviour and well-being 
social support may 
- enhance norms of health-conducive behaviour (cognitive function) 
- advance  well-being  through  promoting  personal  self-esteem  (emotional 
function). 
At  the most general level,  it  is  proclaimed that social  support can  act as  a  "buffer" 
between an adverse life  event and its  mental as  well  as somatic consequences. Over 
the years, the buffer theory has attracted a lot of attention but has, it seems, not been 
able to produce conclusive and undisputed evidence. 
As one of the prominent scholars in this field stated: 
"Even though the evidence for the buffering effect of social support is  equivocal, 
the idea that social support may serve as  a buffer against the potentially harmful 
effect of life  events remains theoretically intriguing and practically inviting"  (Lin  et 
al., 1985, 247). 
In the context of AIDS, those beneficial buffering effects of social support are obviously 
taken for granted. Wherever you look, the importance of social support for the care of 
people affected by AIDS  is  not questioned at all:  it  is  rather emphasized throughout. 
Apparently,  it  is  considered  - in  the absence  of effective  medical treatment - to be 
almost the only means of improving the situation of those persons. 
Let  us  take,  for  example,  the  "Gay  Men's  Health  Manual  for  the  Age  of  AIDS", 
published under the (rather pretentious} title  "Strategies for Survival". A large chapter 
of that volume is dedicated to "social support" which, in tum, is rather loosely defined: 
Berkman,  L.F.  (1986).  Social  networks,  support,  and  health.  American Journal  of Epidemiology 
123(  4), 559-562; 
Waltz, M.  (1986). Social support and coping with physical illness. Social Indicators Research 18, 71-
93; 
Patrick, D. et al. (1986). Psychosocial support and change in the health status of physically disabled 
people. Social Science and Medicine 22(12), 1347-1354; 
Friedland,  J.  and  McColl,  M.  (1987).  Social  support  and psychosocial  dysfunction  after  stroke: 
buffering effects in a community sample. Archives of Physical and Medical Rehabilitation 68,  475-
480. 
In a  "meta-analysis",  results  of 55  empirical research  studies on  the relationships between social 
support and health were reviewed and found to differ considerably; see Schwarzer, R. and Leppin, 
A. (1988). Sozialer Riickhalt und Gesundheit. Gottingen, 240 seq. 83 
"social support - friendship,  companionship, community,  love,  whatever we call  it..." 
(Delaney, 1987, 157). 
There, social support is  associated with  intimate friendship,  with living  in social circles 
in  a  give-and-take  relationship,  with  participation  in  the  gay  community,  and with 
going  public  as  a  homosexual  - all  that  is  presented  as  possibly  the  best  way  of 
becoming able to cope with  antibody-testing,  the diagnosis of AIDS,  with the loss  of 
friends, with the final days of one's own life. 
Take - as another example - the Self-care  Manual,  edited by the AIDS  Project Los 
Angeles.  Again,  social support plays  a  crucial  role;  it  should be provided by family 
members and "significant others
11
,  also by specific 
11SUpport groups
11
,  and it is supposed 
to help promote one's state of health through emotional stabilization. 
But then, this  manual goes a  bit further and entails some paragraphs that deal with 
11tapping social  services
11  and 
11benefits  counseling".  There,  a  different form  of social 
support for persons-with-AIDS is implied:  it is the field of professional as well as public 
support. And the manual gives a lot of advice as to: what sort of assistance one can get 
from hospital social workers and local AIDS agencies, and what legal entitlements exist 
with  respect to  social  security  schemes  and health  or disability  insurances  (Moffatt, 
1987, Section II,  VII and passim). 
Social support systems 
This leads us to a  different level  of consideration altogether. In  our discussion so far, 
11Social support
11  has mainly been confined to be provided by informal relationships and 
networks. But as the subject of this article is "social support systems", and although - in 
a sociological understanding - families  or groups of friends  or colleagues can well be 
conceptualized as social "systems",  it would not be appropriate to limit the view just to 
these. Rather, a distinction has to be made between informal, formal and perhaps even 
semi-formal systems of support, their related sources and the sort of persons who can 
benefit from them respectively, as is outlined in Fig. 1. 
To differentiate between formal and informal support systems is,  of course, no novelty 
in this area of research2).  Nor is  the fact that our description of social support has so 
far  centered  so  much  on informal  systems,  a  mere  coincidence:  it  rather reveals  a 
certain bias- I would call it a U.S. bias. 
For,  in  the United States of America,  a  lot problems are left  to individuals,  to their 
personal capacity of solving them, which  in  many other countries  are dealt with by 
public institutions3).  The literature on social support,  however,  is  - as,  of course,  in 
2) 
3) 
As  long  as  15  years  ago,  Caplan  stated  that  support  systems  consist  of "formal  and  informal 
relationships and groups through which an individual receives the emotional, cognitive, and material 
supports necessary to master stressful experiences". See Jacobson, 1986, 252. 
Consider, as just one indicator, the fact that, in 1987, around 37 million U.S. Americans were found 
not to be covered by any health insurance (see Short, P.F. et al. (1988). Uninsured Americans: a 1987 84 
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Fig. 1.  Social support systems - types, sources and beneficiaries 
many other areas of psychological and socioeconomic research - dominantly American 
in origin. That is  why the term "social" in this context is  mostly used as indicating the 
immediate human environment of a person; rarely it is  also used (as  it would certainly 
be in West Germany) in the meaning of "societal", relating to the society as a whole, to 
its official institutions and legal regulations with respect to sickness and social welfare. 
This observation only confirms what is  well-known  in  essence, but often forgotten in 
reality: that even to a fairly global matter such as AIDS, our approach must - to a great 
extent - be country-specific because: 
"Every society reacts in its own way to infectious diseases, has its own approach to 
the organization and funding of health care, has its own sociocultural history as far 
as sexual emancipation is  concerned, etc  .... All  of the social and economic means 
of reacting to the HIV epidemic, i.e. the regulations for and methods of organizing 
and funding  the  health  care system,  the standards  and values  with  respect to 
sexuality, etc., will in fact both determine the form of reaction to the HIV epidemic 
and be influenced and/or changed by the HIV  epidemic; they exist in  continuous 
interaction" (STG, 1989, 4-5). 
This  is  particularly  true with  respect to the facilities  a  society  provides  for  diseased 
people. In  West Germany for one, quite in  contrast to the USA,  we have a system of 
social security whose classical components are: 
Health  insurances,  covering  almost  everybody  and  almost  every  expenses  for 
medical treatment 
A comprehensive payment scheme for occupational and general invalidity 
profile. NCHSR paper, Nov.,  Rockville, MD). If one adds to these all persons who are obviously 
underinsured,  the  number  of  people  having  no  official  financial  support  in  the  case  of illness 
amounts to some 56  million - more than a fifth  of the total population (see Salmon, J.W.  (1989). 
Letter from USA. Dr. med. Mabuse, 59, April/Mai, 56-7). 85 
An  unemployment  insurance,  mandatory  for  every  worker  and  employee  and 
covering, to different degrees, a few years of joblessness 
And,  as  a  last resort,  a  social  assistance scheme for  all  those who are not (any 
longer)  protected by other provisions  of the social security network and have no 
resources left of their own. 
All  this  is  principally  open to  nearly  every  member  of  society,  including  of course 
people with AIDS  (Nees,  1988, 30 et seq.).  And this  is  similar in  a number of West 
European countries (see Table 1), let alone the ones of Eastern Europe. So, a lot of 
problems  for  which  in  many  parts  of  the  USA  a  sort  of  private  "system"  of social 
support has to come up, are here partly or even completely dealt with in the existing 
framework of what is called the modem welfare state. 
This  is  by no means to say that people with  AIDS  face  no problems for which they 
would need specific social support. Of course, here too, they need 
Relatives and friends, people who care, for emotional support 
Practical information and sometimes legal advice in order to learn how to "tap" the 
social services and to materialize their rights to financial benefits 
The political  backing of  others  in  order to sustain  the pressures  and attacks  of 
some sections of the public that are hostile to them as homosexuals, drug-addicts, 
prostitutes. 
This  is  why,  in  West Germany too,  a considerable number of institutions have been 
established over the last few years whose specific task is  to serve the needs of people 
affected  by  AIDS,  to  provide  them  with  support  - informational,  practical  and 
emotional.  The  basis  of  their  support-giving  function  might  be  called  semi-formal: 
because it  is  personal in  nature but independent of private bonds someone might or 
might  not  have;  also  because  it  is  official,  publicly  funded  (and  therefore  free  of 
charge)  but  anonymously  provided  and  not  depending  on  somebody's  insurance 
status or other forms of legal entitlement. 
Table 1.  Coverage of social security systems in Western Europe. Average percentage of population 
covered by social insurances in 13 West European Countries (1975) 
Subject  Percentage 
Health care  91 
AccidenUinvalidity  81 
Unemployment  63 
Old-age pension  94 
Source: CEC (Commission of the European Communities), 1988; Alber, 1987, 236-239 86 
The institutional setting of these semi-formal social support systems in West Germany 
includes: 
Community-based organizations (especially Deutsche AIDS-Hilfe) 
General agencies for psychosocial AIDS counselling 
Group-/problem-specific  federal  programmes  (e.g.,  women/children/drugs  and 
AIDS) 
About 350 AIDS advisors at local offices of public health. 
Most prominent among these organizations is  the Deutsche AIDS-Hilfe,  originally an 
off spring of self-help initiatives of the gay movement Oust  like  GMHC in  New York}, 
but now working on an even broader basis  and subsidized with  public money, very 
similar  to the San Francisco AIDS  Foundation  (Deutsche  AIDS-Hilfe,  1986,  15).  A 
branch of this  organization can today be found in  almost every major town of West 
Germany. Apart from  that, we have an equally big number of so-called Psychosocial 
AIDS  Counselling Agencies,  usually staffed with  a psychologist and one or two social 
workers and mainly paid for by federal, state or municipal authorities. 
In addition, several federal programmes are to be mentioned in this context: including 
one for 
11Women and AIDS'.,  one for 
11Children and AIDS
11
,  one for 
11Drugs and AIDS
11
, 
one for 
11Home Care for  People with  AIDS
11
,  and yet another one that provides all 
public health offices of the country with, at least, one special AIDS advisor. 
Up  to the year 1991  (which  is  the designated end of their trial  period), the costs  of 
these federal programmes alone - involving about 700 professionals for their field work 
- will  amount to  approximately  145 million  Deutschmark.  There are no comparable 
figures  for  the  related  expenditures  of various  state  and local  governments,  but  it 
appears safe to assume that they, taken together, will easily match that of the federal 
government. 
However,  if  all  this  conveys  the  impression  that everything  is  fine  with  respect to 
psychosocial support for people with AIDS in West Germany and everybody is  looked 
after well,  that picture would be far too rosy.  Rather, a number of qualifications have 
to be made: 
For one thing, there is of course a difference between official entitlement and practical 
availability or accessibility. This may vary from region to region and even from town to 
town, depending on the directions of local AIDS  policies and on the attitudes of local 
authorities. It certainly varies with respect to different groups of people- HIV infected 
drug users,  for  fear  of being criminalized,  surely face  more  difficulties  in  using such 
services than haemophiliacs or even homosexuals do.4) 
4)  In general,  as  we  do  not  know  how  many  people  of this  country are HIV infected  (at present, 
estimates range from 30,000 to 100,000 out of a population of nearly 60 million), let alone how many 
may  be considered  to  belong  to  one  of the  "high-risk  groups",  it  is  impossible  to  estimate  the 
percentage  of those  who  are  actually  benefitting  from  official  support  programmes.  Even  their 
absolute  numbers  are  unknown,  as  there  is  no  comprehensive  record  of utilization  of support 
institutions; and if  there were one, to make a distinction between persons and cases of contact would 87 
Secondly,  the  supply  of support  is  not equally  adequate to  all  persons concerned. 
AIDS  counselling, for instance, has got a certain middle class  bias in  its  contents and 
ways  of  communication;  quite  a  few  people  tend  to  feel  excluded  from  its 
predominantly psycho-cultural approach. 
Also, there is a lot of uncertainty as to the targets of dealing with drug addicts (witness 
the dispute between AIDS  counsellors and drug experts over the methadone issue!), 
which does not help to attract these people to the support-giving agencies. 
Thirdly,  community-based organizations, which play such a pivotal role  as mediators 
between their clients and the social security system, are more and more getting under 
pressure - for at least two reasons: 
One is that the numbers of afflicted and even ill  persons will soon exceed the numbers 
of volunteers to support them (already there is a shortage of people who are prepared 
and capable to look after IV  drug users);  and there is  nobody to replace volunteers 
once they are "burnt out" or fall ill themselves.5) 
Another reason  is  that these  agencies,  the more they get subsidized,  the more  they 
become professionalized  and officialized,  and by  this,  they  may  lose  some  of their 
appeal to the very groups of population whose self-help body, advocates and political 
lobby they used to be. So far they have been able to be a bridge between the different 
"scenes" and the official care and welfare system,  and they won public support (and 
money) for that function, which they fulfill with special competence and - not to forget! 
- with  a large  contribution of donated labour.  In  future,  a  gap might arise  between 
them and those they are supposed to represent and support. 
These  are  but a  few  of  the flaws  in  that seemingly  well-equipped  system  of ours, 
established  for  the  social  support  of  people  affected  by  AIDS.  The  number  of 
shortcomings would increase if we proceeded to differentiate more exactly between the 
different high-risk groups or between persons in  different stages of HIV  infection and 
AIDS  - each has specific needs,  and these vary from  place to place and over time: 
many of these people will not only lose their job, earning and flat in that process, but 
also their relatives and friends - the very sources of informal support they would then 
need more than ever before. 
What I am trying to point out, is: 
If we  are  to  assess  the  importance,  potential  supply  and  possible  impact  of  social 
support systems with respect to AIDS,  we have to look closely at the psychosocial and 
socioeconomic situation of the persons concerned; and this includes that we take into 
account that 
prove to be very difficult statistically. 
5)  If  U.S.-American experiences are anything to go by, voluntary work will remain a vital element in the 
support of PWA and the fight  against AIDS. Its supply, however, might -in the long run- not be 
sufficient to match the needs unless it receives more assistance, material and immaterial, by public 
policy than hitherto. See Arno, 1987, 190 seq. 88 
The  type  and severity  of  problems  depend,  to  a  high  degree,  on the  specific 
characteristics  of the  main  groups  of  affected  people  and  on  the  psychosocial 
corollaries of the different phases of the disease's development. 
The  way  (and  the  extent to  which)  these  problems  can  be  dealt  with  largely 
depends on  the norms  and institutions  that are  characteristic of each country's 
specific  social  security  and  welfare  system,  and  of  the  regional  or even  local 
variations of its implementation. 
Biologically,  the virus  may act similarly  all  over the world;  but how people can cope 
with  it,  varies  considerably.  Social  support  may  not  save  their  life  but  decisively 
improve its quality. Formal support systems, even where they are fairly comprehensive, 
can't do everything; they need to be supplemented by informal as well  as semi-formal 
ones.  And  the latter should be further  promoted  as  a basic and,  probably,  the best 
approach to the problem of AIDS - and not only because (this  is said as a reverence to 
the main topic of this book) they are the most cost-effective one. 
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of AIDS and HIV Infection 
G. Thiers, M. Denayer, A. Stroobant 
Economists who want to study the economic impact of a certain disease on society are 
often  confronted with  the problem  of  the  lack  of reliable  morbidity  data.  Although 
mortality data are often available (d. European Community Atlas of Avoidable Death) 
there  is  still  a  lot  of  discussion  on  their  quality  and  their  comparability  between 
countries  or  parts  of  countries  (Holland,  1988).  Morbidity  data  for  the  general 
population  are  generally  lacking  while  the  use  of  morbidity  data from  hospitals  is 
difficult  since  the  corresponding  population  is  unknown,  the so-called  denominator 
problem. 
In  recent years sentinel systems  have been developed  in  order to  obtain more  valid 
epidemiological information for the general population. Sentinel systems try to  collect 
valid  information  on a  sample  of the total  population,  which  is  called  the "sentinel 
population". 
Sentinel surveillance  is  based on the principle  that information  collected  under high 
quality standard conditions in  a limited  number of places is  preferable to  information 
collected haphazardly everywhere. The collected information is  more reliable because 
among other things it is possible to train and to supervise regularly a limited number of 
data providers (Dondero et al., 1988; National HIV Seroprevalence Survey Centers for 
Disease Control, 1988). 
We are going to describe two different sentinel systems which can presently be used for 
the study  of  certain  aspects  of  the  impact  of  AIDS  :  "Sentinel  General  Practices" 
(SGP's) and the use of a sentinel population comprising by SID patients. 
1.  Sentinel general practices 
In  several countries SGP'  s have been established one or two decades ago.  It is  now 
generally  accepted that they  can provide  reliable  epidemiological information  about 
incidence of diseases or health problems in a population. 
It is  also for this reason that since July 1988 the COMAC - Health Services Research 
has  been  supporting  a  concerted  action  called  eurosentinel.  Its  purpose  is  to 
coordinate  activities  in  the  field  of  SGP'  s  in  the  different  member  states  of  the 91 
European Community, and to assist starting networks. The ultimate goal is to establish, 
if possible, a European network of SGP'  s. 
Given the very low incidence of AIDS or HIV infection in the general population up to 
the present, GP'  s are not an appropriate tool to study the incidence of the disease. In 
Belgium,  however, we have already studied the demand of patients for  a serological 
HIV  test  through  SGP'  s.  Since  May  1988  this  item  is  inducted  in  the  Belgian 
registration programme. 
The objective is  to evaluate in  which way the GP  is  confronted in  its  daily work with 
the AIDS  problem, the epidemiological characteristics of people seeking help and the 
reasons for demanding an HIV test. 
It will be possible to repeat this type of registration at intervals in the future in order to 
evaluate changes in incidence or epidemiological characteristics. All demands for a test 
are registered, whether the GP decides to do the test or not. 
1.1  Frequency of the demand 
Between 2nd May  1988 and 1st January 1989,  668 requests  for  an HIV  test were 
registered  through  a  network  of  172  SGP'  s  in  Belgium.  This  covers  a  sentinel 
population estimated at 160,000 persons. Presently there is less than one (0.5) request 
per month and per doctor. Fig.  1 shows that the largest group of patients who present 
themselves  to the GP with  a  demand for  an HIV  test  is  between 25 and 29 years 
(Institute of Hygiene and Epidemiology, 1989b). 
In  586  of  these  668  patients  (=  87.5%),  the  GP  ordered  a  laboratory  test.  By 
extrapolation it  can be estimated that approximately 55,000 HIV tests are performed 
yearly at the demand of GP'  s in Belgium. 
Before  extrapolation  of  these  figures,  the  following  criteria  were  checked  for  the 
representativeness of the participating GP'  s: 
Age  and sex distribution  of the participating GP'  s in  relation to that of the total 
Belgian GP'  s 
Geographical distribution  of the SGP'  s:  for this purpose, the 43 Belgian  districts 
are  regrouped  in  15 homogeneous  district  clusters.  In  each  cluster  SGP's  are 
working and the population covered by this network e.g. in 1987 was about 1.2% 
of the total population in Belgium (Lobet et al., 1987). 
1.2  Reasons for demand 
Table  1 shows that 55% of the women who ask  for  a test do not present any risky 
behaviour while this proportion is 44% for men. The main reason for demanding a test 
is anxiety. 92 
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Fig. 1.  Age and sex distribution of patients asking HIV tests in Belgian SGP 's 
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Table 1.  Reasons for demanding an HIV test (in %) - Results in Belgium (Period: 02.05.88 - 01.01.89) 
Reasons  Male  Female 
N  %  N  % 
Prostitution  6  1.7 
}~.5% 
24  7.4 
}#.9% 
Contact with prostitutes  43  u.s 
Multiple heterosexual contacts  66  19.1  67  20.7 
Homosexual contacts  44  12.8 
STD patient  11  3.2  8  2.5 
IV drug addict  6  1.7  2  0.6 
Other  19  5.5  44  13.6 
Anxiety  86  24.9 
}43.5% 
80  24.8 
}55.1% 
Administrative reason  34  9.9  17  5.3 
Symptoms suggestive of HIV infection  3  0.9 
Screening before/during pregnancy  40  12.4 
Screening before marriage  4  1.2  12  3.7 
Other reason  23  6.6  29  9.0 
Total  345  100.0  323  100.0 93 
The table also shows that 56% of the men who ask for a test present a risky behaviour. 
These  men  have  either  multiple  heterosexual  partners,  homosexual  contacts  or 
contacts with prostitutes. 
The  proportion  of women  presenting  a  risky  behaviour  is  45%.  They  either  have 
multiple heterosexual partners or they have sexual contacts with persons with  a risky 
behaviour. 
1.3  Results of serological tests 
Of the 586 HIV tests ordered by the GP'  s,  581  have actually been performed. For 8 
persons the screening test as well as the confirmation test was positive : 
1 male LV. drug user 
3 males with homosexual contacts 
3 males with multiple heterosexual contacts 
1 prostitute 
1.4  Eurosentinel 
The Project Management Group decided to introduce the demand for  an HIV test in 
the first year of registration of the Eurosentinel project. The following countries agreed 
to participate: Belgium,  Denmark, the Federal Republic of Germany, France, Ireland, 
Italy, Portugal, Switzerland, and The Netherlands. About 15 centres are involved in the 
project, mainly Institutes of General Practice or Scientific Associations of GP'  s in these 
countries.  It was  proposed to start this  registration  in  October 1989.  Agreement to 
participate is still expected from other interested countries. 
The objectives of the registration in each participating country are : 
To get an idea of the frequency and reasons demanding HIV tests in the general 
practices. 
To identify the population groups consulting for this reason, in terms  of age, sex 
and risk behaviour. 
To  follow  the  evolution  of  the  workload  for  the  GP  in  view  of  the  expected 
increase in HIV infection and AIDS patients. 
The objective of the international registration is to compare the global patterns in each 
country for each of the three above-mentioned items. 
2.  Monitoring HIV  seroprevalence in a sentinel population comprising STD 
patients (Stroobant, 1989) 
Recently,  it  has been decided in  Belgium to  explore the possibility  of developing a 
sentinel network for monitoring HIV infection trends in specific population groups. As a 
first step, SID patients have been selected as the sentinel population for the following 
reasons: 94 
1.  SID patients can be easily defined and are accessible. 
2.  SID patients represent a group at increasing risk  situated between the high  risk 
groups and the general population so that the spread of HIV infection into other 
population groups than the high-risk  groups may be apparent first  among SID 
pati~nts. For this  reason, sentinel surveillance in SID patients might serve as  an 
early warning system. 
3.  HIV  screening  among SID patients  raises  less  ethical  questions  than  in  other 
segments of the population since the physi'cians  taking care of them are usually 
trained  in  counseling,  tracing  contacts  and  similar  activities  which  are  also 
important for  reducing the risk of HIV infection. In  addition,  in  many cases these 
patients are already routinely tested for HIV  or have blood specimens taken for 
other reasons. 
The method for implementing the sentinel HIV monitoring network has been based on 
the guidelines as proposed by WHO  (WHO,  1988). All  patients who enter a  medical 
facility for a documented SID are eligible for inclusion in the sentinel population. The 
sentinel network comprises a  sample of all  the medical facilities  where SID patients 
seek  treatment.  In  Belgium,  the  majority  of  these  patients  are  treated  by  GP'  s, 
gynaecologists and dermatologists, since there are very few specialized SID clinics. 
A minimal  basic  data  set  has  been  defined  in  order  to  achieve  the  goals  of  the 
surveillance without causing difficulties with ethical issues or excessive workload for the 
participating physicians. 
Data to be collected  for  each  patient include  age,  sex,  nationality,  occupation,the 
diagnosed SID('s), risky behaviour and the result of the HIV 1/HIV 2 test. These basic 
characteristics are needed to verify whether the study population remains stable over 
time:  this  is  the most important condition to be considered  as  a sentinel population, 
otherwise it would become impossible to interpret the results. 
The form  used is  anonymous and before doing the HIV test,  informed consent of the 
patient is necessary. In case of refusal, the form has to be completed but the serological 
test is not done. This should allow to assess the bias caused by refusal. 
Every participant receives a limited number of forms  at the beginning of each month. 
This  number was  estimated  according to  the  number of SID patients seen by  the 
different participants in this sentinel network. In this way, before analyzing the data, we 
can compare the number of forms expected each month with the number really sent. 
The sample consists of the first consecutive SID patients, seen by the participants. 
The sentinel surveillance network started in December 1988. The months of December 
and January have been  used  to  test the  form  and to  discuss  other organizational 
points. 95 
In order to illustrate this sentinel network we will  give some preliminary results of this 
first registration period in Belgium (Institute of Hygiene and Epidemiology, 1989a}. 
2.1  Participation 
The participation rate is still irregular. From experience with other networks we know 
that this  situation will  improve after a few  months of registration, by the time all  the 
non-respondents have acquired a good understanding of the network. 
2.2  Medical facilities 
Table 2 shows that there is  a very important variation in the consistency of reporting 
between the participating physicians. The return-rate from SID clinics,  gynecologists, 
dermatologists and medical facilities for students is satisfactory. The number of patients 
reported by GP'  s and family planning centers is still inadequate. 
2.3  Patient characteristics 
When  we  consider  the  high-risk  groups  (homosexuals,  IV  drug  users,  prostitutes, 
patients from  endemic area, sexual partners of these group(s},  syphilis},  a significant 
HIV seroprevalence is found. 
Table2.  Participating centers during the first registration period (01/12/88- 04/04/89)1) 
Participants  Number of  Number of  Estimated num- Number of forms 
physicians  participating  her offo)  to  really sent 
physicians  be sent
2 
N  % 
Dermatologists  14  8  96  61  63.5 
Family planning centres  12  4  80  21  26.2 
Gynecologists  12  6  120  62  51.6 
General practitioners  25  10  80  18  22.5 
STD clinics  3  3  120  50  41.6 
Medical facilities for students  6  5  40  23  57.5 
Urologists  6  4  80  31  38.7 
Total  78  40  616  266  43.2 
1)  The figures presented at the workshop covered only the period 1.12.88- 1.03.89. For the publication 
they have been completed to cover the period 1.12.88- 4.04.89. 
2)  Each participating physician  receives  a  limited number  of forms,  according to  his  practice:  e.g. 
dermatologists receive 3 forms, GP's 2 forms and STD Clinics 10 forms, sent at the beginning of each 
month. The estimated total number of forms to be sent can be estimated by counting the number of 
physicians for each speciality, multiplied by the duration of the registration period (in months) and 
the number of forms sent to them each month. 96 
The seroprevalence in non-high-risk groups is 0.5%, 250 times the prevalence found in 
healthy blood donors. It was stated that HIV seroprevalence in SID patients represents 
the  upper  limit  of  HIV  seroprevalence  in  the  general  population.  The  real  HIV 
seroprevalence should then be situated somewhere between these two values. 
It  is  interesting to observe that most seropositives are encountered by dermatologists 
(see Table 3). 
2.4  Diagnostic categories 
As shown in Table 4, among men seropositivity is  associated with serological evidence 
of syphilis. 
Table3.  Age and sex distribution of patients by category of risk behaviour 
Risk factors  Male  Female  Total 
N  HIV+  N  HIV+  N  HIV+ 
Homosexual contacts  7  1  0  0  7  1 
IV drug use  1  1  0  0  1  1 
Prostitution  0  0  1  0  1  0 
Originating from endemic area  4  1  6  1  10  2 
Sexual contacts with one of these groups  9  0  5  0  14  0 
Syphilis  9  1  6  0  15  1 
Heterosexual contacts  66  1  126  0  192  1 
No risk behaviour identified  6  0  3  0  9  0 
Table 4.  Distribution of the patients by sex and diagnosis 
Diagnosis  Male  Female  Total 
N  HIV+  N  HIV+  N  HIV+ 
Urethritis  30  1  4  0  34  1 
Vaginitis  0  0  56  0  56  0 
Cervi  tis  0  0  47  0  47  0 
Trichomonas vagina/is infection  1  0  27  0  28  0 
Syphilis  9  3  6  0  15  3 
Chancroid  1  0  1  0  2  0 
Condylomata  41  1  28  0  69  1 
Herpes genitales  9  0  8  0  17  0 
Hepatitis B  2  0  2  0  4  0 
Pediculosis pubis  5  0  3  0  8  0 
Scabies  0  0  1  0  1  0 
Other  5  0  3  1  8  1 
Total  103  5  186  1  289  6 97 
Although it  is too early for  conclusions after the first  months of registration,  it may be 
assumed that: 
1.  The  physicians  participate  without  great  difficulties,  but  the  regularity  of  the 
registration has to be improved. 
2.  The figures provided by the network give different information than other sources. 
3.  The monitoring  capacity of the network  as  well  as  its  ability  to  act  as  an  early 
warning seems to be already demonstrated. 
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Tatry-Poprad, 17-19 February (ICP/CDS/032). Services for the Management of HIV Infection: 
Problems for Planners 
A.M. Johnson 
Introduction 
Much  of the work  to  date  examining  the  Health  Setvice  implications  of the  HIV 
epidemic have focused  on cost considerations  and particularly  on cost per case.  In 
conjunction with estimates of the future number of cases, studies have examined the 
future cost to health care services (Bloom and Carliner, 1988). However, few studies 
have focused on the overall pattern of care and the cost effectiveness of different care 
strategies.  Furthermore  the  opportunity  costs  of  investment  in  management of  HIV 
infection for other sectors of the Health Service have not been examined. 
The majority of studies  have been carried out in  the United States  (US)  where the 
provision of health care setvice is  divided between the public and private sectors. In 
such a health care system estimates of cost per case are essential for the calculation of 
insurance premiums, and for reimbursement schemes for health care costs. In countries 
with largely publicly funded health care systems free at the time of need, estimates of 
cost remain important for central funding, but planning the future organisation of care 
remains a priority, particularly at a time of contraction in numbers of hospital beds and 
internal competition for finite resources. 
Previous studies (Bloom and Carliner, 1989; Scitovsky et al., 1986; Seage et al., 1986; 
Johnson et al., 1986) have shown hospital in-patient cost to be a major determinant of 
cost per case. In cities such as San Francisco the development of community care has 
been an important strategy for the reduction of in-patient stay (Amo, 1986), although 
the cost of community care alternatives elsewhere has been poorly documented. In the 
United Kingdom  (UK)  over the last two  years increasing efforts  have been made to 
reduce hospital stay and to develop setvices  in  the community (Kings  Fund Centre, 
1988), although these services have not been subjected to formal economic evaluation. 
The purpose of this  paper is  to describe the way in  which services have developed 
over time in the UK, and to examine the problems which face health care planners in 
determining  the  optimum  strategy  for  service  development  in  the  future.  Such 
strategies have been, and will be, determined by estimates of the current and future 
sizes  of the epidemic,  the geographical  distribution  of cases,  the existing  pattern of 
health setvice organisation and the physical and financial constraints upon the health 
care system. 99 
Epidemiology  of  HIV  and  AIDS  in  the  UK:  current  pattern  and  future 
estimates 
Any  attempt to plan services must take account of the current and estimated future 
number cases of AIDS and HIV infection. 
To the end of December 1988, 1982 cases of AIDS had been reported in the UK, 82% 
of them occurring in homosexual men. In 1988, a Working Party was convened by the 
Chief Medical  Officer  (Chairman, Sir David  Cox)  to provide current estimates of the 
number of persons infected with  HIV  in  England and Wales  and to make short term 
estimates  of the future  number cases  of AIDS  (Adler,  1987). The report reviewed  a 
number of methods for predicting future cases based on extrapolation techniques and 
on  complex  mathematical  models.  The  wide  variety  of  predictions  generated  by 
different models  underlines the difficulty  of making valid  estimates even in  the short 
term.  Nevertheless,  on  the  basis  of  mathematical  prediction  and  empirical 
epidemiological  data,  the  committee  concluded  that  between  20,000  and  50,000 
persons were  infected in  England and Wales  at the end of 1987. They provided a 
11recommended basis for planning,. estimate for  future cases,  calculating 5250 persons 
alive with AIDS at the end of 1992 in England and Wales. 
The geography of the epidemic 
Planning for  future services also demands an understanding of the geography of the 
epidemic. As in other countries, the majority of cases of AIDS have been diagnosed in 
major metropolitan areas. In  the UK  73% of cases of AIDS  have been reported from 
the  four  regional  Health  Authorities  of  the  Thames  Regions  surrounding  London. 
Furthermore,  the  majority  of  these  patients  have  been  looked  after in  three major 
hospitals  in  London. Thus the cost of care of a person infected with  HIV  has fallen 
largely on the National Health Service in  Central London. Since 1985 the three major 
centres have received additional central funding for the management of HIV infection. 
However,  over the last year,  while  the majority  of cases  have still  been diagnosed 
within  the  four  Thames  Regions,  there  has  been some  decentralisation  of  services 
away  from  the  three  major  centres.  Indeed  Regional  Health  Authorities  have 
encouraged other District General Hospitals to  develop services  for  HIV  themselves 
rather than referring cases to specialist centres. 
Service organisation 
The development of services for people with HIV  infection was  in part determined by 
the  history  of the service  structure.  In  the  UK,  there  is  a  network  of  open access, 
publicly funded sexually transmitted disease (SID) clinics. These services were popular 
with homosexual men before the advent of the AIDS  epidemic. They were trusted to 100 
provide an efficient and confidential service for  the treatment of SIDs, often without 
the knowledge of the patient's General Practitioner (GP).  Over 80% of cases of AIDS 
in the UK have been diagnosed amongst homosexual or bisexual men. It is  therefore 
not surprising that the first  cases  of AIDS  were  diagnosed in  London hospitals  with 
large SID clinics particularly favoured by homosexual men.  This service development 
contrasts  with  other  countries  where  care  of  people  with  AIDS  is  often  primarily 
undertaken by infectious disease physicians and oncologists. However the emergence 
of AIDS  amongst injecting drug users may in the future place very different demands 
on the service. This group tend to have poor access to Primary Health Care services 
and may have less physical and community support than, for example, gay men. 
In-patient care 
As  a  result  of  this  situation,  in-patient  care  for  AIDS  patients  fell  largely  on  three 
London  hospitals.  Specialist wards  were  developed  in  order to  centralise  medical, 
nursing and social aspects of care rather than for  control of infection reasons.  In  the 
early  days,  the stigma  attached  to  an AIDS  diagnosis  led  to  difficulties  in  nursing 
patients on open wards. Against the advantages of centralised care were weighted the 
problems of possible stigmatisation of the ward and concerns about staffing. In practice 
the ward has been popular with staff and well-accepted by most patients, but there has 
been  no  systematic work  to  evaluate  the  cost-effectiveness,  patient  acceptability  or 
clinical outcome for patients managed in specialist rather than generalist facilities.  This 
remains an interesting area for future research. 
The shift to community care 
One major disadvantage of this "hospital centred"  approach to care was the lack of 
involvement of traditional providers  for  primary  care,  i.e.  GPs,  District  Nurses  and 
social  services.  In  addition,  hospices  were  initially  reluctant to  take  on the  care  of 
people  with  AIDS  such  that those  who  might  be  more  appropriately  cared  for  in 
hospice facilities  were spending long periods  in  acute  hospital wards  (Adler,  1987). 
Over the  last year,  hospice  facilities  have been developed  in  two  specialist  units  in 
London, thus relieving the pressure on acute in-patient beds. 
There  is  evidence  (Department  of Health  Working  Group,  1988)  that HIV  positive 
people may be reluctant to reveal their HIV status to their GP because of fears about 
confidentiality or a negative reaction from the GP. Inevitably, SID physicians became 
involved  in  providing primary  care for  HIV  positive  patients,  which  might be more 
appropriately provided by GPs.  In  an attempt to improve links  between hospital and 
community services  and to  avoid  unnecessary  hospital admission,  Community  Care 
teams have been developed in London. These teams, comprising clinicians, nurses and 
social  workers,  have  the  function  of  facilitating  early  discharge  from  hospital; 101 
orgamsmg  services  and  providing  assessment  at  home;  and  arranging  referral  for 
hospice care.  They have provided a  much  needed bridge between hospital services, 
GPs and voluntary and statutory social services. These evolving patterns of care make 
future  planning for  hospital  and  Community  Care  facilities  a  difficult  task which  is 
made  all  the  more  complicated  because  of  the  uncertain  magnitude  of the  future 
epidemic. 
The impact of changing patterns of service on in-patient care 
Because of the diversity  of service  use by people with  AIDS,  data which  accurately 
measure and cost use  of service  on an individual basis  are laborious to collect  and 
require large sample sizes followed over long periods of time to adequately reflect the 
variability in  use of services from  diagnosis to death. The tendency has been to study 
only  hospital care. This  is  easily  measurable,  but of course has the disadvantage  of 
ignoring other aspects of care. However, highly detailed costing studies of individuals, 
which include use of community care, may be of limited  usefulness  if patterns of care 
are changing rapidly year by year. Such studies may be out of date by the time they 
are  completed.  An  alternative  approach which  provides  up-to-date  information,  at 
least for hospital planners, is  to develop a bed census which estimates the number of 
hospital beds occupied by patients with HIV infection over time and relates this to the 
caseload of patients with AIDS at any given point in time. 
Such a system  is  being developed  in  the three London centres so that comparisons 
may be made between institutions over time. 
The project involves a computerised data base which documents all  hospital stays for 
HIV related disease (both AIDS and Stage IV disease) by date and length of stay. Thus 
it is possible to generate a census of average number of occupied beds each month. In 
addition,  the  data base  collects  information  on each  case  of AIDS  diagnosed  in  a 
health district and each case of HIV  infection requiring hospital admission. The data 
base  includes  demographic  data,  transmission  category  information,  date  of  AIDS 
diagnosis  and AIDS  indicator  diseases.  From  this  a  ratio  can  be  calculated  of the 
number of beds occupied to the AIDS  caseload (prevalent cases)  at a given  point in 
time. The data set in our District (Bloomsbury) now includes data on 349 persons and 
886 inpatient episodes.  Preliminary  analysis  of this  data set  in  Bloomsbury  Health 
District shows that, while the AIDS  caseload has approximately doubled over the two 
year period (1987-1989) from  the opening of a dedicated ward for HIV infection, the 
number of beds occupied  has  remained  approximately  constant.  Thus  the  ratio  of 
occupied beds to AIDS  caseload has fallen  from  approximately 0.2 in  1987 to  0.1  in 
1989.  This  data  set  provides  constantly  updated  information  for  health  service 
planners but illustrates the uncertainties of planning in the rapidly changing field. Even 
over the short term,  estimates of  future  bed use  may be incorrect when patterns of 
hospital use change rapidly. 102 
The  factors  which  appear to  have  contributed  to  reduced  hospital  in-patient stays 
include the advent of anti-viral therapy, earlier diagnosis of AIDS  indicator diseases, 
changing treatments for  opportunistic infections and the development of hospice care 
and home care. 
Implications of changing patterns of care for economic studies 
Studies of individual hospital and medical cost, while useful for hospital bed planning, 
are restricted in  examining the wider economic and planning implications of the HIV 
epidemic. As care shifts  away from  hospitals, it may become increasingly important to 
measure the overall costs of different services and to develop comparative measures of 
110utput
11  in  terms  not  only  of  numbers  of  patients  treated,  but  also  in  terms  of 
satisfaction  of  patients,  relatives  and  carers.  This  may  also  lead  to  uncomfortable 
questions about how much  society  is  prepared to  invest in  AIDS  as  compared with 
other diseases.  However,  it  may  also  lead to  a  useful  evaluation  of care strategies 
which have implications in service developments in other fields, such as cancer services 
and care of the elderly. 
Conclusions 
In a public health care system with finite resources, studies of costs of care and health 
service  use  for  HIV  infection  are  essential  both  for  the  funding  and  planning  of 
services.  Cost per case  estimates  alone  however may  be of  limited  practical  use  to 
planners unless  they can be linked  more closely  to patterns of care and the overall 
development  of  services.  More  importantly,  much  of the service  development  has 
occurred without regard to the most cost-effective way of providing services. The time 
is  right  for  comparing different service 
11packages
11  in  terms  of patient acceptability, 
costs of care and disease outcome. 
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M. Drummond, L. Davies 
1.  Introduction 
AIDS  is  not  only  a  disease  of  great  social  concern;  it  also  has  major  resource 
implications.  In  most of the developed  countries  governments have been concerned 
about the costs of treating an increasing number of cases and the costs  of mounting 
major  public  information  campaigns  to  prevent  the  spread  of  the  disease.  The 
increased expenditure on treatment has raised questions about the relative priority that 
should be assigned to interventions for AIDS  and HIV infection, when there are many 
other potential uses of scarce health care resources.  The relative value for  money of 
alternative treatment packages has also been a source of debate. 
In principle economic evaluation can assist those making choices in  the allocation of 
health care resources at national, regional and local levels. A number of studies of the 
costs  of  treating  AIDS  and  the  related  consequences  of  HIV  infection  have  been 
published in recent years. Given the increasing concern about the economic impact of 
AIDS and the growing economics literature, this paper: 
Briefly outlines the methods of economic evaluation of health care programmes 
Reviews and interprets existing studies of the costs of treating AIDS 
Specifies how one would undertake an economic evaluation of a programme for 
the treatment of AIDS, using the example of drug therapy. 
2.  Methods for the economic evaluation of health care programmes 
The  methods  for  the  economic  evaluation  of  health  care  programmes  have  been 
extensively documented elsewhere  (Weinstein  and Stason,  1977; Warner and Luce, 
1982; Drummond et al.,  1987), so  only a few  methodological issues pertinent to the 
evaluation of AIDS programmes will be highlighted here. 
First, economic evaluation should embody a comparison of alternatives. These may be 
alternatives  in  prevention,  diagnosis,  treatment  or  the  organization  of  services. 
Therefore, cost of illness studies (Scitovsky and Rice,  1987) are not of themselves full 
economic  evaluations,  although  they  may  provide  useful  background  data  for 
discussions of priorities in research or treatment (Black and Pole, 1975). 108 
Secondly,  economic  evaluations  require  an  assessment  of  the  effectiveness  of  the 
health  treatments  or  programmes  concerned.  Ideally,  this  should  be  established 
through  controlled  studies,  such  as  randomised  controlled  trials.  However,  the 
difficulties in mounting trials in a disease like AIDSIHIV should not be under-estimated. 
Being a life-threatening condition it  has inevitable emotional overtones which militate 
against  random  allocation  of  subjects  to  receive,  or  not receive,  a  new  treatment 
technology.  Also,  treatment  practices  have  changed  rapidly,  making  the  strict 
adherence to trial protocols difficult. However, the danger is that new treatments may 
not be properly evaluated and economists will  have to use guesswork in assessing the 
cost-effectiveness of treatments or programmes. 
Thirdly,  an  appropriate  range  of  costs  and consequences  needs  to  be  considered. 
Fig. 1 gives  the  relevant range  for  the evaluation  of  options  from  the  viewpoint  of 
society. Other viewpoints include those of the hospital, health care system, government 
or  patient.  Different  viewpoints  imply  consideration  of  different  costs  and 
consequences  so  it  is  important  that  the  viewpoint  of  the  evaluation  be  stated 
explicitly.  Economists  argue that the societal  viewpoint,  being the  broadest,  should 
always be considered by health policy makers. 
In  particular, significant amounts of voluntary and informal care resources  are being 
consumed  in  AIDS/HIV  programmes  in  many  developed  countries.  Therefore  it  is 
important that health policy is not determined solely by economic studies that focus on 
a  more  narrow  hospital  or health  care  sector perspective.  Indeed one of the  most 
interesting  issues  for  economic  evaluation  is  the  comparison,  in  terms  of  value  for 
money,  of  comprehensive  community-based  care,  using  voluntary  support,  with 
traditional hospital-based regimens. 
Finally,  more  effort  needs  to  be  placed  on  the  intemretation  of  study  results  for 
decision  making  purposes.  Given  the comments  made earlier about uncertainties  in 
assessment  of  the  effectiveness  of  interventions  and  the  additional  difficulties  of 
interpretation  of  results  from  one setting  to  another,  it  is  important that economic 
evaluations incorporate a sensitivitv analysis, where the estimates are produced using a 
range of values for the key parameters. 
Also,  given the need to assign priorities between programmes for AIDS/HIV and other 
diseases, it is  important that the results of economic evaluation be comparable across 
different health care interventions.  One promising approach  is  the calculation  of the 
cost  per quality  adjusted  life-year  gained  (QAL  Y)  from  different  interventions  (see 
Table 1). If the results for AIDSIHIV programmes are to be included in such tables in 
the future,  data will  be required  not only  of the  extension  of  life  from  treatment or 
prevention, but also of the .9.Y..9.lml of that life  (see Fig. 2). Economists and others have 
developed  a  number of  approaches  for  measuring  the  quality  of  life  (Katz,  1987; 
Teeling Smith, 1988; Walker and Rosser, 1988). C
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Table 1.  'League table' of costs and QUAL  Ys for selected health care interventions (1983-84 prices) 
Intervention 
GP advice to stop smoking 
Pacemaker implantation for heart block 
Hip replacement 
CABG for severe angina LMD 
GP control of total serum cholesterol 
CABG for severe angina with 2VD 
Kidney transplantation (cadaver) 
Breast cancer screening 
Heart transplantation 
CABG for mild angina 2VD 
Hospital haemodialysis 
Adapted from Williams, 1985, 1986 
Present value of 
extra cost per 
QUAL  Y gained (£) 
170 
700 
750 
1,040 
1,700 
2,280 
3,000 
3,500 
5,000 
12,600 
14,000 
CABG: Coronary Artery Bypass Graft; LMD: Left Main Disease; 2VD: Two Vessel Disease 
Perfect Health  1 
With treatment 
Health Index 
Time of treatment  Death  Death 
Time  (Years)-
Fig. 2.  Quality-adjusted life-years added by treatment 111 
3.  Interpreting existing studies of the costs of AIDSIHIV programmes 
A number of studies  of the  costs  of AIDSIHIV  programmes  in  developed  countries 
have been published (Scitovsky  and Over,  1988; Drummond and Davies,  1988) (see 
Table  2).  These  relate  almost  exclusively  to  hospital-based  treatment  or care  and 
confine their consideration to health sector costs.  It  is  important to bear a number of 
points in mind when interpreting these studies. 
Table2.  Costs of treating AIDS (1986 prices) l) 
Source  Year of  Lifetime cost  Length of sur- Cost/person 
estimate  per person ($)  vi  val (months)  per year($) 
USA 
Hardy et al., 1986  1984  155,400  13.0  143,400 
Scitovsky et al., 1986  1984  29,200  7.4  46,700 
Seage et al., 1986  1984  NA  NA  49,200 
Andrulis et al., 1987  1984  NA  NA  38,300 
Kizer et al., 1986  1985  92,800  18.0  61,900 
Kizer et al., 1987  1986  70,000  18.0  46,700 
Lafferty et al., 1988  1985  19,600  7.2  32,700 
Scitovsky and Rice, 1987  1986  NA  NA  33,700 
Pascal, 1987  1986  94,000  15.0  75,200 
Hay et al., 1987  1987  32,900  12.0  32,900 
Hellinger, 1988  1985  58,100  24.0  29,100 
Hiatt et al., 1988  1987  33,900  15.1  24,200 
France 
Debeaupuis and  1986  NA  NA  21,800 
Tcheriatchoukine, 1987 
Germany 
AUK (Berlin), 1987 2)  1986  36,600  18.0  24,400 
UniversiHi.ts Poliklinik  1986 
(Munich) 1987 2) 
11,400  6.6  20,900 
United Kingdom 
Johnson et al., 1986  1984  13,400  5.2  31,000 
Cunningham and Griffiths, 1988  1986  47,200  12.0  47,200 
Rees et al., 1988  1987  NA  NA  24,600 
Australia 
Whyte et al., 1987  1986  17,300  7.2  28,800 
Canada 
Fanning et al., 1987  1983  NA  NA  33,900-47,500 
1)  These costs have been adapted from the papers by Drummond and Davies (1988) and Scitovsky and 
Over (1988). Discrepancies in the costs reported in these papers and the costs presented here are 
due mainly to our use of a more recent version of OECD purchasing power parity exchange rates 
(OECD, 1987). 
2)  Personal communication 112 
First,  most studies  report merely  the  current costs  of care for  people with  AIDS  or 
related  conditions.  Few  discuss  the  question  of  alternative  methods  of  care,  or  the 
effectiveness of the treatments being given. 
Secondly,  in  order to make  informative  comparisons,  the raw  cost data reported  in 
individual studies needs to be adjusted. It has been suggested that the best method of 
adjustment is  to calculate the cost per person per year and to use purchasing power 
parities in  making exchange rate conversions (Scitovsky and Over,  1988; Drummond 
and Davies, 1988). 
Thirdly, there are important differences in  study methodology that are likely  to affect 
the estimates obtained. These include the categories of patients included in the study, 
the range of costs  considered (hospital costs  only,  or including ambulatory care)  and 
the methods of cost calculation (average daily hospital cost, or more detailed study). 
Finally, the studies differ both in their date and setting. Therefore, it  is  likely that they 
reflect different treatment technologies, which have changed through time and varied 
by location. For example, there have been significant changes in  drug therapy and a 
shift towards community-based care. The studies also reflect key features of the health 
care systems  in  which they were  undertaken. For example,  longer hospital stays  are 
likely in a country like the Federal Republic of Germany, where secondary and primary 
care  services  are  not closely  linked.  Also,  the  availability  of  drugs  may  differ  from 
country to country. 
Nevertheless,  a  fairly  constant pattern appears  to emerge  from  the existing  studies. 
Namely, the cost of caring for a person with AIDS is similar to that of caring for people 
with other end-stage diseases, such as cancer or chronic renal failure. As yet there are 
no data on the cost per QAL  Y gained from treatment for AIDS to compare with that of 
other health care interventions. 
4.  Economic  evaluation  of programmes  for  AIDSIHIV:  the  case  of  drug 
therapy 
Given the need for data on the value for money of programmes for AIDS/  ARC and the 
difficulties in  interpreting existing cost estimates,  how should economic evaluations be 
carried out? This  issue  is  addressed below,  using the example of drug therapy. Drug 
therapy has been chosen because of the concerns  about the  cost  of  medicines  for 
AIDS, most notably zidovudine  (Retrovi~). 
The first  methodological issue concerns the alternatives for comparison. Zidovudine is 
now  widely  prescribed  for  patients  with  AIDS  and  AIDS  related  complex  (ARC), 
following  the extension in  the length  of life  of patients shown in  earlier clinical trials 
(Fischl  et  a!,  1987).  It  would  therefore  now  be  considered  unethical  to  compare 113 
zidovudine to no treatment in  these patients, although such a  comparison could  and 
should be made in persons with earlier stages of the disease. The main alternatives for 
patients  with  more  advanced  stages  of  the  disease  are  between  zidovudine  as 
monotherapy  and  combination  therapy  with  other  medicines.  Even  so,  it  may  be 
difficult to undertake controlled trials at the present time, for the reasons stated earlier. 
Ideally economic evaluation should be based on sound evidence of the effectiveness of 
the  medicines  concerned.  Therefore,  where  possible  the  evaluation  should  be 
conducted alongside  a  clinical  trial,  or based  on  evidence  gained  in  earlier  clinical 
studies.  The main measure of effectiveness  in  clinical  trials  for  AIDS/ ARC  patients is 
length  of survival.  This  would  enable  a  cost-effectiveness  analysis  to be performed, 
giving an estimate of incremental cost per life-year gained. 
However,it may be better to adjust the years of life  gained by a measure of the quality 
of the  extra years,  thereby conducting a  cost-utility  analysis.  The  advantage of  this 
approach would  be that drug therapy for  AIDS/ARC  could  be compared with  other 
health  care  interventions  in  terms  of  its  incremental  cost  per  QAL  Y  gained.  This 
approach should clearly be considered since the quality of the added years may be less 
than perfect. Patients may suffer infections, be considerably distressed,  or experience 
side effects  of therapy.  Therefore trials  of drug therapy for  AIDS/ARC  should  either 
include a measure of health-related quality of life, or collect clinical symptomology data 
in a way that would enable the health status of patients to be categorised on a generic 
scale, such as that developed by Kind, Rosser and Williams (1982) (see Table 3). 
Table3.  Valuation matrix for 70 respondents 
Disability rating  Distress rating 
A  B  c  D 
No distress  Mild  Moderate  Severe 
I  No disability  1.000  0.995  0.990  0.967 
II  Slight social disability  0.990  0.986  0.973  0.932 
III  Severe social disability and/or  0.980  0.972  0.956  0.912 
slight physical impairment 
IV  Physical ability severely limited  0.964  0.956  0.942  0.870 
(e.g. light housework only) 
v  Unable to take paid employment  0.946  0.935  0.900  0.700 
or education, largely housebound 
VI  Confmed to chair or wheelchair  0.875  0.845  0.680  0.000 
VII  Confmed to bed  0.677  0.564  0.000  -1.486 
VIII  Unconscious  -1.028 
Source: Kind et al. (1982) 
Notes: healthy= 1.0; dead=  0.0; * =not applicable 114 
Trials  of drugs  in the earlier stages of the disease, such as in  people who are merely 
HIV  positive,  may  use  progression to  AIDS/ARC  as  their primary  end-point. This  is 
acceptable providing there is  no reason to suppose that earlier administration of drugs 
affects the survival of patients in the later stages of disease. Otherwise the length and 
quality of survival should also be assessed in these studies. 
The relevant range of costs to be considered in  an evaluation of drug therapy would 
include not only the cost of the drugs themselves but also: 
The number  of  inpatient  hospitalizations  and the  length  of  stay by  category  of 
ward. 
The number of hospital outpatient visits. 
The  number  and type  of  laboratory  tests,  either  to  assess  suitability  for  drug 
therapy, or to monitor the effects of therapy. 
The costs of diagnosing and treating opportunistic infections and the side effects of 
drug therapy. 
The  number  of  blood  transfusions,  and  whether  these  are  performed  on  an 
inpatient or outpatient basis. 
The costs  of care  given  outside  the  hospital by  other governmental,  private  or 
voluntary agencies. 
A key issue in the analysis of these data would be to assess whether drug therapy adds 
further to costs, through the need for close patient monitoring and blood transfusions, 
or,  alternatively, whether there are savings  in  the use  of health care resources which 
partly offset the cost of the drug.  For example,  patients whose health status  is  being 
better maintained may require fewer hospitalizations. 
Other items that are relevant include the patients' work status and the social security 
payments  received.  The  latter  items  are  particularly  relevant  to  the  government's 
viewpoint,  although therapy in  the advanced stages  of disease  may not affect them 
very much. 
Finally,  the study design should pay attention to the need to interpret the results  in 
different  settings.  This  is  important  since  the  opportunities  to  undertake  controlled 
evaluations  of  drug therapy for  AIDS/HIV  are  likely  to  be  few  and many trials  are 
themselves undertaken in a number of centres, often spanning a number of countries. 
The potential for interpretation and synthesis of economic evidence from  a number of 
locations  or settings  is  the subject  of  one of  the sub-projects  of another European 
Community  Concerted  Action  in  the  field  of  health  technology  assessment 
(Drummond, 1987). A particularly important point is that resource consumption should 
be recorded in terms of the physical quantities (e.g.  hours of nursing time)  as well  as 
the  financial  amounts.  In  addition,  in  health  care  systems  with  extensive  financial 
transactions between providers  and third  party  payers,  it  is  important to  distinguish 
between costs and charges (Finkler, 1982). 115 
5.  Conclusions 
Because  interventions  for  AIDS/HIV  consume  scarce  health  service  resources,  they 
should  be  subjected  to  economic  evaluation.  Such  evaluation  will  be  helpful  in 
searching for more cost-effective strategies and in assigning the appropriate priority to 
this disease compared to others. 
If evaluations  are  to  be  carried  out it  is  important that they  are  methodologically 
sound. Several features of a good economic evaluation have been specified, including 
the comparison  of alternatives,  the assessment  of  effectiveness  through a  controlled 
study,  the  enumeration  of  a  wide  range  of  costs  and  consequences,  and  the 
appropriate interpretation of study results. 
Several studies  of  the costs  of treating AIDS  and the related  consequences of HIV 
infection  have  already  been published.  Care  needs  to  be  exercised  in  interpreting 
study results and the key issues in  undertaking this task have been identified. A fairly 
constant pattern  appears to  emerge  from  the  existing  studies.  Namely,  the  cost  of 
caring for  a person with  AIDS  is  similar to that of caring for  people with  other end-
stage diseases, such as cancer or chronic renal failure. 
Finally  the  example  of  drug  therapy  has  been  used  to  illustrate  how  the  key 
methodological features of economic evaluation can be incorporated into study design. 
It is recommended that this be done more often in the future. 
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Case Study. Sweden 
M. Lagergren 
In the absence of an effective  cure or vaccine for AIDS,  prevention still stands out as 
the only way to combat the spread of the epidemic. WHO has developed a Global 
Programme on AIDS for this purpose, and all countries in Europe are by now engaged 
in fighting the disease through a range of prophylactic methods. 
Possible preventive measures against AIDS include among others: 
Screening of blood and blood products from blood donors 
Organization  of information  campaigns  aimed  at behaviour modification  in  the 
general public or specifically targeted at persons with risk behaviour 
Provision of testing for  HIV antibodies, either voluntary or mandatory and either 
for special groups or for the general public 
Contact tracing 
Organization  of  campaigns  to  encourage  the  use  of  condoms,  for  instance 
including free supplies 
Supply of clean needles to intravenous drug users 
A programme of prevention will  have to  include several  or all  of these measures  in 
order to be efficient. In  designing the programme it  is essential to try to estimate costs 
as well  as  effects  on the spread of the disease for the different preventive measures. 
These estimates can then be used as  a basis for evaluation of alternative programmes. 
The  concept  "costs"  should  be  interpreted  in  this  context  in  the  broadest  sense 
including  direct  and  indirect  economic  costs  as  well  as  political  and  ethical 
considerations. 
Direct economic costs for  preventive measures include e.g. costs for blood screening, 
advertising campaigns, HIV  antibody testing, supply of free  condoms etc.  These costs 
are normally easy to estimate.  Table  1 shows governmental expenditure on different 
items for 1987 in Sweden. 
As  can be seen from  Table  1 the 1987 governmental expenditures on prevention in 
Sweden were far  from  insignificant.  The  total  amount,  256 million  Swedish  kronen 
(MSKr),  can be compared to the cost for treatment of HIV/AIDS patients, which in the 
same year amounted to 57 MSKr.  Such a relationship between costs for  prevention Table 1.  Costs for HIV prevention. The case of Sweden, 1987 
Testing blood donors 
Other HIV testing 
Information campaigns 
Other costs for prevention 
(counselling, research, etc.) 
Total 
Source: Brorsson and Herlitz, 1988 
Total cost (MSKr) 
46 
78 
40 
92 
256 
119 
Cost per inh. (SEK) 
6 
9 
5 
11 
31 
and costs  for care  are almost  unique  for  HIV/AIDS.  The  general  rule  in  the  health 
services is  that expenditures for prevention - albeit difficult to obtain a true estimate -
amount to  a  few  percent of  the total  health  care  expenditures.  The  only  rational 
explanation for this discrepancy must be the general belief that successful prevention 
will save much larger costs in the future. 
Even if the economic costs of prevention, as can be seen from Table 1, are quite high 
they are by no means unsurmountable in  a developed country. The situation  is  very 
different in  developing countries. Even such obvious and relatively cheap preventive 
measures  as  the  testing  of  blood  donors  may  in  some  cases  be too  expensive  to 
implement. 
In  developed countries other. obstacles  rather than pure economic costs  obstruct the 
path  for  the  introduction  of  preventive  measures  (Lee  and  Moss,  1987}.  These 
stumbling  blocks  may  be  ethical  in  nature,  as  e.g.  promotion  of  condom  use  in 
countries  where  moral  and  religious  beliefs  run  contrary  to  such  practice.  HIV 
prevention policies  might come  in  conflict with  other aims  of society,  e.g.  supplying 
free  needles  to  IV-drug  abusers,  which  carries  the  risk  of  promoting  drug  abuse. 
Preventive  measures  could  also  be opposed  on the  grounds  that they circumscribe 
individual freedom or infringe on individual rights. Hard-hitting information campaigns 
carry the risk  of raising unnecessary anxiety and fear among the general population 
with  low  or non-existent risk  of ever catching the disease.  On the other hand those 
who run a real risk may tend to ignore a too soft message. The formulation of efficient, 
behaviour changing messages is thus a very delicate task. 
The benefits of HIV  prevention are as  a  rule much  more difficult to assess than the 
costs.  To  acquire  some  kind  of  quantitave  estimation  one  has  to  rely  upon  a 
mathematical model, that will  calculate the effect of different preventive measures in 
terms  of  e.g.  reduced  number of deaths  in  a  specific  period  of time  given  certain 
specified assumptions. The problem is that precise calculations of this kind require data 
concerning infectivity,  rate  of contacts  and partner change,  patterns of relationships 120 
between different groups etc, that we do not have and in all probability will never get -
at  least  not  in  the  required  detail.  Precise  cost  benefit  evaluations  of  different 
preventive measures will therefore not be possible to make. 
This  does  not mean,  however,  that mathematical modelling  is  useless  as  a  tool  for 
programme evaluation. It only means that we must use the mathematical models in  a 
different way - rather to obtain qualitative insight into the epidemiological process and 
the ways a preventive measure will interfere in the spread of the disease than to get a 
precise  estimate  of  the  outcome.  With  this  general  philosophy  in  mind  we  have 
developed  a  family  of  HIV  epidemiological  computer  models  at  the  Karolinska 
Institute,  starting  from  the  simplest  situation  of one group  of  subjects  and  moving 
gradually  into  the  description  of  more  complex  patterns.  Using  these  fairly  simple 
models the effects of different preventive measures can be illustrated and some general 
conclusions  can  be drawn.  The  basic  principle  behind  the  epidemic  spread  of  all 
contagious  diseases  is  that propagation of  an epidemic  requires  that each afflicted 
person will infect at least one other person. When this holds there will be an epidemic 
and the epidemic will  continue as  long as  the condition is  fulfilled.  When it does not, 
the epidemic will not arise or, if it has already started, will gradually taper down. 
This basic concept, the estimated number of persons infected by each infected person, 
is  in  the case of HIV transmission in  a  homogeneous group given by· the expression 
(Andersson and May, 1987) 
R  =  C*B*D 
where  C  is the number of partners 
B  the probability of transmission per partner 
D  the duration time of infectiousness and 
R  the Basic Reproduction Rate 
If R  is  greater than 1 we  will  get an epidemic,  if  it  is  less  than 1 we  will  not.  The 
magnitude of R will  determine the speed of the epidemic spread. If R is  near one the 
spread in a group may take many decades but if it is above, say 5, it will be a matter of 
years. 
In  theory, to prevent an epidemic breaking out simply means controlling R so that it 
stays less than one. 
In  practice there  are  many problems  to be considered.  The  population  can  not be 
regarded as  homogeneous. It consists  of  a  great number of different  approximately 
homogeneous sub-groups  which  are  distinguished  with  respect to sexual behaviour, 
partner selection and change rate, presence of cofactors with  relevance for  infectivity 121 
and susceptibility etc. These subgroups are more or less connected to each others by 
way  of  partner exchange and in  this  way  the epidemic may  spread from  group  to 
group. 
One  way  of  describing  the  HIV  epidemic  is  then  to  describe  the  incidence  and 
prevalence of HIV  infection in  the different groups involved and the rate of infection 
that  is  carried  between  the  groups.  Some  general  conclusions  from  modelling  the 
epidemic  spread  within  and  between  such  groups  can  then  be  stated.  These 
conclusions all stem from the concept of the basic reproduction rate. 
1.  In  a  group  where  the  conditions  for  an  epidemic  exist,  i.e.  R  > 1,  once  the 
epidemic has started it will not end until everyone in the group is  infected, or the 
basic conditions have changed. 
2.  If the conditions for an epidemic do not exist in  a group, i.e.  if R < 1, the number 
of infected will only continue to increase as  long as  infections are brought in  from 
outside  the  group.  When  these  cease  to  come,  the  epidemic  in  the  group  will 
gradually taper off. 
This  means that if  the incidence rate  is  falling  to  nearly zero  in  a  group before the 
saturation level is reached either some behaviour change has occurred in the group, or 
the group was not properly defined in  the first  place,  i.e.  it was  not a homogeneous 
group with  regard to partner selection.  In the latter case the "real" homogeneous sub-
group has become saturated and the infection of the rest of the group will depend on 
what relations they have with  the saturated subgroup. If the conditions for  epidemic 
spread are fulfilled  in  the remaining subgroup,  a  small  number of  contacts with  the 
infected group will  be sufficient for  the epidemic to continue and gain speed after a 
time lag of perhaps several years. 
When it comes to prevention it is obviously very important to know which one of these 
alternatives is  true. If behaviour has changed in  the whole group prevention must be 
geared at maintaining that good situation. In the other case it becomes paramount to 
identify  the  subgroups  and  direct  the  preventive  efforts  towards  the  non-infected 
group. 
Preventive efforts could have as a goal to 
1.  Reduce the number of contacts with (potentially) infected partners 
2.  Reduce the probability of transmission of HIV virus 
One of the purposes of HIV testing is  to identify the infected individuals so that their 
behaviour can be modified - voluntarily  or by coercion - in  order to stop  or reduce 
their contribution to the further spread of the infection. 122 
The question then is:  What effect will testing a certain proportion of the population (or 
groups  at  risk)  have  on  the  development  of  the  epidemic,  given  that  a  certain 
proportion of those tested and found HIV positive will stop spreading the virus? 
A  computer  simulation  on  a  homogeneous  group  with  high-risk  behaviour  (10 
partners/year;  risk  of infection  per partner 0.2)  yielded  the results  shown  in  Fig.  1. 
(Lagergren,  forthcoming).  The chosen effect  measure is  percentage reduction  in  the 
number of persons in the group dead because of AIDS within 20 resp 40 years. As can 
be seen the death number in 20 years will be reduced by more than 50% if 30% in the 
group are tested each year and 50% of those found HIV positive stop spreading the 
disease. 
It is  important to note thaf the result will  not be as favourable if the period of time  is 
stretched to 40 years.  The reason for this  is  that this  preventive measure will  not be 
sufficient to bring the basic reproductive rate below one. The effect will then only be to 
slow down the spread. The epidemic will be postponed but not inhibited. 
One way of reducing the risk of transmission per sexual contact is the use of condoms. 
The efficacy of condoms has been debated. A very conservative measure derived from 
studies of unwanted pregnancies is  that condoms will reduce the risk for transmission 
of the HIV virus by a factor of 10 (Hearst and Hultey,  1988). What effect will  it then 
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have on the spread of the epidemic if a certain percentage of all members of a group 
use condoms? The result is  shown in  Table 2 for two different groups:  one high  risk 
group with  10 partners per year and one low risk group with 3 partners. Both groups 
are initially above the critical reproduction rate but the spread of the infection will take 
a considerable time  in the second group. The outcome measure is  again the percent-
age reduction of the number of deaths because of AIDS in 20 resp 40 years. 
Another way of describing the effects  of condom use is  by showing the prevalence of 
HIV infection as a function of time in the different cases. It will be noted here that even 
with 75% condom use in the high risk group the epidemic is not brought to a standstill 
but only postponed. In the low  risk group,  however, 75% of condom use is sufficient 
and the prevalence of HIV infection will  actually be decreasing over time  (see Fig.  2a 
and Fig. 2b). 
Given the basic mechanisms of the epidemic it  is  important to be able to evaluate the 
relative effects of barring entrance to a group compared to changing conditions in that 
same  group  through  different  behaviour  modifications.  In  the  last  figure  the  HIV 
prevalence  is  shown  in  a  certain  group  as  a  function  of time  under four  different 
assumptions. 
Alt. A  The members of the group have 3 partners per year.  Of these 0.1  partners 
are from a high risk group with a total of 10 partners per year and initial HIV 
prevalence of 0.001. 
Table 2.  Reduction of the number of deaths because of AIDS by condom use 
Rate of condom 
use per contact 
0 
0.25 
0.5 
0.75 
1 
High risk group 
(10 partner/year) 
Perc. reduction of 
no. of AIDS deaths 
20 yrs 
0 
61% 
85% 
94% 
97% 
Assumed rate of infection/partner 
40 yrs 
0 
23% 
72% 
97% 
99.7% 
High risk group 
Without condom 
With condom 
0.08 
0.01 
Low risk group 
(3 partner/year) 
Perc. reduction of 
no. of AIDS deaths 
20yrs  40yrs 
0 
25% 
44% 
58% 
68% 
0 
57% 
81% 
90% 
95% 
Low risk group 
0.16 
0.03 124 
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As alt. A, but the number of partners from the high risk group is reduced by a 
factor of 10 to 0.01. The number of partners from the low risk group remains 
the same. 
As  alt.  A,  but the number of partners from  the low risk group is  reduced to 
0.9.  The  number of partners  from  the  high  risk  group  remains  the  same 
(meaning that their proportion has increased}. 
As  alt.  C,  but the total number of partn~rs is  reduced to 1 per year with the 
proportion of partners from the high risk group remaining the same. 
The difference in outcome between the strategies can clearly be seen as a question of 
time-perspective.  Barring  contacts  with  the  high  risk  group  has  positive  short term 
effects but if basic conditions for the epidemic spread are unchanged, the epidemic will 
gather speed in the long run despite narrowing the "channel" between the groups. On 
the contrary reducing the number of partners within  the low  risk  group shows small 
advantages  in  the short run  - especially  if  no  corresponding  cuts  are  made  in  the 
contacts with the high risk group - but in the long run this strategy still comes out more 
efficient.  Most  efficient  of course  is  the  fourth  alternative with  reduction  in  partner 
frequency both within and outside the group. 
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Some lessons  can be learned when  it  comes to designing preventive strategies  from 
these  rather simple  computational exercises.  Due to the  long  incubation period the 
time-constant involved in  the development of the epidemic is  very long. All  measures 
must be considered  in  a  time  perspective which  lies  outside  most of the affairs  we 
handle.  Sometimes  there  might  be  a  conflict  depending  on which  perspective  we 
apply. What seems good in the short run might be devastating in the long run. Since 
the spread in the population goes through a number of subgroups or strata it becomes 
important to try to define these groups and direct the prevention efforts towards them. 
General surveys of sexual behaviour seem less  to the point in  this case than selective 
investigations directed toward different groups that are especially at risk. 
The risk  for  a  general spread  of the epidemic  in  the  total  heterosexual  population 
seems at present low since the conditions for epidemic spread do not seem to be met. 
The preventive effort must then be directed towards halting the spread within groups 
at high  risk  and  reducing  as  much  as  possible  the  accidental  infections  that these 
groups  might  spread  out  to  other  groups.  These  efforts  justify  quite  substantial 
expenditures. The problem is to maintain these efforts in the long run when the public 
arousal triggered by the first appearance of the epidemic has subsided. 
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1.  Introduction 
Since  1985 the  analysis  of  the  economic  impact  of  the  AIDS  epidemic  has  been 
increasing in  importance.  One aim  of this  research  is  to provide an estimate of the 
financial effects of AIDS as early as possible. Existing studies assess mainly the costs for 
treatment of AIDS  patients  in  different  health  care settings  (Drummond  and Davies, 
1989). 
Currently,  we  have  neither  an  effective  vaccine  against  the  HIV  infection  nor an 
effective treatment for  AIDS  in  its  different stages. To delay the advance of the HIV 
epidemic,  preventive  measures  are  of  central  importance.  The  costs  of  preventive 
measures must therefore be included in  the analysis of the socioeconomic aspects of 
AIDS.  To meet this objective,  the Institute for  Health Systems Research conducted a 
study to evaluate the various measures for AIDS prevention in the Federal Republic of 
Germany and estimate  the  costs  incurred  by  various  institutions  during  1987.  The 
research was sponsored by the Federal Ministry of Health. 
2.  AIDS prevention measures 
To  carry out this  research, the current AIDS  prevention measures were  divided into 
three categories. The first category comprises common information about the infection. 
Special counselling and educational work is offered to specific risk groups, HIV positive 
persons and their relatives. A HIV  antibody test is  also provided free  of charge. Most 
information  and counselling  are offered  by  state and local  health offices,  voluntary 
non-profit organisations,  health care  associations  and self-help  groups.  The work  of 
these institutions is largely financed by federal and state governments. 
The second category consists of additional hygienic measures taken within health care 
institutions  to  protect  staff  and  patients.  Hygienic  measures  for  the  police,  penal 
institutions and certain parts of the services sector have also to be taken into account. 
The  third  category  comprises  research  aimed  at  developing  a  vaccine,  improving 
treatment or prevention and establishing meaningful figures on the AIDS epidemic. 128 
Some of the  government measures  against  AIDS  induce  private  expenditures.  One 
example  of  private  expenditure  to  prevent AIDS  is  the  requirement that  all  motor 
vehicles  be  equipped  with  safety  gloves.  Since  there  are  no  data  on  the  yearly 
consumption of safety gloves,  no estimate of costs was made. Another example is the 
increase  in  expenditure  associated  with  the  use  of  condoms.  These  are  not easily 
apparent and cannot be attributed solely to AIDS prevention. 
3.  Methods 
First, we identified the institutions engaged in AIDS prevention in the Federal Republic 
of Germany. Secondly, a survey was conducted among persons responsible for AIDS 
prevention measures to inquire into their relevant expenditures in 1987. 
The  survey  results  provide  an  estimate  of  the  cost  of  AIDS  prevention  from  an 
institutional viewpoint  (Leidl,  1988).  The  measures  were estimated according to the 
expenditure data submitted  by the various  institutions.  The  survey was  carried  out 
between March 1st and October 30th 1988. 
A complete enquiry of all federal and state administrations involved,  health insurance 
funds,  welfare  organisations,  professional  groups and other health  care  associations 
was  carried  through.  42  out  of  48  institutions  adressed  replied.  To  assess  the 
expenditures of local governments, a short questionnaire was sent to 46 municipalities 
and 50 county administrations. Answers that could be evaluated were returned by 37 
county administrations  and 34 municipalities.  To  gain  insight into  the costs  of AIDS 
prevention in  the hospital sector, 11  hospital administrators and physicians who have 
experience in  treating of AIDS  patients were interviewed.  In  addition, 24 universities 
with medical faculties were questioned. To  assess the expenditure on AIDS  research, 
the  universities  were  also  asked  to  include  AIDS  related  research  in  non-medical 
faculties. 23 universities answered. 
Most AIDS prevention measures are financed in part by federal or state subsidies. The 
amount of these subsidies  was  established to prevent double counting when federal 
and state funds  were  added.  This  means that those  expenditures  mentioned in  the 
following are always from the institutions' own funds.  The quality of the data is varied. 
The  information  given  by  the  regional  administrative  bodies  can  be  expressed  in 
figures  and  is  comparable  to  a  large  extent.  Health  insurance  funds,  welfare 
organisations  and some  of the  universities  sent a  mainly  verbal description  of their 
activities.  The federal expenditures for some sectors could not be extrapolated. If not 
otherwise mentioned, the following  details refer to 1987. The results presented are a 
conservative estimate of the public costs of AIDS prevention in the Federal Republic of 
Germany. 129 
4.  Results 
The  first  section  includes  expenditure  for  the  production  and  dissemination  of 
information, counselling and financial support of AIDS education centres. Fig. 1 shows 
the financing institutions and their expenditure. A total of 118.4 million OM was spent 
on AIDS information, education and assistance. About 63% of these funds came from 
the Ministry of Health. 43 million  OM were spent on the information campaign by the 
Federal Centre of Health  Education. In  the same year, the states spent 30.5 million 
OM,  or 25.5%  of  all  AIDS  related  expenditure  for  information  and counselling  on 
AIDS. 
Approximately 9 million OM,  or 7.6% of the expenditure for information and personal 
counselling, was spent by the municipal governments. Half of the expenditure arises in 
towns  with  more than 500,000  inhabitants.  Most  of  the towns'  resources  for  AIDS 
Institution 
Ministry of 
Health 
States 
Municipalities 
Voluntary non-
profit orga-
nisations 
Ministry of 
Defence 
Total 
Issue 
Financial support 
of counselling centres 
Information 
campaign by the 
Federal Centre of 
Health Education 
Financial support of 
counselling centres, 
Information 
Person~  counselling 
Personal counselling, 
Information 
Information 
Expenditure  Percentages 
lnMio.DM 
30.9 
43.5 
30.2 
62.9% 
9.0 
4.6 
25.5% 
7.6% 
0.2  4% 
118.4  100% 
Fig. 1.  AIDS prevention 1987, expenditure on information, counselling, fmancial support of counselling 
centres 130 
prevention measures were raised by local public health agencies and by social welfare 
agencies. Expenditures for the municipalities resulted from: 
J-IIV tests, precautionary measures, information 
Subsidies for local AIDS education centres 
Equipment for local AIDS education centres. 
The second sector includes expenditure for AIDS research. Fig. 2 shows the financing 
institutions and the money spent in  1987. A total of 33 million  OM was calculated for 
research work. The largest amount was support given for research in  medical science 
and epidemiological studies. The Ministry of Health and the Ministry of Research and 
Technology  funded  most  of  this  research.  No  evaluation  could  be  made  of  the 
expenditure  in  private  industry  and  private  research.  Thus  total  expenditure  on 
research in AIDS exceeds the amount calculated here. 
Institution 
Ministry of 
Health 
Ministry of 
Research and 
Technology 
Berlin 
Universities 
Total 
Issue 
Federal Health 
Office research 
programs 
Evaluation of coun-
selling programs and 
the national lnfor-
matlon campaign 
Research funding 
(life sciences) 
Local research 
funding 
Research projects 
not funded by 
other authorities 
Expenditure 
lnMio.OM 
15.0 
6.5 
8.0 
2.2 
1.3 
33.0 
Fig. 2.  AIDS prevention 1987, public expenditure on research and development 
Percentages 
65.2 
24.2 
6.7 
3.9 131 
Hygienic safety measures are the third sector which showed high expenditure. Figures 
are available for safety measures in emergency services and precautions with donated 
blood. To protect staff,  emergency services need safety gloves and additional artificial 
respiration  devices.  Expenditure  of  approximately  1.1  million  DM  for  the  Federal 
Republic of Germany was extrapolated from  the figures  given by Schleswig-Holstein. 
Expenditure  that  results  from  screening  measures  for  blood  products  can  be 
determined  without  great  difficulty.  A  screening  method  capable  of  excluding  all 
contaminated blood  has been in  use  in  all  blood donation  centres since  1985. The 
blood donation service of the German Red Cross in  Hamburg and Schleswig-Holstein 
indicates  additional costs  of 3.89 DM  for  each blood sample.  Assuming for  1987 a 
demand of 3.5 million  units  for  blood samples  or other blood products  (Beske  and 
Hanpft, 1986), a total expenditure of 13.6 million DM was estimated. 
We  also evaluated reports of other expenditure from  two federal ministries which do 
not fit  in  any of our categories.  The  Federal Ministry  for  Labour and Social Affairs 
distributed 4 million DM in support to institutions providing care to AIDS patients. The 
same amount was spent by the Ministry for Economic Cooperation in supporting long-
term prevention programmes in developing countries. 
If all  expenditure mentioned above is  counted as for preventive measures, it amounts 
to 174.1 million DM.  The expenditure is  shown in Table 1 for the main areas of AIDS 
prevention and the financing institutions. 
In a further step, we tried to evaluate the expenditure on hygienic safety measures in 
physicians' and dentists' offices  and in  hospitals. Three kinds of safety measures were 
included: 
Additional mechanical barriers  to  prevent contacts with  blood  and other bodily 
fluids 
Disinfection measures 
Longer set-up time for endoscopes. 
Here only a  slight expenditure increase was  attributable to AIDS.  This  is  due to the 
already  high  standard  of  hygienic  safety  measures  in  all  sectors  of  health  care. 
Hygienic safety measures as  a  precaution against various  infectious  diseases  do  not 
differ greatly (Flatten and Allhoff, 1988; Greenspan et al., 1986). 
A marked  difference  in  expenditure was  reported from  hospitals.  Here  expenditure 
depends on the estimated  number of AIDS  patients.  No  influence was  reported by 
hospitals that have less  than 10 AIDS  patients per year. If a  hospital has  10 to 250 
AIDS  patients per year, an increase of 0.10 to 2.00 DM per day of care for  material 
expenditure can be assumed. This was calculated with the help of a model. 132 
Table 1.  AIDS prevention 1987, estimated total public expenditure in million DM 
Issue 
I 
Research and 
development 
II 
Information, coun-
selling work HIV 
testing, financial 
support of counsel-
ling centres and 
self help groups 
m 
Hygienic safety 
measures in the 
emergency serv-
ices and blood 
donor centres 
IV 
Other expenditures 
Total sum 
Institution  Expenditure 
Ministry of Health  15.0 
2.7* 
3.8* 
Senate of Berlin  2.2 
Universities  1.3 
Ministry of Research 
and Technology  8.0 
33.0 
Ministry of Health  30.9 
43.5 
Federal States  30.2 
Municipalities  9.0 
Ministry of  Defence  0.2 
Associations in the  4.6 
health care sector 
II  118.4 
m  14.7 
Ministry for Labour  4.0 
and Social Affairs 
Ministry for Economic  4.0 
Cooperation and 
Development 
IV  8.0 
174.0 
Remarks 
Research projects funded by the 
Federal Health Office 
Evaluation of new prevention programmes 
Evaluation of the information campaign of 
the Federal Centre for Health Education 
Local research funding 
Research not funded by other authorities 
Research funding 
New prevention and counsel-
ling programmes 
Information campaign by the Federal 
Centre for Health Education 
Counselling and HIV testing within 
the army 
Safety gloves, special precautionary 
measures, screening of blood donors 
Financial support to institutions 
providing care to AIDS patients 
Prevention programmes in developing 
countries 
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The expenditures for  AIDS  prevention evaluated in  this  study were  mainly  those  of 
federal, state or municipal administrations. With the exception of the municipalities, the 
expenditures planned for 1988 were also reported. These are compared in Fig. 3. 
The  total  federal  and  state  expenditure  for  AIDS  prevention  measures  in  1987 
amounted  to  approximately  153.5  million  DM.  The  expenditure  increased  to  272 
million  DM  in  1988, towns excluded.  As  in  1987, the largest portion,  or 132 million 
OM, was financed by the Federal Ministry of Health. 
Authority 
Ministry of Health 
Federal Centre of 
Health Education 
Other Federal 
Authorities 
States 
Municipalities 
n  16.2 
l 
I 
D--~  .. 0 
? 
0 
Expenditures 1987, 153.5  D 
Expenditures 1988, 272.0  [J 
I  48.6 
J132 
I  47.3 
I  52.5 
31.6 
32.4 
I  55.9 
l  I 
50  100  150 
million OM 
Fig. 3.  AIDS  prevention  1987-1988:  expenditures  of  public  authorities  in  the  Federal  Republic  of 
Germany in million DM 134 
5.  Discussion 
In  contrast to studies on the costs of the treatment of AIDS  patients, a comparison of 
the expenditures for AIDS  prevention measures lacks  a  defined reference figure.  It  is 
only possible to compare the expenditure per capita for certain regions. Differences in 
the  regional  expenditure  per  capita  may  be  seen  as  differences  in  the  regional 
counselling and information work. 
A regional categorisation was possible for  the expenditure of the state governments. 
The  comparison  included  expenditure  for  information  and counselling  only.  There 
were great differences in  1987 as to the regional per capita expenditure between the 
various states. In  Hesse, the expenditure on information and counselling about AIDS 
was  920 OM  per 10,000 inhabitants;  Hamburg spent 15,000 OM  and Berlin  26,000 
OM  per 10,000 inhabitants. The differences  can be partly explained by the different 
prevalence of AIDS in these cities. 
For further research on the effects of AIDS prevention measures it would be interesting 
to  compare regional differences  in  expenditures  with  the  changing incidence of the 
HIV.  At present, no figures are available for such comparisons in the Federal Republic 
of Germany. 
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Fig. 4.  States' expenditure for AIDS prevention in 1987 per 10,000 inhabitants 
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1.  Introduction 
The  acquired  immune  deficiency  syndrome  (AIDS)  is  a  relatively  new  infectious 
disease, transmitted mainly through blood and sexual contact, which first appeared in 
the US in 1980 and in Western Europe a few years later. 
In the Netherlands there were 450 AIDS cases known by spring 1988. Approximately 
60%  of these were treated at the teaching hospital  of the  university  of Amsterdam 
(AZUNANJ.C),  while  the rest were treated  in  different  hospitals  in  the  country.  The 
AZUNANI.C  hospital was designated as the national"super-centre" hospital for AIDS. 
This means that, in addition to the care and treatment of patients, the hospital also has 
the  responsibility  for  researching  into  new  methods  of  treatment  and  for  giving 
information  about  the  implications  for  hospital  management  of  caring  for  AIDS 
patients. 
Of the 450 known AIDS patients 95% are homosexual men, while the remaining 5% 
are IV-drug  users,  haemophiliacs  and people who  had received  a blood transfusion 
with infected blood. 
Research on the costs of care of AIDS patients has been mainly carried out in the US. 
There  are  large  differences  in  the  results  of  individual  research  projects.  In  the 
Netherlands it was totally unknown until now what the costs of care of AIDS patients 
amounted to. 
In this article are presented the first results of a research project which aims to give an 
insight into  the costs  of hospital  care of AIDS  patients and to  determine the factors 
which  influence  these  costs.  This  article  gives  an  orientation  into  the  size  and 
components of the costs of hospital care of AIDS patients in the AZUNANI.C hospital 
between 1982 and spring 1988. 137 
2.  Data and methodology 
2.1  The data 
In  order to  gain  an insight  into  the  illness  and treatment process,  a  database was 
developed based on individual patient information.  This  database consists  of all  the 
individual data of all 230 patients who were treated between 1982 and spring 1988 for 
AIDS,  ARC  and HIV+  with  opportunistic infections at the AZUNAMC  hospital.  The 
data were taken out of different parts of the hospital information system (ZIS) and from 
medical  and nursing records.  In  order to take  into  account the privacy  aspects,  the 
data were made completely anonymous. An extensive analysis by the AIDS unit under 
the supervision of Dr.  S.  Danner showed that the database contained approximately 
95% of all treatment data. 
The following patient information was collected: 
Personal data: sex, date of birth, place of domicile. 
Characteristics of illness:  date and description of main  and secondary diagnoses 
(ICD9 and CDC). 
Characteristics of treatment: date and description of hospitalization, nursing days, 
interventions, blood transfusions, use of Retrovir and other medication. 
Because the  data about consultations,  Retrovir  and other medication,  and external 
laboratory tests were not available per patient in computerized form,  an estimate was 
made from a sample of the records of twenty patients. 
For the calculation of hospital costs,  national sickness fund tariffs were used. For the 
calculation of the costs of Retrovir, other medication and external laboratory tests, the 
actual cost prices were used. 
2.2  Methodology 
In  a survey article Drummond and Davies  (1988)  give some possible reasons for the 
large  differences  between  the  results  of  research  done  up  to  now  on the  costs  of 
hospital  care  of  AIDS  patients.  Especially  differences  in  methodology  and  in  the 
composition of the patient population appear to have had a  large  influence on the 
results  found.  Because  of this  we  divided  the total  population of patients  into  four 
groups: 
Subgroup I:  Patients who have already died and who had already received treatment 
at the AZUNAMC hospital before AIDS was diagnosed (n=105); 
Subgroup II:  Patients who have already died and who received  no treatment at the 
AZUNAMC hospital before AIDS was diagnosed (n=44); 
Subgroup lll:  Living  patients who  had treatment at the AZUNAMC  hospital  before 
AIDS was diagnosed (n=58); 138 
Subaroup IV:  Uving patients, who had had no treatment at the AZUNAMC  hospital 
before AIDS was diagnosed (n=23). 
The costs are directly dependent on the medical treatment which patients receive. The 
way  patients  are  treated  is  closely  linked  to  the  progression  of  the  disease.  The 
progression of the disease and corresponding treatment are in tum influenced by the 
characteristics  of the  patient,  the  treatment  protocol  and  a  large  number of  other 
factors. These inderdependent relationships are shown in Fig. 1. 
A preliminary exploration was done with the help of the Kruskall-Wallis test in order to 
test the possible relationship between the kind of treatment of patients received on the 
one hand  and  the  age  at which  patients  first  made  contact  with  the  AZV N  AMC 
hospital,  the  possible  use  of Retrovir,  the  main  diagnosis  at first  contact  with  the 
hospital,  the year in  which  treatment started and  finally  a  subdivision  of the  AIDS 
diagnosis into CDC categories on the other. 
3.  Results 
3.1  Some characteristics of hospital care 
In Table 1 are shown some characteristics of the treatment of all230 patients treated at 
the AZUNAMC in the period from  1982 till spring 1988. From Table 1 it appears that 
Characteristics 
of patient 
Progression 
of disease 
Consequences for 
organisation 
Treatment 
p~r 
Characteristics 
of care 
1 
Direct costs 
of treatment ....---------
] 
Total costs 
of care 
Other influencing 
factors 
Direct costs per 
component of 
treatment 
Indirect costs 
of treatment 
Fig. 1.  Characteristics of care and the relationship with treatment costs and consequences for hospital 
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all the characteristics of treatment show a large variation. Minimum and maximum lie 
far apart. This  is  not due to outliers,  as  can be seen from  the fact that the standard 
deviation is  relatively large  in proportion to the mean. The median (the value above 
and below which 50% of observations lie)  lies  below the mean for  all  characteristics. 
This means that the frequency distribution of the characteristics is positively skew. Most 
patients score lower than average on the various characteristics of treatment, while a 
small proportion score much higher than average. 
Table 1.  Some characteristics of hospital care (total population: n = 230) 
Average  Median  Minimum  Maximum  Standard 
deviation 
Total length of care  526.0  374.0  1  2162  491.0 
atAZUNAMC 
hospital (in days) 
Number of hospital- 3.1  2.0  1  22  2.9 
izations 
Number of nursing  60.0  41.0  1  507  66.0 
days 
- Of which number  9.0  0.0  1  375  39.8 
of days in inten-
sive care, resus-
citation and 
isolation 
Number of nursing  23.6  14.6  1  375  36.1 
days per hospital-
ization 
Number of doses  9.0  3.0  1  134  17.4 
of blood (total) 
Total number of  209.0  123.0  2  1601  267.0 
tests/interventions 
- Of which: 
Laboratory test  182.0  102.0  2  1480  247.0 
X-ray  8.5  6.0  1  96  10.2 
In-patient  164.0  75.0  2  1579  268.0 
interventions 
Out-patient  45.0  34.0  1  477  48.0 
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Fig. 2 gives the frequency distribution of the number of nursing days. Another source 
of  variation  is  due  to  the  fact  that some  characteristics,  such  as  the  number  of 
hospitalizations and nursing days, laboratory tests  and X-ray examinations, are to be 
found for almost all patients, while other characteristics, such as blood transfusions and 
nursing days in special units (intensive care, resuscitation and isolation), are only to be 
found for a minority. 
Table 2 shows some characteristics of treatment given  for  the four subgroups of the 
total  population.  There  appear to  be some  large  differences  between the  separate 
subgroups. The living patients (subgroups III  and IV)  appear to be under treatment for 
a  much  longer  period  on  average  than  the  patients  who  have  already  died.  The 
patients who  were already  undergoing treatment at the AZUNAMC hospital before 
AIDS was diagnosed (subgroups I and II)  also show on average, as one might expect, 
a longer period of treatment than the others.  Differences between the subgroups with 
respect to the average number of hospitalizations are not markedly large. 
nursing days 
Fig. 2.  Frequency distribution of the number of nursing days. Total population (n  =  230) 141 
Table2.  Some characteristics of hospital care per subgroup (AZUA/AMC hospital) 
Mean  Median  Minimum  Maximum  Standard 
deviation 
Number of days in care from first contact with hospital 
Subgroup I  533.0  344.0  6  2162  486.0 
Subgroup II  196.0  152.0  1  1048  205.0 
Subgroup III  826.0  635.0  1  2121  549.0 
Subgroup IV  363.0  419.0  1  715  218.0 
Number of hospitalizations 
Subgroup I  3.4  3.0  1  22  3.2 
Subgroup II  2.5  2.0  1  15  2.6 
Subgroup Ill  2.9  2.0  1  10  2.7 
Subgroup IV  3.1  3.0  1  10  2.9 
Number of nursing days 
Subgroup I  84.0  64.0  1  507  80.0 
Subgroup II  42.0  34.0  4  155  37.0 
Subgroup Ill  36.0  25.0  2  132  36.0 
Subgroup IV  43.0  13.0  1  203  57.0 
Number of nursing days per hospitalization 
Subgroup I  34.7  19.0  1  375  48.6 
Subgroup II  18.3  15.5  4  59  14.8 
Subgroup III  12.0  9.9  2  64  12.8 
Subgroup IV  12.5  6.3  1  102  21.2 
Number of doses of blood 
Subgroup I  11.3  3.0  1  134  21.8 
Subgroup II  8.9  3.0  2  82  15.8 
Subgroup Ill  6.2  0.0  1  42  9.9 
Subgroup IV  6.4  2.0  2  36  10.3 
Number of test/interventions 
Subgroup I  295.0  173.0  23  1601  322.0 
Subgroup II  214.0  138.0  3  1308  274.0 
Subgroup Ill  93.0  74.0  2  276  63.0 
Subgroup IV  101.0  88.0  6  328  91.0 
The situation is different for the number of nursing days: the average for patients who 
came to the AZUNAM.C  hospital after the  diagnosis AIDS  (subgroups II  and III)  lies 
slightly below that of other patients. There is  furthermore a visible difference between 
the  two  groups  who  were  treated  at  the  AZUNAM.C  hospital  before  AIDS  was 
diagnosed: the patients who have already died (subgroup I)  had on average twice as 
many nursing days as  the patients who are still  alive  (subgroup III).  The number of 
interventions is  two to three times higher for the patients who have died (subgroups I 
and II) than for the others. 142 
Fig. 3  shows  the frequency  distribution  of  the number of nursing days  for  the four 
separate subgroups. It can be observed on Fig. 3 that the frequency distribution is  less 
positively skew for the patients who have already died (subgroups I and II) than for the 
others. 
For  the  patients  with  the  most  extensive  treatment  at  the  AZUNAMC  hospital 
(subgroup I)  a further investigation was done in order to discover whether there were 
possible relevant factors which  might be linked to the number of nursing days and a 
number of interventions. These factors are: 
% 
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The age of the patient at first contact with the hospital. 
The possible use of Retrovir. 
The main diagnosis according to ICD9. 
The subdivision of the AIDS diagnosis into CDC categories. 
The year in which treatment started. 
30-40  70-80 
nursing days 
subgroup  I  (n = 105) 
subgroup  II  (n =44) 
subgroup  III  (n =58) 
subgroup  IV  (n =  23) 
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This investigations led to the following results: 
With respect to the age at which first contact with the hospital was made: 
patients up to the age of thirty had the greatest number of hospitalizations per 
patient, followed by those of the age group 31-40 years; patients in the 41-50 
years  age  group  had the least  number of  hospitalizations  per patient,  while 
patients in the age group 50+ fell somewhere in between; 
patients in  the so+  age  group had the greatest number of nursing  days  per 
patient while the patients below the age of thirty had the smallest; 
the same pattern was  observed for  the number of interventions:  the patients 
from  the age group so+  had the highest number of interventions per patient, 
the patients below the age of thirty had the smallest. 
With respect to the use of Retrovir: 
- the number of  hospitalizations  of patients who were  given  Retrovir is  clearly 
greater per patient than for the other patients; 
- this also holds for the number of nursing days per patient; 
the number of interventions per patient was clearly lower, however, for patients 
who had received Retrovir than for the others. 
With respect to the main diagnosis at the first  hospitalization: (the main diagnoses 
have been subdivided into the following  five  categories:  AIDS  (pneumocystosis), 
AIDS (kaposi), AIDS (other), ARC, and "other diagnoses") 
- the number of hospitalizations per patient was the lowest for AIDS  (kaposi) and 
"other  diagnoses".  The  diagnoses  AIDS  (other)  and  ARC  give  the  highest 
number of hospitalizations per patient; 
- AIDS  (other)  and ARC  have the  longest treatment period per patient,  while 
AIDS (kaposi) the shortest; 
- the number of interventions per patient is the greatest for ARC patients, but the 
lowest for AIDS (pneumocystosis). 
With respect to the CDC classification: (this classification is only known for patients 
receiving Retrovir) 
the  number  of  hospitalizations  per patient was  the  highest for  the  category 
IV-CI, D (opportunistic infections and secondary malignancies), followed by the 
category  IV-CI  (opportunistic  infections);  the  number of  hospitalizations  per 
patient was the  lowest for  the patients who  received  no Retrovir and hence 
were not included in a CDC category; 
the category IV-CI,  D  had the greatest number of nursing days  per patient, 
while the patients who received no Retrovir had the lowest; 
the number of interventions per patient was highest for the category IV-CI,  D 
and lowest for the category IV-CI and for the other patients receiving Retrovir. 144 
With respect to the year in which hospital treatment was started (because this is  a 
relatively  new disease for  which  no effective  treatment has yet been found,  the 
treatment protocol is constantly being adjusted on the grounds of new experience): 
- the number of hospitalizations per patient appears to be clearly lower in  1987 
and 1988 than in the previous years. 
- the number of nursing days per patient shows a falling trend since 1984. 
- the number of interventions per patient shows no clear pattern, except that they 
tend to be lower in 1987 and 1988 than in previous years. 
3.2  The hospital costs 
Table 3 shows the results of the calculations made for different categories of hospital 
costs.  These  costs  have  been  calculated  for  the whole  patient population  and  for 
subgroup I,  in the group of patients who had the most complete life-time treatment at 
the AZUNAMC hospital. 
Table 3 shows that the average hospital costs per AIDS  patient amount toR. 68,000 
(in  1988 prices), while the life-time  costs  of subgroup I are Fl. 90,000 per patient,  a 
difference of more than Fl. 20,000. 
4.  Discussion 
The care of AIDS patients at the AZUNAMC hospital shows large individual variation. 
The frequency distribution of the various  characteristics of treatment shows that it  is 
Table 3.  The average medical costs  (in Fl.)  of hospital care per patient at the AZUNAMC hospital 
(1988 prices) 
Categories of costs 
Nursing days 
Laboratory tests 
X-ray 
Other tests/interventions 
Total tests/interventions 
Blood transfusions 
Retrovir (in-patient) 
In-patient consultations 
Out  -patient consultations 
Total consultations 
External laboratory tests 
In-patient medication 
Total costs 
Total population 
Subtotal 
2,200 
1,000 
3,000 
500 
800 
(n =  230) 
Total 
44,400 
6,200 
700 
8,000 
1,300 
2,800 
4,600 
68,000 
Subgroup I  (n=105) 
Subtotal  Total 
64,300 
3,000 
1,400 
3,900 
8,200 
800 
6,200 
600 
800 
1,400 
2,800 
6,300 
90,000 145 
not advisable to work with total  averages as such as  representative of the treatment 
procedure. The subdivision into more homogeneous groups helps to overcome some 
of these problems. 
Furthermore another remark should be made at this point. Approximately 80% of the 
patients whose hospital treatment started before and up to 1986 have now died. For 
the patients who first  received treatment in  1987, the figure  is  almost 50%, while  it  is 
30% for those who first  received treatment in  1988. This  means that for  the patients 
who are still alive, only part of the treatment has been included in the calculations. The 
patients whose treatment started in  more recent years and who have died are those 
patients with a relatively short survival time. 
The costs per patient which have been calculated for those patients whose treatment 
started  recently  are  therefore  an underestimate  of  the  costs  which  will  arise  in  the 
future until the whole cohort has died. This problem is  even more significant because 
the proportion  of  patients  whose  treatment  has  recently  started  is  relatively  higher 
because of the recent fast growth in the patient population. 
We have been able to establish that the five factors which we examined were all linked 
to  the  characteristics  of  treatment.  Not  in  all  cases,  however,  is  there  a  clear 
proportional relationship to be established. A further analysis which takes into account 
the  possible  interrelationships  between  these  five  and  other  factors  is  therefore 
desirable. 
In  this study an indication of the hospital costs  has been given by means of sickness 
fund  tariffs.  It  would  have been  better to  have  used  real  costs.  However,  the  data 
required for these calculations do not exist.  This  would also  have entailed a detailed 
time check of the number of working hours spent on each activity and an insight into 
the special prevention measures taken against the risk  of infection of AIDS  inside the 
hospital. 
For this reason tariffs  had to be used in this study. These are based on the "average" 
care of the "average
11  patient in  the hospital.  The care of AIDS  patients, however,  is 
much more intensive than that of the "average" patient. The number of nursing staff 
per bed, for  example,  is  twice  as high  in the AIDS wards as the number found  in  an 
"average
11  ward. 
That the care of AIDS patients  is  more intensive than the care of average patients is 
not only to be seen in the special AIDS units, but also in the supporting units. Because 
the activities carried out on AIDS patients are also more intensive there, one can speak 
of a  loss  of production capacity.  This  means  that the costs  calculated  by  means of 
tariffs  will  be an underestimate of the true costs.  How large this  underestimate  is  will 
have to be established in further research. 146 
The results presented here give an indication of the size  and components of the costs 
of hospital care at the AZUNAMC hospital between 1982 and spring 1988. Because 
treatment has  only just begun for  the majority  of  patients  who  have  recently been 
admitted to the hospital for the first time, the results found cannot be interpreted as a 
correct estimate of the costs of hospital care for an average AIDS patient without due 
caution. The database which  was developed for this  study is  based on the treatment 
and care of the majority of AIDS patients known in the Netherlands. The database was 
set up in such a way as to enable the total progression of the disease and its treatment 
to be followed through time.  This  database therefore offers  a good starting point for 
further economic analysis. 
When the research results are compared internationally with other economic analyses 
on the care of AIDS patients, attention can be drawn to the following points: 
With respect to the size and methodology of the study: 
This  study  has  the  largest  complete  population  (230  patients)  and  the  longest 
research period (6.5 years). The study of Andrulis et al.  (1988)  had data on 5393 
patients,  but was  based  on questionnaires.  Other studies  were  less  up  to  date 
(1984/1985) and were based on a much shorter research period. In this study we 
have been able to establish that an underestimate of life-time treatment costs can 
arise from these kinds of studies. 
With respect to the components of costs and variables included in the study: 
This  study  includes  by  far  the  most  extensive  range  of  cost  components  and 
variables. This is directly related to the possibilities offered by this database. 
With respect to the composition of the patient population: 
In international studies little analysis has been done of such patient characteristics 
as age and sex.  Where this  has taken place, the results are comparable with the 
results of this study. Approximately 90% of patients are male and the majority are 
between 31 and 40 years old. 
With respect to the characteristics of treatment: 
- number of hospitalizations: 
The  average  number  of  hospitalizations  per  patient  found  in  our  study 
corresponds best with  the results  of the studies of Scitovsky et al.  (1986)  and 
Seage et al.  (1986).  The study of Lafferty  (Lafferty et al.,  1988)  gives  a much 
lower number, while that of Kizer et al.  (1986) gives a much higher number. 
- length of hospitalizations: 
The  average  length  of  hospitalizations  in  the  various  studies  shows  a  large 
variation. The average number of nursing days per hospitalization that we have 
calculated is rather high. 
- number of nursing days: 
There  are  similarities  with  respect  to  the  average  number  of  nursing  days 
between this research and that of Kizer  et al.  (1986),  Drummond et al.  (1988) 
for Germany and Seage et al.  (1986). Extremely high outcomes are to be found 
in the study of Hardy et al.  (1986)  and extremely low in the study of Scitovsky 
et al. (1986). T
a
b
l
e
4
.
 
I
n
t
e
r
n
a
t
i
o
n
a
l
 
c
o
m
p
a
r
i
s
o
n
s
 
(
i
n
 
D
u
t
c
h
 
g
u
i
l
d
u
s
)
*
 
S
a
n
 
F
r
a
n
s
.
 
M
a
s
s
.
 
T
e
a
c
h
.
h
o
s
p
.
 
W
a
s
h
i
n
g
t
.
 
F
R
G
 
F
r
a
n
c
e
 
U
K
 
C
D
C
 
C
a
l
i
f
o
r
n
.
 
A
Z
U
A
 
A
Z
U
A
 
S
c
i
t
o
v
s
k
y
 
S
e
a
g
e
 
I
I
I
 
A
n
d
r
u
l
i
s
 
L
a
f
e
r
t
y
 
D
r
u
m
m
o
n
d
 
D
r
u
m
m
o
n
d
 
D
r
u
m
m
o
n
d
 
H
a
r
d
y
 
K
i
z
e
r
 
W
i
g
g
e
r
s
 
B
i
j
l
s
m
a
 
T
o
t
a
l
 
N
o
 
l
o
n
g
e
r
 
a
l
i
v
e
 
N
u
m
b
e
r
 
o
f
 
p
o
p
u
l
a
t
i
o
n
 
N
 
=
 
2
0
1
 
4
5
 
5
,
3
9
3
 
1
6
5
 
1
9
 
3
3
 
2
3
0
 
1
0
5
 
t
o
t
a
l
 
n
u
m
b
e
r
 
o
f
 
a
d
m
i
s
s
i
o
n
 
1
0
0
 
7
0
0
 
3
6
0
 
P
e
r
i
o
d
 
(
y
e
a
r
s
)
 
1
 
(
'
8
4
)
 
1
 
(
'
8
4
)
 
1
 
(
'
8
5
)
 
1
.
5
 
6
5
Y
 
6
.
5
Y
 
-
a
v
e
r
a
g
e
 
c
o
s
t
s
 
p
e
r
 
1
8
,
0
0
0
 
2
5
,
0
0
0
 
1
8
,
0
0
0
 
2
2
,
0
0
0
 
2
6
,
5
0
0
 
h
o
s
p
i
t
a
l
i
z
a
t
i
o
n
 
-
a
v
e
r
a
g
e
 
c
o
s
t
s
 
o
f
 
1
4
-
4
7
,
0
0
0
 
1
0
0
,
0
0
0
 
6
,
8
0
0
 
2
9
5
,
0
0
0
 
1
1
8
,
0
0
0
 
6
8
,
0
0
0
 
9
0
,
0
0
0
 
t
o
t
a
l
 
t
r
e
a
t
m
e
n
t
 
-
a
v
e
r
a
g
e
 
l
i
f
e
-
t
i
m
e
 
5
5
,
0
0
0
 
2
4
,
0
0
0
 
9
0
,
0
0
0
 
c
o
s
t
s
 
-
a
v
e
r
a
g
e
 
c
o
s
t
s
 
p
e
r
 
1
,
5
0
0
 
1
,
3
0
0
 
8
0
0
 
6
0
0
 
1
,
2
0
0
 
1
,
1
0
0
 
1
,
1
0
0
 
n
u
r
s
i
n
g
 
d
a
y
 
-
a
v
e
r
a
g
e
 
c
o
s
t
s
 
p
e
r
 
8
8
,
0
0
0
 
8
5
,
0
0
0
 
4
0
,
0
0
0
 
6
4
,
0
0
0
 
2
8
,
0
0
0
 
2
6
,
3
0
0
 
1
2
4
,
0
0
0
 
2
7
0
,
0
0
0
 
8
0
,
0
0
0
 
4
5
,
5
0
0
 
6
0
,
0
0
0
 
p
e
r
s
o
n
 
p
e
r
 
y
e
a
r
 
-
a
v
e
r
a
g
e
 
n
u
m
b
e
r
 
o
f
 
3
.
2
 
3
.
3
 
1
.
6
p
Y
 
2
.
1
 
6
 
3
.
1
 
3
.
4
 
h
o
s
p
i
t
a
l
i
z
a
t
i
o
n
s
 
-
a
v
e
r
a
g
e
 
l
e
n
g
t
h
 
o
f
 
1
1
.
7
 
2
1
 
1
9
 
1
3
.
3
 
2
0
 
1
0
 
3
1
 
1
4
 
1
9
 
3
5
 
h
o
s
p
i
t
a
l
i
z
a
t
i
o
n
 
(
i
n
 
d
a
y
s
)
 
-
a
v
e
r
a
g
e
 
n
u
m
b
e
r
 
o
f
 
2
2
4
 
3
9
0
 
5
4
0
 
1
5
7
 
3
9
2
 
5
4
0
 
1
5
Y
 
1
.
5
 
y
 
t
r
e
a
t
m
e
n
t
s
 
(
i
n
 
d
a
y
s
)
 
-
a
v
e
r
a
g
e
 
n
u
m
b
e
r
 
o
f
 
3
5
 
6
2
 
3
2
p
Y
 
7
8
 
5
0
 
1
6
8
 
8
9
.
6
 
6
0
 
8
4
 
n
u
r
s
i
n
g
 
d
a
y
s
 
-
a
v
e
r
a
g
e
 
n
u
m
b
e
r
 
o
f
 
1
8
.
4
 
1
0
.
2
 
2
0
 
2
0
 
c
o
n
s
u
l
t
a
t
i
o
n
s
 
-
a
v
e
r
a
g
e
 
n
u
m
b
e
r
 
o
f
 
4
 
9
 
I
C
d
a
y
s
 
-
a
v
e
r
a
g
e
 
n
u
m
b
e
r
 
o
f
 
9
 
d
o
s
e
s
 
b
l
o
o
d
 
e
x
c
h
a
n
g
e
 
r
a
t
e
:
 
$
1
 
=
 
F
l
.
 
2
 
.
J
:
:
-
p
Y
 
=
 
p
e
r
y
e
a
r
 
-
.
.
J
 148 
- length of treatment: 
An average length of treatment of eighteen months corresponds with that found 
in  with that the studies of Kizer  et al.  (1986)  and Drummond et al.  (1988)  for 
Germany. In  those two  studies,  the length  of treatment was  not based on a 
direct calculation, as with our study, but it was indirectly estimated. Scitovsky et 
al.  (1986) and Drummond et al.  (1988) for Great Britain estimate the length of 
treatment to be less than one year. 
With respect to the costs: 
Mention  was  already  made  of the  fact  that the  results  of  various  international 
studies showed great variation in  the characteristics of treatment. The variation is 
even  greater when  it  comes  to  cost  calculations.  One  exception  to  this  is  the 
calculated average cost per hospitalization. 
The  results  of the studies  compared  here  show  large  differences.  This  variation  is 
largely due to differences in 
The methodology. 
The (length of) period observed. 
The composition of the patient population. 
The basis on which costs have been calculated (tariffs or real costs). 
It is interesting to note that the results of the Dutch situation fall within the range of the 
international results,  with respect to the  characteristics of treatment,  as  well  as  with 
respect to the costs. 
5.  Conclusions 
Hospital  care of AIDS  patients  is  characterized  by  large  individual  variation.  These 
variations  in  hospital  care  appear to  be linked  to the following  factors:  age  at first 
contact  with  the  hospital,  the  use  of  Retrovir,  the  main  diagnosis  at  the  first 
hospitalization, the year in which the treatment started and the subdivision of the AIDS 
diagnosis into further CDC categories. 
The  lifetime  costs  of  hospital  care  were  calculated  for  the  patients  treated  in  the 
AZUNANI.C  hospital  in  the  period  between  1982  and spring  1988 and amounted 
Fl. 90,000 per patient. 
The costs  of hospital  care consist of 70%  hospitalization  costs,  while  the remaining 
30%  are  made  up  of  costs  related  to  in- and  out-patient  interventions  and  tests, 
medication, external laboratory tests and blood transfusions. 
The costs  have been calculated using  sickness fund  insurance tariffs.  This  implies  an 
underestimation of the real costs of treatment of Aidspatients. The treatment of AIDS 149 
patients is far more intensive than that of the average patients and the tariffs are based 
on the treatment of average patients. 
AIDS  is  a  relatively  new  and  fast-growing  disease.  The  majority  of  patients  who 
recently started being treated are therefore not yet at the end of the treatment. This  is 
another reason why the  calculated costs  probably will  be an underestimation of the 
true costs of hospital treatment of the average AIDS patient. The results that have been 
found for the Dutch situation are within the ranges given by a number of international 
studies. 
A dynamic database was set up for the purpose of this study, in  which the complete 
progression  of  the  disease  and the  treatment per patient were  registered  from  the 
moment of first contact with the AZUNAMC hospital. The way in which this database 
is organized gives a good starting point for further and more in-depth analysis. 
Acknowledgement. The authors wish to thank Dr.  S.A.  Danner, Prof. Dr.  R.M.  Lapre, 
the  computer  department  of  the  AZUNAMC  hospital,  Drs.  F.J.M.  Werner  and 
colleagues at the AZUNAMC hospital and the NIPG{INO for their helpful comments 
on this article. 
References 
Andrulis,  D.P.,  Beers, V.,  Bentley,  J.P.,  and Gage, L.S.  (1987).  The provision in  US 
public and private teaching hospitals. Journal of the American Medical Association 
258, 1343-1344. 
Drummond,  M.  and Davies,  L.  (1988).  Treating AIDS:  the economic issues.  Health 
Policy 10, 1-19. 
Hardy, A.M.,  Rauch,  K.,  Echenberg, D.,  Morgan,  W.M.,  and Curran, J.  (1986).  The 
economic  impact  of  the  first  10,000  cases  of  acquired  immune  deficiency 
syndrome in the United States. Journal of the American Medical Association 255, 
209-211. 
Kizer,  K.,  Rodrigues,  J.,  McHolland,  G.F.,  and  Weller,  W.  (1986).  A  quantitative 
analysis of AIDS in California. California Department of Health Services. 150 
Lafferty,  W.E.,  Hopkins,  S.G.,  Honey,  J.,  Harwell,  J.D.,  Shoemaker,  P.C.,  and 
Kobayashi,  J.M.  (1988).  Hospital  charges  for  people with  AIDS  in  Washington 
State: utilization of a statewide hospital discharge data base. American Journal of 
Public Health 78, 949-952. 
Scitovsky, A.,  Cline, M.,  and Lee, P.H. (1986). Medical care costs of patients with AIDS 
in San Francisco. Journal of the American Medical Association 256, 3107-3109. 
Seage III,  G.R.,  Landers,  S.,  and Barry,  A.  (1986).  Medical  care  costs  of AIDS  in 
Massachussets. Journal of the American Medical Association 256, 3107-3109. Direct and Indirect Costs of AIDS in Belgium: 
A Preliminary Analysis 
J. Lambert, G. Carrin 
1.  Introduction 
In  this note, we present an analysis of direct and indirect costs of AIDS  in  Belgium. 
Direct  costs  comprise  the costs  of medical treatment and the non-personal costs  of 
public information campaigns and other governmental assistance serving the general 
public.  Indirect  costs  contain  the  costs  of  morbidity  only.  Incomplete  information 
precluded us from also considering the indirect costs due to premature mortality. 
The costs of medical treatment are based on detailed data related to 24 patients that 
were treated at the hospital unit of Antwerp's Institute of Tropical Medicine (ITM). The 
latter unit is  located on the premises of the University Hospital of Antwerp. The data 
sources are patient records and bills concerning inpatient and outpatient care provided 
at the hospital unit.  All  24 patients had AIDS  as  defined by the Centers for Disease 
Control (CDC) and the World Health Organization (WHO). 
The purpose  of this  paper is  to  inform  decision-makers  in  Belgium  about the cost 
implications of AIDS treatment. This information will  hopefully be an incentive to use 
resources  as  effectively  as  possible,  aiming  at preventing  AIDS  and  at  improving 
existing patients' lives. In the following section, we restrict ourselves to the analysis of 
the sample of patients treated at the ITM:  we discuss patient characteristics and present 
the medical cost per patient and the medical cost per patient per year.  In  the third 
section, these cost figures  are used to estimate the global cost of AIDS for the country 
as a whole. The final estimates and their implications are examined in the final section. 
2.  Patient characteristics and medical costs 
2.1  Patient characteristics 
Initially  we selected  20 patients who received treatment during the period between 
April1, 1987 and March 31, 1988. The prime reason for considering this time frame 
was that nearly all hospital bills  related to costs incurred during that particular period 
could be made available. These 20 patients are further divided into three subgroups: 
group A contains five  patients who died during the above mentioned period; group B 152 
consists of six patients who were already being treated before April 1, 1987; group C is 
composed of nine patients  whose treatment started during  the selected  period.  It  is 
important to note that all  patients of groups  B and C were still  alive  on March  31, 
1988. 
We emphasize that 15 patients were still alive at the end of the considered period. This 
means then that our data set may contain insufficient information about terminal costs. 
There is  also the fact that three patients of group A died in  a hospital other than the 
ITM's hospital unit. We therefore decided to partially remedy this bias by adding group 
D,  comprising four  deceased patients that were treated  in  1984-1986, to  the initial 
sample of 20 patients. The costs related to this particular group were adjusted to 1987-
1988 price levels. 
2.2  Cost analysis of medical treatment 
2.2.1  Medical cost per patient (MCP) 
We  present,  in  Table  1, the MCP  based on the hospital bills  concerning the period 
April  1,  1987- March  31,  1988  (for  groups  A to  C)  and the period  1984-1986 (for 
group D).  The costs  comprise those of hospital services  (viz.  nursing care and hotel 
services),  medication  and blood  transfusions,  physicians'  care  and  clinical  biology. 
Note that the costs are related to both inpatient and outpatient care at the ITM. We will 
also  make  a  distinction  between  the  costs  borne  by  the  Belgian  Health  Insurance 
Scheme  (HIS)  and those  paid by  patients  themselves.  Because  of  lack  of accurate 
information,  we  were  not able  to  take  into  account the  cost  of medical  treatment 
outside the ITM, such as health care provided by general practitioners or care given at 
another hospital unit.  For the same reason, the cost of outpatient care for patients of 
group D was not incorporated in the cost analysis. Table 1 also gives the total number 
of months of treatment per patient group. 
Table 1.  Medical cost per patient (MCP), in BEF 
Patient group  Cost  Total number 
of treatment 
Financed  Total  treated  months 
by HIS  by patient 
A  120,564  12,911  133,475  20 
B  218,911  14,662  233,573  72 
c  669,869  24,240  694,109  59 
D  592,605  189,914  782,519  36 
All patients  429,813  47,098  476,911  187 153 
The MCP  in group A is the lowest.  However, it  is  also underestimated due to the lack 
in the data on the terminal cost of three patients. The relatively low level of the MCP in 
group B has several causes: first,  five  patients were ARC patients for  several months; 
secondly, none of the six patients were terminal; and thirdly, the initial treatment costs, 
which  are  generally  high  as  a  result  of  exhaustive  observation  and  diagnostic 
procedures, are not included in the considered period. Group C entails  a significant 
amount of costs, the initial treatment costs now being part of the total cost picture. In 
addition,  group  C' s  high  cost  level  can  be  explained  by  the  substantial  cost  of 
medicines  (in  particular zidovudine  and interferon  A)  and the  completeness  of  the 
data. The cost of group D is  the highest. Yet it is  still  underestimated due to missing 
bills for outpatient care. The part of the costs paid by these patients is higher than that 
for  other groups because  they were  mostly  accommodated  in  single  hospital  rooms 
that involve higher payments. 
2.2.2  Medical cost per patient per year (MCPY) 
Seage  et  a!.  (1986)  have proposed  calculating the MCPY.  This  method  consists  of 
dividing  the  medical  cost  by  the  number  of  months  of  treatment  and  multiplying 
subsequently  by  twelve.  The  use  of this  method  over the  one  above  is  frequently 
recommended. It avoids the disadvantage of the MCP method whereby one disregards 
all costs incurred before and after the study period. It also does not take account of the 
difference between a patient treated over a 12 month period and another treated, say, 
over only one month. However, one unfavourable characteristic of the present method 
is  that the  MCPY  in  certain  groups  of  patients  may  be  subject  to  an  upward  or 
downward bias. On the one hand, this  is the case for the groups that contain terminal 
patients and patients that start their treatment: the significant cost of treatment may be 
translated  into  an overestimated MCPY.  This  method  also  overestimates the yearly 
costs of terminal patients, as soon as their treatment is stopped, due to death, before 
the end of the sample period. On the other hand, there can be an underestimation in 
the case of patients who are still in the non-terminal stages of AIDS. 
In  order to  apply the MCPY  method, we  used all  available data in  the hospital  bills 
related to the period between 1984 and 1988; all costs were adjusted, if necessary, for 
inflation.  The  results  obtained by  means  of the  method  of  Seage et  a!.  (1986)  are 
presented in Table 2. 
We  observe indeed that the MCPY  for  group C is  the highest amongst four groups, 
due  in  part to  some  overestimation.  The  MCPY  for  the whole  sample  amounts to 
917,374 BEF. We judge that the latter figure  is quite plausible. First, in the calculation 
of this  average cost,  a possible  overshooting due to the costs  of terminal patients  is 
compensated by  the  lower  costs  induced  by  patients  in  the  non-terminal stages  of 
AIDS.  Secondly,  it  is  also  acceptable  in  view  of the relatively  high  cost of the most 
recent drug therapies. 154 
Table 2.  Medical cost per patient per year (MCPY), in BEF 
Patient group 
A 
B 
c 
D 
All patients 
Cost 
Financed 
by HIS 
821,505 
260,932 
1,279,001 
753,836 
841,645 
Total 
by patient 
94,856  916,361 
22,605  283,537 
46,520  1,325,521 
197,225  951,061 
75,729  91'7,374 
We  also draw the attention of the reader to the amount paid by patients  themsE~lves, 
viz.  an average of 75,729 BEF per year. We  can compare the latter with earnings in 
Belgian industry, for instance; the mean yearly wage in  1987 varies between 58~1,680 
BEF and 893,328 BEF for blue and white  collar workers, respectively  (Ministeri€~ van 
Economische  Zaken,  1988).  Hence,  we  find  that the  proportion  of  average  annual 
wages payed by patients themselves  varies  between  8.5%  (for white  collar workers) 
and 13% (for blue collar workers).  It thus  appears that AIDS treatment is  fairly  costly 
for patients themselves. 
We now present additional information on the cost shares of the medical inputs. Using 
the hospital bills, we were able to divide total cost into the following categories: 46.3% 
of the total cost  is  spent on the cost  of  hospital services,  28.1% on medication  and 
blood products, 5.1% on physician fees and 17% on lab tests. Notice that the share of 
drug costs  turns  out to  be very significant.  A further  increase  in  drug costs  can be 
expected in the near future because of the growing use of expensive treatments such 
as  zidovudine  and interferon  A treatment.  Zidovudine  is  generally  prescribed  on  a 
continuous basis,  at an average cost of 1300 BEF per day.  Interferon A is  nonnally 
used in  a once-and-for-all episode of treatment,  at an average total cost of 750,000 
BEF per treatment. 
The  shares  of  inpatient  and  outpatient  care  in  total  costs  are  83.1%  and  16.9%, 
respectively. Note further that 88.2% of the total cost is paid by the HIS, the remainder 
by the patient. Given that the inpatient cost occupies a large share of total cost,  it  is 
certainly informative to calculate the mean cost per hospital bed-day. Remark that the 
latter cost  incorporates  all  costs  of  inpatient care,  including the use  of drugs,  blood 
transfusions, physician activities etc. 
First, we observe that the mean cost per hospital bed-day of groups A and D (which 
contain terminal patients) is  below that of groups B and C.  This indicates that it is the 
required length of hospitalization that finally determines total cost, of course. Secondly, 
the main reason for the higher cost of group C is the use of new and expensive drug 
therapies. 155 
Table 3.  Mean cost per hospital bed-day, in BEF 
Patient group  Cost 
Financed  Financed  Total 
by HIS  by patients 
A  5,698  1,672  7,370 
B  6,677  699  7,376 
c  14,380  499  14,878 
D  4,826  1,451  6,277 
All patients  7,529  1,155  8,684 
2.2.3  Pathology-specific costs per patient per year 
We next present the MCPY according to the different dominant pathologies: Kaposi's 
sarcoma (5  patients), Pneumocystis carinii infection  (5 patients) and other pathologies 
(other opportunistic infections or HIV encephalopathy) (14 patients). Both MCPY and 
the cost per hospital bed-day are computed; see Tables 4  and 5.  When using these 
cost figures,  however, the small sizes of the subgroups from which they were generated 
have to be taken into account, especially when thinking of representativity. 
Table 4.  Medical cost per patient per year (MCPY), in BEF 
Patient group 
Kaposi's sarcoma 
P. carinii infection 
Other pathologies 
P. carinii infection 
and other pathologies 
Cost 
Financed 
by HIS 
1,273,531 
639,237 
759,688 
727,990 
Table 5.  Cost per hospital bed-day, in BEF 
Patient group 
Kaposi's sarcoma 
P. carinii infection 
Other pathologies 
P. carinii infection 
and other pathologies 
Cost 
Financed 
by HIS 
16,192 
6,575 
5,957 
6,082 
Financed  Total 
by patients 
85,423  1,358,954 
38,691  677,928 
85,494  845,182 
73,178  801,168 
Financed  Total 
by patients 
2,129  18,321 
450  7,025 
1,130  7,087 
993  7,075 156 
Notice  that the treatment of Kaposi  patients  entails  considerably  higher  costs.  This 
result is  opposite to the findings  of Seage et al.  (  1986) and Scitovsky et al.  (  1986). A 
very likely explanation is that the newer therapeutic methods such as interferon A were 
not yet incorporated in the treatment cost recorded in the mid eighties. However, like 
Seage  et  al.  (1986),  we  only  observe  a  slight  difference  between  the  groups  with 
Pneumocystis carinii and other opportunistic infections. The costs per hospital bed-day 
of  both  groups  are  also  quite  similar.  The  latter  confirms  the  results  obtained  by 
Scitovsky et al. (1986). 
The data also allowed  us to identify the treatment period and related costs of patients 
with Aids Related Complex (ARC). We counted 8 patients and 38 months of treatment 
in  the ARC  stage  of the  HIV  infection.  The  medical  cost per patient per month of 
treatment amounts to 12,666 BEF. The latter cost is far less than that of treatment of a 
full  blown AIDS  patient. It again indicates how large  differences  can be between the 
various stages in the treatment of AIDS. 
3.  Estimation of the total yearly cost of AIDS in Belgium 
The total yearly  cost will  be composed of  direct costs  (viz.  medical  costs  and non-
personal  costs)  and  indirect  costs  (viz.  morbidity  costs).  Only  the  costs  of  resident 
patients  are  considered.  Note  that a  resident  is  a  person  who  has  been  living  in 
Belgium for at least five years. 
First,  we  estimated  medical  costs  by  combining  the  pathology-specific  MCPY  with 
epidemiological  data from  the  Institute  of  Hygiene  and  Epidemiology  (IHE)  of the 
Ministry of Public Health. Note that on the 31st of December 1986, 68 resident cases 
were registered  in  Belgium,  31  of whom had died  already.  On December 31, 1987, 
126 resident  cases  had  been registered,  64 of whom  had died.  Thus  in  1987,  95 
(  = 126-31) patients were treated and 33 (  =64-31) had died.  Of those 95 patients, 25 
had  Kaposi's  sarcoma  while  70  had  Pneumocystis  carinii  infection  or  other 
pathologies. The appropriate MCPY figures were then used to estimate the total yearly 
medical cost for Belgium, presented in Table 6. 
Table 6.  Estimates of the total yearly medical cost of AIDS in Belgium, in BEF 
Patient group 
25 patients with Kaposi's 
sarcoma 
70 patients with P. carinii 
infection or other pathologies 
All patients 
Cost 
Financed 
by HIS 
31,838,275 
50,959,300 
82,797,575 
Total 
by patients 
2,1351575 
5,122,460 
7,258,035 
33,973,850 
56,081,760 
90,055,610 157 
Secondly, we calculated the morbidity cost,  viz.  the loss  of income due to illness  and 
disability during the treatment episode. Given the information on the occupation of the 
16 resident patients in our sample, yearly earnings could be estimated. Use was made 
of earnings data published by the Ministerie van Economische Zaken (1988a, 1988b). 
We  next identified the degree of disability  of each patient from  patient records.  We 
also supposed that the patient was disabled during 20% of the time he resided at home 
and  only  received  outpatient  care.  Combining  then  the  earnings  data  with  the 
morbidity pattern, the morbidity cost per patient per year was estimated to be 269,908 
BEF. The latter figure has to be understood as a minimum:  almost half of the patients' 
records showed treatment over only a few  months. Considering now that there were 
95 resident patients in 1987, the morbidity cost is estimated to be 25,641,260 BEF. 
Thirdly,  we identify the non-personal costs.  These include  government expenditures 
for  research  (20  million  BEF)  and  blood  screening  and  testing  (232  million  BEF, 
including 48 million BEF in support of specialized control laboratories), for special aid 
to  international  organizations  and  developing  countries  (87  million  BEF),  and  for 
information campaigns (46 million BEF). We thus obtain a total amount of 385 million 
BEF. 
Adding the three components of the yearly cost of AIDS, we arrive at a total figure of 
500,696,870 BEF. The latter represents 0.02% of national income in 1987. 
4.  Discussion 
Several lessons can be learnt from the present exercise. First, from the cost estimates it 
can be derived that the burden of the medical treatment of AIDS on the HIS amounted 
to 0.034% of its overall budget in 1987. Considering that this share of the budget may 
increase as a result of a growing number of AIDS patients, it is understandable that the 
future demand for cost-effective treatments will be high on the HIS's agenda. The need 
for cost-effective treatment is  also likely to be spurred by the relatively high burden of 
copayments on patients' incomes. Earlier we have seen that inpatient care accounted 
for the largest part, viz. 83.1 %,  of the medical cost of AIDS. The latter indeed illustrates 
the need to search for  appropriate and cost-effective substitutes for  lengthy  hospital 
treatment. In fact,  recent data already reveal a reduction in  hospital-based treatment. 
The latter trend can only sustained by the establishment of new ambulatory treatment 
methods or the development of innovative drugs that entail a downward effect on the 
need for hospitalization. 
Secondly, the urge to find new ways of treatment not only originates in the desire for 
cost-containment,  of  course.  They  are  also  wanted  for  their  potentially  beneficial 
impact on the quality  of life  of AIDS  patients  and on the  lengthening  of their life 
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Thirdly, how do we have to assess the government budget for information campaigns 
and research in  1987, viz.  66 million BEF ? Let us  remind ourselves that the medical 
and morbidity  cost of the 95 resident AIDS  patients amounted to 115,696,870 BEF 
(=90,055,610 BEF  + 25,641,260 BEF),  or 1,217,862 BEF  per patient per year.  A 
substantial amount of costs will therefore be avoided as soon as information campaigns 
result  in  a  lower  incidence  of  AIDS.  At  present,  however,  there  is  hardly  any 
information on the impact of Belgian information campaigns on the behaviour of risk 
groups.  It  is  thus  premature to say that this  budget should be increased in  order to 
bring costs further down. 
Fourthly, in the present analysis, we were not able to take account of the indirect costs, 
or foregone  earnings,  due to premature  mortality.  Scitovsky  and Rice  (1987)  have 
pointed out that this particular category of indirect costs is even greater than the cost of 
medical treatment. The latter is not surprising since the main group of patients consists 
of normally active men aged between 25 and 45 years. Therefore, the fact that these 
particular  indirect  costs  will  also  be  averted  in  the  event  of  efficient  information 
campaigns adds to the economic rationale of efforts in  the area of prevention. Apart 
from  ethical  reasons,  research  activities  also  find  an  additional  justification  in  the 
potential for lengthening life  expectancy and, therefore, for  reducing the indirect cost 
due to premature mortality. 
To summarize,  countries are well advised to inquire into the desired level  of budgets 
for research and preventive campaigns, in  view  of their potential for  reducing future 
costs  and  for  enhancing  patients'  quality  of  life.  Research  in  particular  needs  to 
concentrate on improvement of the knowledge of the pathology itself, the therapeutics 
and on the possibility of vaccination. 
In  spite  of the limited  sample of patients and the simplifying  assumptions that were 
made, we believe that these preliminary estimates  of the direct and indirect costs  of 
AIDS in Belgium are informative and can contribute to the discussion and elaboration 
of future health policies. 
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B. Olesen, P. G0tzsche, I. Bygbjerg, L. M0ller, V. Faber 
Introduction 
AIDS was first  diagnosed in Denmark in  1981.' By 1 March 1989, 380 AIDS patients 
had been diagnosed, of whom 202 have already died.  The management of patients 
with  AIDS  is  very  costly,  but it  is  largely  unknown  how the  expenses  are  divided 
between  the  basic  cost  of  in-hospital  care  and  the  variable  costs  of  diagnostic 
procedures and treatment. When planning the health care system,  knowledge  about 
these  relations  is  essential.  The  aim  of this  study  was  to  clarify  the  distribution  of 
expenses involved in diagnostic procedures and treatment of AIDS patients. 
Material and methods 
Hospital expenses from  the first  admission to the Department of Infectious  Diseases 
until death were determined for the first 33 AIDS  patients in  a retrospective study of 
patient records. The patients, 32 males and 1 female, were admitted to the department 
in the period from  May 1980 to January 1986. The average age at the time of death 
was  38 years  (range  28-54,  median  37).  One female  and  one male  were  without 
known risk factors, another male had many sexual relationships with women in Central 
Africa, and the rest were homo- or bisexual males. 
The patients were hospitalised for an average time of 95 days (7-352, 82), distributed 
over 4 admissions per patient (1-32, 3). From the first admission the patients spent an 
average  of  53%  of  their  remaining  lifetime  as  in-patients.  The  expenses  were  all 
calculated in 1986 prices. 
Results 
The total  expenses  of  hospital  care  from  the  first  admission  to  death  were  on the 
average$ 50,000 or$ 526 per day. The basic hospital fee made up more than 2/3 of 
the total. It consisted mainly of personnel, inventory, laundry, administration, etc.  and 
amounted  to  $34,037  per  patient.  Laboratory  costs,  made  up  of  microbiology, 
serology I immunology and clinical chemical tests, amounted to $ 4, 784 or 9.6% of the 
total. 161 
Microbiology 
The  average  costs  per patient amounted to  $ 1,979.  Virus  culturing,  which  mainly 
consisted of cytomegalovirus, from respiratory passages, urine and stool was estimated 
at 23% and was, together with bacterial culturing from  the respiratory passages with 
another  23%,  the  most  expensive  item.  Bacterial  culturing  from  the  blood  was 
estimated  at 19%.  Bacterial  culturing  and  protozoan  examinations  from  stool  and 
rectum  came to 16%. The rest of the costs was  made up by bacterial culturing from 
various  places  such  as  spinal  fluid  and  bone  marrow,  catheters  and  ulcers,  tissue 
biopsies and urine. All of them each made up 5% or less. 
Serology and immunology 
This  amounted to  $ 1,675 per patient.  Approximately  half  of this  was  made up by 
qualitative and quantitative lymphocyte investigations. 
Clinical chemical tests 
These amounted to $ 1,130 per patient. Because of the frequency with which the tests 
were  made  (every  3-4 days)  hemoglobin  and  leucocytes  were  the  most  expensive 
parts. 
Out  -patient treatment 
This  amounted to 3.9%  or $ 1,975 per patient.  Most  patients  received  regular out-
patient treatment, on average 8 visits per patient. 
Private duty nurse 
This amounted to 2.8% or$ 1,420 per patient. 19 patients had a private duty nurse for 
9 days on average. 
Medicine and blood products 
This amounted to 8.1% of the total and$ 4,077 per patient. 88% of this was made up 
by drugs.  Range of the cost of drugs was  $ 10 - 23,941, median $ 16,075.  None of 
these patients had been treated with  Retrovir. 26 patients received transfusion with  a 
blood product, on average 8 (0-48, 4). 
Other diagnostic procedures 
This amounted to 2.6%. Gastric, bronchial and rectoscopic examinations incl.  biopsies 
were  $ 291  per patient.  Taking  and  histologically  examining the biopsies  made  up 
approximately 2/3 of the cost. On the average 7 biopsies were taken per patient. The 162 
most frequent examination was  bronchoscopy performed  on average  0.8 times  per 
patient. 
X-ray and CT scan costs amounted to$ 1,033 per patient. 61% of this was made up 
by CT scan (most frequently of thorax and brain), the rest mainly by X-ray of thorax. 
Apart from CT scan 15 X-rays were made per patient (2-45, 13). 
Autopsy 
These costs amounted to 2.3% of the total or $ 1,135 per patient. 23 autopsies were 
carried out;  in  the remaining 10 patients autopsy was  prohibited.  The price  of one 
autopsy  was  $ 1,627,  of  which  microbiological  examinations  of  material  from  the 
autopsy made up 59%. 
Consultants 
This expense amounted to 1.8% of the total or $ 910 per patient. Each patient was on 
average examined by 21  consultants, most frequently a surgeon (6),  an eye specialist 
(4),  a dentist (3)  and a dermatologist (1).  Most patients received physiotherapy, but it 
was not possible to estimate the exact number of treatments. 
Surgery 
This  amounted  to  0.5%  of  the  total  or  $ 238  per  patient.  On  the  average  0. 9 
operations were performed per patient. 4 patients had an open lung biopsy taken, 3 
patients a brain biopsy, and 2 patients underwent laparatomia. 
Other expenses 
These amounted to 0.1% of the total or $ 70 per patient. 
Discussion and conclusions 
In conclusion, the greatest expense in the hospital treatment of AIDS patients was the 
basic hospital  fee,  which  was  2/3  of the total,  while  the expenses  of treatment and 
diagnostic  procedures  comprised  only  about  1/3  of  the  total  costs.  The  expenses 
calculated cannot be used for  future  economic assessments without adjustment. Both 
the number of diagnostic examinations, particularly within virology and immunology, 
as  well  as  expenses  for  medical  treatment  are  increasing.  Treatment with  the drug 
Retrovir, which most AIDS  patients now receive,  will  cost up to $ 12,500 per patient 
per year. Moreover, this calculation does not take into consideration the large nursing 
requirement of these patients, and in  particular the basic hospital fees  are uncertain, 
and the assessment is probably too low. 163 
To reduce the hospital costs in the future, it  is  essential to reduce the length of the in-
hospital  stay.  This  could  be  achieved  by  an  increased  access  to  diagnosis  and 
treatment for  out-patients, better homecare like  the one in  San Francisco led by the 
well-organized  gay  community  (Schietinger,  1986),  and  by  better  psycho-social 
support,  since  some  admissions  of  AIDS  patients  are  mainly  due to psycho-social 
problems. Cost-benefit analyses of diagnostic procedures and treatment (G0tzsche et 
al.,  1988) would also  be useful.  Apart from  the economic aspect, the AIDS  patients 
themselves would highly benefit from all proposals mentioned above. 
In Rigshospitalet Copenhagen the average number of days spent in  hospital per AIDS 
patient has already been reduced in  step with the growing experience with AIDS.  For 
patients who died in  1980-85 the admission time was 95 days,  in  1986 it  had been 
reduced to  72 days,  in  1987 to  54 days,  and for  patients who died  up until  March 
1989, the average time as in-patients was 32 days. The department has now employed 
a  psychologist  exclusively  for  AIDS  patients,  and an extra social  worker  has  been 
engaged. 
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HIV, lAS and AIDS: Methodology, Results and Consequences 
&om a Study in Gennany 
R. Hanpft, F. Reinecke, F. Beske 
Introduction 
For  some  years  now,  the  Institute  for  Health  Systems  Research  in  Kiel  has  been 
studying  some  economic  aspects  of  the  HIV  infection  in  the  Federal  Republic  of 
Germany. An investigation into expenditures for testing blood donations was finished 
in early 1986 (Beske and Hanpft, 1986; Beske and Hanpft, 1987). A study concerning 
the public expenditures for preventive measures is published in this volume (cf. Jenke 
and  Reinkemeier).  Results  are  also  available  from  a  study  that  compared  the 
expenditures  for  the  treatment  of  LAS/AIDS  patients  by  inpatient  as  opposed  to 
outpatient medical services in  a West German hospital (Kook-Walewski  et al.,  1988). 
Another  study,  which  is  presented  here,  has  provided  data  on  the  costs  and 
expenditures  for  diagnosis  and  therapy  of  HIV  infected  patients  in  the  Federal 
Republic of Germany (Reinecke et al., 1988). 
1.  The groups of patients under study 
In  order to  calculate the costs  of,  and expenditures for,  medical care for  a  selected 
group  of  patients,  hospital  and  general  practitioners'  services  were  recorded  in 
retrospect. The patients were assigned to the three stages of infection as defined by the 
original CDC classification: HIV positive incubation, LAS stage and AIDS stage. 
Fig. 1  shows  the  distribution  of the  57  patients  whose  medical  care  records  were 
evaluated. The distribution proved to be fairly equal, both with regard to the stages of 
infection and to the place of treatment. For each patient, the treatment records of 12 
months were covered. As the data are from  1985 and 1986, they do not reflect most 
recent forms  of AIDS  therapy.  For  example,  none  of the patients was treated with 
azidothymidine (AZT).  Furthermore, it must be pointed out that the records evaluated 
are not necessarily representative of all HIV infected patients. 165 
Stage according to  Treatment by  Hospital  Total 
CDC classification  General Practitioner  Treatment 
HIV positive  10  9  19 
incubation 
LAS  10  10  20 
AIDS  8  10  18 
Total  28  29  57 
Fig. 1.  Groups of patients under study 
2.  Evaluation of the treatment by general practitioner 
To  calculate the expenditures that resulted  from  the general practitioner's treatment, 
the services  rendered were  assessed  and then added.  In  addition,  the prices  of the 
drugs prescribed were added as they are recorded in the Red Ust, a drug index of the 
German pharmaceutical industry  (Bundesverband  der Pharmazeutischen Industrie e. 
V.,  1987). For the medical care provided by the general practitioner,  only the crude 
expenditures,  i. e.  the prices of services  charged to the health insurance funds,  were 
considered (Welzel and Uebold, 1986). These figures  give  an appropriate estimate of 
ambulatory services. 
3.  Evaluation of the hospital treatment 
Hospital treatment was evaluated under two different aspects. It had to be considered 
that the expenditures of the health insurance funds and the hospital's operating costs 
may differ  greatly.  So,  on the  one hand,  the  expenditures  of the health  insurance 
funds  for  the required days  of medical  care were  calculated,  and, on the other,  the 
costs of the hospital were assessed  as  far as  possible. Expenditures for  inpatient care 
follow  from  multiplying the patient's length  of stay with the daily rate for  care to be 
covered by health insurance. 
To  assess the costs  of the hospital,  its services were itemized as shown in  Fig. 2.  The 
total costs consist of those for the physician, nursing accommodation and food ('hotel' 
costs),  special diagnostic tests (medical costs) and drugs and physical therapy (cost of 166 
Cost Sector  Data Source 
physician costs  cost accounting centre 
nursing costs  cost accounting centre 
(rated according to intensity)  (corrected by own rating) 
'hotel' costs  cost accounting centre 
medical costs  own evaluation 
cost of materials  own evaluation 
Fig. 2.  Evaluation of hospital treatment costs 
materials)  (Tauch,  1986).  The  annual costs  of physician,  nursing and 'hotel'  of the 
ward  in  which  the patients  lay  were  taken  from  the  cost  accounting  centre  of the 
hospital. Dividing those costs by the number of patient days results in the average cost 
for a single day. It has to be taken into account that the ward also consisted of patients 
not infected with HIV. 
While average costs of the ward were used to evaluate physician and the 'hotel' costs, 
the average daily nursing costs were rated according to the assumed nursing intensity 
of patients in the different stages. For HIV positive patients, the average nursing costs 
were multiplied by the factor 0.6, for lAS patients by 1 and for AIDS patients by 1.6. 
This rating resulted from the following considerations: 
According to studies,  an intensity of 0.6 of the average time for  nursing can be 
assumed when a patient is  still  able to stand up by himself,  at least most of the 
time, and to eat, etc. by himself (Deutsches Krankenhausinstitut, 1987). 
It was assumed that a lAS patient requires the average time for care. 
According to a study by Zollner in Munich, the time of care for an AIDS patient is 
1.6 times as high as that of an average patient. 
The costs for special diagnostic tests (medical costs) and for drugs and physical therapy 
(costs  of  material}  were  evaluated  in  detail  and  separately  for  each  patient.  The 
medical services were assessed using the DKG-NT. This is a schedule of charges issued 
by the German hospital  society for  the determination  of fees-for-services  (Deutsche 
Krankenhausgesellschaft, 1987). The costs of drugs were calculated from the purchase 
price  of  middle-sized  packages  for  hospital  pharmacies.  Certain  medical  costs  also 
comprise services rendered on the ward such as entrance examinations and taking the 
costs  of the  medical  and care  personnel  had to  be excluded,  as  those  costs  were 167 
already included in the costs for physicians' services and nursing costs. These medical 
costs  were  assessed  by  subtracting the  costs  for  personnel,  which  responds  to  the 
difference between full  costs  and costs  for  material in  the scale  of charges from  the 
German hospital society. 
4.  Expenditures and costs 
The  average treatment expenditures  and treatment costs  of the patients  during the 
evaluation period are shown in Fig. 3. 
The results are classified according to the three infection stages. The expenditures for 
treatment by general practitioner are OM 1,567 for  patients in  the lAS stage;  this  is 
about one and a half times more than for patients in the HIV positive incubation stage, 
which amounts to OM 977. The ambulatory treatment of patients with AIDS resulted in 
lower  expenditures  than for  those  in  the lAS stage  - a  reflection  of  the fact  that 
patients with AIDS are mostly treated in hospital. 
To  calculate  the  expenditures  for  hospital  treatment,  an  average  care  rate  of 
OM 348.85 from  seven German hospitals accommodating an above-average number 
of HIV infected patients was used. A comparison between the average expenditures for 
hospital treatment and the approximate  average costs  shows  that HIV  positive  and 
lAS patients led to costs of OM 6, 712 and OM 8,286 respectively;  this  is  slightly  less 
CDC stage 
Place of treatment  HIV positive  LAS  AIDS 
general practitioner  977  1,567  1,201 
Expenditures 
7,0121) 2)  8,4421) 3)  23,1641) 4)  hospital 
hospital 
Costs  -per year  6,7122)  8,2863)  28,3444) 
-per day  334  343  427 
1)  daily care rate DM 348.85  3)  length of stay 24.2 days 
2)  length of stay 20.1 days  4)  length of stay 66.4 days 
Fig. 3.  Average treatment expenditures and treatment costs per year and patient in DM 168 
than  the  expenditures  of  DM 7,012  and  DM 8,442.  The  average  costs  for  AIDS 
patients, however, exceed the average expenditures by about 20%. 
These ratios are also reflected in the amounts per patient day. The average costs for 
treatment per day of care for HIV positive and LAS patients, DM 334 and DM 342, are 
slightly less than the expenditures, which are based on a daily care rate of DM 348.85. 
The daily costs for the AIDS patients are DM 427, thus exceeding the daily care rate by 
about20%. 
5.  Costs in various categories 
It is  interesting to observe those five  cost categories in  which, depending on the stage 
of the infection, differences are so considerable that they obviously affect the total costs 
for hospital treatment. The share these categories have in the total costs of each stage 
of the illness is shown in Fig. 4. 
As  mentioned  before,  average  figures  for  physician's  as  well  as  'hotel'  costs  were 
assumed in  all stages. The costs for nursing increase, according to the rating, from the 
HIV positive stage through the LAS  stage to the AIDS  stage. For the development of 
those  two  cost  categories  where  each  single  individual  service  was  accounted  and 
summed up, it is typical that the costs for drugs and physical therapy, very small in the 
first  two stages, are about 30 times  higher in  the AIDS  stage,  whereas the costs for 
OM 
500 
400 
300 
200 
100 
0 
HIV-positlve stage  LAS  stage 
Fig. 4.  Cost categories of hospital treatment 
AIDS  stage 
Costs for 
D  diagnostic tests 
•  medicine and physical 
therapy 
D  nursing 
D  hotel 
•  physician 169 
diagnostic examinations decrease absolutely and relatively from the HIV positive stage 
through to the AIDS stage but, on the whole, remain at a high level. 
6.  Expenditures for a HIV infected person during the total time of infection 
To be able to sum up the expenditures for one HIV infected patient during the whole 
length  of infection,  hypothetical careers of  illness  and treatment were regarded.  The 
calculation was made under the following assumptions: 
1.  Although the sums for  the average yearly expenditure in  an infection stage were 
calculated by recording the treatment of several patients, they were added to one 
sum for a 
11model patient
11
• 
2.  The maximum  amount of  hospital treatment during the HIV  positive  incubation 
stage was  restricted  to  1 year,  even though  it  was  assumed that this  stage  lasts 
several years. 
3.  For the LAS  stage and the AIDS  stage yearly expenditures for hospital treatment 
and for treatment by the general practitioner were estimated. 
4.  While the HIV positive stage and LAS stage were assumed to have a length of 1 
year to several years, the AIDS stage was assumed to be 1 year only. 
Due  to  this  premise  and  depending  on  the  course  of  the  illness  and  the  varying 
demand  for  treatment,  different  results  may  occur  in  the  expenditures  for  a  HIV 
positive person during the whole period of infection. This is shown by two examples in 
Fig. 5. An infection period of 10 years is assumed in both cases. 
Example 1 shows a patient with a 3-year HIV positive stage, a 6-year LAS stage and a 
1-year AIDS  stage. The patient is  hospitalized  once during the HIV  incubation.  This 
results in expenditures of OM 94,000. 
Example 2  shows a  patient in  which  the  LAS  stage follows  an 8-year HIV  positive 
stage,  lasts  1  year  and  is,  in  tum,  followed  by  an  AIDS  stage  of  1  year.  The 
expenditures amount to OM 42,000. 
When calculating the treatment of different extreme cases which all  have an infection 
period of 10 years, this model results in expenditures of OM 33,000 to 114,000 during 
the whole period of infection. 
7.  Conclusions 
1.  It has to be taken into account that the calculations rely on data from  one hospital 
and one general practitioner as well as  from  a relatively small number of patients, 
also that since the survey period 3 years have passed. 170 
treatment by 
Example  1 
general practitioner 
hoapltal treatment 
treatment by 
Example 2 
general practitioner 
hoapltal treatment 
expenditures depending  total 
on place of treatment  expenditures 
I I  I  I I I  I  I  I  I  I 
13 000 OM 
81  000 OM 
I I I  I I  II I  I  I  I 
10 500 OM 
31 500 OM 
D  one year treatment In the HIV-positlve stage 
D  one year treatment In the LAS  stage 
D  one year treatment In the AIDS  stage 
D  no treatment 
94 OOODM 
42 000 OM 
Fig. 5.  Model calculation of the treatment expenditures during the whole period of infection 
2.  As 20% higher hospital treatment costs than expenditures for AIDS patients were 
determined, it  can be assumed that if the number of AIDS  patients increases, the 
daily  rates  of hospital  care  will  not cover the costs.  The  greatest  cost  increase 
during  the  progression  of  the  disease  can  be  expected  in  the  cost  categories 
therapy and nursing. 
3.  It  was  shown that the expenditures  for  diagnosis  and therapy  of HIV  infected 
patients vary greatly, depending on the course of the illness  and the demand for 
care. When using these calculations for  further forecasts,  different results may be 
expected, depending on the frequency distribution of the infection stages and on 
the degree of demand for care. 
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Introduction 
Since 1986, medical services and the resulting costs for AIDS patients at our outpatient 
clinic have been analysed (the term 
11medical services
11  includes consultations, physical 
as  well  as  technical  examinations,  laboratory  tests,  counselling).  For this  particular 
question,  there  are  hardly  any  data available  in  the  Federal Republic  of Germany. 
Except for the cost analysis regarding ARC  and AIDS  patients, performed by Koock-
Walewski  (Koock-Walewski  and  Stille,  1989),  only  a  few  comparable  studies  (e.g. 
Hanpft et  al.,  1988)  are  known  to  us.  However,  these  studies  mainly  researched 
expenditure for  inpatient care  and,  only  to  a  lesser  extent,  services  performed  for 
outpatients. 
There are a number of US studies analysing costs per patients, some of them based on 
high  caseloads (e.g.  Andrulis  et al.,  1987), but again, these studies mainly deal with 
costs arising during inpatient treatment. As the results of these studies vary significantly 
between different US regions, they are hardly, if at all, comparable with the situation in 
other countries. This is  also true for cost analyses performed by other countries, e.g. 
Great Britain  (Johnson et al.,  1986).  The  differences  of national  health  and social 
security systems  as well  as  differing prices for  pharmaceutical products, etc.,  make a 
comparison  and  a  useful  interpretation  even  more  difficult.  Furthermore,  the 
professional know-how of medical staff will  play a most important role regarding the 
extent of medical expenditures arising. 
The diagnostical and therapeutical standards which have been found to be useful and 
necessary  for  the  treatment  of  the  different  stages  of  HIV  infection  will  have  a 
determinative  influence  on length  as  well  as  frequency  of  hospitalisations.  Another 
important determinant  on cost  development is  the  improvement of life  quality,  i.e. 
patients'  ability  to  work  and  support themselves.  Thus,  in  order to  fight  possibly 
occurring  financial  bottlenecks,  it  is  necessary  to  carry  out retrospective  as  well  as 
prospective studies on service-expenditure development. Such a study is being done in 
a specialised health care institution, the AIDS Outpatient Clinic (AOC). This outpatient 
clinic,  to which a  15-bed ward is  attached, has existed since 1987. Starting in  1982, 
regular office hours for HIV-infected persons were offered. 173 
The aim  of the  study mentioned  is  to  investigate the expenditure necessary for  the 
outpatient treatment of HIV infected persons with manifest illness. To this end, we shall 
present a study of costs  of medical expenditure for  an AIDS  patient who was solely 
treated on an outpatient basis. We  shall further discuss data presented in two service-
cost analyses performed by the Department of Infectious Diseases Frankfurt (Koock-
Walewski  and Stille,  1989; Exner-Freisfeld  and Helm,  1987) which evaluate medical 
interventions performed on patients with full-blown AIDS. After a short survey of these 
studies,  we  shall  compare  the  respective  data  dealing  with  the  expenditure  for 
outpatients with  AIDS.  This  means that only medical interventions performed by the 
AOC will be taken into account. 
Cost analysis I 
This study assesses medical services performed by the AOC  for  an outpatient under 
azidothymidine (AZT,  zidovudine, Retrovir).  The evaluation of services was based on 
the patient's  medical record,  which  was  analysed  retrospectively  until  August  1988, 
and from  then on prospectively. The registration  of data was based on the charges 
according to the fee-for-service schedule for  office-based physicians (GOA)  as  of July 
1, 1988. Pharmacotherapy was calculated on the grounds of "Lauer tax", the German 
standard price list valid from February 1989. 
Medical performances were registered separately for the following areas: 
Services carried out by an outpatient doctor 
Laboratory tests 
Diagnostic services by means of technical equipment 
General pharmacotherapy 
Anti-retroviral therapy (AZT) 
Services performed by consultants from other specialities were not taken into account. 
Patient's history 
At  first  examination  (17  September  1986),  the  35-year-old,  homosexual  patient 
already showed slight focal  symptoms  (paresthesia left thigh)  of toxoplasmosis of the 
brain  which  soon  became  clinically  significant.  CD4  and  CD8  cell  counts  were 
significantly  pathological  with  126/J..d  and  399/J..tl,  respectively.  Thus,  the  patient 
already met the CDC criteria for full-blown AIDS at first presentation at the AOC. 
The patient was treated with AZT (average dosage per day:  1 g)  for 444 days. He was 
not hospitalised during the entire time of monitoring. The acute treatment of not very 
severe toxoplasm encephalitis (early 1987) was also done on an outpatient basis. The 
study was conducted  over a  period  of 900 treatment days  (equalling  10 treatment 
quarters) until the end of 1988. 174 
Results 
For services performed by doctors, laboratory tests and diagnostical services by means 
of  technical  equipment,  expenditures  totalled  OM  17,745.  In  this  sum,  the  highest 
amount by  far  was  caused  by  laboratory  tests  (OM  15,233  =  86%).  The  total  of 
pharmacotherapy amounts to  OM 31,500, 70%  of which  (OM  22,200)  is  due to the 
AZT  therapy  over 444 days.  The  entire  expenditure  for  medical  services  over 900 
outpatient treatment days (10  quarters) had amounted to OM 49,244- including AZT 
therapy - by the end of 1988. Expenditure development for the investigated treatment 
quarters is shown in Table 1. 
The medical services carried out by consultants from other specialities, which were not 
included in  the registration of services performed by the AOC,  were:  10 neurological 
interventions  (follow-up  after cerebral toxoplasmosis),  8 dermatological interventions 
(diagnosis  and therapy of  a  disseminated  Kaposi's  sarcoma,  having  occurred  under 
AZT),  1 ophthalmological intervention due to  suspected CMV  retinitis,  performed by 
the end of the last treatment quarter investigated. 
Discussion I 
Not unexpectedly,  anti-retroviral therapy  (AZT),  with  70%  of  pharmacotherapy and 
45% of total outpatient treatment costs,  has  a  significant influence  on expenditures. 
Also,  the  proportionally  rather  high  costs  for  laboratory  tests  may  be  seen  in 
connection with the monitoring of a newly introduced pharmacotherapy which causes 
a significant number of side effects needing treatment. In this  case, however, no costs 
for interventions due to therapy arose. Considering that survival time after diagnosis of 
AIDS  was  more  than  900  days  and  that  the  patient  was  treated  entirely  on  an 
outpatient basis  over the  whole  monitoring  period  - which  is  quite  extraordinary  -
expenditures up to now do not seem unreasonably high. 
An assessment of 7  4 medical records of patients with  full-blown  AIDS  who had died 
before June 30, 1987 (Helmet al.,  1987) showed a mean survival time  of 25 weeks 
after  AIDS  diagnosis  (the  manifestation  being  CNS  toxoplasmosis;  n=9),  with  a 
minimum  of 3.1  and a  maximum  of 77.1  weeks  (=540 days).  At  present,  it  is  not 
certain if the achieved prolongation of survival times with a rather high quality of life is 
partly due to improved diagnosis and therapy of opportunistic infection as  well  as to 
more adequate psycho-social care. 
In this  context, we should like  to mention the 55 consultations in  the 10 quarters and 
the connected medical services performed by doctors of the AOC,  which, with regard 
to costs,  hardly show in the books at all  (2.2%).  In spite of this,  regarding substance 
and time consumption, they represent the most expensive medical service. T
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Analysis of consultations conducted by doctors of the AOC 
An  unpublished  study  investigating  "Consultations  performed  by  doctors  at  the 
outpatient  clinic  - duration  and  substantial  emphasis"  (Frankfurt  University  Clinic, 
Department of Infectious Diseases) shows that doctor-patient conversations are highly 
time-consuming.  The  investigation  was  based  on  consultations  of  three  outpatient 
clinic doctors who were all  experienced in the treatment of HIV infected persons and 
was carried out during main office hours on various days. 
The investigation was based on 135 consultations, 35 female  and 100 male patients. 
30% of the patients  had AIDS,  45%  PGUARC,  and 14% were asymptomatic HIV-
positive persons. In the remaining 11%, the stage of disease was unclear at the time of 
investigation,  or patients  were  seronegative  for  HIV  but lived  under  circumstances 
which  put them  at risk  of an  HIV  infection.  Infection  risk  was  homosexuality  in  69 
patients, and anamnestic i.v.  drug abuse in 52 patients. Of the remaining 14 patients, 6 
were heterosexual, 6 were bisexual, 1 patient was a hemophiliac, and another patient 
had received an infective blood transfusion after polytrauma. Table 2 shows duration 
of consultation listed according to different groups of patients. 
In  four  cases,  hospitalisation  right after  consultation at the outpatient clinic  became 
necessary due to acute symptoms. The reasons were: 
Necrotic scrotal lesions due to herpes 
Somnolent patient; neurological symptoms 
Icterus in stage PGUARC 
CMV relapse (retinitis). 
In  one case, an acute blood transfusion was  necessary, which was carried out at the 
AOC. 
A total of 28 so-called  crisis-management  consultations  was  registered,  the average 
duration being 40 minutes  (minimum  15, maximum  90 minutes). The most common 
reasons for crises were: 
Danger of suicide, 
Acute relapse into drug abuse, 
Impending psycho-social decompensation, 
Problems in connection with pregnancy, 
Progression to AIDS. 
In  27  cases,  patients  were  accompanied  by  a  life  companion,  spouse,  sibling,  or 
another person helping them because they suffered from  amaurosis, walking disability 
due to paresis, etc. T
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99 patients mentioned somatic complaints, 49 patients gave psycho-social problems as 
reasons for their visit at AOC.  This  means that in  more than 50% of cases, somatic as 
well as psycho-social reasons were given. 
Patients'  histories  were  investigated  in  detail  in  14 cases.  In  14 cases,  a  complete 
physical  examination  was  carried  out,  and  in  7  4  patients,  examinations  related  to 
symptoms  were  performed.  The  latter  mainly  concerned  examination  of  skin  and 
mucosa, palpation of lymph node sites and abdomen, and percussion and auscultation 
of lungs. 
From  67  patients,  blood  samples  were  taken,  in  a  number  of  cases  for  extensive 
laboratory  tests  (57  of these  patients  were  reveiving  AZT).  Swabs  were  done  in  4 
patients, faeces  examinations for  pathogens in  1 patient. In  18 patients, urinary tests 
were done. 
12  patients  were  referred  to  a  consultant  specialist:  2  to  a  neurologist,  7  to  a 
dermatologist, 1 to a hematologist/oncologist, and 2 to a surgeon. 
In 27 cases, telephone calls by doctors had to be made. For 21 patients, short medical 
statements  or  certificates  were  written,  64  patients  received  prescriptions,  and  5 
patients were given a certificate of disability to work. 
Medical services planned and/or carried out by means of technical equipment were: 2 
rest spirographies  (during  consultation),  5  abdominal  sonographies,  4  chest X-rays. 
The following  table lists  the medical services  which  are  reimbursed according to  the 
fee-for-service schedule [Gebilhrenordnung fiir Arzte (GOA), 1988]. 
Discussion II 
The average time of consultation was  26 minutes  (from  the time the patient entered 
the  doctor's  office  to  the time  he  left).  In  5  cases,  the  consultations  lasted  only  5 
minutes  each;  mainly these  had the function  of making  an appointment for  a  later 
date.  In  2  cases,  the outpatient doctor had conversations  lasting  longer than  1 1/2 
hours. The average duration of consultation or examination (26 minutes; minimum 5, 
maximum 90 min.)  did  not differ significantly between the members  of the main risk 
groups: 
Homosexuals:  26 min  (minimum  5,  maximum  90) 
IVDA:  23 min  (minimum 5,  maximum  90). 
14 patients  with  a  risk  background  other than  homosexuality  or i.v.  drugs  had an 
average of 30 minutes' (minimum 10, maximum 60) consultation time. 179 
Table 3.  According  to  fee-for-service  schedule  for  doctors  (GOA)  of July  1,  1988,  the  following 
reimbursable services were performed by doctors in 135 consultations 
#GOA  Service  #Services  Price  Total  (DM) 
1a  Short information prescription  5  3.96  19.80 
1  Counselling/examination  21  7.92  166.32 
< 20min. 
806  Crisis management  28  27.50  770.00 
>  20min. 
14  Short certificates,  5  3.41  17.05 
i.e. work disability 
1b  Detailed counselling  66  16.50  1,089.00 
>  25 min. 
65  Detailed examination  66  11.66  769.56 
1b  Detailed counselling/  43  16.50  709.50 
examination >  15 min. 
605  Rest spirographies  2  26.62  53.24 
Intermediate total: services performed by doctors during consultation  3,594.47 
15  Medical statements with  19  5.50  104.50 
assessment med. letter 
20  Written certificates  3  12.50  36.30 
250  Blood tests without BSR  22  4.40  96.80 
286  Blood transfusion incl.  1  39.93  39.93 
biological pre-testing 
407  Abdominal sonographies  5  66.00  330.00 
5135  Chest radiographies  4  33.00 
Survey plus  227.48 
5137  Additional radiograph  23.87 
Intermediate total: service performed by doctors in addition to consultation  835.01 
Total for all services performed by doctors for 135 individual consultations  4,429.48 180 
Time  of consultation for  newly admitted patients (n=12) differs significantly from  the 
above mentioned findings:  average  consultation time  was 55 minutes  (minimum  30, 
maximum 90)  not regarding two  initial organisational conversations lasting 5 and 10 
minutes. 
Patients who are treated at the AOC on a regular basis (so-called follow-ups;  n=122), 
need an average consultation time of 24 minutes  (minimum 5, maximum 90).  Female 
IVDA  (n=31)  have  the  shortest  consultation  times:  ca.  21  minutes  (minimum  10, 
maximum 50). 
Only  counselling  is  remarkably  rare  in  consultations;  in  most  cases,  physical 
examinations and laboratory tests became necessary. 
The remarkably long duration of consultations for all risk groups shows that the group 
of patients treated at the AOC  is not comparable with the usual patients of a GP. This 
is  also  confirmed by  the subjects  the consultations  and examinations focus  on.  The 
particular  problems  connected  with  HIV  infection  need a  substantial  infectiological 
know-how. Doctors must be able to diagnose opportunistic infections at an early stage 
and treat them adequately; they must be able to render psychological counselling; and 
they must have knowledge about socio-medical aspects. As we found out in our study, 
for a high number of patients, the outpatient doctor is  one of the first places they tum 
to  if  they have questions concerning life  support,  impending loss  of work,  problems 
with  administration  (social  security,  application  for  acknowledgement  of  disability). 
Furthermore, there are groups of patients who need particular treatment, e.g.  IVDA, 
whose addiction  demands detailed  knowledge.  This  boils  down  to  the fact  that the 
outpatient treatment  and  care  of  HIV -positive  persons  or persons  at  risk  for  HIV 
infection demands specialist knowledge to a high degree. 
Cost study III 
In 1987, still before the actual onset of anti-retroviral therapy with AZT,  a service-cost 
analysis on ARC/AIDS  patients of Frankfurt University Clinic was performed (Koock-
Walewski  and Stille,  1989). This  study calculated  care expenditure for  AIDS  in- and 
outpatients at OM 39,000.00,  based on the average total costs and the mean survival 
time of 243 days. 
According  to  this  study,  the  average  medical  costs  (inpatients  and  outpatients) 
amounted to the following sums per patient per year: 
Patients with PGUARC:  OM  11,070.00 
Patients with AIDS:  OM  26,977.00 
Average hospitalisation costs: 
Patients with PGUARC: 
Patients with AIDS: 
OM  7,917.00 
OM  18,191.00 181 
Average outpatient treatment costs were retrospectively calculated on the grounds of 
services  performed  for  a  group  of  16  PGUARC  patients  and  10  AIDS  patients. 
Consultative services from other specialities were included. 
Services performed by doctors on an outpatient basis  (diagnostics and therapy} were 
again  calculated  on  the  basis  of  the  fee-for-service  schedule  (GOA}.  Pharmaco-
therapeutical costs were calculated according to Lauer tax. 
Care expenditures amounted to the following totals per patient per year: 
Patients with PGUARC:  OM  3,153.00 
Patients with AIDS:  OM  8, 786.00 
This  investigation  does  not  separately  list  special  therapies  (e.g.  anti-retroviral}  or 
length and frequency of hospitalisations for outpatients. 
For  10  AIDS  outpatients,  services  performed  by  the  AOC  could  be  calculated 
separately per patient per year: 
OM  391.00  medical services performed by doctors 
OM  4,105.00  laboratory tests 
OM  405.00  services performed by means of technical equipment 
OM  2,618.00  pharmacotherapy 
OM  7.519.00  per patient per year 
Cost study IV 
Also  in  1987, the expenditures for  in- and outpatient treatment (diagnostics, therapy} 
arising for  one AIDS  patient of Frankfurt University Clinic were investigated  (Exner-
Freisfeld and Helm,  1987}.  This study also considers the increasing complex of social 
problems  and  investigates  social  security  expenditures  from  time  of  diagnosis  to 
patient's death. 
At  first  examination  on  28  February  1986,  the  26-year-old  patient  fell  ill  with 
pneumocystis carinii pneumonia (PCP}, this disease also being the AIDS manifestation. 
He soon suffered a relapse, and later developed CNS toxoplasmosis. The monitoring 
period from AIDS diagnosis to death was 580 days. 
Sickness benefits and a number of social security benefits received by the patient (he 
was  not  entitled  to  claims  on statutory  pension  insurance  fund)  amounted  to  OM 
23,300.00.  In  addition,  costs  for  hospitalisation  were  also  calculated.  The  entire 
medical  expenditure  for  269  hospital  treatment  days  amounted  to  OM  46,420.68. 
According to survival time and number of complications in the course of disease, this 
individual case is  in  the average range of patients with  manifest disease. This  sum  is T
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based on the fee-for-service schedule for  doctors (GOA). It does not include the costs 
for housing, catering, medical care and services performed by doctors. 
Considering  a  calculation  based  on  daily  care  expenditure  rates  (169  days  x  DM 
352.65, and 100 days x DM 382.08), the entire hospitalisation costs amounted to DM 
97,806.00. After subtraction of costs  calculated according to GOA, there is  a total of 
DM  51,385.00  for  269  days'  care,  housing,  catering  and the  additional  personnel 
expenditures. This results in DM 191.00 per day. 
The outpatient treatment costs for 311 days (interrupted by 14 hospitalisations with a 
total of 269 days of care) amounted to DM 7,782.00 for medical care and diagnostics. 
The expenditures  for  pharmaceutics  prescribed on an outpatient basis  amounted to 
DM 5,262.00. Thus, for this individual patient there was a total outpatient cost of DM 
13,044.00. The patient spent a  considerable  part of  his  survival  time  (46.4%)  after 
diagnosis of AIDS in a hospital. No special anti-retroviral therapy was performed. 
Finally, the different studies on cost-service relations performed at Frankfurt University 
Clinic were be compared with regard to AIDS outpatients (costs per patient per year). 
Study III  is  based on data of 10 patients but does not mention  any interruptions  of 
outpatient treatment by hospitalisations. Compared with studies IV  and I we estimate 
the  lower  total  expenditures  to  be  due  to  less  service-intense  treatment  intervals 
between hospitalisations. In the calculation of total average cost, the average duration 
of AIDS stage is assumed to be one year. In the meantime, this assumption is outdated. 
A special anti-retroviral therapy is not listed, as this therapy was just about developing 
at the time of cost analysis. 
In  study IV,  the monitoring period  of 580 days  is  interrupted by  hospitalisations  14 
times,  the total days  of care being 269.  Medical  services  performed by doctors  and 
diagnostic  services  were  listed  together;  a  subtraction  of  consultative  services  for 
improving comparability could not be carried out. A special anti-retroviral therapy was 
not performed. 
In study I, the monitoring period of 900 days is not interrupted by any hospitalisation. 
This represents quite an uncommon course of disease. The patient had been randomly 
chosen out of a  group of AIDS  patients treated with  AZT;  usually patients with  full-
blown AIDS  need a  number of  hospitalisations  per year.  The anti-retroviral therapy 
(444 days; average dosage: 1 g/d) is listed separately. 
Resume and outlook 
Looking at the three different cost studies with regard to total expenditures per patient 
per year,  we  get a  rather homogeneous picture  of a  health care institution  treating 
AIDS outpatients and making use of accumulated medical knowledge. 184 
The  opportunistic  infections  and tumors,  which  are  very  likely  to  occur during  the 
course of disease in HIV-positive persons, cause extensively high medical expenditures 
concerning diagnosis as well as therapy. 
However, the duration and frequency of expensive hospitalisations can be lowered by 
means  of  regular,  professional  medical  monitoring  of  the  patients.  This  includes 
laboratory  tests  as  well  as  services  by  means  of  technical  equipment.  By  these 
measures, complications in the course of this rather variable disease can be diagnosed 
early, and adequate therapies can be applied. 
Early  diagnosis  and  exact  monitoring  of  patients  which  helped  to  improve 
therapeutical schemes in consequence led to an improvement of patients' life quality. 
A special therapy aiming at the cause of disease by means of the anti-retroviral agent 
azidothymidine (AZT) was started at AOC in early 1987 (at that time as phase II study). 
By this therapy, which represents a substantial cost factor in the outpatient treatment, 
the  patients'  state  of health  and  course  of  disease  could  be significantly  improved, 
especially during the first 200 days of treatment (Staszewski et al.,  1989). On the other 
hand, the considerable side effects of AZT cause additional expenditures with regard to 
monitoring and possibly therapy (e.g.  blood transfusion).  AZT therapy,  which  in  the 
future will be partly applied in  a modified way (therapeutical intervals), will need - for 
reasons of medical carefulness - quite an amount of medical monitoring. This of course 
is also true for other, newly introduced anti-retroviral agents. 
The progress  in  diagnostics and therapy of AIDS  and associated diseases which  has 
been achieved during the last two years, together with positive effects of AZT therapy, 
relieves the hospital sector. It also promotes treatment on an outpatient basis, which is 
preferred by most of the patients. 
Due to these facts, for specialised health care institutions like the AOC, there will be the 
substantial  problems  as  to  financing  the  necessary  health  care  services  in  future. 
Expenditures  for  services  performed  by  doctors,  laboratory  tests  and  services 
performed by means of technical equipment were calculated by the different studies as 
follows: 
Study  III: 
Study  IV: 
Study  1: 
OM  5,100.00 per patient per year  (n=10) 
OM  9,500.00 per patient per year  (311 days, individual care) 
OM  7,200.00 per patient per year  (900 days, individual care) 
The  services  mentioned  above  are  refunded  according  to  the  institutional  contract 
between AOK Frankfurt (statutory health insurance scheme) and the University Clinic 
Administration  (via  association  of  statutory  health  insurance  physicians; 
Kassenarztliche Vereinigung).  The presently valid lump sum per treatment quarter per 185 
HIV-positive  or AIDS  patient  of  AOC  amounts  to  OM  330.00.  This  total  of  OM 
1,320.00 per patient per year does by no means cover the actual costs. 
With increasing caseload, the deficient cover will lead either to a financial gap or to a 
reduction of health care quality for other patients (Leidl1988). A deficient cover seems 
extremely  likely  because  an  increasing  number  of  diseases  associated  with  HIV 
infection are treated on an outpatient basis. This means that severeness of disease as 
well as degree of complication within the individual patient's course of disease will rise 
significantly  within  the  respective  main  health  care  institutions.  Tendencies  in 
accordance with this assumption have already been noted in the outpatient as well as 
the inpatient sector. 
For these reasons, we believe that a service structure similar to one already existing 
and well-functioning for  other chronically ill people (leukemia,  renal deficiency,  etc.) 
should  also  be established  for  HIV-infected  persons.  The  main  structures  in  these 
schemes are day-care centres,  teams of experts,  high-level  consultative services and 
adequate refund for medical services for AIDS patients performed by specialists. 
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the Case of the Oxfordshire District 
M. Rees 
1.  Introduction 
Two main approaches have been used by the Department of Health's AIDS  Costing 
Project to assess the cost of AIDS/1-UV  in  England. These are patient costing through 
the use of patient records and hospital and district-wide costing, which aims to extract 
AIDS!HIV costs from the hospital or district global cost totals. Both methods have their 
advantages and disadvantages, which this paper will briefly discuss. The main part of 
the paper, however, consists of a short account of the use of the latter method in one 
English district, Oxfordshire. 
2.  Patient versus hospital-wide and district-wide costing 
2.1  Patient costing 
Patient costing  has a  number of advantages  as  an approach.  It  identifies  details  of 
AIDS patient treatment, including treatment given before the AIDS stage. It was found 
that early, pre-1986 diagnosed, AIDS patients at St Stephen's and StMary's Hospitals 
in  London  had  sometimes  been  treated  as  inpatients  for  apparently  HIV -related 
conditions  before  AIDS  diagnosis.  Although  the  average  number of  inpatient days 
involved was small,  a mean of about 4 days per patient, such treatment is  easily to 
overlooked, because it  was  frequently  given  at hospitals  other than the main  AIDS 
treatment hospital. Patient costing gives a comprehensive picture of the progress of the 
disease,  and  enables  costs  to  be  attached  to  its  different  phases.  It  shows  the 
extraordinary variety of AIDS  patient treatment, that there is  really  no such thing as 
the typical or representative AIDS  patient. The method can be used produce valuable 
AIDS patient statistics. For example it enables us to calculate the average length of stay 
per patient or per patient admission. The early London AIDS patients referred to had a 
cumulative length of inpatient HIV-related stay of about 91 days. 
In  spite of these  advantages AIDS  patient costing has significant disadvantages.  The 
first is the confidentiality problem. AIDS doctors are not generally very willing to allow 
outsiders  to  look  over AIDS  patient records,  and if  they  do,  they  demand  careful 
supervision. Records cannot be taken out of the hospital, for example, and usually not 
away from  the ward or clinic.  The records of a particular patient may not be readily 188 
available,  perhaps because they are being used for  research by one of the doctors. 
AIDS patient costing is  very time-consuming, as anyone who has ever seen the size of 
the  medical  records  of  such  patients  will  appreciate.  AIDS  patients  are  the  most 
complex of patients,  with  frequent readmissions  and referrals.  They will  often  have 
separate  inpatient  and  outpatient  records.  The  records  may  be  disorganised  and 
difficult to read, and may have omissions. 
The information  is  usually  obtained from  the. records  of patients who  have died,  in 
order that a comprehensive picture of AIDS patient costs may be obtained. This may 
have  the  disadvantage  that  unrepresentative  samples  of  patients  are  used,  for  if 
sampling is  confined to deceased patients, those who survive for longer than average 
after AIDS  diagnosis will tend to be omitted. Many studies of AIDS patient costs seem 
to have fallen into this trap. If,  however, representativeness is  ensured by sampling at 
AIDS diagnosis, some of the sample will survive for long periods, which means that it 
may not be possible to cost fully  the sample until some years after diagnosis.  This  in 
tum will  mean that the most of the patients in the sample will have died some years 
before the completion of the study, which will be very out-of-date by publication. This 
is important if treatment methods are changing, as is the case with AIDS. 
There is also the problem of both describing and costing individual items of treatment. 
The costing of a referral, for  example, should involve both a count of the number of 
units of treatment given, if economically sensible units exist, and also a costing for each 
unit.  This  may  mean  special  investigations  within  the  departments  concerned  to 
determine  exactly  what treatment  is  given  to AIDS  patients,  the  costs  of a  unit  of 
treatment, and possibly a review of the treatment of individual patients, which may not 
be given fully in the main patient record. 
Finally,  and  very  importantly,  the  patient  costing  approach  omits  many  important 
AIDSIHIV  costs,  such  as  infection  control,  teaching,  research,  some  testing  and 
counselling and administration. Although it might be possible in theory to attach such 
costs to AIDS patients, it would not really be the correct approach because many of 
these costs  are not AIDS patient costs,  and in  any case could not be approached by 
means of the patient record. 
2.2  Hospital or district-wide costing 
This is,  in theory and I believe in practice, the more comprehensive approach. By not 
focusing  solely  on  patients  it  enables  more  accurate  castings  to  be  obtained  for 
financial planning purposes. Such planners generally want an answer to the question, 
How much is  AIDSIHIV costing now,  and how much is it going to cost in the future? 
AIDS patient costing is usually a means to answering questions of this type rather than 
a goal in itself. 189 
The  hospital  or district-wide  approach  does,  however,  have  difficulties.  There  are 
problems in  identifying departments, or individuals, that do AIDS/HIV work. This  can 
be done from  information  given by  those  centrally  involved  in  AIDS  treatment,  via 
leads  like  "so  and  so  does  this
11
,  or  "I  refer  patients  with  this  condition  to  that 
department". Yet clearly however wide a survey of this sort is undertaken, there is still 
the  chance  of omissions.  We,  for  example,  managed to  leave  out the work  being 
undertaken by the Drug Dependency Unit on AIDS  prevention at the Charing Cross 
Hospital in  the Riverside  district,  not being aware of the unit's  existence. It was not 
mentioned because everyone assumed that its work must have been known to us. 
A  considerable  level  of  co-operation  is  required  for  the  hospital  or  district-wide 
approach, because it involves interviewing very large numbers of people. Most people 
working on AIDS/HIV are very willing to give their time to help in studies of this sort, 
some hoping perhaps that somehow additional funding may be forthcoming. But here 
lies  another difficulty,  for  a few  of the more astute, or politically  aware, doctors may 
see  such  costing  exercises  as  part  of  the  financial  bargaining  process,  though 
fortunately examples of this are quite rare. Such is the usual attachment of the medical 
profession to  accuracy, that it  is  normally possible  to  divine  such manoeuvres from 
other statements made about their work. There are often, though, genuine difficulties 
in  making sensible assessments  of  how much AIDS/HIV-related  work  is  being done, 
and  as  time  and  motion  study  would  be  unrealistic,  one  must  rely  on  personal 
statements about the use of time.  This means that such assessments will frequently be 
very approximate. 
3.  General costing methodology problems 
We  can briefly  focus  on some of the main  methodological problems.  These  are the 
issues  of average versus  marginal  costs,  of financial  and non-financial costs,  and of 
direct and indirect costs. 
In  many  respects  those  funding  AIDS/HIV  work  may  be  more  interested  in  the 
marginal  or  incremental  approach,  for  they  wish  to  compensate  hospitals  for  the 
additional work that AIDS/HIV entails.  If the average cost criterion  is  used,  hospitals 
and districts  may be given what appears to be excessive funding for undertaking the 
new activity, which they have been able to accommodate within existing facilities.  The 
overheads allowed might have been incurred anyway in the provision of their regular 
work. 
There are many difficulties  in  adopting marginal cost criteria,  however,  not the least 
the instability of such costs over time. As time goes on marginal cost will tend to rise to 
meet average  cost,  because in  the  long run  all  costs  may be regarded  as  variable. 
When the marginal approach is adopted a cost may be attached to activities arbitrarily, 
depending on the  order in  which  those  activities  were set up.  Usually  the later an 190 
activity starts the less 
11overhead
11  it will  have to bear, and so the less  it will cost under 
marginal criteria.  For such reasons in  practice the average cost approach is  the more 
satisfactory. 
The second issue  is  whether the cost involved appears as  part of the accounts. Take 
the case of a doctor who has found that he is starting to treat large numbers of AIDS 
patients.  As  he  was  employed  before  the  AIDS  problem  started  the  financial 
implications of this  may  not appear in  the accounts.  But the cost may be borne by 
those other patients, whom he is  now unable to see, or by the doctor himself because 
he is  having to work harder. Harder work may be seen as a free good by the funding 
authority,  but  in  extreme  circumstances  it  can  give  rise  to  'bum  out'  and  other 
problems. There is also, naturally, the possibility that the additional patients are served 
through  more  efficient  working  practices,  but my  own view  is  that,  in  the National 
Health  Service,  there  is  now  little  slack,  or  X-inefficiency,  as  some  economists 
grandiosely like to call it. Most of the people involved with AIDS work hard, sometimes 
even too hard. 
AIDS time has generally been casted by estimating proportion of total paid time in  a 
week or month spent by a member of staff on AIDSIHIV work, and multiplying by the 
yearly gross cost of that member of staff to obtain an estimate of the annual cost. The 
alternative approach, of costing hours worked at the formal hourly wage rate plus on-
cost,  has  also  been used,  especially  with  staff  who  are  not centrally  involved  with 
AIDSIHIV treatment. The two methods will  give  different results  if the hours actually 
worked by staff differ from the hours that they are officially assumed to work. If actual 
hours exceed official hours, the formal  cost per hour approach will  give  higher costs 
than the proportion of time approach. 
The final issue discussed in this section is that of so-called direct and indirect costs. No 
attempt has been made to identify costs of the indirect type - the value of the people 
who are dying, man hours of work lost by the patients, etc. - for these costs are outside 
the scope of the project, which  is  concerned solely with health service costs and their 
financial implications. 
4.  District costing in England- districts being costed 
Three of the 190 or so English districts have been selected for detailed costing. 
Riverside 
This  is  an inner London district with  the largest number of AIDS  cases in  the UK.  It 
contains  two  main  teaching hospitals,  the  Westminster  Hospital  and Charing  Cross 
Hospital,  and  also  one of  the  two  largest  AIDS  hospitals  in  the  UK,  St Stephen's 
Hospital. St Stephen's is  about to close in  order to rebuild, but although the inpatient 191 
work is to be transferred to the Westminster Hospital pro tern, much of the day patient 
and outpatient work is  scheduled to remain  on the St Stephen's site.  Riverside  was 
casted in 1987/8. 
Oxfords hire 
This district is centred on Oxford. So far there are only a small number of AIDS cases, 
but the district has the largest haemophilia centre in the UK,  with about 10% of all UK 
haemophiliacs.  The  district  has  made  considerable  efforts  in  AIDS  prevention  and 
education.  It  is  also  a  teaching  district  and  highly  involved  in  AIDS/HIV  research. 
Oxfords hire was casted in 1988/9. 
Brighton 
This district has about the largest AIDS  problem in England and Wales of any district 
outside London. The reason for this is the proximity of Brighton to the capital, and its 
popularity with homosexuals. It also has a substantial drug problem. The costing of the 
district  has  just started,  following  agreement  with  the  district  authorities.  It  will  be 
casted at 1988/9 price levels. 
5.  Particular costing problems in Oxfordshire 
To  illustrate  the  district-wide  costing  approach,  the  case  of  Oxfordshire  has  been 
selected. 
There are special difficulties  in  the costing of AIDS/HIV  in  this district,  most of which 
arise because of the particular nature of AIDS/HIV treatment in haemophiliacs. 
Additional Factor VIII costs 
Haemophiliacs are given Factor VIII  as a blood clotting agent, and indeed it was their 
need for this that caused many haemophiliacs to become infected with HIV. About 130 
HIV-positive haemophiliacs are treated by the Oxford Haemophilia Centre, although 
half of these actually live outside the Oxford Region. HIV infection does not of course 
cause  haemophilia,  but  if  haemophiliacs  become  infected  with  HIV  they  make 
exceptional demands on the health care system, because their HIV must be monitored 
intensively in relation to the underlying haemophilia condition. They frequently have 
severe social and emotional problems, and may also  increase the administrative load 
for  various  reasons.  Non-infected  haemophiliacs are now monitored less  frequently, 
because the Haemophilia Centre has had to divert time from  them to those who are 
HIV positive. The haemophiliac AIDS patients, of which in January 1989 there were 7 
at the Oxford Haemophilia Centre, also take a great deal of time and effort. 192 
One special problem is the substantial increases in the cost of Factor VIII  over the last 
four years, because of the need to  heat-treat the blood to destroy the virus,  because 
slightly more now has to be used for the same clotting effect,  and because additional 
amounts are now given to HIV positives in  order to avoid bleeds. Further, and this  is 
the main  reason for  Factor VIII  cost increases,  the price  has  risen  considerably,  not 
only because of the cost of heat treatment but also  because of a world-wide  blood 
shortage. 
Chronic hepatitis in HIV-positive patients 
A number of haemophiliacs suffer from  chronic hepatitis, which is treated at the Liver 
Unit at the John Radcliffe Hospital.  It  is  a contentious issue as to whether this should 
be regarded as  HIV  related, although all the patients so suffering in  Oxford over the 
past few  years have been HIV  positive.  These patients,  however,  are very similar to 
AIDS patients, and they have picked up their hepatitis from contaminated blood. Their 
hepatitis-related condition and eventual death would result in a "saving" in AIDS  costs 
if  these  costs  were  not included.  The  costs  of  these  patients  have  therefore  been 
included in the study. 
Surgery on haemophiliacs 
Haemophiliacs sometimes require surgery, after bleeding into the joints. Most of such 
surgery is  on HIV-positive patients, because the more severely affected haemophiliacs 
were given  greater quantities of Factor VIII  than those less  severely affected,  and so 
were more  likely  to become  infected  with  HIV.  Only  the additional costs  associated 
with HIV infection were taken into account in the study. 
Additional abortion costs 
Abortions in Oxford have risen from about 100 to 170 a month over the last year. The 
increase is in young, under 25, unmarried women. Opinion in the district is that this is 
an unanticipated consequence of the strenuous AIDS prevention effort at the national 
and at the district/city level.  Young women are coming off the pill because of fear of 
HIV  infection,  and condoms are a  less  reliable means of contraception. The costs  of 
these abortions have not been included in the totals below, but might have been. 
6.  Estimated AIDS/HIV costs in Oxfordshire in 1988/9 
These costs are given in Table  1.  Total district revenue expenditure in Oxfordshire in 
1988/9 will be about £133 millions. Estimated district AIDS/HIV revenue expenditure is 
nearly £1.6 millions,  or about 1.2%  of total  district expenditure.  This  total is  nearly 
double  previous  estimates.  The  difference  is  because  of the  average  cost  method, 
which includes overheads, and because of the more accurate identification of costs. Table 1.  Estimated AIDS/HIV costs in the Oxfordshire District by hospital unit (1988/9) 
Hospital 
Radcliffe Infirmary 
Churchill Hospital 
John Radcliffe Hosp. 
Warneford Hospital 
Littlemore 
Nuffield Orthopaedic 
Other 
Total 
Main HIV function 
HIV outpatients 
Haemophilia, AIDS 
inpatients 
Pathology, some AIDS 
outpatients 
Psychiatry 
Drug abuse 
Operations, 
dentistry 
Miscellaneous 
Note: Totals include some non-NHS expenditure. 
Estimated 
expenditure 
£000s 
234 
996 
208 
94 
90 
74 
86 
£1,782 
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Expenditure 
in% 
13.1 
55.9 
11.7 
5.3 
5.0 
4.2 
4.8 
100.0 
Over  half  the  costs  are  incurred  at  the  Churchill  Hospital,  which  contains  the 
Haemophilia Centre and the AIDS Inpatient Ward. A further 25% are incurred at the 
Radcliffe  Infirmary  and the John Radcliffe  Hospital,  which  contain most of the HIV 
outpatient work and the pathology, respectively. 
Table 2 gives the same cost total broken down by client/activity group. These divisions 
contain elements of arbitrariness but probably give  a reasonable overall picture. It  is 
particularly interesting that in  Oxfordshire only about 16% of total costs is  incurred in 
the treatment of AIDS patients alone.  Hence a  costing that focused on these patients 
Table 2.  Estimated AIDS/HIV costs in Oxfordshire by client group and activity (1988/9) 
Client/activity group  Expenditure  Expenditure 
£000s  in% 
Haemophiliac AIDS  98  5.5 
Haemophiliac HIV  191  10.7 
Additional Factor VIII  453  25.4 
Other AIDS  206  11.6 
OtherHIV  86  4.8 
Drug misuse  98  5.5 
Infection control  123  6.9 
Counselling/testing/admin  276  15.5 
Research/teaching  251  14.1 
Totals  £1,782  100.0 194 
Table 3.  Unit cost per year results for Oxfordshire 
1.  Haemophiliac AIDS patients, excluding F VIII 
2.  Other AIDS patients 
3.  All HIV + haemophiliacs inc. AIDS exc. F VIII 
4.  Non-treatment costs per head of population, exc. research 
£14,000 
£17,000 
£2,800 
£1 
would have missed 84% of total AIDS/HIV costs.  Oxfordshire is  doubtless an unusual 
district in this respect; in Riverside, which is similar in size to the Oxfordshire district but 
with over 6 times the numbers of AIDS patients at the time of costing, nearly 60% of 
total costs were calculated as related to AIDS patient work. 
Haemophiliac  costs,  excluding  research  and  teaching,  but  including  haemophiliac 
counselling  etc.,  are  42%  of total  costs.  An  interesting  percentage,  7%,  is  that for 
infection control. Oxfordshire has made stringent efforts in this direction over the past 
two or three years. 
Unit costs are given in Table 3. Unit costs per year for non-haemophiliac AIDS patients 
are about £17,000. It is  based on only 12 patients, but is  very similar to the figure  for 
Riverside for  1987/8, which was based on 120 AIDS  patients. The non-factor costs of 
haemophiliac AIDS patients is slightly lower, at about £14,000. Although AIDS patients 
seem to live on average less than 18 months, the mean c0st of an AIDS patient in the 
UK from  diagnosis to death is  probably at least 1.5 times the £17,000 figure,  because 
currently patients are weighted towards the initial, and hence less treatment intensive, 
part of  the  disease.  AIDS  patient  numbers  are  growing,  which  means  that  more 
recently diagnosed patients are entering than deceased patients are leaving. 
It is  also worth noting that the non-treatment costs, excluding research, in Oxfordshire 
work out at about £1 per head of population in the district. These costs are incurred on 
providing HIV drug misuse services, infection control, counselling, administration and 
prevention. If such services were provided nationally to Oxfordshire per capita levels 
the cost would be about £50 millions. 
7.  Conclusions 
The method of district-wide costing gives  comprehensive estimates of AIDS/HIV costs 
in single districts and is probably to be preferred to AIDS patient costing using patient 
records. Many of the district-wide costs are not associated with AIDS patient, and even 
HIV-positive patient, treatment. Although  the results  from  a  single  district  cannot be 
generalised  readily  to other districts,  it  is  hoped that the results  from  a  number of 
districts will give a reasonable picture of the overall situation. But even the results from 
this  single  district  indicate  that  AIDS/HIV  costs  can  be  considerably  higher  than 
previously thought. The Regional Costs of AIDS in Spain 
J. Ginestal G6mez 
This paper has, as its  main target,  a short-term forecast of hospital resources needed 
for AIDS patients. For this we shall use the data available up to April1989. The bulk of 
the problem consists  in  using,  as  efficiently  as  possible,  the few  data that are so far 
available, as this is the first work on that subject made in the Basque Country (and in 
Spain). 
Work on the problem at stake is relevant for two reasons: First it can give a good idea 
to health authorities  of the resources  used by AIDS  at present (and probably in  the 
near future).  Second, a forecast of physical resources needed in the short run, with  a 
fixed supply of hospital beds, can be at least as important as money costs. 
It  is  only with  such information that the near future can be planned. This,  however, 
does not imply an agreement with the 
11status quo
11  of care pattern; it only implies the 
likely impact of that 
11status quo
11  in terms of physical resources. Therefore the trade-offs 
betwen  different  group  of  illnesses  can  be  assessed  properly.  Moreover,  a  rough 
attempt to evaluate those resources in  terms of money is  offered.  But,  due to lack of 
relevant data, the estimation of costs can only be an approximation. 
The  paper will  be  divided  into  several  sections.  The  first  section  will  give  a  brief 
description of AIDS in  the Basque Country, as  of March  1989. Some simple forecasts 
will  be made in  the second section and in  the third a  very  rough cost study will  be 
found. The final section will deal with some resources forecast. 
1.  Overview 
AIDS  is  a  difficult  problem  as  it  involves  habits  of  an  affected/at  risk  population. 
Therefore, the spread of the HIV is not decreasing at a rate one would expect once the 
ways of transmission are known. This  is  particularly the case for those areas in which 
the main focus  of infection are drug abusers. Such a situation is  the one faced in  the 
Basque Country. 
At a first  glance,  it is  74.3% of the 362 AIDS  cases  (registered as of April  1989) that 
correspond to the i.v.  drug users group. However, if we include all those cases related 
to that group (i.e.  people infected by drug abusers or drug abusers with  another risk 
activity),  the figure  would approach 82%.  Regarding age  and sex,  patterns are very 196 
similar to other countries: 79.28% of the cases are male, and their average age is 26.9 
years. 
The trend followed  by the infection  does not follow  the same pattern for  every risk 
group.  As  should be expected, drug abusers (and related groups)  are growing faster 
than the remaining groups, the growth rate of which is, in fact, declining. 
Survival time  has been steadily growing over the past years; this is  mainly due to two 
factors.  First,  illness  is  diagnosed  earlier  and,  second,  the  treatment  with  AZT  is 
progressing.  Considering the last cohorts only and assuming that the median equals 
the  mean  (Fig. 1),  the  average  survival  time  is  now  around  15  months.  A proper 
survival  analysis  has  not been carried because of the small  sample. Regrettably,  this 
problem will only take a short time to disappear. 
2.  Projections 
As  we  have  mentioned  before,  our target  is  to  set  a  framework  to  study  hospital 
resources as  referred to AIDS.  Therefore projections become a key  issue  if  one is  to 
calculate the likely impact of AIDS on hospital resource allocation. 
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At  this  stage,  we  have not considered complex  mathematical and statistical  models. 
This  is  for  two  reasons:  First,  there  is  a  lack  of suitable  data both in  quantity  and 
quality;  secondly,  those  models  have  performed  relatively  poorly  at  predicting. 
Although  more  complex  models  are  more  suited  to  interpret  and contrast theories, 
experience points  to the fact  that simple  models  are far  more  accurate in  short-run 
predictions.  Hence,  we  will  only  show  here  an  exercise  for  very  simple  regression 
models, which are basically nothing but "trend finders",  i.e. by regressing the number 
of  cases  against  time  (under  different  functional  forms),  one  tries  to  capture  the 
underlying trend, at least in the short-run. We have tried several models, and the best 
performance has been shown by the simplest models, particularly linear and log-linear 
ones. These results  have been interpreted as a confirmation of our initial hypothesis, 
namely that we are at the begining of the explosive period. 
Two  considerations have to be made,  however: First,  since it  is  hoped that the trend 
will  eventually change, these figures  will  have to revised periodically;  in  addition we 
will  try more  complete  models,  those  which  weight  observations  according to  their 
location  in  time,  to adapt the model of changes in  the trend  (MA),  and those which 
incorporate  changes  in  the  pattern  (logistic  family).  However,  up  to  now,  the 
performance  of  the  alternatives  mentioned  has  been  relatively  poor  (probably 
indicating a consistent pattern). Second, patterns  are quite different for  different risk 
groups,  as  was  indicated  above; so  we  will  have to  keep record  of isolated  groups, 
especially drug abusers1). 
Data are  in  themselves  a problem,  particularly because  of  lags  in  recording.  In  our 
case, the last three observations cannot be considered as they will change substantially 
in  the  years  to  come.  There  are  some  techniques  to  deal  with  this  problem  by 
correcting these  data to  the  likely  final  figures.  However,  previous  information  has 
been consistently substituted by the updated one, so that the actual records only retain 
the last figure.  Hence, it is  impossible to estimate the lag pattern. A serious implication 
of that lack of information is the need to predict(!) the past. For our exercise we have 
included fifteen observations only (from March 1985 to September 1988), although the 
last observation was March 1989. 
We  have to stress  that,  although  some luck  has to  be taken into  account,  previous 
documents  have  predicted  the  figures  for  June  1988  and  September  1988  quite 
accurately. Results for the linear and explosive model (semi-logarithmic) are presented 
below because of their good performance.  Quarterly evolution of cases  is  shown as 
well (Table 1). 
1)  Results for isolated groups are available at request. 198 
Table 1.  The quarterly evolution of the AIDS cases 
Quarter  Cases  predicted  predicted 
observed  In (1 +x)  (linear trend) 
1  1  4 
2  2  6 
3  3  4 
4  4  13 
5  5  9 
6  6  11 
7  7  13 
8  8  16 
9  9  20 
10  10  21 
11  11  21 
12  12  24 
13  13  31 
14  14  28 
15  15  40  31 
16  16  46  33 
17  17  53  35 
18  18  61  37 
19  19  70  39 
20  20  80  41 
3.  Cost considerations 
The exercise in this section corresponds to hospital costs for 1987 only. These costs are 
calculated, as we shall see, in  a very rough way and only for full  AIDS  patients. Any-
how, such  an exercise  is  a  relevant one to  delimit the necessary information,  apart 
from being an approximation to the real costs. Of course, its being a rough measure is 
due to the lack of data; so the main point of the exercise was not only to decide what 
data should be collected but also how. This point is not a trivial one since lack of data 
is due to a negative predisposition by hospitals and physicians. 
At first we will set the main direct costs involved. Such costs accrue at: 
Hospitals (inpatient) 
Outpatient facilities 
Primary care facilities 
Other services (psychiatric, social, etc.) 
Community and family care 
To calculate the full total, one would need a flow  chart (see Fig. 2) of patterns of care, 
which  would  tell  us,  for  different  types  of  people,  the  average  frequencies  of 
attendancy at the different medical facilities. Once these frequencies are converted into 
units, the problem is to calculate the cost of each unit. 199 
.}--------~  COMMUNITY  CARE 
DOMICILIARY  CARE 
Fig. 2.  Patterns of care 
At  present,  given the available data, this  exercise  is  not possible at all.  Therefore we 
have calculated,  for  one year (1987),  inpatient cost only,  taking  data available.  This 
could be taken as a bottom limit for costs.  Our data refer to two hospitals {Aranzazu 
and Basurto),  the  only  ones  with  {few)  available  records.  The  record  contains  the 
following information: 
Number of inpatient spells 
Number of inpatient days each time 200 
Patients with AZT treatment 
Costs of AZT. 
Full blown AIDS  is  assumed to begin at the time  of the first  inpatient spell,  which  is 
probably  an  underestimation.  To  approach  the  costs  roughly,  average  current 
expenditure per bed are used. This  is estimated at 17,920 pts per day for Basurto and 
20,824 pts per day for Aranzazu.  The cost of AZT  is  estimated at 1,300,000 pts per 
patient per year.  With  such an approximation  we  can  calculate  17,100,000 pts  and 
21,150,000 pts  of AIDS  costs  for  1987 in  Basurto  and Aranzazu  respectively.  These 
costs correspond to 811 inpatient days in Basurto and 890 days in Aranzazu. We have 
to take account for the fact that few people (2 in each hospital) were being treated with 
AZT at that time.  By weighting each case by the survival period within that year, we 
can have an approximation to average yearly cost per patient. Once the weighting is 
performed,  such  a  cost  results  in  2, 736,000  pts  in  Basurto  and 2,500,000  pts  in 
Aranzazu per patient per year. 
Even a short glance at the above methodology will show the weakness of the results. 
However, until more data are collected, those figures provide hospital managers with, 
at  least,  an  indication  of  real  costs.  Two  main  points  are  distorting  the  results 
downwards. First the assumption that an AIDS patient consumes the same amount of 
resources as an average patient, and second, the small number of patients treated with 
AZT.  Moreover,  given the big share of the AZT cost in  the individual's total cost, one 
can expect big increases of the figures  in the future.  For instance,  if 30% of patients 
had been treated with AZT in  1987, the cost would have risen by 38% or 31% in each 
hospital. 
4.  Resources projection 
To  know  the impact  of AIDS  on hospital resources  is  as  important as to know  the 
money costs of those resources. Again many caveats arise because of the quality and 
quantity of data, but then, this approach is still better than pure intuition, and it would 
give us a better grasp of the information needed . 
The data used are the ones of the projections in the second section, of the expected 
survival  (15 months as previously stated)  and of average use of facilities  per year in 
outpatient as  well  as  inpatient visits.  For outpatient visits,  the  mean in  the  Basque 
Country is 4.5 (calculated from treatment protocols and confirmed as an average use). 
For days of hospital bed occupation, our sample shows 5, 5, 12, 12 and 14 days for 
each term of survival as average. Now it only remains to apply the survival time both 
to the known cases and to future (projected)  cases to obtain a projection of the likely 
future resources used by AIDS patients. 201 
The results are shown in Fig. 3a and 3b; Fig. 3b shows the results for a 10% decrease 
in the average inpatient and outpatient care per patient. In Fig. 3a, 2,000 bed days are 
predicted to be occupied by AIDS patients in the Basque Country in the first quarter of 
1990. Similarly,  near 1,000 outpatient consultations  will  be required  in  that period. 
Notice that these figures  double those for  the last quarter of 1988 (the first  predicted 
quarter). A straightforward conclusion would be the necessity to shift away the bulk of 
AIDS  care from  hospitals,  lest these become completely congested.  Apart from  that, 
most  qualified  opinions  point to  the  fact  that alternative  care  would  improve  the 
patients' well-being anyway. 
5.  Conclusions 
This  is  the overall work we are trying to  complete.  The need  is  not only  to  update 
averages and projections but to make them more accurate. To do the latter we would 
need  better  data.  To  achieve  the  former,  the  use  of  scenarios  and  more  suitable 
statistical  techniques  seem  to  be  the  obvious  path.  This  too,  however,  depends 
crucially on data. 
This framework  is  to be taken as a flexible  one, for  more data and more satisfactory 
methodology will  have to be implemented within it,  and changes in the AIDS  patterns 
are to be expected. These changes refer not only to epidemiological trends but also to 
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care patterns. The epidemiological trends will make the use of the more adaptative and 
complete statistical forecasting techniques necessary. Moreover, the evolution of those 
trends (as  we have already mentioned) and the likely change of attitudes towards the 
illness in the future, will presumably change the care pattern. Indicators and Trends of Direct and Indirect Costs of AIDS 
on a National Level: Results &om Switzerland 
M.R.H. Pedergnana 
1.  Introduction 
1.1  Problem 
The  epidemic  of  acquired  immune  deficiency  syndrome  (AIDS)  will  be  severe  in 
Switzerland.  Although  there  has  been  a  swift  and  comprehensive  nationwide 
prevention programme since February  1987, which  slowed  down the new  infection 
rate, the Federal Office of Public Health (FOPH)  in Switzerland estimates from a wide 
variety of epidemiological data that between 20,000 and 30,000 persons are infected 
with the human immunodeficiency virus (HIV)  (FAC and FOPH, 1989, 7).  Cumulative 
estimates range from 9,000 to 15,000 persons with AIDS  (PWAs)  until the end of 1995 
(FAC and FOPH, 1989, 7; Pedergnana et al., 1988, 42-47). Since the beginning of the 
AIDS epidemic, there have been 702 PWAs reported up to December 31, 1988 (FAC 
and FOPH, 1989, 18). 
Are  there  enough  resources  (hospital  beds,  hospital  personnel,  etc.)  to  cope  with 
between 5,000 and 10,000 PWAs  in  1995? Who will  pay the cost? Can Swiss  health 
care insurers  afford to pay (their share of)  the  costs  for  treating PW  As?  Does AIDS 
threaten the solvency of Swiss life  insurers? How high will the direct and indirect costs 
be? How large  is  the projected social burden of illness  and premature death due to 
AIDS  and HIV  infection  relative  to  other diseases?  How  much  will  AIDS  influence 
overall medical care expenditures across the nation until 1995? 
In  this  study,  the  questions  outlined  above  are  investigated  by  combining 
epidemiological projections with data from a multi-center medical care cost study and 
with data from  various other studies.  Furthermore, we  inquire whether factors  other 
than inpatient treatment are of prime importance for medical care costs. 
Switzerland has for many reasons a unique, decentralized health care system. All acute 
care beds are in purely state- or community-run nonprofit hospitals, whose capacities 
are  approved  by the  majority  of  voters  in  a  given  state  or community.  Hospitals 
provide expensive and sophisticated care. Public financing of inpatient care via taxes 
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further  characteristics  in  a  country  where  more  than  98%  of  the  population  are 
members of the so-called social (and nonprofit) health care insurance co-operatives.1) 
The  main  problem  is  that,  due  to  the  lack  of  effective  incentives,  health  care 
expenditures  have been rising  with  an average  growth  rate  of 10% for  the last 25 
years.  Economists  seriously  doubt  whether  the  efficiency  and  effectiveness  of  the 
health  care  system  has  been  improving  during  the  same  period  (Sommer  and 
Gutzwiller,  1986).2)  In  such  a  system,  AIDS  is  an additional  factor  intensifying  the 
current illness of the Swiss health care system. 
1.2  Objective, assumptions and procedure 
This  paper  presents  the  results  of  a  comprehensive,  two-year-long  study  on  the 
influences of AIDS  on the Swiss  health care system. We  try to summarize trends and 
indicators of direct and indirect costs  of AIDS  in  Switzerland in  the near future.  As a 
time-horizon, we have chosen the end of 1995 because the economic impact of AIDS 
in Switzerland has become fairly predictable for the next six years. 
We  have  tried  to  consider  changes  in  diagnostic  and  therapeutic  technology  and 
experience,  and based our study on four  assumptions.  As  do many experts, we too 
believe that, first,  there will be no drug available to cure AIDS  or to prevent an HIV 
infected person from developing AIDS  until at least the mid-1990s. Second, we expect 
a prolonged life  expectancy from  diagnosis to death of PW As. Third, we assume that 
no vaccine against HIV  infection will be on the market until 1995. Fourth, we assume 
that FOPH's  estimate  of  20,000 to  30,000 HIV  infected  persons  in  Switzerland  is 
correct. 
The purpose of the second section  is  to  give  up-to-date epidemiological information 
and indications of the possible outcome of the AIDS epidemic until 1995. In the third 
section, we will have a look at the cost dimension to present an order of magnitude of 
the economic impact of AIDS on the Swiss health care system, and we glance at those 
who have to bear the costs. 
2.  Epidemiological aspects of AIDS in Switzerland 
We  present the descriptive  epidemiology  of  AIDS  and HIV  infection  in  Switzerland 
based  on data  up  to  December  31,  1988.  All  data  are from  the  FOPH,  which  is 
responsible for national AIDS surveillance and epidemiology as well as prevention and 
education programmes on a national level. 
1)  Health Maintenance Organizations (HMOs), Preferred Provider Organizations (PPOs), Diagnosis 
Related Groups (DRGs) and other alternative insurance models are all forbidden in Switzerland. 
2)  Medical care is more likely to produce improvements in so-called subjective components of health 
rather than improvements in morbidity and mortality rates. In Switzerland, one typically buys more 
caring, but little additional curing. 205 
2.1  HIV epidemic in Switzerland 
As a result of several investigations and evaluations, and based on 10,279 confirmed 
seropositive tests  (34.4%  in  the Canton Zurich,  17.5% in  the  Canton Geneva), the 
FOPH  estimates  that  15%  or 15,000  of  the  estimated  number  of  homosexual  or 
bisexual male population and 50% or 7,500 of the estimated number of IV drug users 
are  HIV  infected.  While  the  new  infection  rate  has  practically  come  to  a  standstill 
among homo- and bisexual men, the FOPH believes that HIV is still spreading among 
IV drug users (FAC and FOPH, 1989, 14-25). 
2.2  AIDS epidemic in Switzerland 
Not surprisingly, given the data on the HIV epidemic, the number of newly diagnosed 
AIDS  cases  has increased substantially since  1982 (see  Fig. 1).  Table 1 describes  the 
patient groups of AIDS  cases, indicating a large majority of homo- and bisexual men, 
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Table 1.  Reported AIDS cases in Switzerland 
Homo- or bisexual men 
IV  drug user (m: 131; f: 65) 
Heterosexuals in contact with HIV infected people (m: 31; f: 32) 
Children, hemophiliacs, transfusion and others (m: 35; f: 24) 
Total on December 31, 1988 
384  (54.7%) 
196  (27.9%) 
63  (  9.0%) 
59  (  8.4%) 
702 
and a rapidly increasing proportion of IV drug users. Fig. 2 shows the 702 AIDS cases 
(33.6% in  the Canton Zurich,  13.0% in  the Canton Geneva) by sex and age. 71% of 
the AIDS  cases  are in  the range of  15 - 44 years  (FAC  and FOPH,  1989,  14-25). 
Though we cannot draw stringent conclusions for the whole population, it is interesting 
(and relevant for indirect costs) that among PWAs, men are older than women, mainly 
because homosexual men are older than IV drug users. 
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2.3  Forecasts 
Every forecast is made uncertain by unknown factors  (number of HIV infected people, 
time of infection, incubation time). Nevertheless, estimates of the likely progress of the 
epidemic are  necessary because there must  be thorough planning of care for  those 
infected, those with manifestations and those dying. 
The  further  development  of  the  HIV  epidemic  is  uncertain,  but the relatively  low 
number of  confirmed  seropositive  test  results  (835)  (FAC  and FOPH,  1989,  18)  in 
1988 gives  hope that the nationwide,  concerted, vigorous  and sustained STOP AIDS 
preventive campaign  has been very  effective  so far.  FOPH epidemiologists  estimate 
with  sophisticated statistical and epidemiological modeling that cumulatively between 
13,000 and 15,000 PWAs have to be expected at the end of 1995 (FOPH, 1988, 539-
542). Earlier estimates (Pedergnana et al.,  1988, 33-51) range from  9,000 (optimistic 
case) to 15,000 (pessimistic case), with the probable estimate of 12,000 PWAs. In order 
to estimate the impact of AIDS  on health care institutions, we have to be more precise 
and take  into  account  a  slowly  increasing  average  life  expectancy  of a  PWA  from 
currently 15 months to  24 (pessimistic),  36 (probable)  and 48 (optimistic)  months by 
1995 (Pedergnana et al.,  1988,  40-42).  These three  estimates  were  combined  with 
three differently increasing life  expectancy rates, but in this paper we will  concentrate 
on what we consider the most probable estimate of all:  we  expect 6,800 living PW As 
(2,500 diagnosed in 1995, and 4,300 diagnosed earlier) at the end of 1995 (Fig. 3). 
To assess the direct and indirect costs  per year,  it  was  necessary to divide  all  PWAs 
into three patient groups: 
Group 1:  Those who were newly diagnosed and did not die; 
Group 2:  Those diagnosed in a prior year who lived all 12 months; 
Group 3:  Those who died during the year (we  applied the same methodology as 
the one described in Scitovsky et al., 1986, I-1). 
Group 4:  was drawn for better understanding of the first half of the probably S-like 
epidemic of cumulative AIDS cases (Fig. 3). 
Some Swiss  epidemiologists believe that the HIV  epidemic is  reduced to the original 
risk  groups  (male  homosexuals  and  IV  drug  users)  and  has  not  affected  the 
heterosexual population. They question the current estimates of the FOPH that there 
are 20,000 to 30,000 HIV  infected  people and criticize  the prevention program that 
started in  1987 and was first  addressed to the broad heterosexual population instead 
of high-risk groups (Pedergnana et al., 1988, 98). We believe that according to today's 
knowledge,  such doubts can be justified.  But we  should also  take into  account and 
prepare for the worst possible case. 208 
in  thousands 
16 
15  c==J  Group 1 
-- ~-- ---- ------
14 
wm:::::::::::ml  Group 2 
13  -Group 3 
12 
- Cumulative AIDS death cases 
1 1 
10 
9 
8 
7 
6 
5 
4 
3 
2 
0 
1986 1987 1988 1989 1990 1991  1992 1993 1994 1995 
Fig. 3.  Best estimate of AIDS epidemic in Switzerland 
3.  The cost dimension 
Total costs of AIDS  comprise direct,  indirect, and intangible costs.  The latter are costs 
not measured in  money: We  think  in  this  context of the grave psychic load and the 
personal grief of all people concerned with AIDS.  There was especially great concern 
about high  direct  costs.  The  indirect  costs  of this  fatal  disease,  however,  are  many 
times greater, because 75% of all  PWAs in  Switzerland are between 20 and 50 years 
old and belong to a highly productive age group that had enjoyed low morbidity and 
mortality rates up to now. 
The major impediment to data collections and cost analyses (all  estimates are in 1988 
constant Sfrs.)  concerning the AIDS  epidemic in  Switzerland was a strong skepticism 
towards health economics. Nevertheless, we are now able to give fairly  exact data on 209 
direct costs of the HIV epidemic and rather good indicators of indirect costs for  1986 
through 1988. 
3.1  Direct costs 
Direct costs  are the costs of health and social care including both personal care and 
nonpersonal services  like  screening of blood donations,  voluntary serostatus testing, 
prevention and information programmes, health education, staff training, research and 
various support services. Our estimates are prevalence-based, because they proved to 
be very  useful  for  hospital  and federal  budget planning  (compare  Scitovsky  et al., 
1986,  IV-1).  Unlike  in  incidence-based  estimates  where  all  medical  care  costs  are 
attributed to the year in which the patient was diagnosed, with the prevalence-based 
approach we  estimate  the  costs  (and  need for  resources)  for  a  given  year.  This  is 
especially  important  when  estimates  are  made  for  a  still  young  disease  where 
diagnostic  and  therapeutic  experience  is  growing  fast,  and  life  expectancy  from 
diagnosis to death is very likely to increase significantly within a few years. 
3.1.1  Personal treatment costs 
An investigation carried out at three University hospitals in Switzerland (Zurich,  Basel, 
and Lausanne;  all  of them  having outpatient departments)  showed that patterns  of 
health service use and treatment costs of PW  As are similar. 104 PW  As or about 30% of 
all  PW  As  who had been treated between 1982 and 1988 and who  had died before 
summer 1988 were selected for costing research (Table 2). In  a retrospective analysis, 
detailed data on inpatient and outpatient treatment were abstracted from  the medical 
Table 2.  Personal health care costs of people with AIDS in Switzerland (in 1988 Sfrs.) 
Hospital  n  Inpatient  Range  Cost per  Station.  Ambul.  Lifetime 
days  day  care cost  care cost  costs 
CHUV
8  26  63.5  6-156  722  46,200  1,600  74,000 
UHBb  18  59.4  6-187  900  53,500  5,700**  59,200* 
usz
1
c  44  57.0  3-293  753  42,900  15,000**  57,900* 
usz d  16  39.9  1-119  753  30,000  27,400**  57,400*  2 
Total  104  56.5  1-293  772  43,600  11,900  74,000 
Source:  a  Griffiths et al. (1988) 
b  Rufli et al. (1989) 
c  AIDS-Kommission des Kantons Ziirich (1988) 
d  Amberg and Pedergnana (1989) 
*  These costs are not lifetime costs since only the medical history of the patients' main hospital could 
be considered. They include no institutional care in other acute hospitals, psychiatric clinics, nursing 
homes or hospices. 
*  *  Only ambulatory care provided by the outpatient departments of UHB and USZ were considered. 210 
records  of each patient and casted,  using  1988 tariff scales  intended  in  principle to 
cover full  current (hospital budget) running costs. Capital costs and amortization costs 
are included;  drugs were  casted at hospital prices  (20%  below market prices).  In  all 
analyses,  costs  incurred  following  a  confirmed  full-blown  AIDS  diagnosis  (following 
CDC  definition)  were  considered.  The  majority  of  the  patients  analyzed  were 
diagnosed in  the years 1985 and 1986 (range 1982-1987). There were no substantial 
methodologic differences among the four studies. 
A prevailing trend in these data could not be found. The average number of days per 
case has stayed fairly  stable since the start of the epidemic. Institutional utilization and 
inpatient costs per case did not drop significantly. 
Estimated lifetime costs of PWAs in Switzerland are 74,000 Sfrs., including ambulatory 
care,  inpatient acute care,  chronic  care  in  hospices  and custodial  facilities  (e.g.  for 
dementia)  and the various  forms  of  extensive  outpatient support.  The  data do  not 
consider  time  costs  of  the  patients.  The  value  of  the  services  provided  by  family 
members, friends and others in support of the person's basic activities of daily living is 
also  not  included.  Though  unpaid,  these  services  nevertheless  represent  a  real 
consumption of resources, and hence a real cost. 
The CHUV study is the only one in Switzerland analyzing the whole medical history of 
AIDS patients. The 26 PWAs spent an average of 92.9 days in institutional care (range 
23-226 days): 
63.5 days in the CHUV (range 6-156 days), 
9.0 days in other acute hospitals (range 0-113 days), 
13.7 days in psychiatric clinics (range 0-156 days), and 
6.7 days in nursing homes (range 0-61 days). 
At 722 Swiss francs per day -just one patient was treated in  an intensive care unit-
total inpatient costs amounted to an average of 67,000 Swiss francs. According to the 
authors, it seems reasonable to suppose that the total costs  of all  medical and home 
care, from  diagnosis to death (lifetime  costs),  of PWAs  treated at the CHUV  as  their 
main, but not only hospital, were 74,000 Sfrs (Griffiths et al., 1988, 4). 
The CHUV  study further showed that 50% of  PW As  were living  alone  (  6 lived  with 
their family,  and 7 were married or lived with another person). It was estimated that 
PWAs were hospitalized 
11for social reasons
11  in 35% of all days spent in institutions, i.e. 
patient days in  acute inpatient care facilities  did  not require the technical services of 
the  institutions  concerned,  but the  lower  level  of  support  they  required  was  not 
available or was refused at home (Griffiths et al., 1988, 2). 211 
There are no substantial differences in  the average number of days of hospitalization, 
except for those 16 patients with  adult Kaposi's sarcoma at USZ who required fewer 
inpatient days but, on the other hand, a lot more outpatient care (AIDS-Kommission 
des Kantons Zurich, 1988, 10).3) 
Compared with  the  University  hospitals  in  Lausanne  and Basel,  outpatient care  in 
Zurich  is  substantially higher. This is  partly due to some medical research projects on 
the  effects  of alpha-interferon  and zidovudine.  But  most  interesting  is  that,  though 
treatment patterns differ within Switzerland, the effect on total treatment costs of the 
patients'  main  hospital  remains  small.  From  a  perspective  of  institutional  costs  or 
resource allocation and utilization  associated with  PW As,  it  is  important to. focus  not 
simply  on  inpatient  care  but  also  on  outpatient  treatment.  This  is  especially  true 
because we can expect improvements in outpatient care of PW As as medical personnel 
and  institutions  are  still  learning  how  to  treat them.  The  availability  of  outpatient 
treatment in  Zurich  (studies  USZ1  and USZ2)  has  improved rapidly  in  the last three 
years as community care and home support have extended their health services field 
to PWAs.  From  this  point of view,  it  is  unlikely  for  inpatient  care to become more 
dominant in the future of PWAs within the Canton Zurich, and, on the long run, within 
Switzerland.  It  is  rather likely  that outpatient care is  being further substituted for  in-
patient care. Care alternatives merit a lot more attention than they have received until 
now. 
Some  of  the  most  expensive  treatment  patterns4)  can  be considered  experimental 
because the  disease  is  still  new  and few  standards  have  emerged.  On  the  whole, 
however,  the four analyses  are revealing remarkably  little  variation  in  average daily 
hospital charges.  The average  of 772  Sfrs.  per inpatient day appears to  be typical. 
Compared with  other patients, PW As do not account for  higher per-day-costs within 
University hospitals. At USZ  overall level,  PWAs cost even 100 Sfrs. per inpatient day 
less than the average patient (Amberg and Pedergnana, 1989, 7). 
One particularly noteworthy aspect of these data is  that PW As'  health care  insurers 
covered  only  50.5%  or  61.1%  of  all  inpatient  costs  and  18.5%  or  57.1%  of  all 
outpatient costs at USZ (Amberg and Pedergnana, 1989, 8) and at UHB (Pedergnana, 
1989, 14-16). The remaining uncovered costs  (excluding the fixed  part like  overhead 
charges, capital costs and costs covered by others due to various reasons) mainly led to 
an increase in  the hospital budget deficit which is  covered indirectly by the Canton's 
taxpayers. 
If new  therapeutic treatment or drugs  are developed with  the result that PW As  live 
longer,  then  lifetime  costs  will  not  necessarily  increase.  As  time  passes,  increased 
3)  On average,  PWAs had 26  ambulatory consultations at USZ per year,  or an average consultation 
rate of 45.5 per patient (range 0-85). A retrospective study at USZ
2 further showed that persons with 
lymphadenopathy syndrome had 8, and with AIDS related complex 16 consultations per year. 
4)  e.g. one PW  A who spent 6 days in an intensive care unit got treatment for 51,400 Sfrs.; another PW  A 
spent 293 days in a university hospital and cost 220,000 Sfrs. 212 
training and experience of physicians and nurses should lead to lower per patient costs 
and to earlier discharge. The efficacy of therapeutic measures will obviously increase. 
Thus  we  believe  that average  lifetime  costs  of  PW As  in  Switzerland  will  remain  at 
74,000 Sfrs. 
Personal medical care costs for all PW As in a given year are estimated to increase from 
8 million Sfrs. in 1986 and 12 million Sfrs. in 1988 to 60 million Sfrs. by 1991 and 225 
million Sfrs. in 1995 (FAC and FOPH, 1989, 68). 
Finally, but of prime importance, it has to be pointed out that we analyzed the average 
total costs and not the marginal or extra costs of treating an additional (AIDS) patient. 
To get the marginal costs, we would have to subtract all fixed  costs, e.g. the costs for 
an empty hospital bed. It  must be emphasized that marginal costs  are between 20% 
and 25%  lower than the average  total  costs.  This  is  especially true  as  long  as  new 
nursing facilities  (existing acute hospitals have an average occupancy rate of 80%)  do 
not become  necessary.  No  separate  facility  fully  dedicated  to  AIDS  care  has  been 
opened yet in Switzerland. 
Marginal  costs  have to  considered  when  new  treatment  strategies  are  planned.  A 
substitution of hospital care by community-based services is  generally favorable, but it 
is  not always cheaper. We  are strong opponents of unpaid personal health services 
(Aids  Regionalhilfestellen,  Pro Familia, Samariterbund and so on)  that substitutes for 
long-term  institutional care, the way Swiss  health care insurers  favor  it.  Many  Swiss 
cities started to order nonprofit health care organizations to take care of PW As and pay 
them,  but  because  treatment  at  home  still  depends  heavily  on  the  continued 
participation of unpaid volunteers,  it  might not be easily copied abroad. These costs 
are often ignored, since they do not have to be covered in  health agencies' budgets, 
and because there are usually few  data from  which to estimate them. However, their 
omission  can  lead  to  suboptimization  in  choosing  care  strategies.  For  example,  a 
community  care-oriented  strategy  is  almost certainly  cheaper than  a  hospital-based 
one.  However,  it may be considerably  less  economic than it  seems at first  once the 
costs of unpaid services are added and may also place a heavy cost burden on families 
and other unpaid sources of care. 
Further analysis,  especially  in  the fields  of  alternative courses  of  action,  is  required. 
There are no studies which  provide a  valuable,  active  management support for  the 
benefit  of  decision-makers  in  the  health  care  system.  A simulation  model  which  is 
geared  to  Switzerland  should  evaluate  the  efficiency  and  effectiveness  of  different 
interventions and its  impact on the health care system and also on various third-party 
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3.1.2  The impact of AIDS on Swiss hospitals 
The impact of AIDS  on Swiss  hospitals has been overestimated in  the past.  Only  an 
estimated 0.01%  of all  inpatient days  in  acute care  hospitals  in  1988 can be traced 
back to PW As. 
35 of all 45,600 acute beds in Switzerland would  have been enough for all  inpatient 
care of PWAs according to our estimate of 13,000 acute hospital days needed in  1988 
(Ag. 4).  Even  in  1995,  the  estimate  of  165,000  hospital  days  translates  into  a 
requirement of only 450 acute beds or just 1.0% of all acute beds.  Furthermore, the 
estimate  of 55,000 days  in  psychiatric  clinics  for  PWAs  with  severe neurologic and 
psychological manifestations  additionally requires  150 beds or 1.0% of all  their bed 
capacity in  1995. This  explains why,  at an average occupancy rate of well below the 
optimal  rate  of  85%  for  acute  care  hospitals,  there  is  no  need  for  supplementary 
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hospital facilities for PW  As. AIDS is not a problem of hospital capacity but undoubtedly 
accents the severe lack of health care personnel in Switzerland (FAC and FOPH, 1989, 
71). 
3.1.3  Prevention, information and education 
AIDS has been institutionalized in the political arena fairly quickly. It was recognized as 
a problem rather early,  and first of all,  a broadly representative ad hoc Federal AIDS 
Commission  (FAC)  with  25 members was  established in  1984. In  the meantime, the 
FAC has been supplemented by a Federal Commission to Control AIDS  Research and 
by an Interdepartmental Working Group for  Questions Related to AIDS.  On the state 
level, there are another 13 AIDS  Commissions, and on the community level, there are 
numerous working groups. A comprehensive, sustained, successful and internationally 
acknowledged national STOP AIDS  Program was launched in  February 1987. Public 
awareness of the dangers of AIDS has considerably increased. 
The FOPH further focused on health education, a key to AIDS prevention and control. 
Including  all  expenditures  for  training  of  hospital  personnel,  the  FOPH spent 20.1 
million  Sfrs.  on  all  preventive  measures  from  1986 to  1988  and  was  assisted  by 
Cantonal measures (Table 3). 
Table 3.  Estimated direct  costs  of AIDS  and HIV  infection  in  Switzerland  (in  million  Sfrs.)  (from 
FAC/FOPH, 1989, 68) 
1986  1987  1988 
Personal medical care costs  6.0  8.0  12.0 
Information, prevention  1.5  8.6  10.0 
Blood donor screening  7.0  7.0  7.0 
Blood HIV testing  6.0  12.5  12.5 
Research  2.0  4.5  10.0 
Other direct costs*  1.5  5.8  8.5 
Total  24.0  46.6  60.0 
Payers: 
- Federal Government  2.5  13.2  19.3 
- State & local governments  4.3  6.2  9.1 
- Health care insurers  3.0  4.0  6.0 
- Other payers  12.9  20.8  22.0 
*  Including Switzerland's personal, technical and financial support of WHO's Global Program on AIDS; 
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3.1.4  Compulsory screening of blood donations 
Since the introduction of HIV antibody screening in November 1985, around 650,000 
blood donations  are tested  each year.  It was  certainly worthwhile,  because no new 
transfusions associated with HIV infections have been reported since November 1985. 
Today blood transfusions appear to be as safe as  before the emergence of the AIDS 
epidemic (Frey-Wettstein et al., 1988, 149-153). 
But  the  costs  for  the  screening  of  all  blood  donations  including  the  costs  of 
replacement of blood5), both covered primarily by the Swiss Red Cross which had to 
increase  its  price  for  blood  products  by  10 Sfrs.  or  16%  to  70  Sfrs.  per  unit  in 
November 1985, amount to 7.0 million Sfrs. yearly (FAC and FOPH, 1989, 72). 
3.1.5  Voluntary HIV antibody testing 
There were around 250,000 HIV antibody tests taken in the past two years for various 
individual reasons. Pre-test and post-test counselling associated with serologic testing 
cost between 30 and 80 Sfrs.  (50 Sfrs.  on average)  amounting to total costs of 12.5 
million Sfrs.  (FAC and FOPH, 1989, 72). Most tests were taken by general practitioners 
and then tested in private laboratories. Laboratory support for confirmation tests and 
serostatus diagnosis is given by the FOPH National Center for Retroviruses and by five 
University laboratories. 
3.1.6  Research expenses 
Research expenses have been increasing rapidly in the last three years (Table 3). There 
have  been various sources  of public  (mainly  FOPH)  and private  institutions  which 
supported  research  mainly  at  Departments  of  Medicine  at the  five  universities  in 
Switzerland. 
3.1. 7  Development of direct costs 
Non-personal  costs  for  prevention,  research,  blood  screening  and testing  exceeded 
personal medical care costs by a factor of 5 in  1988 (Table 3). This is  going to change 
very soon as non-personal costs are not expected to rise a lot above their current level. 
If we look at the payers, the biggest burden is carried directly by federal, cantonal and 
local governments and indirectly by the unaffected employed society, e.g. through the 
marginally  decreasing  (or  less  increasing)  production  and consumption  process  and 
through marginal premium or taxation increases. 
5)  Self-deferral of donors belonging to high-risk groups was instituted (before and after donations) in 
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There  is  some  concern that the AIDS  epidemic  places  a  financial  burden  on Swiss 
health care insurers,  since  1% of the population has a special private insurance plan 
and more  than 98%  are covered  by the standard  governmentally subsidized  health 
care insurance plan (Pedergnana et al., 1988, 76).6) From the point of view of hospital 
deficits,  it  is  necessary  to  know  that the Swiss  health  care system  typically  has  two 
categories  of  patients:  those  in  private wards  (one  bed rooms),  and those in  public 
wards (up to eight beds to a room). Patients in private wards typically have a superior 
health care insurance plan. Their insurers are supposed to come up with  all expenses 
at  the  hospital.  Patients  in  public  wards  have  a  standard  health  care  insurance 
coverage. Their insurers pay a digressive per diem  reimbursement for  each inpatient 
day, depending on length of stay,  number of beds in  the room, cantonal (provincial) 
domicile  and  citizenship,  but regardless  of  all  diagnostic  and  therapeutic  measures 
taken?) As  a matter of fact,  an additional patient in public wards adds marginally to 
the hospital deficit which is covered directly by the Finance Department of the canton 
(state) and indirectly by the canton's taxpayers. The normal patient in a public ward or 
his health care insurer as the regular third-party payer typically covers only 50% of the 
real overall medical care costs. This rate is not significantly higher or lower for PW As. 
Yearly  expenditures of all  400 Swiss  health  care insurers  amounted to  more than 8 
billion Sfrs.  in 1988 and have risen annually by 10% for the last 30 years. Relating the 
increase of their 1988 expenditures of around 800 million Sfrs. to the PW As' treatment 
costs of 6 million Sfrs., it seems fairly clear that the current and future burden for Swiss 
health care insurers is relatively low and certainly manageable (FAC and FOPH, 1989, 
68). 
With  60 million  Sfrs.  or 0.3%  of total medical care expenditures in  1988, we  cannot 
say that AIDS  has  led to  a  major resource reallocation within the Swiss  health care 
system.  Even  with  increasing  direct  costs  due  to  AIDS,  the  health  care  costs  of 
rheumatism (Pedroni and Zweifel,  1986) and alcohol consumption (including costs of 
automobile accidents  due to  alcohol:  Leu  and Lutz,  1977),  if  they do not decrease 
immensely,  will  be far  higher in  1995 (Fig. 5;  data on other illnesses  or diseases  in 
Switzerland is  not available). 
6)  There has been no case of an uninsured or underinsured PWA up to December 31,  1988. Besides 
that, self-pay (out-of-pocket expenses) is strictly limited in the Swiss health care system. 
7)  e.g. at the UHB University Hospital Basel, inpatients or their health care insurers of Swiss citizens 
from Basel (Canton Basel as their residence) have to pay 260 Sfrs. per day for the first 30 inpatient 
days in public wards. After 90 and 180 inpatient days of the same patient in the same calender year, 
the per diem reimbursement falls to 145 and 115 Sfrs. respectively, or between 10% and 20% of the 
patient's daily medical care costs, regardless of what diagnostic or therapeutic measures are taken at 
the hospital. The figures differ from canton to canton, and from hospital to hospital. 217 
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Fig. 5.  Estimated direct costs of AIDS,  alcohol consumption and rheumatism in % of all  health care 
expenditures in Switzerland 
3.2  Indirect costs 
The  indirect  costs  of  AIDS  and  HIV  infection  involve  measuring  and  somehow 
weighing the life  years lost  due to  illness  and premature death. Although  these costs 
have  tended  to  be  ignored  by  Swiss  health  authorities,  AIDS  as  a  fatal  disease 
represents  a  substantial loss  of  future  productivity.  As  other studies  have suggested, 
these costs  are five  times  higher than direct  costs  due to  AIDS  (Pedergnana,  1988; 
Scitovsky et al., 1986). 
Enough has been written on how to value the premature loss of life years and on the 
importance  of  indirect  costs  (Mishan,  1971;  Landefeld  and Seskin,  1982;  Rice  and 
Hodgson,  1982; Jones-Lee,  1985;  Drummond et al.,  1987).  We  applied the  human 
capital  approach for  both  morbidity  and  mortality  costs  despite  the  appeal  of  the 
willingness-to-pay approach on theoretical grounds. Without going into further details 
(Pedergnana et al., 1988), we want to present our findings for Switzerland. 218 
3.2.1  Morbidity costs 
Morbidity costs  consist of the productivity  losses  to  society,  as  measured by wages, 
salaries  and supplements,  resulting  from  the  days  lost  from  work  among  currently 
employed  persons  and those  unable  to  work  because  of  illness.  Assuming  a  50% 
working ability8) between AIDS  diagnosis and death, we estimate morbidity costs due 
to  AIDS  will  grow  from  6.7  million  Sfrs.  in  1988 to 31.7  million  Sfrs.  in  1991,  and 
eventually to 129.9 million Sfrs. in  1995 (Pedergnana et al.,  1988, 67), or far less than 
the morbidity costs due to tobacco smoking, alcohol drinking and rheumatism (Fig. 6) 
(FAC and FOPH, 1989, 73). 
3000 
Rheumatism (2600) 
2500 
2000 
1500 
1000 
Alcohol consumption (600) 
500 
Tobacco smoking (300) 
130 
2  7  3Q  -!=1 
~  .....  I  0 
1986  1987  1988  1989  1990  1991  1992  1993  1994  1995 
Fig. 6.  Estimated morbidity costs of AIDS and HIV infection and other illnesses in Switzerland (in 1988 
million Sfrs.) 
8)  The awareness of the infection by the patient's employer or colleagues can have repercussions on the 
employment of such a patient, even if the infected is perfectly able to perform his duties on a full-
time basis. 219 
3.2.2  Mortality costs 
Mortality  costs  are  the  discounted  present  (4%)  values  of  wages,  salaries  and 
supplements,  and  the  imputed  values  of  housekeeping  services  lost  following  the 
premature death of persons who would have otherwise been productively employed 
or keeping house. 
Table 4 shows an increasing number of potential life years (between 1 and 70) lost due 
to AIDS.  In  1987,  3,000 or 1.1%  of all  life  years  lost  were  due to  AIDS  and HIV 
infection. The rate of premature deaths due to AIDS is  going to increase dramatically. 
An estimate, based on average life  expectancy per sex and age minus 10% because of 
the large number of IV drug users, shows an increase from 4,800 life years lost in 1988 
to 46,600 life years lost in 1995 (Fig.  7). 
These estimates may question the solvency of Swiss  life insurers. However, the actual 
and potential impact of AIDS on Swiss private health care and life insurances has been 
grossly  overestimated.  Until  the  end  of  1988,  we  estimated  cumulative  losses  and 
expenses  due  to  AIDS  and  HIV  infection  at  less  than  20  million  Sfrs.,  which  is 
practically  nothing related to total  (ordinary  and group)  life  insurance premiums  of 
more  than 12 billion  Sfrs.  each year.9)  Although  we  expect a  rise  of AIDS  related 
expenses for  life  insurers,  we  estimate  that the  impact will  not rise  above  0.3%  of 
overall premiums before 1995 (Pedergnana et al., 1988, 76). The solvency of Swiss life 
insurers  is  and will  not be threatened by AIDS.  Male  and female  applicants of a  life 
insurance coverage of 100,000 Sfrs.  or above have to take the HIV  antibody test to 
Table4.  Potential life years lost due to AIDS and other death causes in Switzerland in 1980,  1986 and 
1987 (Bundesamt fur Statistik, Abteilung Gesundheitsstatistik) 
Death causes  Year 
1980  1986  1987 
Men  Women  Total  Men  Women  Total  Men  Women  Total 
AIDS  37  0  37  2,000  187  2,187  2,367  594  2,961 
Tuberculosis  432  150  582  357  65  422  265  112  377 
Stomach cancer  2,292  1,297  3,589  2,052  1,087  3,139  2,057  1,180  3,237 
Lung cancer  11,175  1,890  13,065  11,727  2,165  13,892  10,725  2,457  13,182 
Diabetes mellitus  1,292  1,435  2,727  1,680  1,060  2,740  1,587  910  2,497 
Coronary diseases  31,564  9,050  40,614  29,977  7,757  37,734  28,764  7,194  35,958 
Traffic accidents  26,819  7,531  34,350  24,397  6,241  30,638  21,838  5,735  27,573 
Suicide  27,012  10,730  37,742  25,185  9,115  34,300  25,992  8,362  34,354 
All death causes  186,794  92,914  279,708  177,325  86,866  264,191  178,858  83,281  262,139 
9)  It is not surprising that the Swiss Life Insurance Association (VPL) decided to collect AIDS related 
claims data, but not to publish the results. 220 
in  thousands 
60 
50 
40 
30 
20 
10 
0 
1986 1987 1988 1989 1990 1991  1992 1993 1994 1995 
Fig. 7.  Estimated life years lost due to AIDS in Switzerland (Pedergnana et al., 1988, 72) 
further reduce the insurer's exposure to AIDS related costs. Until now, there have been 
no signs that strong antiselection took place in Switzerland10>,  but precise figures about 
seropositive applicants have never been published. 
Estimated mortality costs show an increase from 80 million Sfrs.  in 1986 to 400 million 
Sfrs.  in  1991, and to 1  ,200 million  Sfrs.  in  1995, and will  by then reach the current 
level of mortality costs due to alcohol drinking (Fig.  8}  (Pedergnana et al., 1988, 67}. 
3.3  Intangible costs 
The intangible costs cannot be expressed in  terms  of money owing to measurement 
difficulties,  but  the  cost  of  psychical  and  physical  pain,  discomfort,  anxiety, 
impairment, disability,  handicap, etc.  are going to intensify with expected illness  and 
death rates  in  the future.  We  also  mean the so-called  third  epidemic of economic, 
10)  Information provided by A. Chuffart, Swiss Re in Zurich, Switzerland, in October 1988. 221 
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Fig. 8.  Estimated mortality costs due to AIDS and HIV infection in Switzerland (in 1988 million Sfrs.) 
social,  political  and  cultural  reaction  to  AIDS  and  HIV  infection,  which  follows 
relentlessly the HIV and AIDS epidemic. The influence on morals, habits, attitudes and 
prejudices is indisputable, but the question is: How much does society have to pay for 
it? 
3.4.  Social costs 
~  a consequence of the chapters outlined above, social costs  due to AIDS  and HIV 
infection are estimated to rise from  0.11 billion Sfrs. in  1986 to 1.6 billion Sfrs. in 1995 
(Fig. 9), especially because of the high death toll among the economically and socially 
most productive age groups. All estimates are reliable in so far as we can foresee that 
AIDS  is  not a  major threat to the Swiss  health care system.  Nevertheless we have to 
undertake measures to cope with  the AIDS  epidemic in  the most efficient way,  not 
wasting scarce (health care) resources. 222 
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4.  Summary 
Indicators and trends show that the economic impact of AIDS on the Swiss health care 
system  will  increase rapidly within the next six  years.  Prevalence-based estimates  of 
total direct and indirect costs of AIDS  in Switzerland show an expected increase from 
110 million Sfrs. in 1986 to 1.6 billion Sfrs. in 1995. 
To  assess  the  likely  future  impact  of the  cumulatively  estimated  12,000 PWAs  in 
Switzerland, we combined epidemiological data with cost studies. 
The direct costs of AIDS in Switzerland (nursing care, research, screening, information 
etc.}  added up to 60 million Sfrs. in 1988, equaling 0.3% of total health care costs. The 
direct  costs  are  estimated  to  rise  to  255  million  Sfrs.  or 1.0%  of  total  health  care 
expenditures by 1995,  even though a  17  -fold  increase compared with the 702 AIDS 
cases thus far has to be expected. AIDS therefore is probably not responsible for either 
the  .. explosive..  increase  of  Swiss  health  care  expenditures  or  a  major  resource 223 
reallocation.  AIDS  will  influence  the total  consumption of medical care  resources in 
Switzerland only marginally. 
Because  of the deadliness  of the  disease,  the  indirect  costs  of AIDS  (value  of  lost 
productivity  and  future  earnings  due  to  illness  and  premature  death,  affecting 
predominantly younger people) are about five times greater than the direct costs. 
The average lifetime costs of a PWA are estimated at 74,000 Sfrs.  On average 50% of 
all  inpatient and outpatient costs are covered by the PWA's  health care insurer.  The 
remaining costs are carried by governmental institutions. Swiss health care insurers had 
to carry a much smaller load than was originally expected. We can even say that the 
costs of health care and life  insurers in  Switzerland have been negligible so far.  The 
solvency of Swiss  health care and life  insurers  is  not threatened due to AIDS  related 
claims until 1995. 
The social costs of AIDS  in  1995 will  exceed the social costs  of tobacco smoking but, 
though  considerable,  will  still  be  far  less  than the  social  costs  of  rheumatism  and 
alcohol consumption. 
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Nr. 8, Bern, Stuttgart and Toronto. Costs of AIDS in a Developing Area: 
Indirect and Direct Costs of AIDS in Puerto Rico 
D.S. Shepard 
Despite the fact  that over half of the world's  officially  reported cases  of AIDS  were 
diagnosed in  the United States, the burden of AIDS  affects  the developing countries 
even more than the industrialized ones. A number of developing countries, particularly 
in  Africa  and the Caribbean, face  a  devastating combination  of a high  incidence of 
AIDS,  strained  health systems,  and stagnating economies.  In  a  model similar to the 
work of Over, Bertozzi and Chin (1989), this paper presents a framework to measure 
the total economic impact of AIDS in a developing area and applies this framework to 
the  island  of  Puerto  Rico  and  its  capital  city  of  San  Juan.  The  measurement  of 
economic  impact  is  needed  to  determine  the  magnitude  of  the  problem  of  HIV 
infection,  to  rank  that  problem  in  relation  to  other  health  needs,  and  to  guide 
prevention and control efforts. 
Categories of costs of HIV 
The costs of HIV infection can be categorized according to the sector of the economy 
and the type of person affected (Table 1). The economic sectors distinguish the health 
sector from  all  other sectors.  Persons  affected  are both the individuals  infected with 
HIV and their families,  and uninfected persons. The category of costs which has been 
most examined  is  the  costs  of  persons with  AIDS  to  the health  sector.  These costs, 
termed  the  direct  costs  in  the  health  economics  literature,  measure  the  costs  of 
treatment  of  HIV  and  its  complications.  The  next  most  examined  category  is  the 
indirect cost - the loss outside the health sector from persons infected. Indirect costs are 
the value of foregone economic output, which is often measured by lost earnings. 
The  elements  in  the  lower  part  of  Table 1  include  public  costs  for  surveillance, 
prevention,  research,  and screening - costs  generally borne by persons not infected. 
Costs  in  the final  category - uninfected persons outside the health sector - are more 
difficult to quantify and have been less studied. They consist of secondary impacts  in 
such areas as: international travel and migration, tourism, quality of life, and anxiety. Table 1.  Categories of costs of HIV 
Person affected 
Persons infected with HIV 
and their families 
Uninfected persons 
Sector affected 
Health 
Direct costs 
(treatment) 
Public costs 
(e.g. surveillance, 
prevention, research, 
screening) 
Measuring the costs of AIDS to people infected 
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Other 
Indirect costs 
(foregone economic output) 
Secondary impacts 
(e.g tourism) 
The direct cost of AIDS  per case  is  measured as  the product of the average cost of 
treatment per year times the number of years of survival with AIDS. The treatment cost 
per year obviously depends on the setting: inpatient hospital care is most expensive. 
The  indirect costs  of  AIDS  is  the sum  of  mortality  and morbidity  components.  The 
mortality component is measured as the number of discounted "prime" years of life lost 
times the output per year that otherwise would have been attained. Prime life  years 
are the  adult period  of  life  during which  economic contribution  would  normally  be 
greatest, defined here as the span from ages 15 through 64. The number of discounted 
life years lost is  the discounted remaining life  expectancy of prime years at the age of 
death.  Remaining  years were  discounted to  reflect the  fact  that years  in  the  distant 
future are less valued than years in the immediate future. 
The number of prime  life  years lost was  calculated by  considering the distribution of 
age  at diagnosis  of  AIDS  cases.  The  age  at death  was  assumed  to  be  18  months 
beyond  the  age  at  diagnosis.  For  each  adult  age  category,  the  remaining  prime 
discounted life expectancy up to age 65 was calculated based on life tables. 
The  author  summed  for  each  prime  year  beyond  the  age  5  the  product  of  the 
probability of survival multiplied by a discount factor.  Then he calculated a weighted 
average of these sums based on the proportion of AIDS cases with death in  each age 
category. For pediatric cases, the number of discounted years lost is the present value 
of each of the prime years (ages 15 to 64) times the conditional probability of survival 
to each of those years. The conditional probability is conditional on survival to age 5, 
the approximate age of death of pediatric cases.  The morbidity  cost per year is  the 
number of years of illness times the lost output for each year of illness. 
Costs of research and prevention while not included in this report are the value of the 
resources expended (generally by public or non-profit agencies) for that purpose. 228 
Although  the  requisite  data  are  difficult  to  obtain,  it  is  possible  to  outline  a 
methodology for  estimating secondary  impacts.  Theoretically,  secondary  impacts  of 
AIDS  on  quality  of  life  could  be  valued  through  willingness-to-pay  surveys.  For 
example, to reduce the risk of sexual transmission,  some public education campaigns 
counsel monogamy or abstinence(!)  in  sexual relations.  In  some listeners,  the advice 
will evoke anxiety but no change in behavior. Others in the audience may deliberately 
change their lifestyles  to  be more  conservative  in  their sexual relationships.  Among 
both groups,  the  threat of AIDS  probably  reduces  their  quality  of  life.  A thorough 
analysis,  however,  would  need  to  consider  possible  beneficial  effects  of  enhancing 
existing relationships and reducing the risk of other sexually transmitted diseases. 
AIDS  may restrict or discourage international travel.  Residents from  a country with  a 
high prevalence  of AIDS  may find  their entry to other countries  impeded.  Business 
travelers or tourists may avoid certain destinations out of fear of AIDS.  In the former 
case, the loss  from  denied travel is  the difference between the expected value to the 
traveler of a potential international trip and the expected cost of that trip. In the latter 
case, the loss to the destination country is the difference between the expected value 
of the goods and services that would  have been consumed by the overseas visitors 
(including  exports  arranged during such visits),  and the resource  costs  of providing 
those goods and services. 
Numbers of AIDS  cases to date are based on official  surveillance data. In  this  study, 
numbers  of  cases  are  analyzed  based  on  date  of  diagnosis,  rather  than  date  of 
reporting.  This  approach minimizes  bias  due to varying  lags  in  reporting of cases to 
surveillance authorities.  As reporting of cases appears to  have been incomplete in the 
first years of the epidemic, the apparent explosive growth prior to 1984 may overstate 
actual growth rates. 
Future estimates of the costs of AIDS were developed on two alternative projections on 
the number of cases:  (1) the number of cases will continue to grow at the same rate as 
they have in the most recent past; and (2)  the rate of growth in the number of cases 
will  moderate,  as  it  has been doing over several years.  For assumption  (1),  a linear 
projection, the author calculated the growth rate from 1987 to 1988 and assumed that 
same rate would continue through 1992. Thus only the most recent two years (1987 
through 1988) were used. This  is  termed a linear projection because the logarithm of 
the number of cases was calculated as a linear function of time.  For assumption (2),  a 
quadratic projection, the natural logarithm of the number of cases was regressed on 
both the year and the square of the year. Data from the last five years (1984 through 
1988) were used. Although other researchers  (e.g.  Over et al,  1988)  have estimated 
costs of persons infected with HIV, this analysis begins with numbers of AIDS cases, as 
an infected person incurs relatively few costs before he develops AIDS. 229 
Estimates of direct costs for Puerto Rico 
Research underway in Puerto Rico provides estimates of most of the cost components. 
Among direct costs, the costs of inpatient care are most important (Table 2). Average 
inpatient costs  over a patient's lifetime  range from  $9,653 to $25,000 depending on 
the health system  managing the patient's care.  The lowest cost was achieved by the 
San Juan AIDS  Institute. It  is  the private institute to which the Health Department of 
the Municipality of San Juan contracted the management of AIDS care for patients for 
which it was responsible beginning January 1, 1988. It replaced the system of ad hoc 
care by the San Juan Municipal. Through appropriate economic incentives (a specified 
annual level  of payment) and better management, the average length  of stay for  an 
AIDS  related  admission  averaged  11.3  days  under  the  San Juan  AIDS  Institute, 
compared to 21.5 days under the pre-existing municipal hospital system. 
Blue Cross of Puerto Rico  (apparently typical of other private insurance systems) was 
the most expensive reimbursement system,  at $25,000 per year. As these systems are 
similar to the health insurance systems  in the mainland U.S.,  it shares those strengths 
and weaknesses.  On the one hand,  they provide partial financial  access to the best 
care available on the island of Puerto Rico.  Blue Cross insurance pays for most of the 
cost  of private  medical  care  and anti-viral  drugs,  such  as  zidovudine  (AZT),  for  its 
subscribers.  On  the  other  hand,  these  systems  provide  neither  incentives  nor 
procedures for controlling costs. 
The  lifetime  cost of  outpatient care  for  a  person  with  AIDS  ranges  from  $1680 to 
$29,000 (Table 3).  The lower  amount applies  to  care  delivered through an efficient 
private  clinic,  without the  anti-viral  drug  AZT.  The  higher  cost  includes  $800  per 
month for AZT. The lifetime cost of other modes of care (home, extended, and hospice 
care) averages only $526 per person with AIDS  (Table 4). Although the importance of 
these types of care is increasingly being recognized, they were used by only a minority 
of patients in 1988, the base year for these data. 
Table2.  Cost of inpatient care 
Setting  Length  Cost  Episodes  Cost per  Years  Lifetime 
of stay  per  per pt.  pt. per  alive  cost per 
(days)  day  per year  year  after  pt. 
($)  ($)  Dx  ($) 
San Juan AIDS Institute  11.3  341  1.67  6,435  1.5  9,653 
Private hospital; no AZT  16.4  387  1.67  10,599  1.5  15,899 
Municipal hospital  21.5  354  1.67  12,710  1.5  19,065 
Private hospital; with AZT  16.4  417  1.67  11,421  2.0  22,842 
Blue cross of P.R.; AZT*  NA  NA  NA  NA  2.0  25,000 
*  Assumes half of total cost is for inpatient care 230 
Table3.  Cost of outpatient care 
Setting  Visits per  Cost  Cost per  Years alive  Lifetime 
pt. per year  per visit  pt. per year  after Dx  cost per pt. 
San Juan AIDS Institute  4.4  255  1,120  1.5  1,680 
Private doctor; no AZT  11.2  116  1,300  1.5  1,950 
Private doctor; with AZT  15.6  929  14,500  2.0  29,000 
Table 4.  Cost of other types of care 
Setting  Units  Quantity  Cost per  Lifetime  % ofpts.  Expected 
unit  cost per  receiving  lifetime 
($)  pt.  cost per pt. 
($)  ($) 
Home care  Visits  6  127  762  10%  76 
Extended  Days  15  150  2250  4%  90 
Hospice  Days  30  200  6000  6%  360 
Total  526 
The overall lifetime direct cost of care per person with AIDS  is the sum of costs of care 
in  inpatient,  ambulatory,  and other modes. Among groups of patients studied within 
San Juan, this sum ranged from  $11,773 for  patients treated by the San Juan AIDS 
Institute to $51,842 for private patients receiving AZT  (Table 5).  No comparable data 
have yet been compiled for the island of Puerto Rico as a whole. 
As a working assumption, the author assumes that the cost of public patients in Puerto 
Rico is comparable to costs of the San Juan AIDS Institute. In the past, the absence of 
case  management  and  well  structured  outpatient  care  probably  increases  use  of 
expensive inpatient care. But other patients may have not received much care. For the 
Table 5.  Lifetime cost of care per patient ($) 
Setting  Assumed  Input  Output  Other  Total 
Share  care  care  care  care 
San Juan AIDS Institute  70%  9,653  1,120  526  10,773 
Private; no AZT  15,889  1,950  17,839 
Municipal hospital  19,065  19,065 
Blue cross  30%  25,000  NA  NA  50,000 
Private; with AZT  22,842  29,000  51,842 
Weighted average  100%  22,541 231 
future,  however, AIDS  officials throughout the island are scrutinizing the results from 
the San Juan AIDS  Institute and seeking to develop models to replicate  its  benefits. 
Also,  it  is  assumed  that  the  cost  of  private  patients  taking  AZT  in  San  Juan  is 
representative of private patients throughout the island. 
In  both San Juan and Puerto Rico  as  a whole,  approximately 70 percent of patients 
are  medically  indigent.  The  remaining  30  percent  are  generally  insured  with 
employment based  insurance  which  will  allow  a  person with  AIDS  to  obtain  AZT. 
Thus, the overall direct cost of AIDS  is  a weighted average of the costs  in  the public 
and private sectors, weighted by the relative share in each sector. This overall average 
is $22,541 per year. 
Indirect costs for Puerto Rico 
The bulk of indirect costs from AIDS are losses from illness and death during the prime 
period  of  life.  Table 6  shows  the  number  of  discounted  prime  years  lost  from 
premature  mortality  in  adults.  The  adjusted  percentages  are  based  on  1988 
surveillance data from the Municipality of San Juan, which follow  a pattern similar to 
the official  surveillance data for the entire island.  The number of life  years lost from 
morbidity is  based on a disability  level  of 50 percent. Each pediatric case leads to a 
smaller loss  in  discounted life years than an adult case. Although the absolute loss  in 
life years is less for a pediatric case, the life years are more heavily discounted. There is 
no morbidity loss  in  a pediatric case because the morbidity occurs prior to the prime 
period. Table 7 shows the overall number of years lost per case. 
Determining the economic value  of each of these lost years  is  a  difficult problem  in 
Puerto  Rico,  as  in  many  developing  areas,  because  only  a  small  share  of  the 
population  is  employed  in  a  formally  recognized  job  (Table 8).  Only  70  percent  of 
Puerto Rico's 3.3 million persons are over age 15, and only about half of those are in 
the labor force  (i.e,  working or looking for work).  Among those in the labor force,  the 
Table 6.  Prime life years lost from mortality per adult case 
Age  Mid-point  Age at  Prime  Disc. expect.  Lost 
category  death  adj.%  prime years  (at 5%) 
lost 
13-19  16  17.5  0.7  45.2  16.8 
20-29  25  26.5  24.6  36.6  15.7 
30-39  35  36.5  52.0  27.0  13.8 
40-49  45  46.5  17.9  17.5  10.8 
50+  55  56.5  4.9  8.2  6.2 
Weighted average  26.8  13.36 232 
Table 7.  Discounted prime life years lost per AIDS case 
Source 
Mortality 
Morbidity 
Total 
Adult 
13.36 
0.74 
14.10 
Table 8.  Puerto Rico: selected labor market data, 1986 
Group 
Total population 
Age 16 and over 
In labor force 
Employed 
Working 35 hours or more 
Unemployment rate 
Sources: Government of PR 
Number (1000s) 
3276 
2303 
986 
809 
579 
Pediatric 
9.88 
0.00 
9.88 
Percent 
100.0 
70.3 
30.1 
24.7 
17.7 
18.9 
unemployment rate is 18 percent. Furthermore, even among those working, some may 
be involuntarily working part time. So overall, only about one out of six Puerto Ricans 
is working in a formal job during a given week. 
Studies on the cost of illness in the United States value lost time primarily based on the 
average  wage  of  people  employed.  That  computation  would  be  inappropriate, 
however, where only a small share of the population is formally employed. Although a 
literature search could not find  any macro-economic studies of the shadow wage  of 
labor, Puerto Rican economists consider the minimum wage on the island ($3.70 per 
hour) as a good estimate. Taking unemployment into account, the economic value of a 
year of prime  life  is  then  $5,700 (35  hours  per week x 48 weeks  x  $3. 70,  less  18 
percent). This amount reflects all productive activities - market employment, running a 
business, caring for children and other dependents, etc. 
In Puerto Rico, the majority of persons with AIDS were intravenous (IV)  drug users at 
the time they acquired the infection. According to official surveillance data, IV drug use 
was the only risk factor for 57 percent of adult or adolescent cases, and was a joint risk 
factor in another 11 percent of cases in persons who were both homo- or bisexual and 
an IV drug users. 
Some critics would argue that the economic activity for these persons has no economic 
value, or indeed, that it is negative. This paper does not follow this reasoning. First, the 
designation of IV drug use the risk factor for AIDS indicates a condition at the time of 
infection.  The latency period until  diagnosis  averages some 7 years and a  user may 233 
well  have successfully quit such use  in  the interim. Although only about a quarter of 
treatment attempts successfully maintain abstinence for  at least a year (Hunt, Barnett, 
and Branch,  1971),  the  cumulative  effect  of multiple  attempts  over seven  years  is 
undoubtedly greater. Waiting lists to enter drug treatment programs testify to the desire 
by many IV drug users to break their habit. 
The present value of the indirect costs of an AIDS  case is thus $80,000 (13.29 years 
times $5,700 per year) for an adult case and $56,000 for a pediatric case. To interpret 
these amounts, it is  helpful to  compare them to the 1988 per capita GDP of $ 5,600. 
For an adult case, the direct costs are 4.2 times the per capita GDP; indirect costs are 
14.8 times, and total costs are 19.0 times.  Among the 2869 cumulative cases reported 
as of July 10, 1989, 981 new cases were diagnosed during 1988, and 2,761 cases had 
been diagnosed cumulatively through December 31, 1988. Thus, the economic cost of 
AIDS  cases diagnosed in  1988 (the  latest year with  complete data), the direct cost of 
AIDS was $22 million, the indirect cost was $78 million, and the total was $100 million, 
or 0.54 percent of the GDP of Puerto Rico. 
Numbers of cases 
This  study  uses  the  number of  officially  declared  AIDS  cases  by  the  Puerto  Rican 
surveillance authorities reported as  of July  10,  1989, but diagnosed as  of December 
31,  1988  (Latin  American  Center  for  Sexually  Transmitted  Diseases  [ClETS], 
unpublished data,  1989). Fig. 1 shows the historical  and projected numbers of AIDS 
cases through 1992. The trend projections forecast a cumulative number of AIDS cases 
through 1992 of 10,240 (quadratic projection) to 15,340 (linear projection). The lower 
estimate  is  based on the  quadratic estimate  (with  a  steady  reduction  in  the  rate  of 
growth), while the higher estimate maintains the recent rate of growth. 
Fig.  1 displays the costs  of AIDS  from  persons infected based on the linear or trend 
projection.  Fig. 2  displays  these  costs  based  on  the  more  conservative,  quadratic 
projection. In both figures,  the lower bar denotes direct costs,  and upper bar indicates 
indirect costs. Under the trend projection, the combined direct and indirect costs would 
be $541.2 million.  To  appreciate the magnitude of that amount for  Puerto Rico,  it  is 
2.6 percent of the present GDP of Puerto Rico  or about $164 for each inhabitant of 
the island. 
A similar linear projection was applied to the municipality of San Juan, the capital of 
Puerto Rico.  San Juan deserves  particular study  because its  incidence  of AIDS  per 
100,000 population is  second only to Washington,  D.  C.  among all the metropolitan 
areas of the United States. Combining direct and indirect costs, the projected total for 
1994 will amount to $270 for every person in the municipality. The per capita costs are 
relatively  higher  for  the  municipality because the AIDS  cases  are  concentrated  in  a 
smaller population. 234 
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Discussion and implications 
The only other developing areas for which the author is  aware of published studies of 
the costs  of AIDS  on a population basis  are Zaire  and Tanzania (Over eta!, 1988). 
While Over eta!. (1988) report primarily the cost per person infected with HIV, we can 
derive the cost per case of AIDS (termed "symptomatic HIV+") by dividing the cost per 
infected  person  by  0.354.  This  divisor  is  the  time-adjusted  proportion  of  infected 
persons  which  Over  et  al  assumed  would  become  symptomatic  before  dying  from 
some other cause. The total (indirect and direct) cost per AIDS case ranges from  $940 
to $3230 for Zaire, and $2460 to $5320 and Tanzania. The Zaire numbers range from 
15 to 54 times the per capita GOP;  the Tanzania numbers range from  24 to 52 times 
the per capita GOP.  The estimate for Puerto Rico,  mentioned earlier,  is  19 times the 
per capita GOP. 
The multiples  of GOP are higher for the two African  countries because there HIV  is 
transmitted primarily  heterosexually and AIDS  affects  persons employed productively 
in  the  modem sector  disproportionately.  The  groups  primarily  affected  by  AIDS  in 
Puerto Rico - IV drug users and homosexuals - do not enjoy above average income. In 
Puerto  Rico,  as  in  the  United  States  as  a  whole,  the  transmission  of  HIV  follows 
primarily  "pattern  I"  (homosexual  and  IV  drugs).  According  to  the  epidemiologic 236 
patterns  used  by  WHO,  these  African  countries  exhibit  Pattern  II  (homosexual) 
transmission (Mann et al, 1988). 
A final difference concerns the ratio of indirect to direct costs. The indirect costs are 3.6 
times  the  direct  costs  in  this  study.  In  the two  previous studies from  Tanzania  and 
Zaire, they ranged from  5 to  66 times. The direct costs  are relatively higher in  Puerto 
Rico  because the island's  health  costs  are relatively  high  for  its  GDP.  This  situation 
arises because health costs of the employed Puerto Rican population are covered by 
private health insurance, and costs of many others are covered by Medicaid or other 
public assistance, underwritten in part by the federal government of the United States. 
These calculations demonstrate that the payoff to an effective educational program will 
be substantial. To illustrate,  consider the expenditures on AIDS  education in  1988 in 
San Juan.  In  that year,  the  municipality  spent $300,000 to  reduce  risk  behaviors, 
primarily  by  IV  drug  users,  homosexuals.  The  decline  in  risk  behaviors  and  new 
infections  among  male  homosexuals  in  the  United  States  over  the  last  five  years 
indicates that sustained education has been successful for this group. It is assumed that 
this expenditure could cut the number of new infections with HIV+ by 10 percent over 
the next year. As about 30 percent of HIV infections develop AIDS over four years, the 
educational program would cut the number of AIDS cases by about 3 percent in 1992. 
The present value of these savings would amount to $7 per capita. The expenditure is 
70 cents per capita. Thus we would see a savings of $10 for every $1  invested. To be 
more  precise,  behavioral  measures  and  the  timing  of  any  changes  need  to  be 
considered  more  carefully.  Nevertheless,  these  studies  of  direct  and  indirect  cost 
confirm  our conventional wisdom  that prevention  is  a  sound  economic  use  of the 
services. 
As the initial framework indicated, AIDS also imposes other types of costs. Loss of life 
imposes  burdens  beyond the  economic  costs  derived  here.  Alameda  and  Martinez 
(1989)  have also  noted the importance  of this  component for  Puerto Rico,  but the 
adequate data for estimating these losses are lacking. Thus, the costs presented in this 
paper can be considered lower bounds of the complete costs of AIDS. 
This work leads to several conclusions. The trend projections show that there are very 
substantial economic impacts of AIDS.  For cases newly diagnosed in 1992, the costs in 
San Juan will be about $270 per person. For the island of Puerto Rico as a whole, the 
costs will be about $164, which  is 2.6 percent of the gross domestic product. Because 
of these high costs, even a modestly successful educational program promises to have 
a high payoff. 
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180. Financial Aspects Some Implications of AIDS for Permanent Health Insurance 
A.D. Wilkie 
I am an actuary from  the United Kingdom.  Actuaries are responsible for  advising life 
assurance companies and pension funds about mortality rates and sickness rates. 
In  Britain  most health  services are provided by  the National Health Service.  Private 
medical  care,  paid  for  through  medical  expenses  insurance,  is  relatively  small,  and 
used mainly for elective surgery, rather than for what may prove to be terminal care. 
Medical  expenses  insurance  is  provided  on  a  yearly  renewable  basis,  that  is  the 
premium rates and policy conditions can be changed by the company at each annual 
renewal  date.  It  has  therefore  been  legally  and  commercially  possible  for  the 
companies  providing medical  expenses  insurance  to  exclude  treatment for  AIDS  in 
their policies.  They have therefore not been very interested in  assessing the possible 
costs of treating those with HIV infection. 
A different class of insurance business in Britain is called "Permanent Health Insurance" 
(PHI).  This  form  of insurance is  offered by a  number of life  insurance companies.  It 
provides a  monetary payment each week or each month, for so long as someone is 
sick  - as  defined  by  the  policy  conditions.  For  some  policies  the  benefit  starts 
immediately, or at least as soon as the insured person has been sick for one week.  In 
other cases the benefit only starts after the insured has been sick for a deferred period 
such as 13 weeks or 26 weeks. 
The  longer  the  deferred  period  the  more  the  insurance  is  like  a  benefit  for  total 
disability, rather than for sickness. 
The word "permanent" in the title relates to the fact that the policy is  on a permanent 
basis. An  individual may effect a policy, perhaps at age 30, which will continue on the 
same guaranteed terms until age 60 or 65. The benefit of so many pounds per month 
is  paid for by a fixed premium of so many pounds per year. The insurance company 
does not have the right to change the premium rates  or the policy  conditions.  The 
companies are therefore very much concerned about how  much claims  may  rise  on 
existing policies because of AIDS. 
For new policies, the companies have usually  introduced an exclusion  clause,  either 
excluding  payment  if  the  insured  is  sick  with  AIDS,  or  excluding  all  benefit,  and 242 
refunding premiums, if the insured is found to be HIV positive. This may avoid a future 
problem, but there is still the problem of the policies on the books. 
The actuarial profession in Britain many years ago set up a committee {the Continuous 
Mortality Investigation {CMI)  Committee) to investigate the mortality  ratE~s experienced 
by life offices, which also investigates the morbidity experience of PHI offices. I happen 
to be the chairman of that committee. The offices  send in  data, which are analysed 
and published, and from  these data it  is possible to construct standard tables, against 
which the experience of different offices can be measured, or which offices can use in 
the absence of their own experience. 
During  1986 I began to  develop  a  model  to  represent the spread  of AIDS  in  the 
population,  which  would  be  of  use  to  both  life  insurance  companies  and  PHI 
companies.  This  model  has  formed  the  basis  of  Bulletins  published  by  the  AIDS 
Working Party of the Institute of Actuaries {AIDS Working Party, 1987a, 1987b, 1988, 
1989).  An  important feature  about a  model  for  AIDS  for  these purposes  is  that it 
should be age-specific, that is,  it should take into account the potentially very different 
experience of different  age groups.  Ordinary  mortality  and sickness  rates  vary very 
considerably with age. Mortality and sickness rates also vary considerably by sex, but 
so far  in  Britain the vast majority of AIDS  cases have been among males,  and much 
too little is known about the extent and spread of the epidemic among females for any 
calculations to be usefully carried out. We are therefore only considering the effect on 
males. 
The  model  simplifies  reality  by  assuming  that  the  only  spread  of  HIV  is  among 
homosexual males,  and that all cases recorded so far have been in this group. In  fact 
over 80% of UK AIDS cases have been among homosexual~. It is possible that in due 
course the separate epidemics among injecting drug users  and among heterosexuals 
may grow to an extent which is  worth considering, but at present too little  is  known 
about the rate of spread of the disease, at least among heterosexuals. 
A second simplification we make is to assume that each age cohort, that is the group of 
people born in  the same year,  can be treated independently.  Those born in  year Y 
only infect  others born in  year Y,  and there  is  no  cross-infection  between those of 
different ages. To the extent that sexual activity between homosexuals of different ages 
balances out, this is not an unreasonable simplification. 
A diagram of the model we have used is shown in Fig. 1. It is  quite a simple one. The 
population living  at any one age is  divided  into four states which  we  call:  Clear,  At 
Risk, HIV Positive and Sick with AIDS. Those who are Clear have no chance of getting 
AIDS. Those who are At Risk do have a chance of getting AIDS,  if they are infected by 
someone in  the Positive state. Those who are Positive are infectious, but not yet sick. 
Those who are Sick with AIDS are treated as not contributing to new infections, and to 
have a high chance of dying from AIDS. Clear 
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Those in  any of the living states may die from  causes other than AIDS,  and we  have 
assumed the same mortality rates for  all  these states.  Those who are sick  from  AIDS 
may die from normal causes or may die from AIDS.  The age of the cohort is taken into 
account. Since each cohort is  treated separately,  it  is  possible to  take account of the 
calendar year passed through as well. The period of time that someone has been in the 
Positive or Sick states  is  also taken into account, so that, for  example, the chance of 
someone who  is  Positive  developing AIDS  can  depend  on  how  long  he  has  been 
Positive. 
Lines with  arrows in  the diagram represent the possible transitions between states. It 
will  be seen that those who are At Risk  may move to the Clear state. We  use this to 
represent a change in behaviour, so that they no longer have any chance of becoming 
infected.  Those who  are  At  Risk  may  instead  become Positive,  and those  who  are 
Positive may become Sick. 
The model does not represent varying degrees of sexual activity among those At Risk 
or  Positive.  However,  we  have  to  some  extent  represented  the  fact  that  highly 
promiscuous  homosexuals  are  likely  to  have  been infected  first,  while  those with  a 
lower degree of sexual activity may be infected later, by allowing the parameters that 
affect the infection intensity to reduce with calendar year. 
The proportions in  each state in  the population at any time are controlled by a series 
of  differential  equations,  which  I  shall  not  describe  in  detail.  They  are  the  usual 
equations for  representing continuous transfers between states, except for the rate of 
new  infections,  which  depends  both  on  the  number At  Risk  and  on the  number 
Positive.  It  is  now possible  in  the model to represent different degrees  of infectivity 244 
among those who are Positive, depending on how long they have been in that state, 
but in the figures I shall show this was not taken into account. 
I shall  not give  full  details  of  the numerical values  of the proportions and transition 
intensities that we  have assumed as  the basis of the model. A full  description of the 
model,  the  formulae  and  the  numerical  values  are  available  in  Wilkie  (1988)  and 
Daykin et al.  (1988). 
It is possible, using the model, to count the number of people who are forecast to be in 
each state at each future date, and therefore possible to forecast the number who will 
be in the Sick from  AIDS  state. It is  also possible to tell how long these have been in 
this state, and therefore whether they would have an eligible claim under a PHI policy 
with a deferred period of so many weeks. 
In  the first  instance the Institute of Actuaries AIDS  Working Party used three models 
which they called A,  BC and F.  The essential features  of the models  are as  follows: 
basis A assumed that 5% of the male population at the peak ages was At  Risk,  with 
lower  proportions  among  older  ages  and younger  ages.  It  assumed  no change  in 
behaviour, and no effect of drugs such as AZT. 
Basis  BC  assumed two  types of behavioural change, first  a  transfer from  At  Risk  to 
Clear, at the rate of 10% a year, starting in  1987, and secondly a fall  in the infection 
intensity,  so  that  the  doubling  time  of  the  epidemic,  which  began  at  one  year, 
lengthened to two years by 1992. 
Basis F assumed both of these behavioural changes, but assumed only 2.5% of males 
in the At Risk category, and assumed also that AZT would have the effect of doubling 
the expected lifetime  of the Sick from  about 1.4 years  up to 1987 to 2.8 years after 
1992, with a gradual change in between. 
All these bases were calibrated against observed numbers of cases and deaths in  the 
United  Kingdom  up  to  1987.  Many  of the  features  of  the  model  were  based  on 
experience outside Britain, particularly in the USA, but also from the Frankfurt study. 
In  fact  the number of new cases  of AIDS  in  1988 in  the UK was  only  a  little  up on 
1987, and the number of deaths fell.  These numbers were well below anything we had 
forecast, and we are in the process of revising our forecasts in order to try to take these 
new facts  into account, perhaps by assuming an earlier behavioural change, perhaps 
by infectiousness that varies with the duration that somebody has been Positive. New 
forecasts for mortality have just been published in the UK (AIDS Working Party, 1989), 
but new forecasts for sickness have not yet been constructed. 
The model simplifies reality by assuming that there is a straightforward transition from 
HIV Positive to Sick with AIDS.  The reality is  of course much more complex. We do 
not yet know at what stage  in  the development of the disease someone will  have a 
justifiable claim under a permanent health insurance policy.  We therefore carried out 245 
calculations  on  two  assumptions  - one  that  a  period  of  eligible  sickness  only 
commenced when someone became Sick  with  AIDS  and was  continuous  from  that 
time onwards till  death, the other that the period of sickness commenced as soon as 
someone  became  HIV  positive  and  continued  through  sickness  to  death.  The  first 
assumption gives  figures  that are probably too low;  the second gives  figures  that are 
almost certainly far too high. But they form useful outer limits of possibility. 
We also considered two types of policy- one where benefit commences after one week 
of sickness  - virtually immediately as  far  as  AIDS  is  concerned, and the other where 
benefit commences only after 26 weeks  of sickness.  We thus have four different types 
of comparison, each on three sets of assumptions. 
Results  on the  first  of  our assumptions  are  shown  in  Fig. 2,  which  shows  rates  of 
sickness by age, for someone aged 30 in 1988, which is the worst age in our model, on 
the assumption that benefit is  only paid when someone is  Sick with AIDS  but is  paid 
immediately.  The rates are in  weeks  of sickness  per year, and four lines  are shown. 
Three of these are forecasts on bases A,  BC and F,  and the fourth, which has quite a 
different shape, shows the claim rates experienced by PHI  offices in the years 1975 to 
1978 on their ordinary business, as published by the CMI Committee (1984). 
It can be seen to what a relatively small extent sickness claims are increased in those in 
their 30s  and 40s.  There  is  quite  a large  proportional increase  at these  ~ges, claims 
from  AIDS  being perhaps an extra 30% to 60%  of the normal claims.  But when we 
consider the sickness that is  likely  to develop anyway above age 50 or so, the extra 
claims from AIDS do not bulk very large. Since most UK policies give  cover up to age 
60 or 65, the addition of AIDS  claims, though significant,  is not likely to be disastrous 
for the companies. 
The position would be different if claims were paid as soon as someone became HIV 
positive. Fig. 3 shows the results on this assumption, again for an immediate claim. The 
extra AIDS  claims  are considerably larger,  but are still balanced by the normal claims 
above age 50. 
In Fig. 4 we have a comparison on a 26-week deferred basis. That is,  no claim is paid 
for the first 26 weeks of sickness either for AIDS or for other claims. The vertical scale is 
different  from  that of the earlier graphs.  AIDS  claims  are relatively  greater,  and in 
Fig. 5, which shows claims on the assumption that they are paid from  26 weeks after 
someone becomes HIV positive, they are much larger still. 
These results  may not be very  important for  those concerned with  the provision  of 
medical care, but they show a possible approach which  can be used to estimate the 
requirements for  medical  care  for  those  who are  infected with  HIV  or are suffering 
from AIDS. In order to mak~  such forecasts one would need to have information about 
the medical care requirements of individuals  at different states in  the development of 246 
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their illness.  These may not be the same for haemophiliacs or drug users or women as 
for homosexual men, which  is  all  that our model represents so far.  More complicated 
models would be necessary to include these categories specifically. 
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115, 839-853. Scenarios and Policies Planning for AIDS or HIV Related Services in Greece: 
First Steps towards Operational Schemes 
M. Diomidis, A. Sissouras 
Abstract 
The epidemic of the acquired immune deficiency syndrome (AIDS)  necessitates early 
planning  of  services  and  allocation  of  resources.  This  paper  aims  to  provide 
preliminary  information  on  the  epidemiology  of  AIDS  in  Greece  and  the  use  of 
hospital  resources  by patients  with  AIDS  in  two  Athenian  hospitals.  AIDS  patients 
required on average 25 days of inpatient hospital care, each at an estimated current 
average lifetime cost of $ 6,880. Sociodemographic data and information on medical 
utilization were obtained from review of outpatient and hospital records. 
The usefulness of operational research for the development of expert advisory systems 
and for evaluation studies (i.e. of HIV testing) is discussed and suggestions are made to 
study costs  and financing  of AIDS  more  systematically  and to  invest  in  preventive 
services throughout Greece in  order to reduce the future social and financial costs of 
AIDS. 
Introduction 
It is  always difficult to discuss the planning and economics of a terminal or debilitating 
disease because the focus of attention must be on the devastation it brings to its victims 
and their families.  AIDS  is  no exception. However, a discussion which includes service 
planning for  people with  AIDS  is  made even more complicated by the mystery  and 
fear that surrounds this  disease. There  are several characteristics  of the disease that 
distinguish planning for AIDS from planning for other epidemics: 
1.  AIDS being a relatively new disease, there is absence of longitudinal studies on the 
transmission dynamics and the development of the disease. This causes problems 
of both estimating future demand for health services by client group, and defining 
the stages of the disease. 
2.  The client group is  a heterogeneous mixture of people of different ages,  lifestyles 
and stages of the disease, who therefore require a broad variety of services. Some 
high risk groups are reluctant to collaborate with the services they are entitled to, 
resulting  in  consequences  both  for  their  own  health  and  the  spread  of  the 
infection. 252 
Medical treatment for the victims of AIDS,  particularly when delivered on an inpatient 
basis, is costly. The treatment required for the systemic infections characteristic of AIDS 
patients tends to be lengthy and frequent.  Information on average length of hospital 
stay for  AIDS  victims  is  sporadic and ranges  from  12 to  as  high  as  150 days.  The 
estimated costs associated with these admissions range from$ 42,000 (Seage, 1986) to 
147,000  (Hardy,  1986).  In  England,  attempts  to  estimate  the  costs  of  clinical  and 
preventive services  for  an  inner London  health  district  that has  treated 18% of the 
cases  in  the  United  Kingdom,  led  to  an  average  lifetime  cost  of  $ 6,800,  with  an 
average of 50 days of inpatient hospital care (Johnson, 1986). 
Although  a  substantial  amount  of  research  has  been  done  on  epidemiologic, 
immunologic and clinical  aspects of AIDS,  there has been little  investigation into the 
economic aspects of the disease, and even less  into the role that operational research 
and systems science can play in the fight against AIDS.  In England, there is  a growing 
movement to introduce operational research models to tackle the problem of planning 
and resource allocation,  using the dynamic systems approach. In fact,  an AIDS  study 
group  has  been  rather  uniquely  formed  within  the  British  O.R.  society,  which  is 
generating a great deal of interest in the area. Various studies are reported (see a brief 
in the O.R.  Newsletter, Feb. 1989 about a special conference on O.R. in AIDS) such as 
the work by Dr. Shahani (1988) at the University of Southampton on the development 
of simulation models and Tom Bowen's from  the DHSS  discussing the development 
and  dissemination  of  a  microbased  model  to  assist  Health  Authorities  in  resource 
planning for service delivery. Dr.  R.  Hurrion of the University of Warrick introduced a 
microcomputer system  developed  as  an expert advisory  system  for  consultation  by 
individuals, in particular nonclinical categories, as a contribution to public education. 
Quality assurance for AIDS services and assistance to AIDS counselling groups are two 
other  areas  where  operational  research  could  be  used  in  the  future;  but  further 
investigation,  more  cooperation  and  exchange  of  information  between  the  people 
involved in  economics and operational research on AIDS  at an international level  is 
more than necessary in our fight against this disease. 
The epidemiology of AIDS in Greece 
In  our country, the Ministry of Health responded very quickly to the oncoming AIDS 
epidemic. The first case in Greece occurred with a bisexual student from Zambia living 
in  Athens  (day of diagnosis:  25.10.83). During  1984 five  more  cases were  identified 
(three bisexual,  one homosexual  and one heterosexual).  From  1984 until  1989 the 
number of  AIDS  cases  has  increased  dramatically.  Currently,  226  AIDS  cases  are 
registered, of whom 91  have already died. The estimated number of HIV carriers runs 
from 8,000 to 16,000. 253 
According to the Ministry  of Health & Social Welfare (see Table 1), the percentage of 
haemophiliacs who received blood or blood products not screened for  HIV  is  rather 
high. Since 1985, blood and blood products are screened for the presence of the virus 
in  all blood banks of the country, according to EEC recommendations. Homosexuals 
comprise the second highest risk  group of people infected with  HIV.  There is  a  high 
percentage of homosexuals among HIV  carriers  in  the major area of Athens  (12%), 
compared  with  the  rest  of  the  country  (16%).  Homosexuals  are  a  well-organized 
group, supporting each other in  cases of crisis. Hopefully, they have responded quite 
well to public education campaigns; currently, the incidence rate among them, at least 
in the capital area, is decreasing (-2%)  (Ministry of Health, 1988). 
The incidence of the disease among drug users in the major area of Athens is  0.5-3%. 
Greek drug users usually live in ghettos and they do not interact with other people. For 
this  reason,  the  incidence  of the  disease  among them  is  still  low.  Information  and 
education of this high-risk group requires special efforts and, for a long time, has been 
rather difficult.  This is so because many drug users are not known to the public health 
services and treatment units (like Ithaki, Strophi), and only a small number are regular 
users of specialist health or social services (e.g.  Centre of Mental Health and Hot-line 
for drug users) (Ministry of Health 1988). 
Prostitutes  are  also  a  well-organized  group.  Prostitution  is  legalized  in  Greece; 
registered  prostitutes  are  screened  and  followed  up  every  month  by  the  AIDS 
Reference Centre at the School of Public Health in  Athens. The incidence of AIDS  in 
this  high-risk  group  has  not increased  lately  (Papaevangelou  and Kallinikos,  1986). 
The incidence of AIDS  in the general population as  of August 1988 is  believed to be 
around 0.02% according to WHO; for 1989 600-1,600 cases are expected. 
Table 1.  AIDS cases in high risk groups beginning 1988 in percent 
High risk groups 
Homosexuals 
Prostitutes 
Call-girls 
Drug-users 
Foreigners 
Blood donors 
Blood recipients 
Haemophiliacs 
Source: Ministry of Health & Social Welfare 
% of AIDS cases 
13.6 
6 
1.8 
4.9 
1.9 
0.02 
4.3 
47.1 254 
Clinical management 
Infected  individuals,  whether  asymptomatic  or  with  more  or  less  severe  clinical 
manifestations of HIV infection, will  need inpatient and outpatient services. Data from 
30 AIDS patients treated in two Athenian hospitals are shown in Tables 2 and 3. 
The average cost of an inpatient day in  an Athenian teaching hospital,  where these 
patients were treated, was $ 127 (1988 prices, Laikon Hospital, cost statements 1987-
88).  The average  lifetime  cost for  patients with  AIDS,  managed  in  general  medical 
wards, was- based on 50 days of inpatient care-$ 6,360. The total cost of 1,003 days 
of inpatient care amounted to$ 127,581. 
The average lifetime cost of outpatient care, on the basis of 10.9 visits per case over a 
mean of 24 weeks, came to$ 520 (Laikon cost statements 1987). The heterogeneity of 
clinical problems in patients and the small sample size prevented us from  analysing the 
hospital use by diagnostic category. Thus the total cost of life-time hospital care on the 
basis of current patterns amounted to $ 6,880. 
While  staying in  the hospital,  AIDS  patients  required  many operative investigations. 
This  is  significant  not because of  the  extra  resources  required  in  terms  of staff  but 
because of the difficulties  of sterilizing  the  equipment,  which  makes  it  necessary  to 
provide special equipment for the treatment of AIDS  patients. Only 5% of admissions 
in the group studied required intensive care. This may reflect recent evidence that the 
outcome for patients treated in intensive care units is very poor. 
A number  of  specific  requirements  arise  for  clinical  management  as  the  epidemic 
grows.  Special equipment is  just one of them.  Many AIDS  patients will  require side-
rooms,  not  necessarily  because  they  pose  an  infection  risk  to  other  patients  but 
because  they  are  very  sick  or  demand  certain  procedures  that  require  extra 
precautions for health care staff. 
Table 2.  Length of stay per admission in two Athenian hospitals (  n = 30) 
Number of admissions 
Mean length of stay per admission 
Table 3.  Lifetime length of stay per case in two Athenian hospitals (n = 15) 
Mean weeks of follow-up 
Mean bed days per case 
62 days 
25 days 
24 
50 255 
The question arises  of providing specialized  wards.  As  of the beginning of 1989, we 
have  unified  in- and outpatient services  in  seventeen different  hospitals  (Teaching, 
District and Provincial Hospitals) around the country. 
Unfortunately, the question of dental services  is  the one largely  debated in  Greece. 
Current guidelines advocate that HIV carriers should inform their doctors and dentists 
of their antibody status and that dental care should be undertaken in  general dental 
practice, but patients found most of the times their practitioners unwilling to treat them, 
particularly  in  areas where many of HIV  carriers  reside,  like  Athens.  A proposal to 
consider specialized  dental  services  in  certain  hospitals  is  under  discussion  in  the 
National Advisory Committee on AIDS. 
Prevention in high-risk groups 
The goal of prevention is to reduce the rate of spread of the virus. In the absence of a 
simple strategy like a vaccine, this has to rely on changes in behaviour. The role of the 
antibody test in this process is  only one part of a long process which involves lifestyle 
and behavioural change. In Greece the antibody test is offered free-of-charge by seven 
Reference Centers around the country. Screening for the general population is offered 
free at two University Laboratories in Athens. 
As we have estimated, during the last two years approximately 1,000 people attended 
the seven Reference Centers across the country and asked for testing and counselling 
services. 
Recently, we looked at the groups attending the AIDS Reference Center at the School 
of  Public  Health  in  Athens.  Among  the  people  who  have  asked  for  testing  and 
consultation there, 70% were homosexuals, 20% were bisexual men and another 10% 
were heterosexuals. The costs  of providing the services include expenses for  trained 
counsellors, for  laboratory staff to do the antibody testing, and for kits and laboratory 
procedures. We anticipate the costs of an AIDS Reference Centre (they are all funded 
by the Ministry of Health) to be in the order of $ 73,000 this year. 
Health care staff 
Health care staff require regular training in 
11what does and what does not constitute a 
risk for HIV infection  ...  This includes control of infection policies and good health and 
safety practices. 
The major financial cost is the implementation of the guidelines of the National AIDS 
Advisory Committee. For the training of health professionals, workshops focusing on 
AIDS  prevention have been promptly held.  Health education material  especially for 256 
health  care  staff  has  been prepared  and sent to  Community  hospitals  and Health 
Centres. Funding for planning guidelines and service implementation has amounted to 
$120,000. 
Blood and blood products 
Before  1986 we  did  not  have  any  AIDS  cases  among  haemophiliacs  or  patients 
receiving blood and blood products. During 1987, 14 cases (26.4%) of haemophiliacs 
with  AIDS  and  7  cases  (13%)  of  patients  receiving  blood  or blood  products  were 
reported. As  of 30.9.1988, the number of haemophiliacs and transfused patients with 
AIDS  somehow decreased:  out of a total of  151  cases,  there were only 4 (6.3%)  of 
haemophiliacs and 5  (7.9%)  other patients  receiving blood or blood products. Since 
1985 by  govermental decree,  all  blood and blood products  (domestic and imported) 
have been screened in  all blood banks of the country for the presence of HIV.  During 
1987 only 0.02% of blood donors, mostly homo- and bisexuals, were found to be HIV 
carriers.  The cost to  the National Blood Transfusion Service for  testing  kits  alone  is 
approximately$ 2 million per year (Ministry of Health, 1986). 
Planning arrangements at a national level 
In  view of the projected increase in the number of AIDS  cases and in  the underlying 
pool of HIV infection,  a National Advisory Committee of AIDS  residing at the Ministry 
of  Health  was  formed  in  1983.  The  task  of  this  committee  is  to  plan  for  the 
development  of  inpatient  and  outpatient  services  and  to  allocate  appropriate 
resources. Any commitment of resources, though, will depend on both the current and 
future size  of the epidemic and on the geographical distribution of the problem, while 
planning strategies  need to  be considered  at National,  Regional  and District  levels. 
Resource needs for clinical care are, for the time being, centered on Athens since over 
80%  of  the  AIDS  cases  have  been  reported  in  the  capital  area.  Resources  for 
preventive strategies must be considered nationwide if the spread of the virus is to be 
reduced.  Districts  and regions  outside  Athens  may  not see the  control  of the  HIV 
epidemic as a current priority, though by the time they see their first case of AIDS, it is 
likely that they will already have a significant problem on their hands. 
For 1988 the Ministry  of Health  has  committed  $ 145,000 specifically  to  AIDS.  For 
1989 the earmarked money for AIDS  will amount to$ 1,180,000. This money will go 
to five general areas: 
Clinical management of infected individuals 
Advice and prevention for high-risk groups 
Protection and education of health care staff 
Safety of blood and blood products 
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Public health education campaign 
Public Health Education Campaigns have two purposes. The first is to allay the kind of 
hysteria  which  has been part of  much  of the  media  coverage,  focusing  on fear  of 
acquiring the virus  from  cups  and  door handles.  The second purpose  is  to provide 
information  and  guidelines  to  those  at  high  risk  who  will  not  be  health  service 
attenders.  The  recent  Public  Health  Education  Campaign  in  Greece  has  a  cost  of 
approximately$ 470,500. 
We should, however, not underestimate the contribution of the voluntary and private 
sector in  leading initiatives  on health information and providing imaginative strategies 
for risk reduction both within and outside the health service. 
According to our opinion, the message for AIDS prevention should be mostly provided 
outside health service institutions in  gay pubs and clubs  and at "street level"  to work 
with  drug  users  and prostitutes.  For  this  purpose  health  care  personnel,  voluntary 
organizations  and  leaders  of  the  high-risk  groups  should  cooperate  locally  and 
nationally. Adequate funding should be invested to ensure a better flow of educational 
material, an evaluation of preventive programmes, a sharing of local strategies and a 
closer local monitoring of the HIV epidemic both within and outside high-risk groups. 
Although  the  National  Advisory  Committee  on  AIDS  has  caught  the  prevention 
message it  has done very little  with  the issue this year. The School of Public Health, 
Department of Sociology,  in  collaboration with  the  Ministry  of Health  and WHO  is 
conducting a study to evaluate the level of knowledge, the attitudes and belief of the 
general  population  in  Athens,  as  they  have  developed  after  the  Public  Health 
Education Campaign. Meanwhile at the University of Crete Medical School a study on 
the evaluation of the effectiveness of the AIDS health education campaign in Greece is 
under way (Philalithis et al., 1988). 
Some methodological issues regarding HIV testing 
Meta-analysis, decision analysis and cost-effectiveness analysis can be especially useful 
in  the  study  of  testing  for  the  HIV.  For  example,  meta-analysis  can  be  used  to 
synthesize the results of studies reporting the performance of the test.  In prelicensure 
tests,  the  EUSA test was  found  to  be both  highly  sensitive  and specific  (Johnson, 
1987). However, this test was done under specified conditions that are not present in 
regular testing situations, so that the actual accuracy of the tests as used is likely to vary 
from these benchmark values (MMWR, 1988). 
Meta-analysis can answer three questions: 258 
1.  What is the average effect of treatment? 
2.  Where and with whom is a treatment particularly effective or ineffective? 
3.  Is treatment at all feasible? 
The results of the meta-analysis can be put into models for decision making based on 
tree diagrams. Decision analysis is useful in modelling HIV testing in three ways: 
1.  Calculation of post-test probability 
2.  Deciding whether to test or not to test 
3.  Comparison of tests and testing sequences. 
Finally, the values from meta-analysis and decision trees can be used for a cost-benefit 
and a cost-effectiveness analysis. 
Cost-benefit  analysis  compares  investments  in  different  programmes  and values  all 
outcomes, including mortality and morbidity. Cost-effectiveness analysis determines the 
most efficient or productive use of limited resources; for that, a monetary value of life 
and health to be assessed is not required (Weinstein, 1980). In the case of AIDS cost-
effectiveness analysis can be used in various ways: 
1.  To evaluate alternative HIV testing methods including newly developed tests. 
2.  To  estimate  the  distribution  of  the  financial  burden  of testing  among  different 
populations and in different settings. 
3.  To  evaluate  the  cost  implications  of  currently  available  testing  methods  under 
different settings and for different populations. 
A final  point to  support the usefulness of meta-analysis,  decision  analysis  and cost-
outcome analysis in HIV testing is  the role of risk and uncertainty in decision-making. 
Clinicians have always had to make decisions without definitive information, since tests 
often  leave the  health care professionals  still  unsure  about a  diagnosis  (Sox,  1986). 
Probability is  a useful tool to quantify uncertainty;  however, studies have shown that 
many physicians do not objectively analyse pre-conditional and post-test probabilities 
and use them in  decision  making.  The general population  uses  objective probability 
estimates even less  than physicians.  People want to believe that a test can be 100% 
accurate and give  them a perfect answer.  Testing for  HIV  involves  choices,  none of 
which  are  perfect,  a  fact  that is  important for  the  public and the policy-makers  to 
realize.  Meta-analysis,  decision  analysis  and  cost-outcome  analysis  can  make 
probability estimates more accurate and render the choices clearer. 
In this era of cost-containment, the appeal of techniques that objectively examine the 
allocation  of  resources  is  undeniable.  By  improving  our  ability  to  predict  the 
consequences of alternative  policies  and providing  a  framework  for  assessing those 
consequences, meta-analysis, decision analysis and cost-outcome analysis can lead us 
to  better  decisions.  However,  we  should  remember that the value  of  any  analysis 259 
depends on how its  results are translated into  changes in  practice (Weinstein,  1985). 
The irony of evaluation research is  that the more we  know,  the harder it  is  to make 
decisions.  As  Oliver in  the comic strip  "Bloom  Country" said when asked  about the 
purpose of life:  "Life is the futile passion for the pursuit of rationality." 
Going back to  the case  of  AIDS,  apart of the sensitivity  and specificity  of the HIV 
antibody tests, it is more than necessary to point out that it is this service that provides 
practical and acceptable guidelines to reduce the risk of either acquiring or transmitting 
the virus,  and that therefore it should be regularly used both in  high-risk groups and 
for random anonymous testing for low-risk groups. 
Comments 
It is well known that individuals with AIDS require a substantial amount of health care 
resources.  Our study  population  received  its  care  at two  sites,  which  may  not be 
representative of other institutions. Furthermore, our sample size was limited and may 
not have been representative of AIDS patients as a whole. 
An extension of this study to include an additional five  hospitals that care for 80% of 
the AIDS cases in Athens is to be undertaken in the forseeable future. An evaluation of 
data from  a variety of clinical settings with different patient characteristics will  allow us 
to refine these preliminary findings  and to clarify  differences in  patterns of care and 
different subgroups of patients. And although our paper is  a descriptive one, we hope 
that our results provide at least baseline and preliminary data for policy-makers. 
Conclusion 
AIDS  has become an important public  health  problem  in  Greece,  and there will  be 
some people arguing that it  might absorb too many resources and too much  media 
time,  and there will  be others who argue for  the opposite. Resources  are one thing, 
action is  another. Both should be planned and implemented to have a positive out-
come for the control of the AIDS epidemic in our country. 
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1.  Introduction 
A rapidly  growing,  multidisciplinary  body of  literature  on the spread of the  human 
immunodeficiency virus (HIV), which causes the acquired immunodeficiency syndrome 
(AIDS),  is  available. Among the fields  involved, virology,  immunology,  epidemiology 
and clinical studies prevail.  In  recent research  attention  is  also  paid to  mathematical 
models  for  HIV  transmission  and  the  economic  and  sociocultural  aspects  of  the 
epidemic.  In  this  paper we  discuss  the incorporation of these three components into 
AIDS  research  directed  to  scenario  analysis.  Scenario  analysis  is  a  technique  of 
sutveying the future by means of scenarios. Application of relevant techniques aim to 
support decision making in public health problems. 
We  present some general features of scenario analysis, followed  by an outline of the 
current state of AIDS  research using  epidemiological models.  The phases where one 
meets methodological problems on the way from basic research to scenario analysis in 
support  of  public  health  policy  making  are  indicated.  We  present  a  conceptual 
framework for scenario analysis  of the social,  cultural and economic impact of AIDS. 
Our ongoing research projects are reviewed to illustrate their potential contribution to 
the establishment of AIDS scenarios. 
2.  Scenario analysis 
Scenario analysis  emerged during the early 1950s as  a technique applied to military 
problems in  Santa Monica at the Rand Corporation. In this respect we could mention 
the name of Kahn, "the father of the scenario technique". Since then scenario analysis 
has become the vogue in other fields as well (Organisation for Economic Co-operation 
and Development,  1979;  International Institute  for  Applied  System  Analysis,  1980). 
Nowadays  public  health  is  a  major  field  for  applications.  This  is  the  case  in  the 
Netherlands (e.g.  Steering Committee on Future Health Scenarios, 1985, 1986, 1987, 
1988).  Scenario  analysis  is  a  technique  to  scout  the  future  society  by  means  of 
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A scenario is  a description of a possible path, governed by a series of developments, 
leading from  the prevailing state of a part of society to a future state, with the goal to 
gain  insight  into  the mechanisms that determine the ·path, the  future  state and the 
possibilities  of  influencing  these  mechanism  (Hoogeveen  and  Brouwer,  1989).  An 
important publication on future studies (Kahn and Wiener, 1967) defines a scenario as 
a hypothetical sequence constructed for the purpose of focussing  attention on causal 
processes and decision points. The latter definition stresses mainly the strategic aspects 
of scenarios. 
It  is  useful  to  classify  scenarios  as  exploratory  and  strategic  (target  setting) 
(Pannenborg, 1985; Brenner, 1986). An  exploratory scenario could be defined as an 
outline of a  natural or expected course of events. They explore the future  assuming 
particular developments that might occur. The so-called zero scenario is an exploratory 
scenario. It describes a future in which all developments continue their current course. 
It  is  an extrapolation of trends that already exist in  society.  It  might be a prediction, 
given  unaltered policy.  With  respect to AIDS  we might imagine a zero scenario as  a 
description of the path of the incidence of AIDS  cases  or HIV infected  patients in  a 
surrounding in which no new developments (behaviour change; therapeutics; vaccine) 
or prevention activities occur. The other family  of scenarios that makes up the class of 
exploratory scenarios is the what-if scenario. These scenarios explore a future in which 
certain,  clearly  defined, new developments occur.  An  exploration of a  future with  a 
vaccine  that  renders  resistance  against  HIV  is  a  what-if  scenario.  Fig. 1  presents, 
schematically, exploratory scenarios. We  find ourselves on the left,  in the present. Via 
different  paths  different  future  states  are  arrived  at  on the  right.  One  path  could 
represent the zero scenario, the others different what-if scenarios. 
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A second type of scenario is  the family  of the strategic scenarios. In  these we aim  at 
reaching a  desired goal.  A definition  that applies here is  a  hypothetical sequence of 
events,  constructed for  the purpose  of focussing  attention  on causal  processes  and 
decision points. This type of scenario shows the strategy, the causal sequence of efforts 
to  cope  with  a  problem  in  society,  and  the  effects  of  the  strategy.  The  effects, 
nevertheless,  can  only  be  recognized  by  comparing  the  strategic  scenario  with  the 
natural course of events, which is  described in  the zero scenario. In the absence of a 
zero  scenario  a  strategic scenario  has  to  be compared with  another scenario  as  a 
reference. In this  case it  is  difficult to evaluate realistic effects  implied by the relevant 
scenario, so strategic scenarios cannot exist in isolation. 
With  respect to the AIDS  epidemic we  could  imagine  a  strategic scenario  e.g.  as  a 
chosen programme that blocks  needle exchange amongst intravenous drug users and 
the effect of the blocking on the epidemic,  leading to the desired future  state.  Fig. 2 
exhibits  strategic  scenarios.  We  find  ourselves  on the  left  again,  in  the  present.  A 
desirable  future  state  of  society  is  defined.  This  future  state  can  be  reached  via  a 
number of strategies. 
In  Brenner (1986)  a third type of scenario is  recognized.  This  category comprises the 
resource  allocation  scenarios,  which  delineate the  resource  implications  of strategic 
scenarios. The strategic scenario shows the implication of a strategy, the corresponding 
resource  allocation  scenario  gives  insight  into  the  feasibility  of  the  strategy  in  an 
economic sense. The strategic scenario might be extended with a cost-benefit or cost-
utility analysis for this purpose. 
Let  us  return  to  the  strategic  scenario  with  blocking  needle  exchange.  The 
corresponding resource  allocation scenario should present an overview of costs  and 
beneficial  (economic)  effects.  We  can  think  of  the  costs  of  the  programme  and 
prevented  disease  and  alleged  prevented  production  losses.  We  have  presented  a 
current 
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hierarchy of scenarios. Resource allocation has to be based on strategic scenarios, and 
strategic  in  tum  cannot  function  without  exploratory  scenarios.  The  exploratory 
scenario assesses the magnitude of the problem, the strategic scenario provides a way 
to cope with the problem, and the resource allocation scenario checks the feasibility of 
the latter. 
The resource allocation scenario lays emphasis on the implications for the economy of 
a  strategic  scenario.  We  could,  however,  also  think  of  scenarios  that  deal  with 
epidemiological,  social,  demographical  or  cultural  aspects.  With  respect  to  social 
aspects  one  can  think  e.g.  of  the  impact  of  the  epidemic  on  quality  of  life  as 
experienced by patients, stigmatization  and discrimination of groups at risk  and legal 
measures taken. 
In  principle  we  have  a  categorization  into  two  types  of  scenarios:  exploratory  and 
strategic  (see  Table  1).  A  parallel  categorization  is  based  on the  aspects  that  the 
scenario pays most attention to,  e.g.  economic, epidemiological, social,  demographic 
or cultural impact. 
3.  Position of epidemiological models in AIDSIHIV scenario analysis 
This  section  indicates  the  role  and  position  of  epidemiological  models  in  current 
quantitative research on the spread of HIV aimed at the support of public health policy 
making  (prevention,  health  care  planning).  Referring  to  our own  work  carried  out 
under the auspices of the Ministry of Welfare, Public Health and Cultural Affairs in the 
Netherlands we present an outline of the present state of this research, and we will try 
to  define  further  research  priorities.  Fig. 3  shows  the  position  of  disciplines  and 
research activities involved. This scheme might be helpful in a discussion of (1)  results 
of research already obtained and (2) remaining problems. 
The integrated application of data collection, statistical data analysis and mathematical 
modelling takes  a  central position  (Fig. 4).  Many  mathematical models  have already 
been developed,  and we refer the reader to  the several reviews  now available  (Her 
Table 1.  Categorization of scenarios 
Scenarios 
<
zero 
exploratory 
what-if 
strategic 
Aspects 
epidemiological 
social 
demographic 
cultural 
economic 
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policy-making 
i 
scenario  analysis 
prediction  and  simulation 
reconstruction  and  descrrption 
social 
research 
epidemiological 
surveillance 
modelbui  I  ding 
i 
data  analysrs 
i 
data  collection 
economic 
research 
biomedical,  epidemiologi-
cal  and  social  research 
Fig. 3.  Overview  concerning  the  position  of  disciplines  and  research  activities  involved  in  the 
quantitative analysis  of the AIDS epidemic. Surveillance and basic research render the epidemiological 
data that are collected. After and together with data analysis model building is commenced. The aims of 
model building are, while integrating social and economic research, first,  description and reconstruction, 
next,  prediction and  simulation and finally,  scenario analysis.  The last  one is  primarily undertaken to 
support policy making. 
Majesty's  Stationary  Office,  1987,  1988;  Jager and  Ruitenberg,  1988;  Statistics  in 
Medicine, 1989). AIDS modelling represents a new area for research, motivated by the 
complexity  (several  linked  risk  groups,  heterogeneity in  behaviour involved  in  virus 
transmission,  geographical  differences)  of  the still  extending epidemic.  The  present 
mathematical  models  may  crudely  be divided  into  two  main  groups:  statistical  and 
population dynamic models. 
Table  2  summarizes  the  main  characteristics,  the  general  aims  and  the  ensuing 
scenarios of these two groups of models. The main difference between the two groups 
is  found  in  the nature of the models.  The population dynamic models explicitly take 
into account the transmission mechanism that rules the course of the epidemic (Bailey 
and  Estreicher,  1987;  Anderson,  1988;  Dietz,  1988;  Isham,  1988).  The  statistical Table 2.  AIDS/HIV mathematical models and scenarios 
*  Statistical models 
*  Population 
dynamic models 
empirical 
mechanistic 
simple 
mechanistic 
complex 
- description 
- short  -term 
prediction 
- description 
- reconstruction 
- long-term 
prediction 
- parameter 
estimation 
- sensitivity 
analysis 
- simulation 
- generating 
hypotheses 
- incorporation 
of heterogeneity 
- sensitivity 
analysis 
- simulation 
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- zero 
scenario 
-all 
types of 
scenarios 
- zero 
excluded 
models are empirical. They are based on statistical methods applied to AIDS incidence 
data  (Morgan  and Curran,  1986;  Downs  et al.,  1987;  Healy  and Tillet,  1988;  Her 
Majesty's  Stationary  Office,  1988;  Brockmeyer  and  Damiano,  1989).  The  use  of 
statistical (empirical)  models mainly remains restricted to the description of the course 
of the epidemic and only allows  extrapolation for  a short period (e.g.  2 years). Their 
application can lead to zero scenarios. The so-called simple mechanistic models might 
be useful over a much broader range of analysis - including reconstruction, prediction, 
simulation  and  scenario  analysis.  If the  relevant  mechanistic  model  is  of  a  rather 
complex nature, validation by data becomes difficult - their main use is the generation 
of hypotheses - and the assessment of a zero scenario is excluded. 
Statistical models 
Now we tum to statistical modelling  (Table 2).  We  have paid much attention to the 
path from  epidemiological surveillance to  modelling  (Fig. 3)  to make maximal  use  of 
the  data  collection  on AIDS  cases  (carried  out by the State Supervision  of  Public 
Health, Division of Infectious Diseases, Rijswijk, the Netherlands). In collaboration with 
the WHO Collaborating Centre on AIDS,  Paris,  a procedure has been developed for 
the statistical analysis of reported AIDS  incidence, the first epidemiological data which 
have become  available  since  1984 (Downs  et al.,  1987,  1988;  Heisterkamp  et al., 
1988a,  1988b).  By  means of a  maximum  likelihood  method the actual  numbers  of 
diagnosed  AIDS  cases  are  adjusted  for  the  well-known  phenomenon  of  reporting 
delay. The fonnal statistical method is summarised in Heisterkamp et al.  (in press). The 268 
present application of the method makes use of the exponential model. However, it  is 
possible to apply the method with  all  kinds  of parametric functions.  This  enables the 
link of this empirical method to mechanistic models. 
Fig. 4  shows  the  results  of  the  applications  to  AIDS  incidence  reported  in  the 
Netherlands  up  until  January  1,  1989.  Extrapolation  of  a  fitted  exponential  model 
provides predicted numbers of  new AIDS  cases.  The prediction might be connected 
with  economic  information  and  alternative  economic  developments  resulting  in 
economic scenarios  for  the short-term.  The  method might  also  be applied to  AIDS 
cases  which  come  from  a  specified  risk  group  and/or  geographical  area  (e.g. 
predictions for the city of Amsterdam). 
The usefulness  of the  method can  be increased  further by the incorporation of the 
distribution of the incubation time  (see  e.g.  Brockmeyer and Damiano, 1989, for the 
intended approach) and of other relevant HIV  infection stages (CDC classes). Then it 
becomes  possible  to predict  prevalences  for  these  stages,  including  the  final  stage 
preceding  death.  The  latter  requires  the  incorporation  of  mortality  data.  These 
intended  elaborations  will  be  profitable  for  short-term  projections  and  economic 
scenarios. A further perspective is the combined use of this method with a mechanistic 
model, which  could lead to strategic scenario building,  projection and scenarios that 
exceed the short-term range. 
Hardy et al.  (1986)  and Scitovsky and Rice  (1987)  estimated the economic impact of 
AIDS  in  the  USA,  by  means  of empirical  projections.  Application  of our empirical 
model  in  a  similar  approach  leads  to  exploratory  economic  scenarios  for  the 
Netherlands. We  might think of economic scenarios based on alternative assumptions, 
e.g.  concerning substitution of inpatient by  outpatient care.  However,  data that are 
suited for combination with the empirical models that render incidence figures  are not 
yet  available.  The  economic  information  (see  below  under  Recording  system  for 
hospital  care)  that  is  available  namely  seems,  at  the  moment,  most  suited  for 
combination  with  prevalence  figures.  Prevalence  figures  can be obtained  from  the 
incidence figures when information on mortality and progression becomes available. 
Population dynamic model 
Our  mechanistic  modelling  started  with  the  development  of  a  model  for  HIV 
transmission  within  the  group  of  homo/bisexual  men  - a  simple  model  - and was 
extended to a multigroup transmission - though more complex - model (van Druten et 
al., 1988; van Druten et al., 1989; van Druten et al., submitted). The basic frame of the 
multigroup  model  is  presented  in  Fig. 5.  Only  the  main  modes  of  transmission  are 
considered,  viz.  unprotected  anal,  vaginal  intercourse  and  needle  sharing.  The 
HIV  I  AIDS  epidemic is  a composite of several overlapping and linked epidemics, each c::J reported 
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Fig. 4.  The  reporting  pattern  in  the  Netherlands  is  exhibited  in  a  (Source:  Bijkerk,  1989);  the 
phenomenon of reporting delay is  obvious.  In b it is shown that reporting proportions are fairly stable 
over time. Some other European countries possess a less stable reporting pattern. The number of AIDS 
cases per half-year period, adjusted for reporting delay is given in c. An essential magnitude in describing 
the epidemic is the doubling time (see d); one exponential curve (characterized by a constant doubling 
time) could never achieve a satisfactory fit.  Therefore the use of time windows has become the vogue. 
Predictions and confidence limits based on the most recent time window (consisting of six  half-yearly 
periods including the last half year of 1988) are presented in e. 270 
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Fig. 5.  The AIDS  epidemic  is  the  resultant  of a  number  of overlapping epidemics  in  different  risk 
groups. This figure shows possible contacts (with the risk of virus transmission) between and within risk 
groups. The three transmission modes in this model are unprotected anal (a), vaginal (v) intercourse and 
needle sharing (n). 
with its  own dynamics and time course. A major objective of the model concerns the 
way  from  the  biomedical,  epidemiological  and  social  (sexual  behaviour,  needle 
sharing) information to modelling (see Fig. 3) of the epidemic in the major risk groups. 
The  model  is  designed  to  clarify  which  basic  data  are  needed.  It  provides  a  link 
between basic information from biomedical, social and epidemiological studies and the 
mathematical  formulation  of  the  model  (see  Fig. 3)  in  the  form  of  a  transmission 
matrix.  Table  3  presents  a  numerical  example of this  matrix.  The formula  in  Fig. 6 
specifies in a simplified way the information needed to attach figures to the matrix and 
to run the model. With this  method of presenting formulas  we aim at making models 
more easy to understand for non-mathematicians. We illustrate  here the computation 
of the value 0.05 in the second row,  first  column  (Table 3), which  is  the transmission 
potential from  highly promiscuous homo-/bisexual males (group 1) to less promiscuous 
homo-/bisexual males  (group 2).  Transmission  takes place only via unprotected anal 
intercourse. So in the summation in Fig. 6 vaginal intercourse and needle sharing need 
not be considered for this particular matrix element. The proportion of group 2 which 
has partners in group 1 is 0.1. The number of new partners in group 1 of an individual 
in  group  2  is  25  per year.  The  probability  of  infection  per  partnership  is  0.02. 
Multiplication  of these three figures  renders 0.05,  the matrix  element.  The reader is 
referred  to  van  Druten  et  al.  (1988)  for  a  detailed  mathematical  description  and 
motivation of the model. 272 
Table 3.  The transmission  matrix T.  The magnitude in the i th row and the j  th column reflects the 
annual transmission potential from j to i;  we  could refer to this magnitude times the size of group i and 
divided by the size of group j as the yearly basic reproduction rate from j in i. Where no entry has been 
made transmission between or within is  theoretically impossible by one of the three transmission routes 
(vaginal and anal intercourse and needle sharing). 
1  2 
1  1.5  0.2 
2  0.05  0.5 
3  0.17  0.043 
4  0.013  0.011 
5 
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3  4 
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Source: van Druten et al., 1989 
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Fig. 6.  The entries in the transmission matrix in words. The capital sigma stands for  a summation over 
the three transmission modes a, v and n (see legend Fig. 5) 
Furthermore, this model can be used to perform theoretical experiments (see Table 2, 
e.g. sensitivity analysis and simulation). For instance we can study the effects of various 
intervention (prevention) strategies like blocking the transmission of the virus in groups 
of intravenous drug users which occurs via needle sharing or blocking the transmission 
between or within other main risk groups. The model is  useful for the assessment of all 
types  of  scenarios.  If sufficient  data  are  available,  application  could  lead  to  zero 
scenarios, as a reference to what-if scenarios. 
Recording system for hospital care 
To  enable  the  connection  of  mathematical  models  and  (causal  backgrounds  of) 
hospital costs for HIV infected patients, a recording system has been developed. Jager 
et al.  (1988) presented four other objectives of the system. 
Development of a method for monitoring and describing costs, related to hospital 
care and treatment of AIDS and HIV infected patients 
Assessment  of  a  quantitative  basis  for  the  set-up  of  efficient  AIDS  services  in 
hospitals:  classification  and recording  system  for  observed variables  concerning 
treatment and care, and corresponding database structure 
Development of a survey to measure the quality of life 273 
Monitoring,  prediction  and simulation  of  costs  related to  the  course of disease, 
according to CDC classification 
Table  4  summarizes  the  items  which  are  being  obsetved  continuously  on  all  HlV 
patients in the University Hospital Utrecht.  In total about 350 variables are obsetved. 
The recording is operational for a period of more than two years, and the data for the 
first  1~ years are analyzed (Borleffs and Jager, 1989). Cost estimates are obtained for 
all activities involved in care and treatment. 
Table 5 presents a summary of costs.  Extension of the recording system  in  time  and 
place (other hospitals) increases the scope of such results. The continuous registration 
enables the detection of fluctuations and trends. The detailed level of recording allows 
the detection and definition of disease stages relevant from  a social and/or economic 
viewpoint. 
It should be realized that hospital costs are not the only relevant costs (see e.g. Kahn, 
1988; Drummond and Davies,  1988). Other cost categories are related to care (social 
setvices,  (ambulatory)  mental health  care,  primary health care and home care)  and 
more general impacts  of AIDS  on society  (research, prevention, education, life  years 
lost,  production  losses,  quality  of  life  aspects).  We  noticed  the lack  of a  universally 
accepted  terminology  for  the  classification  of  costs.  The  development  of  such  a 
terminology can  help to  clarify  which  cost categories are relevant in  our attempt to 
connect social and economic research with epidemiological modelling. In addition such 
a classification can support targeted data collection. 
Table 4.  Components of database system on treatment, care and costs, designed by AZU and RIVM 
Demographic data 
Risk group -general 
Risk group -specific 
Relevant medical listing 
CDC classification 
Clinical parameters 
Characteristics of care 
Treatment 
Diagnostic procedures 
Cost per item 
Quality of life 
date of birth, residence, ... 
sexual orientation, IV drug use, occupation, ... 
number of male/female partners, number of years of IV drug 
use, activity in prostitution, ... 
sexual transmitted diseases, hepatitis B, ... 
fever, weight loss, recent infection, dyspnoea, fitness, ... 
admissions, consulations, artificial ventilation, ... 
medication, blood transfusion, ... 
endoscopies,  pulmonary  function  studies,  haematological, 
immunological  and  biochemical  tests,  diagnostic  imaging, 
biopsies, serological and microbiological studies, ... 
social background, medical state, distress, well-being activities 
of daily life, prognosis, ... (fixed questionnaire every 4 months) 274 
Table 5. Costs (in- and outpatient) for treatment and care of 40 HIV infected patients under observation 
in the University Hospital Utrecht between January 1,  1987 and July 1, 1988 (amounts are given in Dutch 
guilders). Total costs and the mean per patient per year of observation are given. 
Number of  Mean period under  Total costs  Mean costs/ 
patients  observation in years  (1.5 years)  patient in year 
CDC II  13  0.504  33.524  5.115 
CDC III  12  0.999  43.525  3.629 
CDC IV  18  0.534  387.229  40.267 
Total  40*  0.704  464.277  16.486 
Source: Borleffs and Jager (1989) 
*  Three patients progressed through several CDC stages during the observation period. 
Finally,  we would  like  to draw  attention  to two  points  concerning the allocation  of 
funds  for  health  care.  First,  relevant  with  respect  to  this  allocation  might  be  the 
application  of  analogous  database  systems  to  other  diseases,  so  that  comparisons 
between them become possible. Second, besides the economic side of the problem the 
study also  incorporates the social aspects of the quality of life  of patients. Results on 
this point are expected in the next publication of the study. A customary procedure in 
allocating funds is relating the quality of life gained and the costs to do so.  The reader 
might consult Rees and Roberts  (1988), who reflect on and criticise this  procedure in 
the special case of AIDS and infectious diseases in general. 
AIDS scenarios 
Based on the initiative of the World Health Organization and the Steering Committee 
on  Future  Health  Care  Scenarios,  the  Netherlands,  we  recently  started  an  AIDS 
scenario study on the social and economic impact of AIDS  on society.  A conceptual 
model for this study has been designed (Fig.  7).  The intended scenario project should 
give  insight not only  into the course of the  epidemic but also  into  future  effects  on 
society.  So,  three  aspects  are suggested  for  a  simultaneous  study:  epidemiological 
modelling linked with social-scientific and economic information. 
The point of departure is  that it  is  useful to distinguish  groups at risk.  So the model 
(Fig. 7)  will  be filled  in  for  multiple  groups:  homo-/bisexuals  intravenous  drug users, 
IVDU  prostitutes, prostitutes,  health care personnel,  etc.  For each group the level  of 
risk is  influenced by the engagement in high-risk behaviour, the existence of high-risk 
situations  in  the surroundings  and the prevalence of the infection.  Risk  may  lead to 
infection  and transmission.  These processes together with  the progression  (the  flow 
through  the  CDC  classes  after  infection)  may  be  represented  in  epidemiological 
models. 275 
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Fig. 7.  A conceptual model for  the Dutch scenario project on the sociocultural and economical impact 
of AIDS on society. 
The medical technology includes all  efforts to improve care for  and treatment of HIV 
infected individuals. Also  the search for  a vaccine might be placed here.  Next to and 
closely  related  to  medical  technology  is  the  health  care  policy,  one  of  the  three 
components that influences health care. It  covers all  efforts  in  the areas of guidance, 
support, care and treatment of HIV  infected individuals. So the funding of supply of 
care, regulations and instruction for health care workers are situated here. We  might 
say that the health care policy is directed towards fulfilling the task that faces society, to 
provide  care  for  HIV  infected  persons.  Public  health  policy  is  concerned with  the 
containment  of  the  disease  (prevention,  education).  General  health  policy,  finally, 
represents all laws and regulations in relevant fields. 
The economy in  the scheme is  placed at the bottom right.  Medical technology shows 
the limit of what is possible. Together with the prevalence in the different CDC classes 
it establishes the objective need. Supply and need of course settle demand. 
As far as we know the development of AIDS scenarios is still in its infancy. We refer the 
reader to Leidl (1988,1989). 276 
Methodological problems 
Next  to  the  so-called  'data  needs'  (Institute  of  Medicine,  National  Academy  of 
Sciences,  1988)  which  are  specified  by  mathematical  model  builders  (HIV 
seroprevalence,  sexual  and  needle  sharing  behaviour,  transmission,  infectiousness, 
progression  and size  of  risk  groups),  there  are  also  important gaps  with  respect to 
methodology. We would like to stress three problems (see Fig. 3). 
When moving from  epidemiological surveillance and basic biomedical, social and 
epidemiological  research  to  mathematical  modelling  we  noticed  that  a 
methodological apparatus for the connection of models and multiple data sources 
is lacking.  The transmission matrix discussed above is  a first  approach for solving 
this problem, but statistical estimation problems remain. 
The  development  of  the  connection  of  models  with  social  and  economic 
information requires theoretical studies, such as the development of a classification 
of costs which play a role in the epidemic. 
The interface between models and policy making shows many shortcomings. How 
should a policy maker use the results emerging from  the complex path from  basic 
research to scenario analysis? 
The  formulation  of  these  methodological  problems  has  developed  during  various 
international meetings. 
International collaboration 
The present studies on modelling contribute to the Concerted Action (CA) on Statistical 
Analysis  and Mathematical  Modelling  of AIDS  of the European Communities.  The 
National Institute of Public Health and Environmental Protection of the Netherlands is 
charged with this CA.  Recently the proceedings of the first workshop (December 1986) 
appeared (Jager and Ruitenberg, 1988). For the second workshop (July 1988) a report 
is available. In an upcoming workshop (December 1989) attention will be asked for the 
above-mentioned problems:  connection of models with  economic, social and cultural 
information and modelling in support of policy making. 
Proceedings  from  similar  other  recent  meetings  on  mathematical  modelling  have 
appeared  (special  issues  Journal  of the  Royal  Statistical  Society,  1988;  Statistics  in 
Medicine,  1989;  Institute  of  Medicine,  1987).  At  the  request  of  the  World  Health 
Organization the Dutch Steering Committee on Future Health Care Scenarios (STG)  is 
preparing  an  international  scenario  project  on the  impact  of  AIDS  on  society  in 
cooperation with The Netherlands Institute of Mental Health (NcGv)  and the National 
Institute  of Public Health  and Environmental  Protection  (RIVM).  Guidelines  for  the 
setup of this study are available on request. 277 
4.  Summary and conclusions 
This paper presents a discussion on methodological aspects of research which forms a 
basis  for  reliable  AIDS  scenario  analysis  in  support  of  policy  making  concerning 
prevention and health care planning. The integrative role of mathematical modelling is 
considered. Assessment  of AIDS  scenarios requires  information from  many research 
areas: basic biomedical and epidemiological research,  social and economic research. 
The position of these disciplines  around a skeleton of epidemiological modelling has 
been outlined. Types of models, their aims (possibilities) and types of related scenarios 
are described and illustrated by ongoing projects. 
The way from basic research on HIV and AIDS to scenarios, concerning the social and 
economic impact of HIV  infections,  is  complicated.  The success  of scenario building 
will  depend on the development of sound methodologic links between the disciplines 
involved. We have mentioned the most important requirements: 
Development of a  structured  data collection  suited for  model building,  e.g.  the 
specification  of a  'transmission  matrix'  and a  recording system for  hospital  care 
and treabnent 
Identification of links  between models and social and economic information,  e.g. 
classifications  of  costs  and  specification  of  relevant HIV  stages  (observation  of 
distributions leading to prevalence models starting with incidence models) 
Development of the interface between modelling and policy making 
A preliminary  conceptual model  as  a  basis  for  the establishment  of socioeconomic 
scenarios is formulated. 
We  have  considered  AIDS  research  with  the  ultimate  aim  of  predicting the future 
course  of the epidemic and the  building  of scenarios.  This  should  motivate  careful 
attention to theoreticaVmethodological activities that support the execution of research, 
viz.  (1)  stating of the problem and (2)  the objectives,  (3)  planning the data collection. 
These points deserve further study. 
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R. Leidl 
1.  Assessing future  economic  impacts  of AIDS:  a  deterministic  scenario 
approach 
Considerations about the possible future  of AIDS  and its  economic impacts are often 
struck by considerable uncertainty of data, both for  assumptions  (like  the number of 
people  infected)  and  for  results  (like  the  total  expenditures  for  care  last  year). 
Theoretical background  and consequently functional  properties  of epidemiologic  as 
well  as impact elements are not yet (well)  understood. Time series to be used for  an 
empirical  specification  of  functions  are  often  too  short  to  derive  reliable  results. 
Stochastic  approaches  show tremendously  increasing  confidence  intervals.  Most  of 
these problems already apply to individual elements  of predicting economic impacts 
(like the number of people infected),  let alone interrelated aspects (like the number of 
people infected, treatment patterns and transition probabilities). 
At the moment, the modelling of the economic impact of AIDS seems characterized by 
a number of interrelated, unknown and not yet testable functions. To promote some 
understanding of the problem and its  possible developments, it seems  useful to start 
with rather simple models. From such a basis, variables can be extended and functions 
incorporated step by step, covering more details and replacing sections that are better 
understood theoretically or empirically, at later stages. With this background, scenarios 
based on a deterministic simulation methodology and on extensive sensitivity analyses 
are proposed to  describe  possible,  alternative  futures.  Rather than predicting  exact 
points or ranges for  indicators,  the understanding of the dynamics  of epidemiologic 
developments and economic impacts under different assumptions is considered as the 
main purpose of this approach. 
Basically,  an epidemiologic model is  here combined with  economic impact functions 
(Leidl,  1988).  The scenario methodology  introduced  is  looked  upon as  one tool to 
describe, in a transparent way, the starting points, impact functions and consequences 
of AIDS.  By integrating different empirical backgrounds, it can be adapted to different 
populations and country contexts. It can be applied in three ways: 
Testing the consistency of  different assumptions with  empirical results  obtainable 
for the past 
Predicting futures by a type of "if - then" reasoning, with comprehensive sensitivity 
analyses 283 
Analyzing the effects  of interventions,  like  the impact of prevention programmes 
on  economic  consequences,  or  medical  advances  like  drug  therapies  or 
vaccination programmes. 
This paper will deal with the first two of these issues  (for the third, see Leidl,  1989). It 
introduces  the  model  to  be applied,  then  investigates  the  impact  of different  cost 
assumptions,  among them the  effects  of  case-specific costing.  Finally,  for  alternative 
epidemiologic scenarios possible futures are described for a case-mix indicator, which 
is supposed to be meaningful both in medical terms and in terms of resource use. 
2.  The epidemiologic model and the economic consequences 
The  epidemiologic  development  of  HIV  infection  and  the  resulting  diseases  in  a 
population is  described by an infection function and, starting for each infected person 
at the  time  of  seroconversion,  a  "development  of  the  disease"  model.  These  two 
components are formulated for a high- and a normal-risk group in a population. Thus 
the  epidemiology  of  HIV,  pre-AIDS  stages  and  AIDS  is  described  by  a  highly 
aggregated model, taking into  account the objective  of linking impact functions  with 
the yearly prevalences in each of the stages. 
The infection function is a logistic one. It displays an exponential type of growth in the 
very beginning, and, proportionally to the share of people already infected, turns and 
approaches  an  assumed  satiation  limit.  The  function  is  described  in  detail  in  the 
Appendix. It has been chosen for its theoretical plausibility, because it can be tuned to 
fit  observed  data,  and  because  of  its  flexibility  during  processing.  Effects  like 
behavioural  change  can  be  operationalised  in  changes  of  one  parameter,  i.e.  the 
growth rate of infection. 
The development of the disease in the model used here is defined by the probabilities 
of progression from HIV to ARC  (AIDS-related complex, taken as a label for pre-AIDS 
symptomatic stages) or to AIDS  for  16 periods. Actual parameters were derived from 
epidemiological studies as far as available (i.e. data for 10 years; see also Appendix). 
Both epidemiologic elements, the spread of the infection and the onset of the natural 
history of the disease model for the cohort infected, taken together can generate yearly 
prevalences of cases in  each stage.  Economic impact functions,  formulated  per case 
type,  can  then  be  linked  with  these  period  prevalences  to  produce  total  impact 
indicators. 
The operationalisation of the economic consequences is summarized for direct costs in 
two sectors of care and for one indicator of indirect cost (Table 1). 284 
Table 1.  Indicators for economic consequences 
Information needed 
Hospital care 
- Days per year per case (AIDS) 
- Days per year per case (ARC) 
- Daily inpatient rate 
Outpatient care 
- Cost per year per case (AIDS) 
- Cost per year per case (ARC) 
Social burden 
- Age of patients at time of death 
- Age-specific life expectancy 
Impact indicators 
Beds needed: 
Direct cost: 
Direct cost: 
Indirect burden: 
cases * days/310.25 
(occupancy norm: 85%) 
total days * daily rate 
cases* cost 
cases * mean years lost 
(mortality only) 
For the purpose of clarity and simplicity, the further discussion will  however focus  on 
direct cost of care indicators only,  i.e.  indicators for  health  care expenditures, which 
are especially relevant for health insurers. 
Both  the  epidemiologic  and  the  economic  part  of  the  model  have  to  be  filled 
empirically. For epidemiology, this  is accomplished by using study data on the natural 
history of the disease, and.by retrospectively fitting assumptions for the two risk groups 
so  that the  resulting  AIDS  cases  will  match  the  number  of  AIDS  cases  reported 
officially. This also produces figures for the still unknown numbers of cases in pre-AIDS 
stages. 
The economic data may be taken from  cost studies. The implications of some of their 
variation  is  discussed  in  the next section,  where  possible  fits  for  the  epidemiologic 
development and the results of German cost studies are used to add empirical weight 
to  the  model.  With  alternative  assumptions  therefrom,  the  effects  of  different  cost 
assumptions in describing the past are explored. 
3.  The sensitivity of total  expenditures with  respect to type  of epidemic, 
level of cost, patterns of care and case-specific resource needs 
In  the  following  applications  of  the  model,  the  basis  of empirical  reference  is  the 
Federal Republic  of  Germany.  As  described,  the  number  of  AIDS  cases  reported 
officially is used to 
11tune
11  the model to a population (about 60 million) and a spread of 285 
AIDS matching the one in the FRG  (1669 cases at the end of 1987 for the time being, 
which will have to be revised for reporting lags later). In the economic part, cost studies 
are used to define possible values for  assumptions as well  as some upper and lower 
limits  (Hanpft et al.,  1988; Reinecke et al.,  1988; Koock-Walewski et al.,  1988; Koock-
Walewski  and Stille,  1989). The available studies  use classifications of cases in  three 
stages: HIV cases, lAS/  ARC  cases as types of symptomatic disease and AIDS  cases as 
the full-blown type. For the purpose of this paper, it  is assumed that case definitions in 
both the epidemiologic and the economic part sufficiently  overlap to be linked  with 
each other. 
First,  the overall sensitivity  of  cost  is  discussed  for,  as  an example,  the total yearly 
expenditures in  1988. Cost indicators comprise inpatient days for ARC and AIDS  and 
outpatient cost for  all  three stages. Three sets of assumptions were selected as "low
11
, 
11medium
11  and "high
11  cost levels. They range from very low - not to say from the lowest 
- plausible values to ones close to  a  plausible maximum,  as  available from  the cost 
studies. All cost sensitivity analyses will be performed within this framework (Table 2). 
Before the above economic assumptions are discussed,  some results from  tuning the 
epidemiologic parameters have to be integrated: different sets of assumptions produce 
almost similar useful fits  up to the present state, while differing in their future spreads. 
Thus different basic types of spread should be used for scenarios. 
The  alternative  basic types  of spread  of the HIV  infection  were  developed  by  the 
following procedure. An exploratory universe of 31,680 sets of parameters was drawn 
from all possible combinations for the eight epidemiologic parameters in the two-group 
Table2.  Cost assumptions for sensitivity analyses 
Yearly indicator  Low  Medium1)  High  Increase relation
2
) 
Inpatient days3) 
AIDS  40  60  80  30+10i 
ARC  10  20  30  5+5i 
Outpatient cost4> 
AIDS  1,500  3,000  9,000  1250+250 * 2 (i-l) 
'  ARCS  1,000  2,000  3,000  500+500i 
HIV  100  300  500  lOOi 
1)  used as standard for case-mix index 
2)  i = 1/3/5 for low/medium/high; values 0 to 5 were checked 
3)  to be multiplied by a daily rate of DM 300.-
4)  inDM 286 
model, restricting them roughly to plausible ranges (e.g. restricting the number of AIDS 
cases in the normal-risk group below 10%). Then, the ranges were classified. For each 
set, the number of AIDS  cases for 1981 to 1987/8 was calculated and compared with 
the cumulative yearly prevalences of full-blown  AIDS  cases officially  reported by the 
Bundesgesundheitsamt in  Berlin - omitting the problem of reporting lags.  The fit was 
measured in terms of the mean root of square errors. In successively focussing steps, 
the results were screened 
According to the best fits 
According to the parameters varying with  increases  in  fits  for  different high-risk 
group sizes 
For plausible shares of normal-risk group AIDS cases 
For redundancy 
For heterogeneity among the remaining types. 
The procedure resulted in  four basic types, which differ especially in  the size of their 
high-risk  group  (1:  180,000,  II:  100,000,  III:  60,000  and  IV:  20,000;  for  other 
parameters, see Appendix). 
For these four basic types, cost sensitivity for yearly expenditures 1988 in the FRG was 
calculated.  The  analysis  was  performed  for  all  low,  all  medium  and  all  high  cost 
parameters. The results are displayed in Fig.  1. 
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Ill 
Type  of HIV- Spread 
Fig.l.  Sensitivity of yearly expenditures (1988); 3 cost levels 
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One main source of variation in  Fig. 1 stems from  the number of cases  in  pre-AIDS 
stages. These cases need a considerable amount of resources for  care, are empirically 
unknown in  their extent and vary between the four basic types; i.e. the same number 
of AIDS  cases may be observed with different numbers of cases in  pre-AIDS stages. 
The variation between the four  epidemiologic types increases with the level  of cost 
parameters  (high/medium/low)  assumed.  Sensitivity  differences  between  cost  level 
assumptions within  the framework  of Table 2  are more significant than between the 
epidemiologic types;  only two scenario combinations (1/medium  and IV/high)  overlap 
across cost levels. Overall,  a significant uncertainty of total 1988 AIDS  expenditures is 
displayed. 
Fig. 2 deals with the effects of two other types of variations: one is a description of the 
inpatient-outpatient relation in  the care of ARC  and AIDS  patients, the other one an 
alternative  description  of  resource  needs  in  just  one  stage  of  the  disease,  here 
exemplified for the ARC cases. 
Within  the  framework  of the  assumptions  displayed  in  Table 2,  descriptions  of the 
inpatient/outpatient  relation  in  care,  which  can  be  viewed  as  possible  alternative 
treatment patterns, were operationalised in the following way: 
"High"  level  assumptions  for  the  cost  of  outpatient  care,  stemming  from,  e.g. 
intensified ambulatory care 
"Low" level assumptions for inpatient days resulting from reduced hospital care 
Expenditures  in  Mio.  DM 
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And  a  combination  of both to  describe  a substitution  of inpatient by outpatient 
care. 
The effects  of "low"  inpatient costing  exceed the "high"  outpatient cost assumptions; 
combining both resulted in  a decrease of overall cost as  compared with the "medium" 
standard. 
Clearly outside the range of this sensitivity picture, however, the different assumptions 
for  just one stage of the disease,  the pre-AIDS  symptomatic "ARC",  display an even 
greater variation. High cost ARC treatment within the framework of Table 2 would lead 
to more expenditures in all four epidemiologic types than just assuming a high level for 
outpatient cost. Case-specific resource needs for pre-AIDS symptomatic stages thus can 
be considered an especially important {sensitive) input for calculating overall cost. 
4.  Future case-mix developments 
As  shown  above,  total  needs  for  care  in  a  population  for  a  period  of  time  are 
significantly related to the specific types of disease stages. This is of course also true in 
a  time-series  perspective:  during  the spread  of  the  disease,  resource  needs  will  be 
significantly influenced by the case-mix to be cared for.  Case-mix is  understood as  a 
measure covering both  medical  elements  (like  diagnoses  or functional  abilities)  and 
resource  elements  (like  days  of  inpatient  care  needed).  To  describe  possible 
developments  in  case-mix,  an  indicator  for  the  severity  of  the  disease  within  a 
population is  proposed. It  originates  from  case-mix tools  applied  with  classifications 
that have earlier been developed for patients in different types of health care settings. 
The  most  famous  case-mix  oriented  classification  system  are  the  diagnosis-related 
groups- DRGs- for hospital patients (cf. Leidl, 1987). 
To define a case-mix measure, HIV infected patients must be classified by stages of the 
disease  development.  In  principle,  the  following  technique  is  applicable  to  any 
classification  of AIDS  patients,  e.g.  to the definitions  by the US  Centers for  Disease 
Control, to the Walter-Reed classification or to specific AIDS-DRGs as they have been 
developed, and are experimented with, for financing purposes in the city of New York 
{Knickman,  1988).  Thus,  different perspectives on the disease and different types  of 
medical meaningfulness can be incorporated. 
However, it must be kept in  mind that the classes have to be homogeneous enough in 
terms of resource use as to allow the identification of a representative mean value for 
the  figure  indicating  resource  needs  in  each  stage.  If,  furthermore,  definitions  of 
disease stages differ significantly in  different parts of the model, as between the ARC 
definition in the development of the disease part and in the parameters derived from 
cost  studies,  this  may  severely  impede  the  validity  of  results.  For  the  simulation 
examples presented here, sufficient similarity of case definitions has to be assumed. 289 
With 
j as number of classes defined by a classification system 
p i as the percentage of patients from  a population of n HIV  infected patients in 
class i 
r  i as the mean resource use in  class  i (e.g.,  average cost or days of hospital care 
per year) 
the case-mix of a cohort infected at time t can be defined as 
(I)  emt  =  sum 1 ..  j of (Pit rit). 
em t  denotes  the  average  resource  use  needed  by  the  population  at  time  t. 
Consequently,  total  resources  needed  equal  em t *  n.  With  a  reference  point  or a 
standards (a point of time or a reference population) case-mix can be expressed by an 
index emit , describing the difference to the standard (which equals 1) 
(II)  emit  =  em tl  ems  . 
Independent from the total number of cases and its development, which also has to be 
accounted for,  this index comprises both medical severity and resource needs within 
the  cohort of  infected  persons.  It  indicates  the  intensity  of  medical  and  economic 
problems to be coped with by society. If it increases, the average medical severity and 
the  average  resource  needs  of  the  cohort  have  become  greater;  if  it  decreases, 
problems on average have diminished. 
The index refers to the total number of people infected. Thus, at the current structure 
of care, a reduction in the number of HIV infected people per AIDS  case will  increase 
the  index,  because  the  average  need  for  care  in  the  population  will  grow.  In 
consequence, however, when one just thinks of AIDS  cases, the only data commonly 
available  today,  the  index  may  be misinterpreted:  its  "increase"  may  result  from  a 
reduction  in  the  invisible  number of people  in  pre-AIDS  stages.  Yet  the  approach 
proposed  here  is  considered  meaningful,  since  it  accounts  for  the total  number of 
people infected  and describes  - independently from  data availability - the complete 
challenge  of  AIDS  for  the  treatment  system.  In  the  future,  this  perspective  could 
significantly  gain weight with  the emergence of standard treatment for  asymptomatic 
HIV-infected persons (which also may make them visible). 
With  equation (II)  and the four basic epidemiologic types that have been developed 
above, the long-term properties of the model can be analysed and used to describe 
possible future developments in  case-mix. As  reference point the case-mix of the year 
1986 is taken, the time when cost data were collected. This means, emi 1986 equals 1 
for  all  four basic epidemiologic types.  As  a standard for  resource needs in  the three 
classes HIV,  ARC and AIDS, the "medium" option of cost assumptions in  Table 2 was 290 
applied  to  calculate  cmi t·  Experiments  with  other  indicators  of resource  need,  like 
inpatient days per year only, did not result in major deviations from patterns observed. 
Fig. 3  shows  the development  of  cmi t from  1981  to  2020.  Under the  assumptions 
made  here,  i.e.  also  for  the  virtually  theoretical  framework  of  an  unchanged 
environment,  e.g.  with  respect to  behaviour or medical  technology,  cmi t would  be 
expected to  stay,  as  compared  1986,  within  the  range  of  a  slight  decrease  and a 
maximum threefold  increase until  the year 2000.  Furthennore, the analysis suggests 
the following hypothesis. 
Case-mix  is  anything  else  but  constant.  Along  with  increasing  numbers  of  people 
infected, the case-mix to be coped with by the health care system has been increasing 
since  the  beginning  of  the  epidemic.  It  will  continue  to  do so  further,  depending 
especially on the size  of the high-risk  groups;  then  it  will  decline  for  a while,  and -
again after a while - increase again. Possible lengths for each of these time periods can 
be read from Fig. 3. 
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Furthermore,  Fig. 3  clearly  warns  against  simple  extrapolations  of  epidemiological 
patterns  found  once:  the 
11tip  of  the  iceberg
11
,  as  the  AIDS  cases  are  described 
sometimes, is  not a valid picture for health care planners, since the amount below the 
visible part is significantly changing over time and cannot be derived from the tip as for 
an iceberg. 
5.  Conclusion 
The  development  of  a  computer-based  tool  to  describe  possible  futures  of  the 
economic impact of AIDS  was shown, emphasising the indicator expenditures and the 
specific role  of case-mix.  At the  current level theoretical and empirical knowledge  of 
the significance of the model's elements and parameters is heavily restricted. Thus, the 
development of methods to assess the dynamics of the economic impact of AIDS was 
considered a  research  objective  prior to  exact estimation,  but also  for  the concrete 
valuation of different scenario results, e.g. by attaching probabilities to scenario types. 
Even in the past, considerable uncertainty about the overall treatment cost for persons 
with  HIV  infection  or  later stages  of  the  disease  was  found  by  applying  scenario 
techniques: possible ranges of total cost displayed considerable variation for different 
sets  of  assumptions  concerning  cost  levels  and,  less  sensitive  among  the  scenarios 
compared  here,  types  of  spread.  Furthermore,  scenarios  discussed  in  this  paper 
suggest  that  case-mix  should  be  thoroughly  considered  in  cost  studies  and 
incorporated in assessments of the future economic impact of AIDS. This is first backed 
by the significant influence that case-specific resource needs have displayed for overall 
cost calculations, as has been shown for a pre-AIDS symptomatic stage, and secondly, 
by the significant variations of case-mix over time that can be hypothesised since the 
beginning of HIV spread as well as for the years to come. 
6.  Appendix 
The infection function 
It  is  a logistic function,  derived  from  an exponential function  Et with  growth rate w, 
starting at point A (the number of people infected in the beginning) 
and a linear weighting function g: 
(2)  g  =  1-A/  (A-sP)+ Xti(A-sP). 292 
g is  1 at A and decreases linearly to 0 at s *  P (the maximum rate of people susceptible 
to infection) in population P; the infection function X t then is defined by 
(2) in (3) solved for X t gives 
(4)  X t 
sP-A+Et 
For each population, the infection function thus can be described by four parameters: 
P,  A,  w, s.  In the two group model used here, the size of the high-risk group and its 
growth rate tum out to be the most sensitive parameters in  time  frames  of about 15 
years from 1980 on, accounting for the low number of people with AIDS reported from 
the normal-risk group so far. 
In  the model actually  used, some minor modifications were made in  the part of the 
low-risk  group.  Resulting from  the tuning process  (as  described  above),  the sets  of 
parameters  selected  for  the  four  basic  types  of  spread  are  displayed  in  Table  3 
(parameters set identical for all: P = 6 *  107, s =  .2, s HR = .9). 
The development of the disease functions 
It is defined by the cases infected multiplied by the probabilities p of progression from 
HIV to ARC or to AIDS for 16 periods: 
(5)  ARCt 
(6)  AJDSt 
P arc 1 *  HIV t-1 + · · · + P arc 16 *  HIV t-16 
Paids1 * HIVt-1 + · · · + Paids16*HIVt-16 
Actual  parameter values are derived from  epidemiological studies as  far  as  possible. 
Since data are available only until year 10 for AIDS and only partly for ARC (Hessol et 
al.,  1988), the remaining parameters are fictitious.  They could, however, be fitted  to 
Table3.  Parameters for the four basic types of spread 
Type  A  w  p  1) 
AHR 
1)  w  1) 
HR  HR 
I  140  10  180,000  1,300  75 
II  220  40  100,000  1,300  75 
III  60  70  60,000  1,500  75 
IV  100  70  20,000  500  225 
1)  HR for parameters of the high-risk group 293 
Table4.  Percentage distribution over disease stages for an HIV-infected cohort over 16 years 
Year  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16 
HIV  91  79  66  55  46  35  24  20  17  12  9  6  4  3  2  2 
ARC  9  19  29  35  39  42  43  43  43  40  36  32  28  24  21  18 
AIDS  0  2  5  10  15  23  33  37  40  48  55  62  68  73  77  80 
estimations of the future  course of the transition function.  Those parameters actually 
used are reported in  Table 4  as  a percentage distribution over disease stages for an 
HIV infected cohort over 16 years. Furthermore, it was assumed that of the full-blown 
AIDS cases 80% survive only 1 year, 15% two years and 5% three years. 
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1.  Introduction 
Policy makers are curious people. Every future-oriented study gets their attention as long 
as the conclusions are in line with their expectations about future events. Those in favour 
of more money for AIDS  campaigns will come up with  studies which indicate that there 
will be disastrous developments as far as AIDS is concerne; those in favour of less  money 
for AIDS will embrace studies that show a relative decline in the number of AIDS cases. It 
does  not matter whether the study  is  based  on  mathematical-econometric  models  or 
apocalyptical visions. 
Future studies are as  old as the world.  Over thousands of years all kinds of people have 
made statements  on  future  developments.  In  ancient  Greece  the  policy  makers  were 
interested  in  the  explanations  of the  murmured  sounds of priestesses,  later  on  in  the 
flights  of the birds,  crystal balls,  how cards were laid.  In the Bible the dream-explainers 
play an important role. The Etruscans studied the livers of slaughtered exes. In Italy there 
were  universities  with  astrology  departments.  Queen  Elizabeth  I based  her strategies 
against the Spanish fleet on the predictions of astrologers. 
Today we  have  more  sophisticated  methods  for  making  predictions  about the future. 
Every self-respecting company or government ministry has specialised future researchers. 
They  are  not  referred  to  as  prophets,  dream  explainers  or astrologists,  but strategic 
planners, policy analysts, scenario experts, etc. 
In  the  Netherlands  we  had  future-oriented  policy  units  in  almost  every  sector  of 
government: the economy, defense, education, etc. but not in the health sector. 
Nevertheless, important measures had to be taken in this sector, and information about 
possible future developments were lacking. Therefore the Steering Committee on Future 
Health Scenarios (STG) was created in 1984. I am the project coordinator of this Steering 
Committee. 
We  have  now  completed  a  number  of studies,  and in  this  paper I will  focus  on our 
experience with  these projects,  the structural setting and the impact of the conclusions 
and recommendations on the actual policy making process. 296 
2.  The Steering Committee on Future Health Scenarios 
2.1  Background 
The major reasons for establishing the STG were: 
Failure of traditional planning structures and methods 
Good experiences in the industry with scenario methods 
The Dutch debate on the implementation of the Health-for-all (HFA) strategies. 
2.2  The terms of reference of the STG 
After  weighing  several  alternative  structures  for  the  "scenario  operation"  in  the  Dutch 
health care sector, it was decided to establish an independent Steering Committee for this 
task. 
This Steering Committee is composed of people who have extensive experience in health 
policy-making: three former Ministers  of Health,  the chief Medical Officer, the chairman 
and the vice-chairman of the Dutch Health Council, the director of the National Institute 
for Health and Environment and the chairman of the Dutch Medical Society. In order to 
secure experience with the scenario method,  a  former  member of the Dutch Scientific 
Council for Policy Development was asked to join the STG. A close link with the actual 
policy-makers- without interfering in the scenario-making process itself- was established 
by the nomination of the Director-General of Health as chairman of the Committee. Also 
for  this  reason the secretariat of the Steering Committee was incorporated in  his  Staff 
Bureau for Health Policy development. The STG got the financial support of the Ministry 
of Health and other organisations which regarded one or more projects as valuable. 
The chief task of the Steering Committee - describing alternative futures  in  the field  of 
public health - is  done by commissions supported by outstanding research institutes. The 
members  of  these  commissions  are  appointed  in  a  personal  capacity.  A  formal 
representation of interest-groups is avoided in the scenario commissions. 
The  first  topics  for  scenarios  were  selected  on the  basis  of  social  relevance  and the 
possibility for future research. Recently, more or less spontaneously topics were suggested 
by the Second Chamber of Parliament,  medical associations,  etc.  The WHO  suggested 
the development of an international scenario project on "The Impact of AIDS on Society". 
The STG projects can be categorised according to diseases,  determinants of health and 
patterns of health care facilities. 
The reports  of the different scenario commissions  should give  clear insights  into  future 
developments  of  disease  patterns,  changing  concepts  in  the  health  care  sector  and 
influences of "environmental'• factors on the health of the population. The conclusions of 
the  commissions  and the  policy  recommendations  of  the STG  should  enable  policy-297 
makers  (politicians,  administrative  bodies,  insurance  companies,  professional 
organisations) to make more rational - or less irrational - decisions about investments and 
priorities in the health care sector. 
3.  The Dutch experience 
The STG completed a number of scenario studies (projects) on: aging, disease categories 
(cancer, cardiovascular diseases, accidents) and future medical technology. In my view all 
these  projects  provided  interesting  information  on  future  developments.  The  most 
successful projects in  terms of its  impact on the actual policy-making process were those 
that focussed on disease categories. 
In these projects the major questions are: 
1.  How will  the incidence and mortality from  a certain disease category develop in 
relation to the size of the population? 
2.  What development will there be in the demand for care? 
3.  What developments might take place in the supply of care? 
4.  How would it be possible to influence the developments named under 1 and 2? 
For each scenario project, a number of alternative futures are drawn. 
Generally,  the  scenario  commissions  draw  their  own  conclusions  at the  end  of  each 
project. For instance, the cancer project produced the following results: 
It seems likely that between 1985 and 2000 there will  be a sharp increase in  the 
number of cancer patients (1.5% per annum). 
A sharp increase in the demand for diagnosis and treatment is expected. 
No real breakthroughs in cancer treatment are likely in the coming 15 years. 
The results  of the scenario projects  are widely distributed  and presented to parliament, 
with  a governmental point of view.  In the next section, a number of experiences on the 
impact of these projects on the actual policy-making process are presented. 
4.  The impact of scenarios on the actual policy-making process 
Generally speaking,  all  scenario projects provide an interesting comprehensive data set 
on the  topics  studied.  Amidst  the  numerous  reports  dealing  with  specific  issues,  the 
scenario  reports  present an overview  of epidemiological  and treatment trends  and  of 
expected future developments. 
For this reason the reports are widely used. It is difficult to evaluate the total impact of a 
STG project.  The number of reports sold could be calculated. The same is  true for the 298 
number of articles  in  (health) journals,  literature references,  etc.  Not measurable  is  the 
changing future  orientation of policy-makers, the impact on new research programmes, 
the needs, felt for better long-term health policies, etc. 
It is  felt that a better link has been established between the scientific community and the 
policy-makers because of the activities of the Steering Committee. Without any exception 
the reports are used as long-term policy documents of the national health administration. 
The  impact  of  the  reports  in  a  scenario  project  also  depends  on the presentation  of 
models,  data,  etc.  As  with  other reports, the formats  and presentation are of essential 
importance if  it  is  to be read and acted on by busy managers. Every report contains a 
clear summary and in some cases an 
11executive summary
11  1 page long. 
5.  Conclusions 
Based  on  our 5-year experience  with  scenario  projects  we  could  draw  the following 
conclusions. 
Structure of the STG 
The structure of the STG - independent but linked with the Ministry of Health - proved to 
be very  fruitful.  Much  external expertise  has  been brought to the  policy-makers.  The 
scenario commissions  have not been hampered in  their work by formal  representation 
problems of vested interests. 
A relatively  small  disadvantage  of  the  STG  structure  is  the  impossibility  of  frequent 
meetings of the Steering Committee itself.  Much of the coordinating work has to be done 
by  STG  secretariat.  Another  disadvantage  is  the  lack  of  direct  links  with  the  Dutch 
Medical  Society,  the  Dutch  Hospital  Association,  the  insurance  companies,  etc.  These 
organisations have to be involved in the various stages of a scenario project on an ad hoc 
basis. 
Methodology for scenario projects has to be improved 
All scenario projects needed to deal with the following issues: 
The  demographic  structure  of  the  population  now  and  in  the  future,  divided 
according to age, sex, health status, profession, etc. 
Existing and future medical services/treatments, etc. 
Risk and exposition indicators. 
Policy  measures,  i.e.  prevention  programems,  enlarging  or diminishing  medical 
facilities, etc. 
Economic forecasts. 
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These issues have been dealt with rather autonomously by all the scenario commissions. 
This hampered the linking of the results of different scenario exercises, for instance with 
respect to competing morbidity and mortality patterns. A major research effort has now 
been made to "streamline" the new and the already developed scenarios. A new start with 
scenario development for  instance for  AIDS  will  avoid this  methodological problem by 
giving more attention to these issues in the very first stage. 
It turned out that a sound "model" is absolutely essential for a successful scenario project. 
Economic aspects of scenarios 
Policy-making within severe financial constraints requires a thorough financial analysis of 
strategic  alternatives.  The  financial  translations  of  the  conclusions  of  the  scenario 
commissions and the recommendations of the STG are made extremely difficult inter alia 
by the  lack  of relevant  data and the  lack  of  resources  for  these  cost-benefit  analysis 
studies. Health economists, certainly in the Netherlands, are not yet familiar with this kind 
of scenario study. In the international scenario project "The impact of AIDS" we will try to 
incorporate relevant economic data. 
The communication processes 
A  scenario  project  is  divided  into  a  number  of  phases.  The  report  of  a  scenario 
commission  is  only  one  important  step  in  a  scenario  project.  This  report  has  to  be 
discussed  in  many scientific  and policy-making  communities.  This  demands  articles  in 
newspapers,  scientific  magazines,  summary reports  for  a  wider  distribution,  workshops 
and  symposia  supervised  by  the  STG.  Researchers  and  also  the  commissions  are, 
generally  speaking,  very  much  focussed  on  the  research  aspects  and  not  on  the 
communication process. 
From scenarios to health strategy development 
The experiences with scenarios highlighted the need to increase the competence of health 
managers to use strategic information. In  countries with pluralistic health systems like the 
Netherlands and the FRG, long-term policies are impossible without the support from  the 
major  actors  in  the  health  field:  insurance  funds,  professional  groups,  provider 
organisations  and  the  national  health  administrations.  The  scenarios  are  seen  as  an 
instrument to bring these  groups together in  order to discuss strategic issues.  After this 
discussion the Dutch government will present a governmental point of view to parliament 
in order to get a kind of national consensus on major issues. 
The need for strategic health policy units 
A conclusion based on our experiences is that policy-oriented scenarios can thrive within 
an organisation only if  it  incorporates a  department devoted to future research  and or 300 
strategic policy-making. This applies not only to national health departments, but also to 
insurance companies, provider organisations, etc. 
Monitoring systems 
Conclusions  and recommendations  based on scenario  projects  have  to  be checked  at 
regular intervals - for instance every two years - on their assumptions, trend analysis, high 
impact-low probability events, etc.  Otherwise these projects have only a  limited value a 
few years after the designing stage. 
Regional scenario projects 
In  the  Netherlands,  as  in  many  other  countries,  large  differences  exist  in  mortality, 
morbidity, demographic and many other factors between the different regions. Therefore 
scenario projects on a regional level may be an important feature for further action. 
6.  The international scenario project "The Impact of AIDS" 
At  the request of WHO/Euro  the STG  started  an international scenario project on the 
impact of AIDS in the future. The results of the feasibility studies - based on the guidelines 
of the STG - will  be discussed in  a workshop  in the Netherlands from  25th to 26th May 
1989. 
The  main  project  will  start  September  1989.  This  project  comprises  a  study  on  the 
possible epidemiological,  economic and sociocultural effects  of the AIDS  epidemic in  a 
number of European countries in the next decade. The first written results of this project 
are expected in  1991. The project will be coordinated by the WHO/Euro and the STG. 
This project will be closely linked with the EC-COMAC study on the Economic Aspects of 
AIDS and HIV infection. 
Bibliography 
Klein,  E.  (1981).  The  use of scenarios in  corporate planning,  eight case studies.  Long 
Range Planning 5, 69.60 77. 
Pannenborg, Ch.O. (1985). Scenarios as a method of probing and planning the future of 
health care. Paper presented in the International Meeting on Future Health Systems. 
Bellagio, May. 301 
Schaars, S.P.  (1987).  How to  develop  and use  scenarios.  Long-Range  Planning 20(1), 
105 60 114. 
Schreuder,  R.F.  (1988).  Scenarios  for  health  planning  and  management.  The  Dutch 
experiences. The International Journal of Health Planning and Management 3(2). 
Steering  Committee  on  Future  Health  Scenarios  (1987).  Anticipating  and  assessing, 
health care,  Technology,  Volume  I-VIII,  (eds.  D.  Banta and A.  Geleijns),  Martinus 
Nijhoff, Utrecht. 
Steering  Committee  on  Future  Health  Scenarios  (1987).  Growing  old  in  the  future, 
scenarios on health and ageing. Scenario report 1985. (eds. C.F. Hollander and H.A. 
Becker), Martinus Nijhoff, Utrecht. 
Steering  Committee  on Future  Health  Scenarios  (1987).  The  heart of  the  future,  the 
future  of  the  heart.  Scenario-report  1986.  (eds.  E.J.  Dunning  and W.I.M.  Wills), 
Martinus Nijhoff, Utrecht. 
Steering Committee on Future Health Scenarios (1988). "Cancer in  the Netherlands". In 
Scenarios on cancer. (ed. F.J. Cleton), Martinus Nijhoff, Utrecht. 
Steering  Committee  on  Future  Health  Scenarios/  WHO  (1987).  Scenarios  and  other 
methods  to  support  long  term  health  planning,  (theory  and  practice)  (eds.  J.J. 
Brouwer and R.F. Schreuder) v. Arkel, Utrecht. 
WHO/Euro (1985). Planning and management for health. Euro reports and studies 102. 
WHO/Euro (1986). Health projections in Europe. WHO-publication. Main Polley Issues of the Social and Economic Impact 
of AIDS from the Perspective of a Health Ministry 
X. Scheil-Adlung 
More  than many  other diseases,  AIDS  has  a  social  and  economic impact both  on 
individuals  and on society.  These social and economic repercussions cover not only 
individual  behaviour  (sexual  practices,  drug  abuse  and the  like);  there  is  also  the 
problem of the ability of those affected to earn a living, the question of providing them 
with appropriate nursing and care, as well as assistance in  coping with discrimination 
and stigmatisation. From the point of view  of a health ministry  on the federal level in 
the  Federal  Republic  of  Germany,  such  AIDS-related  repercussions  can  only  be 
overcome in a satisfactory manner when solutions which focus  on the causes of AIDS 
are found; in other words, when a vaccine or curative can be made available. As  long 
as this  is  not the case, the number of AIDS  cases will  continue to rise,  and the social 
and  economic  impact  will  persist.  Since,  according  to  the  current  state  of  medical 
knowledge,  such  a  solution  to  the AIDS  problem  cannot be expected ·for  the  time 
being, central significance should be accorded to preventive strategies and measures to 
provide psychosocial and nursing care for people with HIV and AIDS. 
As  early as the end of 1986/beginning of 1987, the Federal Ministry for Youth, Family 
Affairs,  Women  and Health  had devised  and introduced the relevant strategies  and 
accompanying measures. According to the ministry's designated responsibilities these 
measures are defined as those outside the social security system. 
The conception of the individual measures starts from the premise that education and 
counselling are the key to achieving the behavioural and attitudinal changes which are 
necessary to  maintain health.  They can at least reduce the number of new cases  of 
infection  while  constituting  an  appropriate  means  of  handling  and coping with  the 
problem  complex.  The  individual  measures  are  meant to  limit  the  repercussions  of 
AIDS to those which are socially desirable and - economically - at least feasible under 
current budget constraints. One indispensable component of all measures is continuous 
scientific evaluation which finds  its way directly into the ongoing political development 
of preventive strategies. 
The  programmes  and  projects  of  the  Federal  Ministry  for  Youth,  Family  Affairs, 
Women and Health revolve mainly around the various areas of AIDS  control via the 
health  offices,  psychosocial  care,  out-patient  care  by  social  workers,  streetwork, 
women's  programmes,  prevention  among  young  people,  children  and  foreigners. 
Other areas of focus  are discrimination, drug use,  sexual practices, prevention of HIV 303 
infection among the mentally retarded, as well as  "AIDS and prison". Altogether, over 
700 skilled personnel, scientists and practitioners are involved in these programmes. In 
addition, extensive education is pursued via the mass media, and personal discussions 
are offered and likewise evaluated. Since 1987, the Federal Ministry for Youth, Family 
Affairs, Women and Health has been allocating some OM 135 million per year to such 
programmes and projects.  Additional funds  are provided by the Lander (states)  and 
the municipalities.  The first  politically relevant results  give  reason to believe that it  is 
indeed possible to educate and advise the population and to provide care for those 
affected if the situation is tackled in the appropriate way. The need for the interplay of 
research  and  policy  becomes  clear  especially  in  the  development  of  preventive 
strategies. The following research findings serve as an illustration: 
Approximately 89% of the adult population in  the Federal Republic of Germany 
were familiar with  the way  in  which  AIDS  is  transmitted,  although  it  should be 
pointed out that elderly  persons  are less  well-informed  and that differences  are 
evident depending on the level of schooling. 
Approximately  half  of  the  respondents  who  are  actively  seeking  a  partner, 
revealed that they exercised  caution in  their sex life.  The frequency with  which 
these persons use condoms is clearly above average. 
Emotional resistance to condoms exists among the public at large for a variety of 
reasons.  For  example,  35%  of  adults  fear  that  the  "mood"  will  be  spoilt. 
Reservations towards the use of condoms are more widespread among men than 
among women;  young people  express  the  least  reservations.  Most  reservations 
(44%) are expressed by those who have several partners in  the course of a year. 
This aspect will  have to be given greater consideration in safer-sex counselling in 
the future (Table 1). 
To  date,  6%  of  the  citizens  of the  Federal  Republic  of Germany  have  taken 
advantage of personal AIDS  counselling;  there was a high prevalence of persons 
with  several partners,  and persons  in  the 16-20 years  age-group  accounted for 
13% (Table 2). 
In  1988, counselling was carried out to a lesser extent than in  1987 by the family 
doctor (30% vs. 41% in 1987) and to a greater extent by hospital physicians (16% 
vs. 12% in 1987). Also on the rise was the number of counselling sessions given by 
health offices (from  12% in 1987 to 22% in  1988) and by AIDS assistance groups 
(up  from  3% to 9%)  as  can be seen from  Table 3.  These results point towards 
structural changes over time in the needs for counselling. 
On the whole, it is  homosexuals who make the most use of counselling, followed 
by women.  A trend  can be  observed  in  all  pertinent models  towards  a  strong 
increase  in  the number of  women  taking  advantage  of counselling  services.  In 
1987, the proportion of such women in the Federal Republic of Germany was 6%, 
in  1988 the figure  had already risen  to  10%.  Consequently,  the content of the 
counselling services will have to be designed in a more sex-specific manner in the 
future. The same also  applies to other measures aimed at providing psychosocial 
support for affected women. There is a need to pay greater attention, for example, 304 
Table 1.  Attitude toward condoms 
Total no. of respondents 
(16 to 65 years) 
Men 
Women 
By age-group 
16 to 20 years 
21 to 29 years 
30 to 44 years 
45 to 59 years 
60 years and over 
Respondents with several 
sexual partners in the 
previous year 
Source: FORSA-Institute, Dortmund 
Representative survey for the FRG (n=2,000) 
Table 2.  Use of AIDS counselling services 
Respondents who were of the opinion that the use 
of condoms spoils the mood during love-making 
35% 
38% 
31% 
27% 
35% 
37% 
35% 
33% 
44% 
Respondents who have received counselling on AIDS: 
Total no. of respondents 
Age 
16 to 20 years 
21 to 29 years 
30 to 44 years 
45 to 59 years 
60 years and over 
Sex 
Men 
Women 
School-leaving certificate 
Secondary modern school 
Intermediate school 
School leaving exam and univer-
sity entrance qualifications, 
university degree 
Percentage of 
all respondents 
6 
13 
10 
7 
4 
2 
6 
6 
4 
7 
9 
Source: FORSA-Institute, Dortmund 
Representative survey for the FRG 
Percentage of respondents 
in need of counselling 
1988 
11 
15 
15 
10 
10 
3 
12 
10 
7 
13 
14 
1987 
9 
11 
10 
11 
8 
5 
13 
6 
8 
9 
12 Table 3.  AIDS counselling centres 
Family doctor 
Health office 
Hospital physician 
Lectures, school 
AIDS assistance groups 
Friends and family 
Other counselling centres 
Self-help groups 
Source: FORSA-Institute, Dortmund 
Representative survey for the F.R.G. 
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No. of respondents who received counselling from: 
1988 
30% 
22% 
16% 
13% 
9% 
6% 
5% 
2% 
1987 
41% 
12% 
12% 
3% 
to the drug-related behaviour of women (who, in contrast to men, are more likely 
to become involved in prostitution than in crime in order to procure drugs) and to 
focus more on the desire to provide assistance to prostitutes who wish to give up 
their activities. Within the framework of the model programme "Women and AIDS" 
this is  achieved, inter alia, by providing overnight accommodation under the care 
of social workers  for  drug-addicts and prostitutes,  offering  counselling to people 
with  debts,  creating  training  opportunities,  giving  assistance  in  coping  with  life 
crises, etc. 
The HIV  antibody test occupies a special place in counselling. Approximately 8% 
of the population over 16 years of age has already taken such a test in the Federal 
Republic of Germany. Among persons with several sexual partners, the proportion 
was 22% (Table 4). 
At  the  health  offices  alone  (excluding  those  of the  Saarland and  North-Rhine 
Westphalia)  250,000 tests  had been conducted by  October.  An  above-average 
number of positive test results  were reported in  Hessen (1.9% compared with  an 
overall average of  0.99%).  One likely  explanation for  this  result  is  the fact  that 
more people at risk  avail themselves  of tests  in  large population centers such  as 
Frankfurt since they wish to be tested in the anonymity of a big town. 
The attitude of the population to persons infected with HIV  and those suffering from 
AIDS  is  of similar significance in  the development of strategies against the impact:  in 
1988 only 7% of the adult population was in favour of isolating people suffering from 
the  disease.  This  is  an unmistakable  decline  in  comparison  with  1987 when  15% 
advocated  exclusion  and,  above  all,  with  1985 when  over  one-third  (36%)  of the 
citizens of the Federal Republic of Germany were in support of this solution. 306 
Table 4.  Use of HIV antibody tests 
Total no. of respondents 
Respondents with several sexual 
partners in the previous years 
Age 
16 to 20 years 
21 to 29 years 
30 to 44 years 
45 years and older 
Source: FORSA-Institute, Dortmund 
Representative survey for the F.R.G. 
No. of respondents who have taken 
an HIV antibody test: 
1988 
8% 
22% 
8% 
16% 
9% 
4% 
1987 
4% 
14% 
8% 
7% 
5% 
2% 
The changes in  knowledge,  attitude and behaviour which  can be discerned already 
over the past two to three years facilitate  an insight into the dynamics inherent in the 
AIDS  question.  Therefore,  in  the  process  of  developing  long-term  health  policy 
measures, we have to take into consideration changing perspectives in  the social and 
economic impact of AIDS. 
Above  all,  such perspectives  and scenarios should provide clues  about the infection 
potential present in various groups of the population and their economic and social 
characteristics.  Furthermore,  knowledge  on the  development  of HIV  infections  and 
AIDS  should  be  compiled  in  order to  ensure  sufficient  medical,  psychosocial  and 
nursing care for the affected persons. Finally, a qualitative analysis of the social impact 
of AIDS  and its  dynamics in  the affected  groups and in society should be conducted. 
The aim of such an analysis would be to facilitate the quest for an appropriate solution 
to the problem with the aid of suitable political and administrative measures. 
Policies in  general - and AIDS  policies  in  particular - need the findings  generated by 
research  to  be able  to  devise  effective  strategies  and implement the  corresponding 
measures.  For the  AIDS  policy  of  the  Federal  Ministry  for  Youth,  Family  Affairs, 
Women and Health, this means that research findings should constitute a tool which 
Serves to interpret the observations made 
Supports  the  planning  and  implementation  of  measures  (including  those  to 
promote research) 
Contributes to the selection and differentiation  of objectives  (for  example  in  the 
field of education or in interventions aimed at preventing epidemics) 
Discourses possible and predicts probable future trends. 307 
From the point of view of the Ministry,  it  is  of vital importance that research and the 
various scenarios be practice-oriented and relevant to the decision-making process. As 
a  result,  it  is  not  sufficient  for  a  researcher  to  possess  only  the  requisite  expert 
knowledge. He/she must also be familiar with the authority of the Ministry within the 
Federal  Government  and  with  the  legal  and  political  competence  of  the  Federal 
Government on the one hand and the Lander on the other. The danger that findings 
might be misinterpreted in the press or by the public as a result of prejudice is  another 
aspect which the researcher must bear in mind. 
Particularly  those  researchers  who  deal  with  cost  estimates  and  global  social 
repercussions should be aware that although AIDS may bring with it financial burdens 
for  the  entire  society,  the persons  most  seriously  affected  are  the victims  of  AIDS. 
Clearly, from the point of view of a health ministry, the provision of care and support 
for the sufferers and of prevention for the others are the top priorities. In this  context 
economic and financial  impacts are looked upon as a need to be looked after rather 
than a resource constraint. 
• Prospects The Economic Evaluation of Care Programmes 
for Patients with HIV-AIDS 
A. Maynard 
Introduction 
The purpose of this  paper is  to  analyse  economic  aspects  of care  programmes for 
patients with HIV-AIDS. These programmes may extend over seven to ten years after 
the diagnosis of the patient's infection and will  consist of alternative combinations of 
health care, involving varying mixes of primary and hospital care, and support in the 
community by a  range  of carers.  One  of the  main  arguments  in  the paper is  that 
existing  economic  analysis  of  care  programmes  in  HIV -AIDS  has  been  concerned 
mainly  with  health  care,  and  that  social  care  networks,  housing  problems,  labour 
market  issues,  insurance  regulations  and other  inputs  into  the  caring  process  have 
been relatively ignored. Yet these issues may influence the health of HIV-AIDS infected 
people significantly and have profound implications for the costs of health care and the 
cost  effectiveness  of  total  care  packages.  To  elucidate  these  issues  the  familiar 
framework  of topics for  analysis  in  any economic evaluation will  be used  (e.g.  as  in 
Drummond et al., 1987). 
1.  Evaluating the care of HIV-AIDS patients 
1.1  What is the question? 
During the more intensive  phase of the infection  drug therapy is  used to treat skin 
cancers and pneumonia. Once the infection is diagnosed, drugs such as Retrovir (AZT) 
can be used to maintain the efficiency of the immune system. Thus, in the health care 
sector  the  question  to  be  answered  by  the  evaluation  may  relate  to  the  cost 
effectiveness of these drug therapies. 
However,  there  are  additional  questions  to  be  answered  by  economic  evaluation. 
Between phases of hospitalisation and health care in primary, the HIV infected person 
will live  in the community, and his health stock will be affected by a variety of inputs, 
some of which are listed in Fig. 1. 
Let  us  review  each of these.  The  HIV  infected  patient will  need resources  to  fund 
dietary changes, enhanced hygiene to reduce the incidence of what for some are trivial 
infections, and a variety of other goods and services necessary to maintain health and 312 
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the  quality  of  life.  However,  the  HIV  infected  patient  may  encounter  sharp 
discrimination in the labour force which leads to enforced job changes and reductions 
in disposable income. Thus, a pilot with this infection may be removed from the flight 
deck  of planes  even  though the  risks  to  passengers  when HIV  is  non-symptomatic 
appears to be no different from the rest of the population. 
What are the cost-effective  ways  of regulating  labour markets so that the income of 
infected people is  not reduced by discrimination? Such income reductions may have 
impacts on psychological and physical well-being which will increase the use of health 
care. Thus, such regulation of the labour market may reduce  health care and social 
care costs as well as meet civil rights and ethical obligations. 
Social security can replace labour market income. However, access to benefits is often 
related to income (labour market participation), capital and age characteristics. Thus, 
access to public assistance is generally means tested, and high marginal tax rates may 
inhibit labour market participation. Some benefits, for instance, attendance allowances 
in the UK,  are related to significant physical or mental dependence during the day or 
night or,  in the case of the invalid  care allowance,  related to minimum  caring inputs 
(35  hours  per  week).  Such  conditions  may  not  be  met  when  the  infection  is 
asymptomatic or symptomatic and in its early stages. 
Income from the labour market and social security may be crucial in  maintaining the 
HIV-AIDS  infected  person's capacity to  buy goods and services  and maintain their 
physical, social and psychological well-being. High marginal tax rates at the boundaries 
of the employment and social security systems may complement the effects of labour 313 
market discrimination  in  reducing their capacity  to maintain  their health and avoid 
usage of the health care system. 
The HIV-AIDS  infected person may be a poor actuarial risk.  The consequence of this 
may be that all policy applicants in  areas of high HIV-AIDS  incidence may be unable 
to  get  insurance  cover.  This  will  reduce  access  to  life  and  health  care  insurance 
markets.  It is  the former  which  is  important  in  the  UK  because  it  affects  access  to 
housing. 
As in the labour market there is evidence of discrimination in the housing market: there 
is  evidence  that landlords  seek to  deny  HIV-AIDS  patients  access  to  housing.  The 
maintenance of the supply of stable,  hygienic  housing services  may  have significant 
effects on health, physical and psychological. The problems posed by loss of housing 
and inadequate  housing may be very  acute for  this  patient group,  especially when 
their expected survival time is often all too short. 
Perhaps the most important input into the case  of HIV-AIDS  infected  people is  the 
social care networks, which includes respite care. The immediate networks provided by 
partners, families  and neighbours may dissipate after diagnosis of infection or anyway 
for  groups  such  as  intravenous  drug  users.  These  networks  are  supplemented  by 
voluntary agencies,  e.g.  gay  groups providing  advice,  support services  and "buddy" 
arrangements. 
These private sector responses to the heterogeneous social care needs of these groups 
are being increasingly but unevenly supplemented by statutory agencies  in  the UK. 
However, access to home help services and other local authority social service (lASS) 
support activities  is  very unequal for  other clients let alone this group. The efficiency 
and the equity of these arrangements are largely unknown. 
So what is the question to be addressed by economic evaluation? Often the question 
relates to that part of the care process provided by health care professionals. However, 
equally important questions can be asked about the efficiency of labour market policies 
to counter discrimination,  housing market policy to  improve  access to good quality, 
secure accommodation, and social care programmes,  in  a wide variety of public and 
private forms,  to support HIV-AIDS people in  the community and minimise,  in  a cost 
effective fashion, their movement into high cost health care systems. 
However,  even  if  a  broad range  of  health  care,  social  care  and other policies  are 
evaluated, how comprehensive is  the evaluation? The majority  of work to date (for 
surveys see Drummond and Davies, 1988; Scitovsky and Over, 1988) has been merely 
costing  studies.  There  has  been  little  attempt  to  measure  the  outcomes  of  these 
expensive caring policies in terms of well years or quality adjusted life years (QALYs). 
The economic logic  of evaluation  concerned  only  with  costs  is  absent:  it  does  not 314 
supply information relevant to make choices between alternative ways of treating HIV-
AIDS consumers. 
Thus the questions addressed by economic evaluation of caring policies for HIV -AIDS 
consumers produce inadequate castings of all aspects of care and provide no evidence 
about outcomes. A vast amount of research activity is producing results of very limited 
use to decision makers. 
1.2  What are the alternatives? 
It  is  better that the health care system,  especially  hospital care,  should be provided 
only  for  occasional,  acute  episodes  and that the  majority  of  care  would  be some 
combination  of  social  care,  supplemented at the margin  by medical  (primary  care) 
inputs. Indeed some argue for community care only as the most appropriate means of 
care for  HIV-AIDS  people. Clearly,  the alternative combinations of health and social 
care are numerous,  and their identification  must be related to the definition  of the 
illness episode being evaluated. 
1.3  How is effectiveness measured? 
The objective of the economic evaluation of the effects  or consequences of care is  to 
identify its  impact on physical, psychological and physical well-being.  Using an index 
with a range of 0 (dead) to 1 (perfect health) it is possible to derive (Gudex and Kind, 
1988)  an estimate of the QAL  Y  s produced by alternative treabnent patterns. This  is 
illustrated in Fig. 2. 
The number of QALYs  (Williams,  1985)  or well  years  (Kaplan  et al.,  1988)  can be 
calculated and casted to produce estimates  of the cost of producing well  years with 
different treabnents. Some cost-well year data are set out in Table 1 which reproduces 
data from Kaplan's work on the cost effectiveness of induced changes in the behaviour 
of non-insulin dependent diabetes patients (NIDDN). 
Whilst single outcome measures have many attractions, there is  a range of choice of 
such measures and of other instruments to determine the quality of life, e.g. Karnofsky 
and Worbnan. These illustrative examples are set out in Appendix 1 together with the 
York quality of life measure from which Rosser QALYs can be calculated. 
It  is  unfortunate that to date such techniques have been used  rarely  in  conjunction 
with  costing  studies  to  give  estimates  of  the  cost-outcome  attributes  of  competing 
policies. Until such work is done the cost effectiveness of alternative caring policies for 
HIV-AIDS  people will  be unknown,  and policy choices will be based on rhetoric and 
guesses about the efficiency of a wide range of caring options. Perfect 
health 
Quality 
of  life 
Dead 
0 
No 
treatment 
Time  of  infe'ction 
Fig. 2.  Quality adjusted life years gained by treatment 
Years  of  !ife 
1.4  How are costs to be identified, measured and valued? 
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Whilst  it  is  relatively  easy to  identify,  measure  and value  many of the  costs  in  the 
health  care  system,  it  is  less  easy  to  identify,  measure  and  value  the  costs  in  the 
informal care system.  In  the UK  the norm  is  to assume that leisure time  is  valued at 
25%  of  work  time.  However,  a  wide  variety  of  circumstances  and thus  costs  face 
principal  carers,  and the  adoption  from  transport  economics  of  the  25%  norm  is 
attractive from  the point of view of simplicity but inappropriate in  terms of its  lack of 
accuracy.  As  Wright  (1987)  has  argued,  there  is  a  need for  a  substantial  research 
programme to identify the value of informal care and the opportunity cost of the work 
of principal carers. 316 
Table 1.  Cost utility of competing interventions 
Pneumococcal vaccine, older adults 
Pheylketonuria screening 
Screening for severe hypertension (diastolic blood pressure above 105) 
Behavioural intervention in NIDDM 
Screening for mild hypertension (diastolic blood pressure 95-105) 
Oestrogen replacement in post menopausal women 
Rehabilitation in chronic obstructive pulmonary disease 
CABG, two vessel disease 
Pneumococcal vaccine, young children 
CABG, single vessel disease 
Source: Kaplan et al. (1988) Table 5, 337 
Cost ($ US 1987) 
per well year 
1,500 
7,000 
9,200 
10,870 
18,600 
23,500 
24,600 
32,700 
114,900 
516,500 
1.5  Other issues: time preference, margins and sensitivity analysis 
Whilst it  is  necessary to discount streams of costs and QAL  Y to take account of time 
preference, to identify where possible the magnitude of the margins and to carry out 
sensitivity analysis, there are no special problems in attempting to do this for the social 
care sector.  As  for  the health  care sector these processes  are  made difficult  by  the 
absence of good data. 
1.6  Overview 
The evaluation of social care of HIV-AIDS infected people must meet the pre-requisites 
of a good economic study. Also  it must provide the policy-maker with  the results she 
needs. These needs may vary: 
1.  The policy-maker might  require  to  know  the cost per person year of treating 
AIDS.  Drummond  and  Davies  (1988)  and  Scitovsky  and  Over  (1988)  have 
reviewed costing studies for AIDS patients in a variety of countries. These studies 
tend to emphasise the health care costs, at the expense of social care costs and 
show that the cost of treatment is very high, e.g. £ 27,000 per patient year in the 
UK (Rees and Roberts, 1988). However, whilst such studies may inform bids for 
increased public expenditure, they tell decision makers little  about the efficiency 
of such care. 
2.  The  policy-maker may  wish  to know  if such  treatment is  cost effective.  There 
seem to  be few  studies  of the  cost  effectiveness  of AIDS  treatment.  The  cost-
QAL  Y data shown in Table 2 indicate that the most inefficient therapy generated 
a  QALY  for  £ 14,000. Treatment of AIDS  patients appears to be less  efficient 
than this. 317 
2.  Efficiency and ethics 
A Benthamite approach to the use of the data in Table 2, and ignoring for the moment 
the issue  of the identification of marginal values,  would lead to advice to the policy-
maker to  create the  greatest benefit  from  the  finite  health  care  budget by  putting 
resources into those activities which have the lowest cost per QAL  Y (or well year}. This 
would  result in  the treatment of  end stage renal failure  and AIDS  being deprived of 
funds: such investments are inefficient use of resources. 
The  Benthamite would  argue  that  inefficient  resource  allocation  deprives  potential 
patients of care from  which they could benefit.  Thus, the £ 27,000 spent to treat an 
AIDS  patient for  one year could produce over 160 QAL  Y  s if spent on GP advice to 
stop smoking. 
But can patients  with  HIV-AIDS  be deprived  of  care?  The  final  decision  is  for  the 
politician  to  take.  Humanitarian  responses,  even  if  inefficient,  will  always  influence 
resource allocation  in  health care.  The results  of economic evaluation inform but do 
not  decide  resource  allocation  in  health  care.  Such  results  show  clearly  that  the 
opportunity  cost  of  humane treatment  of  these  patients  is  high.  Of  course  such 
behaviour begs  the  question  of  why  act  inefficiently  towards  this  group?  and  the 
answer may be that some relevant costs and benefits which are difficult to measure, for 
instance the social and political  consequences  of behaving differently,  are excluded 
from economic evaluations. 
Table 2.  UK data on costs and QAL  Y  s (Williams) 
GP advice to stop smoking 
Pacemaker implantation for atrioventricular heart block 
Hip replacement 
Valve replacement for aortic stenosis 
CABG for severe angina with LMD 
CABG for severe angina with 3VD 
CBAG for moderate angina with LMD 
GP control of hypertension 
GP control of total serum cholesterol 
CABG for severe angina with 2VD 
CABG for moderate angina with 3VD 
CABG for mild angina with LMD 
Kidney transplant 
Breast cancer screening 
Heart transplant 
Hospital haemodialysis 
Source: Williams (1985, 1986); Department of Health and Social Security (1987) 
167 
700 
750 
900 
1,040 
1,270 
1,330 
1,700 
1,700 
2,280 
2,400 
2,520 
3,200 
3,309 
5,000 
14,000 318 
3.  Conclusions 
1.  Much  of  the  economic  work  concerning  HIV -AIDS  has  consisted  of  costing 
studies which emphasise the resource consequences of treatment provided by the 
statutory  and private  (e.g.  hospices)  community  agencies.  There  is  a  relative 
neglect of the informal  care  element of social  care because these services  are 
difficult to identify, measure and value. 
2.  Many policies  other than those in  the  health and social  care sectors  affect the 
well-being  of  HIV-AIDS  infected  people.  Furthermore,  factors  such  as 
discrimination  in  labour and  housing  markets  and  difficulties  in  accessing  the 
social security system may influence the use of statutory health and social care 
programmes, well-being and survival to a considerable extent. 
3.  Although  many  HIV-AIDS  treatment  packages  have  been  evaluated 
incompletely,  it  is  clear  that  AIDS  treatment  is  costly.  As  yet  the  systematic 
evaluation  of  the  costs  and  outcomes  (e.g.  cost  per  QALY)  of  competing 
treatments for HIV -AIDS people is absent, and so the efficiency of care is unclear 
but in all probability relatively cost ineffective. Is it ethical to be efficient? Efficient 
resource allocation might leave AIDS patients untreated. Is inefficiency unethical? 
Treating AIDS  patients deprives  other patients  of care from  which  they could 
benefit.  These  questions  have  economic  answers,  but  economics  does  not 
always, and perhaps should not always, determine resource allocation. 
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Appendix  Quality of life measures in social care 
(1)  Kamofsky performance status index 
Definition  %  Criteria 
Able to carry on normal activity  100  Normal; no complaints; no evidence 
and to work  of disease 
90  Able  to  carry  on  normal  activity; 
minor signs or symptoms of disease 
80  Normal  activity  with  effort;  some 
signs or symptoms of disease 
Unable to work. Able to live at  70  Cares  for  self.  Unable  to  carry  on 
home, care for most personal  normal activity or to do active work. 
needs  A  varying  amount  of  assistance  is 
needed 
60  Requires occasional assistance but is 
able to care for most of needs 
50  Requires considerable assistance and 
frequent medical care 
Unable to care for self  40  Disabled;  requires special  care and 
Requires equivalent of  institutional  assistance 
or hospital care 
Disease may be progressing rapidly 
30  Severly  disabled;  hospitalisation  is 
indicated although  death not  immi-
nent 
20  Very sick;  hospitalisation  necessary; 
active  supportive  treatment  neces-
sary 
10  Moribund; fatal  processes progress-
ing rapidly 
0  Dead (2)  The York quality of life questionnaire 
General mobility 
Which one of these statements best describes your situation? 
I can move round indoors and outdoors on my own with no aids or help 
I can get about indoors and outdoors on my own but I have to use a walking 
aid e.g. stick, frame, crutch, wheelchair, etc. 
I can move around the house without anyone's help but I need someone's help 
to get outdoors 
I spend nearly all my time confined to a chair (other than a wheelchair) 
I have to spend nearly all my time in bed 
Do you have difficulty with any of the activities listed below? 
Ifyou.QQ, do you also need help from someone else to do them? 
no difficulty  some difficulty 
at all  but cope on 
my own 
Washing yourself  0  0 
Dressing yourself  0  0 
Eating or drinking  0  0 
Using the toilet  0  0 
0 
0 
D 
0 
0 
such difficulty 
that I need 
someone's help 
D 
0 
0 
0 
321 322 
Usual activities 
1.  Tick the activity below that best describes your present situation. 
In paid employment (at work  D  Retired  D 
or from home) 
Housework or looking after  D  Unemployed  D 
family 
Studying  D  Other  (please specify)  D 
........................................ 
2.  Does your current state of health make you cut down on, or use special aids for this activity? 
yes  D  no  D 
3.  Have you had to change from a different activity that you were doing before, because of your state of 
health? 
yes  D  go to 
0.4 
4.  What was this activity that you were doing before? 
In paid employment (at work 
or from home) 
Housework or looking after 
family 
Studying 
D 
D 
D 
Retired 
Unemployed 
Other  (please specify) 
no  D  goto 
0.5 
D 
D 
D 
5.  If  your present state of health has made you cut down or change  your usual activity,  how seriously 
does this affect your life? 
Mark a cross on the line. 
not at 
all 
0  10 
extremely 
seriously 
This question does not apply to me because my usual activity is not affected by my health  D 323 
Over the last two weeks has your state of health led you to experience any of these feelings? 
If  so, how much distress have they caused you? Mark a cross on the line. 
no distress  extreme 
no  yes  at all  distress 
Feeling sad or depressed  D  D 
Feeling anxious or worried  D  D 
Pain  D  D 
Feeling sick  D  D 
Breathlessness  D  D 
Difficulty sleeping  D  D 
Lack of energy  D  D 
Dissatisfaction with your  D  D 
appearance 
Incontinence (i.e. lack of  D  D 
control over bladder or 
bowel movements) 
Embarrassment  D  D 
Uncertainty about the future  D  D 
An~er  or resentment  D  D 
Guilt  D  D 
Loneliness  D  D 
Loss of self-confidence  D  D 
Feeling dependent on a  D  D 
machine for my health 
Inability to concentrate  D  D 
Poor memory  D  D 
Difficulty in speaking  D  D 
Difficulty in hearing  D  D 
Difficulty in writing  D  D 
Difficulty in seeing  D  D 
Any other problems that  D  D 
cause you distress? 
Please specify 324 
How much does your state of health distress you overall? 
Mark a cross on the line. 
no distress 
at all 
Summary 
How would you rate your overall quality of life? 
Mark a cross on the line. 
extremely 
good 
What aspect of your state of health most upsets you? 
Social and personal relationships 
Does your state of health seriously affect any of the following? 
Your social life 
Seeing friends or relatives 
Your hobbies or leisure activities 
Your sex life 
Has your financial situation been affected by your state of health? 
If  yes, please indicate how severely. 
not at 
all 
extreme 
distress 
extremely 
bad 
yes  D 
yes  D 
yes  D 
yes  D 
yes  D 
extremely 
severely 
no  D 
no  D 
no  D 
no  D 
no  D 325 
(3)  The social support scale 
Social support scale developed by Dr. Camille Wortman for coping and change: a study of Chicago men. 
The next questions are about how things are currently going between you and the people in your personal 
life - lovers, friends, relatives, etc. Please answer in terms of how things have been going for you in the 
past month. 
Note:  Questions 1-12 are rated as never (1), rarely (2), sometimes (3), frequently (4), or all the time (5). 
In the past month: 
1.  Did you feel that the people in your life let you down by not showing you as much love and concern 
as you would have liked? 
2.  Have the people in your personal life really got on your nerves? 
3.  Did the people in your personal life make you feel respected? 
4.  Have you felt loved and wanted? 
5.  Have you felt isolated from others? 
6.  Have you felt that no one really knows you well? 
7.  Have you felt as though you were part of a group of friends? 
8.  Have you felt tense from arguing or disagreeing with people in your personal life? 
9.  Have you felt irritated or resentful towards people in your personal life? 
10.  Have you wished for more friends? 
11.  Have you kept pretty much to yourself? 
12.  Did you feel misunderstood by the people in your personal life? 
Next, we would like to ask whether people would be available to help you deal with different problems or 
situations that might arise. 
Note:  Questions 13-23  are rated as  definitely not (1),  probably not (2), possibly (3), probably (  4),  or 
defmitely (5). 
13.  Is there someone who would help take care of you if  you were confined to bed for several weeks? 
14.  Is there someone you could turn to if  you needed to borrow  5,  a lift to the doctor, or some other 
small, immediate help? 
15.  Is there someone you could turn to if you  needed to borrow several hundred pounds for a medical 
emergency? 326 
16.  Would the people in your personal life give you information, suggestions or guidance if  you  needed 
it? 
17.  Would someone be available to talk to you if  you were upset, nervous or depressed? 
18.  Is there someone you could turn to if  you needed advice to help make a decision? 
19.  Is there someone you could contact if  you  wanted to talk about an important personal problem you 
were having? 
20.  Is someone around to confide in or talk to about yourself and your problems if  you want to? 
21.  Do the people in your personal life approve of the way you do things? 
22.  Do the people in your personal life tend to size up things and people the same way you do? 
23.  Is  there  someone  you  feel  you  can  tell just  about  anything  to,  someone  you  can  count  on  for 
understanding and support? If  so, how many such people are there? 
No one .............................................................................................. 1 
1 person ........................................................................................... 2 
2 or 3 people ................................................................................... 3 
4 or 5 people  ................................................................................... 4 
6 or more people ............................................................................ 5 
Now we'd like to ask you  a number of questions about your interactions With  friends and relatives  and 
about your social activities. 
24.  About how  often do  you  get  together with  friends  or relatives  (for  example, visiting  each other's 
homes, going out together, or participating together in recreational activities)? 
Every day ......................................................................................... 1 
Several days a week ........................................................................ 2 
About once a week ......................................................................... 3 
2 or 3 times a month ....................................................................... 4 
About once a month  ...................................................................... 5 
5 to 10 times a year ......................................................................... 6 
Less than 5 times a year ................................................................. 7 
25.  During the past month, about how often were you involved in a social interaction or exchange that 
was  unpleasant or distressing? Please include interactions with your lover, your friends and family, 
your co-workers, people in shops, etc. 
Every day ......................................................................................... 1 
Several days a week ........................................................................ 2 
About once a week ......................................................................... 3 
2 or 3 times a week ......................................................................... 4 
About once during the month  ...................................................... 5 
Not at all  .......................................................................................... 6 327 
26.  About how many groups or organizations do you belong to just because you want to -- like clubs, 
church groups, lodges etc? 
(write in number. If  none, enter "0" and go to question 28 below). 
Number: ________  _ 
If  you belong to any groups or organizations: 
[For gay men only] 
a.  How many of these are gay organizations or groups? 
(write in number. If  none, enter "0"). 
Number: ________  _ 
b.  How active are you in the groups or clubs you belong to? 
(If  you belong to a great many, just count those you feel closest to.) 
Very active; I attend most meetings ....................................... 1 
Fairly active; I attend fairly often ........................................... 2 
Not active: I belong but hardly ever go  ................................. 3 
27.  In the past year, of the times you got together with friends and relatives, how often were you the one 
who planned or initiated the activity and invited others to participate? 
Not applicable:  Hasn't gotten together with 
friends and relatives in the past year ........................................... 8 
Never ................................................................................................ 1 
Not too often ................................................................................... 2 
Sometimes ....................................................................................... 3 
Pretty often ...................................................................................... 4 
Almost every time  ............................................................................ 5 International Research Needs for AIDS 
S. Wayling, H. Zollner 
Health-for-all targets in Europe 
Health for all  - global, regional and in  countries - is  the most ambitious health policy 
ever set. The member states of WHO  have chosen a far-reaching goal:  health for  all 
people by the year 2000. At the heart of the health-for-all movement is a new look at 
health with a broader perspective. 
The European member states  have taken the first  steps towards their revolutionary 
goal.  Through  their  representatives  in  the  Regional  Committee  for  Europe,  the 
parliament of the Regional Office, they adopted 38 regional targets as concrete goals 
to work towards, and 65 regional indicators by which to measure their progress. Briefly 
put, the targets describe how present conditions must be changed to reach health for 
all. Most countries reflect health for all in their national health policies. 
The structure of the targets suggests six broad tasks: 
Describing every aspect of the health of the population so that progress towards 
the targets can be monitored (target 32) 
Finding out what biological factors detennine health (targets 1-12) 
Assessing the part that lifestyles play in maintaining or endangering health (targets 
13-17) 
Studying  the  ways  in  which  the  physical,  biological  and  social  environments 
(including the basic prerequisites for  health)  detennine the health of individuals 
and populations (targets 13-25) 
Developing effective  and efficient methods of providing people with  appropriate 
care (targets 26-31) 
Improving policy-making, planning and management in programmes for health for 
all (targets 32-38). 
Target  4  specifically  includes  AIDS  although  it  is  realised  that  AIDS  is  implicitly 
addressed in all groups of targets, and especially lifestyles and health (targets 13-17). 
WHO European regional programme on AIDS 
In  Europe the infection continues to spread, and the number of cases has doubled 
each year,  with  a  total  of 16,960 cases reported by 30 European Region  member 329 
states by the end of December 1988 (Albania and San Marino have no detected AIDS 
cases so far),  and an estimated 500,000-1,000,000 asymptomatic people are infected 
with the human immunodeficiency virus (HIV). 
In September 1987 the Thirty-seventh Session of the Regional Committee for Europe, 
by Resolution EUR/RC37/R5,  called on the Regional Office  for Europe to expand its 
involvement in AIDS  activities along the lines set forth  in the Global Programme and 
the suggested an European Regional Programme on AIDS. 
The  Regional  Programme  on AIDS  is  directed  by  a  medical  officer  and  a  social 
scientist, reflecting the duality of the disease. They are supported by other professional 
staff with  expertise  in  the subject areas.  These  include  public  policy,  education  for 
health, counselling, care, media and national programme support. 
The Regional  Office  Programme forms  an integral part of the overall WHO  Global 
Programme on AIDS  (GPA).  The team works in  close cooperation with headquarters 
and makes  use  of the expertise available from  various related Regional Office  units. 
Since its inception in January 1988, the Regional Programme on AIDS has become the 
largest technical unit in the Regional Office. 
In  1988  the  European  Regional  Programme  on  AIDS  focused  mainly  on  further 
improving the existing regional AIDS surveillance system, on various AIDS prevention 
activities,  and  on  assisting  member  states  in  the  development  of  comprehensive 
national programmes on AIDS prevention and control through information, education 
and counselling. For 1989, the objective is to build upon the momentum generated in 
1988 with increased emphasis on supporting the development of comprehensive and 
integrated AIDS/1-UV policies and programmes in the European region. 
The Regional Programme on AIDS continues to work within four broad subject areas. 
1.  Epidemiological surveillance 
The  WHO  collaborating  centre  in  Paris  has  established  a  European  regional 
epidemiological surveillance  system  for  AIDS.  Thirty  European member states  send 
regular  quarterly  information  on  AIDS  to  the  centre,  which  processes  it  and 
redistributes it  to the countries  in  the form  of a  detailed epidemiological analysis on 
various  aspects  of HIV  infection  characterising the trends  of the AIDS  epidemic in 
Europe  - a  prerequisite  to  evaluating  the  efficacy  of  European  programmes  and 
policies. 
The AIDS  reporting  forms  were revised  and endorsed for  use  as  'WHO European 
regional  surveillance  forms  for  AIDS  cases"  at a  WHO  consultation  on information 
support for the AIDS surveillance system held in Czechoslovakia, in February 1988. At 
this  meeting,  it  was  agreed  that  the  existing  surveillance  system  in  Europe  was 330 
functioning  well  and  that  significant  problems  of  underreporting  had  not  been 
encountered.  Countries  of  the  Region  have  established  testing  facilities  for  HIV 
seropositivity at a national level; most also have them at a regional level,  and although 
some do not have them at district level,  this  may reflect the geographical size  of the 
country and the distribution of its population. 
To facilitate reporting in a timely manner, a uniform computerised system in Europe is 
under  review.  Meanwhile,  a  faster  system  of  electronic  mail  is  being  established 
between  European  countries  for  reporting  data  on  surveillance  of  AIDS  and  HIV 
seroprevalence. An agreement has been reached between member states that reports 
of total numbers of AIDS  cases should be made available at monthly intervals to the 
WHO  Regional  Office  so  as  to  minimise  the  unavoidable  delays  in  reporting  the 
information  collected  by  the  WHO  collaborating  centre.  Information  on  the  total 
numbers of AIDS cases in Europe is now available at monthly intervals, and the figures 
are published regularly by the GPA secretariat in Geneva. 
Surveillance of HIV seropositivity is rapidly becoming both an important and a difficult 
issue.  There is  an urgent need for sentinel HIV seroprevalence studies, covering both 
general  population  groups  and  at-risk  groups.  Draft  guidelines  for  a  standardized 
methodology of HIV serosurveys specifically aimed at the installation of sentinel HIV 
serosurveillance have been distributed to all member states. 
2.  National programme support 
Since AIDS  cannot be stopped in any one country unless it is stopped in all countries, 
every  Member  State  needs  a  comprehensive  national  AIDS  programme,  to  be 
implemented  under the  direction  of  a  national  committee  on  AIDS.  The  Regional 
Office was the first WHO entity to react to the AIDS  epidemic when, together with the 
Danish Cancer Society,  it  convened in  1983 a first  European meeting on AIDS  with 
the participation of 17 European member states. Since then, at the Regional Office's 
suggestion, national committees on AIDS prevention and control have been formed in 
almost  all  European member states,  ;:tnd  activities  on surveillance,  reporting,  health 
education and public information have been developed. Close collaboration between 
national AIDS  committees and the Regional Office through initial assessment visits  or 
exchange of information has been established with more than 25 member states. 
In  1988,  WHO  provided  general  assistance  to  Albania  and Turkey,  including  the 
assignment of teams of experts for initial assessment and development of a short-term 
plan.  In  close  collaboration  with  the  governments,  the  Regional  Office  is  now 
developing  a  cooperative  medium-term  programme  for  a  period  of  2-3  years  on 
various aspects of health, taking into account WHO's objectives regarding health for all 
by the year 2000 as set forth  in  the European Strategy and the resources available, 
including  in  those  programmes  provision  for  AIDS  activities.  Preparation  of  such 331 
programme components for Bulgaria, Greece, Poland, Romania and Spain has been 
completed. 
In 1989, the Regional Office continues to evaluate the European activities in support of 
the member states. WHO guidelines for the development of national AIDS prevention 
and  control  programmes  have  previously  been  distributed  to  all  national  AIDS 
committees. And as the next step, the Regional  Office will  promote the evaluation of 
such  programmes  according  to  further  guidelines  now  being  developed  by  the 
programme. 
A National AIDS  Policy  study of all  member states  is  underway to support member 
states in  meeting the pre-existing objectives.  The study integrates the activities  within 
the regional programme so that a comprehensive overview and data base is  available. 
Specific areas of interest are: 
The  different  and  evolving  aspects  of  National  AIDS  Committees,  their 
membership and roles 
The need and availability of integrated, comprehensive medical and psychosocial 
care services 
The special role of counselling and counsellors, both professional and lay persons, 
in prevention, management and care services. 
3.  Prevention of the spread of HIV infection 
In  the absence of vaccine and effective  chemotherapeutic drugs for AIDS  prevention 
and treatment, intensive and frank health education remains the way of attacking the 
problem. 
Two  international consultations on public education and AIDS  prevention and AIDS 
education in the workplace, respectively, were organized in Cologne, Federal Republic 
of Germany,  by the Federal Centre for  Health Education in  1987 and 1988.  They 
were attended by participants from 20 European countries and the USA who, among 
many  other  points,  stressed  the  importance  of  developing  an  international  health 
education network oriented to AIDS prevention. A third meeting is planned in autumn 
1989. 
A pilot study of AIDS prevention among male homosexuals, including an examination 
of the attitudes and behaviour of the general population towards homosexuality has 
now been completed. This  study incorporates experience  gained in  those European 
countries  in  which  the  disease  is  spread  mostly  among homosexual  and bisexuals, 
including Denmark, Federal Republic of Germany, Norway and Sweden. 
In cooperation with the WHO Collaborating Centre for Health Information, a study on 
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Regional Office  for Europe. The study will  also consider the social attention given to 
HIV seropositives and AIDS patients. 
A  review  of  the  present  situation  in  Europe  concerning  the  management  of 
neuropsychiatric  aspects  of  AIDS  is  being  undertaken  and will  be followed  by  the 
development of a proposal for European countries. 
To cope with the growing dilemma of health legislation and ethics in the prevention of 
HIV  transmission  and  treatment  of  AIDS  patients,  a  joint  WHO/Norwegian 
Government meeting on this issue was held in Oslo in Aprill988. Participants reviewed 
the legislative situation of AIDS and HIV infection in Europe and noted that control of 
biological  products  is  now  being  practised  in  all  European  member  states.  They 
strongly recommended not to use compulsory HIV screening of the general population 
or particular groups, or testing without consent. 
There was a consensus that AIDS should not be considered as a separate category of 
infectious disease and that it does not require a separate legislative approach. Thus, 
the  existing  national  laws  for  control  and prevention  of  infectious  diseases  will  be 
reexamined  as  to  whether  they  are  appropriate  for  the  new  epidemic  and  are 
adequate to protect individual and community rights. 
To  promote  appropriate  counselling  and social  and  medical  care  services  for  HIV-
positive  individuals,  AIDS  patients  and  their  contacts,  the  Regional  Office  has 
organised an analysis of counselling and care services for these people, which is being 
undertaken in  12 European member states. A protocol for  country contributions has 
been developed and distributed to the national AIDS  committees. The data received 
through this analysis were reviewed at the meeting of a working group on counselling 
and care services for HIV-infected people at the end of November. These activities are 
aimed at developing a model for counselling for use in European member states and at 
determining rational health care settings for AIDS patients at various stages of disease 
progression. 
To  estimate  future  developments  with  regard  to  the  health,  social,  cultural  and 
economic impact of AIDS on individual member states and on the region as a whole, a 
first  meeting on the development of scenarios for this purpose was  organized by the 
Regional Office  in  Kiel,  Federal Republic of Germany, at the end of 1987. A second 
meeting,  on the development of scenarios,  took place in  August 1988 in  Geneva. A 
European regional  meeting on the financial  implications  of the  growing  problem  of 
AIDS  is  now being prepared by  the Regional  Office  in  close  collaboration with  the 
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4.  Cooperation with intergovernmental organisations 
Close cooperation is being maintained with the European Community, the Council of 
Europe  and  the  Nordic  Council  through  exchange  of  information  and  joint 
participation  in  meetings.  Efforts  have  been made  to  coordinate  the  AIDS  control 
activities undertaken by WHO, the European Community's research working party on 
AIDS  and  the  Council  of  Europe  in  the  fields  of  AIDS  among  intravenous  drug 
abusers, HIV surveillance and counselling. 
Regional  staff  have  participated  in  various  meetings  organized  by  the  global 
programme as  well  as  in  various  meetings  organised by  countries  or the European 
Community, including meetings on clinical manifestations of AIDS,  on HIV variability, 
and on progress in the development of HIV vaccines. 
A joint meeting of the Regional Office's Standing Committee on AIDS and global staff 
was  convened  so  as  to  review  progress  in  developing  the  European  regional 
component of the global programme and to outline the activities that can be delegated 
to the Regional Office in 1989. 
A report on the current situation of the HIV epidemic in the region and on activities of 
the Regional Programme since the last session in September 1987 were presented at 
the  thirty-eighth  session  of  the  Regional  Committee  and  widely  discussed  by  the 
delegations, who affirmed the importance of AIDS prevention and acknowledged the 
progress made by the member states and the WHO Regional Office for Europe in AIDS 
prevention and control. 
On the  occasion  of  the  World  AIDS  Day  an  international  day  of  awareness  and 
education  about  AIDS  was  held  in  the  Regional  Office,  drawing  attention  to  a 
comprehensive care model, including medical as well as psychosocial support to those 
affected  by  HIV/AIDS.  There  was  an  exhibition,  panel  discussion  and  moving 
deliberations of HIV-infected people. All these events made the day outstanding in our 
struggle with stigmatisation and discrimination of HIV/AIDS sufferers. 
Health-for-all research policy in Europe 
Target 32 of the European health-for-all strategy specifically demands that all member 
states  should  have  formulated,  before  1990,  research  strategies  to  stimulate 
investigations which improve the application and expansion of knowledge needed to 
support their health-for-all developments. 
A common research strategy was approved by the Regional Committee at its  thirty-
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publication "Priority research for health for all", Copenhagen, WHO Regional Office for 
Europe, 1988 (European health for all series, No.3). 
Priority areas for research are those that are 
Highly likely to contribute to the attainment of the regional targets 
Closely linked to the Regional Committee's suggested solutions for attainment 
Ukely to yield results that can be translated into health policy and action 
Unfortunately, likely to be neglected otherwise, despite their importance. 
The regional targets  share  common themes,  vital  elements  of their success:  equity, 
disease prevention, health promotion, primary health care, community participation, 
and intersectoral and international cooperation. Similar themes run through research 
for health for all. They include three areas of research: 
Health policy and organizational behaviour 
Inequities 
Community participation and intersectoral collaboration 
and two essential tools: 
Better information systems and indicators for the targets 
International comparative studies. 
Many concrete research questions  can touch several themes.  The importance of the 
themes will vary from country to country. 
To provide the necessary knowledge,  health research must venture for the first  time 
into fields  that lie  outside its  traditional domain. To succeed, health researchers must 
seek  cooperation  with  people  in  all  the  disciplines  that can  contribute  the  expert 
knowledge  necessary.  This  will  especially  involve  the  biomedical,  behavioural  and 
social sciences. 
As regards targets 1-12, they aim at reducing health inequities, morbidity and mortality 
from specific causes, and at improving the quality of life. 
Increased research is needed: 
To improve the data base 
To redirect research towards public health needs 
In the forms of longitudinal studies and small area data. 
Setting up a reliable data base on inequities, morbidity, mortality and the quality of life 
is  of  primary importance.  It  is  needed to  provide information  for  the monitoring of 
progress towards the targets. 
Priority  should be given  to  research  projects  aimed  at prevention  of treatment  or 
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quality of life is  equally important. Research objectives should not therefore be limited 
to  issues  affecting  only  selected  target  populations,  such  as  hospital  patients,  but 
should extend to problems  of morbidity  in  primary  care and the community.  While 
better, broader assessments of high-powered modem technology are urgently needed, 
more  attention  should  also  be  paid  to  diagnostic  and  therapeutic  strategies  and 
evaluative research in primary health care. 
To  give  a  wider  focus  to  health  policy,  health  surveys  should  include  people's 
perceptions of their health and that of their families.  Both retrospective and, in  most 
cases, prospective longitudinal studies will  also  be necessary. Small area data on the 
need  for  health  services  and  their  provision  and  results  are  required  to  plan  and 
evaluate  intervention  programmes.  These  data  should  be  collated  with  relevant 
community or regional data. 
With regards to AIDS under target 4, epidemiological studies on people with AIDS and 
those  who  have  human  immunodeficiency  virus  (HIV)  are  required,  especially 
innovative  research  into  the  psychosocial  and  economic  aspects  of  the  problem. 
Member states should develop educational programmes for  health personnel and the 
general public to prevent or limit  the spread  of HIV.  These  programmes should  be 
monitored for effectiveness. 
European research activities on AIDS in 1989-1990 
The number of AIDS cases in  Europe continues to increase at approximately the same 
rate as in the last few years, and this calls for an intensified effort to combat the disease 
throughout the region. Considerable progress has been made in the implementation of 
the regional programme on AIDS; however, it is a priority to continue the efforts of the 
past years. A carefully monitored surveillance system for AIDS together with the system 
planned for  HIV  infection  in  Europe  is  making  it  possible  to  keep  the  European 
community  aware  of  the  growing  magnitude  of  the  epidemic  and  hence  to  take 
collective action. 
Important issues such as  HIV serosurveillance and uniform  computerized systems are 
under scrutiny, legislative and ethical issues inherent in AIDS/HIV are a major concern 
and are being carefully reviewed as are strategies to evaluate various approaches and 
components policies  and programmes.  This  is  being accomplished through  intensive 
efforts in  the Regional Office  for Europe and with  close  cooperation between WHO, 
member states and the major European intergovernmental organisations. 
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1.  Programme direction 
This includes the continuing collection of country-specific AIDS information in order to 
establish  a  comprehensive  data  base.  Of  particular  interest  is  the  question  of 
seroprevalence data and the legal, medical and ethical questions implicit in this subject. 
Seroprevalence, in itself,  is  considered a good indicator of the efficacy of programmes 
and as such deserves investigation. 
New  initiatives  also  include  establishing  closer  links  with  non-governmental 
organisations,  evaluating  the  role  and  impact  of  the  media  and  reviewing  AIDS 
discrimination particularly as applied to insurance. 
2.  Initiatives on intravenous drug abusers (IVDA) 
The forecast  is  that by mid-1990,  over 50% of new AIDS  cases  will  be intravenous 
drug users with the added consideration that an associated increase in paediatric AIDS 
through neonatal transmission  can  also  be expected.  Social and psychosocial  IVDA 
issues  in  terms  of  risk  reduction  programmes  and  further  development  of  possible 
interventions are priorities. 
3.  Health and social services 
Developing  strategies  for  a  comprehensive  and  integrated  care  continuum  form  a 
priority for 1989. As a starting point, an evaluation and assessment of care practices in 
the European region will  be undertaken. The needs of people with AIDS/HIV,  their 
families  and  the  providers  of  care  will  be  addressed.  Following  this  activity,  two 
projects are planned - one oriented to nursing care practices and the other meeting the 
concerns of health care professionals. 
4.  Epidemiological support and research 
To use better the improving epidemiological data base, workshops will be convened on 
the  evaluation  of  prevention  programmes  with  emphasis  on  resource  allocation 
methods. Additionally, national participants will be trained and evaluations initiated. 
5.  Health promotion 
Building on the work of the Regional Office and the inroads made in the development 
of health promotion as a policy focus,  the AIDS  unit will  initiate projects to develop 
models  in  a  series  of  venues.  The  results  will  help  train  national  participants  in 
appropriate health promotion  methods  and how  best to  implement programmes  in 
different locations including schools and the workplace, and for target groups including 
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6.  Social and behavioural research 
Counselling  became  a  priority  in  1989,  starting  with  an  evaluation  of  counselling 
services in selected countries. These outcomes are to be added to existing knowledge 
and implemented through a series of three sub-regional workshops which also include 
an evaluative component. Health workers' roles and response to this responsibility are 
also to be evaluated. 
7.  Economic impact assessment 
As  regards the economic aspects,  a  study has been initiated in  cooperation with the 
Health Services  Management Centre,  The  University  of Birmingham,  England.  The 
objectives  of the study are twofold.  First,  to  collect  essential economic data from  a 
number of countries as  an input to the scenario project described in the next section. 
Second,  to  specify  the  contribution  that  economic  analysis  can  make  to  the 
development of policies for this important public health problem. The study comprises 
the collection of existing data on the costs  of programmes for preventing and treating 
AIDS and the development of appropriate methodologies for the economic analysis of 
AIDS policies. 
A meeting was held  in  Tewkesbury,  United Kingdom,  5-7 July 1989, addressing the 
key economic issues. The topics considered at the meeting included: 
The economic burden of AIDS 
Cost-effectiveness of treatment strategies for AIDS 
Economics of prevention programmes 
Costs of safety measures and subjective assessment of risks from AIDS 
Social security effects of AIDS 
Priority setting for AIDS and other health care programmes. 
The meeting demonstrated that economists were actively studying aspects of the AIDS 
epidemic. Most of the work has been on estimating the direct costs to the health care 
sector,  and  economists  are  beginning  to  overcome  the  methodological  problems 
involved in generating such estimates. Nevertheless, this work is in danger of becoming 
too narrowly focussed and lacking integration with other relevant disciplines.  Priorities 
for further economic analysis of AIDS and HIV would include: 
Cost-effectiveness  studies  of treatment  options,  based  on  controlled  or natural 
experiments 
The analysis of prevention strategies,  using assumptions generated by consensus 
approaches when firm data do not exist 
The identification of the main needs for better epidemiological data, as judged by 
the sensitivity of estimates of economic impact to these data 
The  development  of  more  dynamic  approaches  to  economic  evaluation,  to 
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The exploration of the incentives and disincentives facing key people, particularly 
at risk  of AIDS,  as  a  first  step towards  designing better interventions to  change 
behaviour 
The identification  of the wider economic effects  of AIDS,  particularly  when the 
policy objectives of different ministries/sectors may conflict 
The exploration of the distributional consequences of the AIDS  epidemic and the 
equity aspects of the various intervention strategies. 
8.  Multi-national study on scenarios on social and economic impact of AIDS 
This  activity  has special relevance in  view of the EC-COMAC-HSR  Conference. The 
Office  has  initiated  an  international  scenario  on  the  psychosocial  and  economic 
impacts  of  AIDS.  This  is  a  coordinated  research  project  which  integrates  activities 
related  to  AIDS  with  a  special  emphasis  on  the  psychosocial  and  economic 
implications.  The project is  being coordinated by the Steering Committee on Future 
Health Scenarios, Ministry of Welfare, Health and Cultural Affairs, the Netherlands. 
There  are  at present five  countries  with  an official  institutional  commitment in  this 
project:  Federal Republic of Germany, Italy,  the Netherlands, Spain and Switzerland. 
The United Kingdom  is  considering joining the project as are several other countries. 
This component of the project is designed to serve as an information exchange forum 
regrouping  the  interested  member  states  to  review  AIDS  developments  in  shared 
scenarios for the future. 
It  may  sometimes  be  difficult  to  identify  common  denominators  among  projects 
because  of  their  country  specificity,  but  it  is  considered  essential  to  compare 
methodological approaches and results as the country projects develop. 
The choice of topics is being made according to 
Common interests  as  a  policy  priority topic of the countries participating in  the 
project 
The possibility  of developing both the economic and psychosocial facets  of the 
topic 
Minimum information available. 
A meeting of national coordinators was held in  May 1989 to refine the two-year plan 
of  work  and  review  presentations  from  participating  countries.  In  addition,  a 
preparatory meeting on the social  indicators  advisory  group was  held.  Its  role  and 
relationship with  the economic advisory  group  were reviewed.  A meeting to  review 
developments of these country-based activities is planned for autumn 1989. 
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The scenario study will  receive technical input from  two advisory groups, one on the 
economic implications and the other on the psychosocial implications. 
Close collaboration will  be maintained with  other international organisations working 
in  this  field,  such as the European Communities and the Organization for Economic 
Co-operation and Development. 
The  main  task  ahead will  be the  coordination  of  the various  aspects  of  research: 
medical and social science  research, basic and applied research,  positivistic research 
and action research, research on facts and research on values and perception. 
WHO strategy for AIDS - the global challenge 
The  Fortieth  World  Health  Assembly  (May  1987)  defined  a  Global  AIDS  Strategy 
which was supported by the United Nations General Assembly.  The World Summit of 
Ministers  of  Health, which  took place  in  London  on 28 January 1988, stressed the 
need for urgent action by all governments and people the world over to implement this 
strategy. 
The World  Health Organization  global AIDS  plan, which  has the generous financial 
support of governments and industry, rests on five key concepts. 
1.  HIV  infection and AIDS  can be stopped; concerted action,  coordinated at global 
level, can prevent its spread. 
2.  In  the absence of a vaccine and a cure, the developments of which are in  hand 
but cannot be  expected  to  be  available  for  at  least  five  years  in  the  case  of 
vaccines,  education  is  the  key.  Changes in  behaviour,  directed  away  from  risk 
activities,  will  prevent the  spread  of  the virus.  This  requires  messages  that will 
convince people that they themselves hold the answer and thereby persuade them 
to change their behaviour. 
3.  Behavioural change will not happen overnight and therefore the commitment must 
be a long-term one. 
4.  Programmes  to  prevent  and  control  the  epidemic  must  be  developed  and 
implemented at national level. 
5.  Because the  epidemic  is  truly  worldwide,  worldwide  coordination  is  necessary. 
Guidance and leadership at global  level  can  ensure that we  learn  as  quickly  as 
possible, and the resources coordinated and channelled appropriately. In  order to 
be most effective,  moreover, all AIDS control and prevention programmes should 
be integrated into national health systems and national health plans. 
Within this conceptual framework, the Global Programme on AIDS has established the 
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Prevention of infection 
Care of people with HIV/AIDS and 
Unification of efforts against AIDS at international and national levels. 
To meet these objectives, programme strategies include the following. 
Prevention of sexual transmission 
As already described, this  depends on education and behavioural changes, combined 
with provision of appropriate health and social services, in the context of a supportive 
social environment. 
Prevention of transmission through blood 
Increasingly, blood is  being tested and blood products treated to avoid transmission. 
Similarly, donations of semen and organs can be screened. Where risks  lie  in  the use 
by more than one person of unsterilised skin-piercing equipment, those risks  can be 
minimised by education, and by the availability of suitable sterile equipment. 
Action on perinatal transmission 
This  difficult  area  should  emphasise  prevention  and  the  provision .of  advice  to 
prospective, but HIV-infected or high-risk mothers and to women of child-bearing age 
whose partners are infected on the likelihood of bearing an infected child. Success will 
depend  on a  number of factors  including:  the  sensitivity  with  which  the  advice  is 
handled; the pressure on families to go on having children, especially in  areas of high 
infant mortality; social beliefs, attitudes and legislation on contraception or abortion. 
Impact reduction 
This involves the individual,  his or her family,  friends and community, as well as the 
tangible and intangible costs  borne by society  at large.  Direct financial  costs  can be 
overwhelming at the family level;  they will also significantly affect health care systems. 
Indirect costs include the political and social as well as  economic ramifications in lives 
and productivity loss. Psychological crises arising from  HIV infection and disease need 
particularly sensitive responses. The discrimination that is increasing in parallel with the 
epidemic is counterproductive, alienating the very people that need to be reached and 
involved  in  programmes,  as  well  as  undermining the  fundamental values  on which 
society is  founded.  Reduction of these impacts will  require a massive,  conscious and 
coordinated response  around the world  and across  boundaries of nationality,  race, 
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Therapeutic agents 
As  therapeutic agents become more available,  their use will  become an increasingly 
important  part  of  programmes  for  the  prevention  of  AIDS-related  morbidity  and 
mortality. At present and in the foreseeable future, such agents are expensive, far from 
being universally available and limited in their efficacy. 
Vaccines 
The development of a vaccine is  still at least five years away and probably more. Even 
when developed,  distribution  and use  will  require formidable  logistic  arrangements, 
and such a vaccine will not be of use to persons already infected. Strategies involving 
the widespread  use  of  vaccines  and therapeutic drugs  are currently  in  a  different 
category of priorities in the WHO global programme. Research in these areas is a high 
priority and is coordinated at global level. 342 
APPENDIX 
Key socio-economic issues in AIDS 
1.  Effect on attitudes 
attitude change to other vulnerable groups 
services to other vulnerable groups 
risk perception (individual and society) 
human rights 
ethics/legislation 
discrimination and tolerance 
attitude towards dying 
social networks 
2.  Effects on the economy 
productivity 
employment - job qualification 
distribution 
local economy (geographical pockets) 
participation (lost earnings, individual, societal) 
international exchange (goods and services) 
social security schemes 
dependents/family - support system 
3.  Effects on technology 
diagnostic and treatment equipment 
management insurance schemes 
safety standards 
information technology 
4.  Effects on health care 
health 
manpower - staffing 
quality of services (positive effect on safety regulations, blood circuit, 
confidentiality mechanisms) 
hospital management and planning 
efficiency 
pharmaceutical (industry) 
infectious diseases health insurance schemes 
alternative resource allocation 
take-home technologies 
research 
epidemiologic pattern (e.g. mortality notification bias) 
attitude towards health professionals 
comparative effect on other public health authorities 
public/private mix 
alternative care 
5.  Effects on demography 
age sub-division of society (age-divided society) 
immigration 
ruraVurban 
6.  Effects on education/prevention 
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education and values (openness and explicitness of previously concealed matters) 
health education approaches 
prevention/promotion strategies Future Research Policies 
H. Stein 
This paper intends to point to some aspects that might be important for future research 
on AIDS. Doing that I shall, however, not restrain myself to research policies. Indeed, it 
would  be more  appropriate to put this  word  of  my  paper's title  - research  - into 
brackets. I shall try to outline frame, content and purpose of EC cooperation in fighting 
AIDS  and to show what effective contribution this  meeting, the COMAC-HSR and a 
"concerted action" will possibly be able to make. In addition, this is  an attempt to give 
at least part of an answer to the question what objectives research on the economic 
aspects of AIDS should try to attain. 
Research is  of course an integrated part of EC cooperation;  in  fact,  as  happens so 
often,  research  was  there  from  the very  beginning,  and was  the  first  field  of  EC 
cooperation; all the others -policy, public health administration, etc. -followed years 
later.  Nevertheless,  even  in  fighting  AIDS,  research  - especially  "health  services 
research" - cannot be a goal in itself;  it does not exist for its own purpose but must aim 
at improving public health and public health policy - and nobody can deny the need 
for that. 
In this context I would like to thank Dr.  Zollner and Prof. Maynard for having pointed 
out and stressed the importance of the social  aspects  of AIDS  and of the measures 
taken, something that up to their contribution played too small a role in this conference 
and was sometimes even neglected. 
We always have to keep in  mind that economic aspects,  important as they may be in 
some respects, cannot and must not be the main concern of AIDS policy. Its main aim 
(at least  here in  the Federal Republic of Germany)  is  not to minimise  costs,  but to 
prevent people from getting infected and to care for those who have been infected or 
are already  ill and are going  to  die.  And  this  has to be done at whatever costs  -
"reasonable" or not. 
In order to make an acceptable and accepted contribution to improving public health 
policy in this respect, research has to know - and to try and influence!  - what is  going 
on, has to make its results and findings  known to policy-makers and administrators in 
an understandable way, has to build bridges between research and politics. 
It  is  the purpose of this paper to assist  in  building this  bridge or - should it  already 
exist - to fortify  it.  I feel  legitimised to do so because I helped not only to create the 
CO  MAC HSR in 1980 but also the council's ad-hoc group on AIDS in 1986. 345 
The general prospect for the future can be summed very briefly: 
Economic aspects of AIDS - and these go far beyond the costs of treatment - and, even 
more,  social  aspects  of  AIDS  are  so  important  and  have  such  manifold  political 
implications that research on them cannot and should not be a "one day event" but 
must be continuous. 
The questions however are: 
Who shall define the tasks of research? 
Who shall perform them? 
Who is going to finance all that? 
In  order to address these questions,  I would  like  to  make a  few  remarks  about the 
general EC background in health policy and health research policy. 
EC health policy 
As  the EC's legal basis- the treaty of Rome of 1957 or the "European Single Act"  of 
1986 - does not provide the EC Commission with any competence for health matters 
as  such,  it  is  a  very  open question  how  far  EC  activities  can  go  in  this  field.  The 
situation  is  quite  similar  to  the  one  in  the  FRG  where  the  constitution,  the 
Grundgesetz, gives very little  competence in  health matters to the federal government. 
However,  as  far  as  AIDS  is  concerned,  the  Lander,  i.e.  the  regional  governments 
(which  otherwise  watch the  central government very closely  to  see that it  does  not 
exceed its  constitutional competence)  were in  this  case  quite  glad  to  accept federal 
money for several AIDS programmes. 
AIDS,  therefore,  has had an impact on the constitutional division  of power between 
central and regional governments in West Germany. I believe the same is happening in 
Brussels. Officially,  however, there has been up to now no common EC health policy. 
Yet a great number of health and health related activities are going on as, for instance, 
the programme "Europe against cancer" or the "EC strategy against AIDS". 
EC strategy against AIDS 
As early as 1984, the European Parliament demanded EC activities against AIDS. First 
steps were taken in the field  of medical research when, within the Third Medical and 
Public  Health  Research  Programme,  a  special  group  on  AIDS  was  created. 
Cooperation started in medical and epidemiological research. 
The political and economic implications of AIDS  were grossly  underestimated at that 
time.  This  is  clearly  shown by the fact  that the budget proposed for  AIDS  by  the 
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being asked how high it rated the political importance of AIDS, agreed to these cuts - it 
did not give AIDS a very high research priority. 
I  can  easily  call  this  a  very  poor judgement  and  a  gross  underestimation  of  a 
tremendous problem  since,  at that time,  I was  the chairman  of that body.  But,  as 
always,  there  is  an explanation if  not an excuse:  we  had, then, very  few  facts  and 
figures  at hand, especially  concerning the potentially fearsome  economic and social 
implications of that disease; we just had to guess, and our guess was a bad one. 
It has been argued that resource allocation and proper criteria for  it  are one of the 
main reasons for  doing research on the economic aspects of AIDS.  At  the moment, 
lack of money is  not a problem as far as AIDS  is  concerned - at least not in the FRG. 
Yet, there is a need for this kind of research work because there is not only the danger 
of giving too little money, but also the danger of allocating too much, which I have the 
feeling  is  sometimes  the  case  with  AIDS  research.  AIDS  at a  national  as  well  as 
international  level  - this  includes  the  EC  - seems  to  be  the  magic  word  to  open 
treasurers' chests. However, the time will come -and it may not be far away -when 
researchers  and  others  have  to  give  account  of  for  what  purpose  and  with  what 
success all that money was spent. 
To return to the EC situation: 
Only a few years later, in 1987, a common EC AIDS strategy was agreed upon by the 
member states in the Health Council. AIDS was declared to be an international health 
problem of the utmost importance. A number of general policy principles were set up: 
The prime importance of information and education 
The refusal of systematic and compulsory screening 
the creation of a rapid communication system for epidemiological data 
No discrimination of affected people 
Need for guaranteeing complete freedom of movement. 
It is  my assumption - but I may be wrong - that this sudden interest in AIDS at the EC 
level was not caused by a deep concern for health matters. If that had been the case, 
action  against  cardiovascular  diseases  would  have  been  much  more  appropriate. 
Rather, the motive seems to have been the fear of uncontrollable consequences of an 
economic, social and political nature of AIDS,  of the effects of measures taken to fight 
this spreading disease, and of its  impact on the production of goods and services, on 
gross national product, trade and tourism. 
This  argument is  strengthened by the fact  that at practically the same time,  in  June 
1987, the World  (Trade)  Summit in  Venice  agreed upon a very strong statement on 
AIDS,  describing  it  as  being  the  biggest  potential  health  problem  in  the  world  -
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Here again we can note the strange phenomenon that, although it was the economic 
and social implications which led to the interest of the heads of state in Venice or the 
health ministers in Brussels, this background and motivation were not mentioned in the 
statements; instead, the latter as well as the measures and actions proposed were of a 
purely medical nature. 
This, of course, is not surprising for two simple reasons: 
1.  Since AIDS is considered a health problem, the solution to overcome it must in the 
end be a  medical  one:  a  therapy,  a  vaccine  or  - as  at the  moment  - health 
education. 
2.  Very little  is up to now known about the possible and feared economic and social 
effects  of AIDS,  including the side  effects  of measures taken to prevent or slow 
down the further spreading of the disease. 
Despite  this  deplorable  lack  of  knowledge,  not  enough  has  so  far  been  done  to 
improve the situation. First and notable steps in  this direction  are the WHO  activities 
for multi-national studies on the social and economic impact of AIDS and this EC-HSR 
meeting. 
New  and  more  knowledge  is  very  definitely  needed  to  prevent  politicians  and 
administrators from  taking steps into wrong directions. This,  however, does not mean 
that I am demanding a complete reorientation of the AIDS  strategy towards a much 
more economic direction.  This  again would be wrong and inappropriate. Economic 
and financial impacts of AIDS are not of prime relevance, but they cannot be neglected 
either.  And  in  order to  avoid  ill-conceived  policies,  the  decision  makers  must  be 
supplied with more and substantial information on the socio-economic effects of AIDS. 
It is research that has to provide it. 
Having remained very general so far, I will now draw some rather concrete conclusions 
for the future work on AIDS at the EC level: 
1.  The EC should continue its endeavours according to the political decisions of the 
Health  Council  prepared  by  the  Council  ad-hoc  group  on  AIDS  and  by  the 
Commission. The new topics to be taken up - AIDS and the work-situation, AIDS 
and health personnel, AIDS  and social discrimination,  etc.  - should generally be 
more oriented towards economic and social issues. 
2.  The  ad-hoc group  and the Commission  need help  and assistance;  they cannot 
produce all the results by themselves. They need research results. 
3.  At the moment the only field  of cooperation between the Council's ad-hoc group 
on AIDS  and the research groups on AIDS  is  the epidemiology data base at the 
Paris centre. 
4.  Concerted research activity could very well serve as a "think-tank" for the Council's 
group and provide data, facts, findings and proposals even for political action. 348 
5.  For  the  resulting  future  activities,  direct  working  relationships  between  the 
administration and the research groups should be considered. References 
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